TrialID,url,Scientific_title,Conditions,Interventions,Public_title,Source_registry,Date_registration_format,Date_enrollment_format,Day_inferred,Study_type,Study_design,Phase,Target_size,Primary_sponsor,Countries,Bridging_flag,Retrospective_flag,Date_registration,Date_enrollment,Trial_prefix,Unknown,SecondaryIDs,Public_Contact_Firstname,Public_Contact_Lastname,Public_Contact_Address,Public_Contact_Email,Public_Contact_Tel,Public_Contact_Affiliation,Scientific_Contact_Firstname,Scientific_Contact_Lastname,Scientific_Contact_Address,Scientific_Contact_Email,Scientific_Contact_Tel,Scientific_Contact_Affiliation,Recruitment_status,Secondary_sponsors,Source_Support,Agemin,Agemax,Gender,Inclusion_Criteria,Exclusion_Criteria,Primary_Outcome,Secondary_Outcomes,Bridged_type,Childs,type_enrolment,results_actual_enrollment,results_url_link,results_summary,results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan,results_IPD_description,results_date_completed,results_yes_no,Ethics_Status,Ethics_Approval_Date,Ethics_Contact_Name,Ethics_Contact_Address,Ethics_Contact_Phone,Ethics_Contact_Email
ACTRN12619000423112,https://anzctr.org.au/ACTRN12619000423112.aspx,STimulating ß3 Adrenergic Receptors to improve change in exercise performance on a graded treadmill  in patients with Peripheral Arterial Disease.,Peripheral Arterial Disease; <br>Peripheral Arterial Disease;Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system,"(1) Initial therapy with Mirabegron (50 mg/day) for 12 weeks.<br>-Mirabegron (produced by Astellas Pharmaceuticals) is a film-coated prolonged release oral tablet and it will be administered at a dose of 50 mg/day. <br>OR<br>(2) Placebo <br><br>Strategies used to monitor adherence to the intervention:<br>-At 4 weeks and 12 weeks participants will be self-reporting medication adherence (patient diary). <br>-Participants will be instructed to return unused capsules at 12 weeks and returned capsules will be counted by the study team and returned to Pharmacy department at RNSH<br>-Blood tests through the whole study (Screening, baseline, Week 4, Week 12).<br><br>",The STAR-PAD trial is testing a new treatment for Peripheral Arterial Disease (PAD).,ANZCTR,2019-03-14,2019-03-14,FALSE,Interventional,Purpose: Treatment; Allocation: Randomised controlled trial;,Phase 2,100,North Sydney Local Health District,Australia,NA,NULL,14/03/2019,14/03/2019,ACTRN1,15 July 2019,Nil Known,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Recruiting,NULL,Heart Foundation,40 Years,80 Years,Both males and females,Inclusion criteria: 1) Age 40-80 yrs;<br>2) Atherosclerotic PAD (uni- or bi-lateral) with a resting ankle-brachial index (ABI) <0.90;<br>3) Stable intermittent claudication for the previous 3 months not requiring revascularization; <br>4) Ability to walk 1 to 12 minutes on a treadmill with a variability of PWT between 2 consecutive screening treadmill tests <25%; <br>5) Adherence to a stable medical regimen for 3 months <br>,"Exclusion criteria: 1) Ischaemic rest pain, ulceration or gangrene, or previous major amputation; <br>2) Acute coronary syndrome or revascularization of coronary/peripheral arteries in last 3 months; <br>3) Uncontrolled hypertension (>180/100 mm Hg); <br>4) Active inflammatory, infectious, or autoimmune diseases; <br>5) Significant renal impairment (eGFR<45); <br>6) Concomitant illness, physical impairment or mental condition that could interfere with effective conduct of the study during its duration, including life expectancy <3 months.<br>7) Contraindication to mirabegron<br>","Change in exercise performance on a graded treadmill, reflecting the peak exercise capacity of the patient, as reflected by peak walking time.[Peak walking time at t=12 week vs screening and baseline, according to the Skinner-Gardner protocol.]","Initial claudication distance as assessed by graded treadmill[Data will be compared between baseline and 12 weeks visit (end of treatment)];Walking Impairment Questionnaire [At baseline visit and 12 Weeks(end of treatment) follow up visit.];Ankle brachial index (ABI)-A validated and clinically utilized tool, will be measured after 10 minutes of supine rest with a hand-held Doppler.[At screening visit and 12 weeks (end of treatment( follow up visit];MRI measurements of flow-arterial blood of the lower limb coil[At baseline visit and 12 weeks (end of treatment) follow up visit];MRI measures of tissue perfusion[At baseline and 12 weeks (end of treatment) follow up visit];MRI measure of arterial stiffness[At baseline and 12 weeks (end of treatment) follow up visit];Quality of life questionnaire-SF36[At baseline visit and 12 weeks (end of treatment) follow up study];Initial absolute claudication distance as assessed by graded treadmill.[Data will be compared between baseline and 12 weeks (end of treatment) follow up.]",NA,NULL,Actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Yes,"What data will be shared? At the completion of the study, all data will be analysed in a blinded manner and reports with conclusions will be generated. Patients will be allowed access to the summary results at their request.   	When will data be available (start and end dates)? Individual participant data will be collected after they signing the consent, and all data will be up-loaded to Redcap database. After anyalysis of this data and the end of patient follow-up all data shall be stored in accordance with research guidelines and destroyed after 15 years in accordance with the Australian code for the responsible conduct of Research.   	Available to whom? -Patients will be allowed access to the summary results at their request. -Researchers -Any event that meets the definition of a SUSAR will be reported to the local HREC and the -relevant regulatory authorities as per local requirements and ICH Clinical Safety Data Management.  	Available for what types of analyses? Analysis of covariance (ANCOVA)-Primary and Continuous secondary outcomes.  Kruskal-Wallis analysis of variance and Wilcoxon rank sum tests-QOL measures and brachial artery flow-mediated dilation. Log-binomial regression-binary endpoints  Pre-defined subgroup analyses  	By what mechanism will data be made available? Data access authorization-PI",NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Northern Sydney Local Health District Human Research Ethics Committee,NA,NA
ACTRN12619000720112,https://anzctr.org.au/ACTRN12619000720112.aspx,Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer,Prostate Cancer; <br>Prostate Cancer;Cancer - Prostate,68Ga-PSMA-PET/CT scan will be administered in a registered nuclear medicine department by a nuclear med physician. This scan is considered standard of care for patients and this trial requires 1 additional scan under the same conditions as a standard PSMA scan. All participants are will be undergoing enzalutamide as standard of care. PSMA scans takes approx. 2-3 hours to complete.  The second scan will be 7 weeks from the baseline scan. The Enzalitamide dosing is based on clinician choice (medical oncologist) Enzalutimdie will commence at Week 5 (4 weeks post the 1st PSMA Scan) will continue throughout study as prescribed by treating Med Onc.,Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer,ANZCTR,2019-05-13,2019-06-03,FALSE,Interventional,Purpose: Diagnosis; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy;,Not Applicable,40,GenesisCare,Australia,NA,NULL,13/05/2019,03/06/2019,ACTRN1,16 September 2019,ENHA01,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Recruiting,NULL,Telix Pharmaceuticals,18 Years,No limit,Males,"Inclusion criteria: •Male, aged 18 years or over <br>•Metastatic prostate cancer with demonstrated resistance to standard ADT <br>•Eastern Cooperative Oncology Group (ECOG) score 0 or 1 or 2<br>•Willing and able to comply with all study requirements, including all imaging and pre- and post-study assessments<br>•estimated glomerular filtration rate (eGFR) greater than or equal to 40 mL/min/1.73 m^2<br>","Exclusion criteria: •Prostate cancer with significant neuroendocrine or sarcomatoid component<br>•Chemotherapy within previous two months<br>•External beam radiotherapy within previous two months<br>•Current use of abiraterone, or use within previous two months<br>•Known intolerance or hypersensitivity to enzalutamide, or patient in whom enzalutamide is contraindicated<br>•Known hypersensitivity to CT imaging intravenous contrast agent<br>•Known hypersensitivity to any isotope of Ga in any chemical form, or any of the PSMA-targeting ligands<br>•Significant urinary incontinence<br>•Any mental condition or cognitive impairment that may render the patient unable to adequately understand the requirements, nature and possible consequences of the study<br>","To evaluate if diagnostic sensitivity of 68Ga-PSMA-PET/CT imaging in patients with metastatic prostate cancer is enhanced by androgen blockade with enzalutamide, as measured by any increase in SUV (max) OR any increase in number of lesions detected in an individual patient[The second 68Ga-PSMA-PET/CT scan performed 14 days following the start of enzalutamide treatment]",NIL<br><br>[NIL],NA,NULL,Anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,No,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Bellberry Human Ethics Committee,NA,NA
ChiCTR1900022258,http://www.chictr.org.cn/showproj.aspx?proj=36344,Effects of coenzyme Q10 on endothelial and cardiac function in patients undergoing hemodialysis: a pilot randomized controlled trial,end-stage renal disease,intervention group:Coenzyme Q10 400mg;placebo:placebo;,Effects of coenzyme Q10 on cardiovascular function in patients undergoing hemodialysis: a pilot randomized controlled trial,ChiCTR,2019-04-02,2019-04-22,FALSE,Interventional study,Parallel,0,intervention group:30;placebo:30;,the 306th Hospital of Chinese PLA,China,NA,NULL,2019-04-02,2019-04-22,ChiCTR,27 April 2020,NULL,Jianjun Gao,NA,"9 Anxiang Road North, Chaoyang District, Beijing",gao306kidney@126.com,+86 15010914203,The 306th Hospital of Chinese PLA,Yongxing Xu,NA,"9 Anxiang Road North, Chaoyang District, Beijing",xuyognxingstar@163.com,+86 15901339247,"Department of Nephrology, the 306th Hospital of Chinese PLA",Pending,NULL,Grant from the 306th Hospital of Chinese PLA (No.19ZX47),18,85,Both,Inclusion criteria: Patients receiving thrice weekly hemodialysis for at least 3 months; aged more than 18 and less than 85 years; Life expectancy greater than 1 year.,Exclusion criteria: Poor adherence of dialysis or medications; severe systemic or local infection; malignancy; kidney transplant less than 12 months before study enrollment; hospitalization within 30 days; history of a major atherosclerotic event within 3 months; pregnancy or lactation; current use antioxidant other than vitamin C; use of hemodialysis catheter.,LV systolic function;cardiac diastolic function;myocardial performance index;endothelial-dependent flow-mediated vasodilation of the brachial artery;,death or hospitalization due to cardiovascular events;all-cause mortality;chang of Coenzyme Q10 concentration; ratio of reduced Coenyme Q10 (ubiquinol) to oxidized Coenzyem Q10 (ubiquinone);oxidative stress markers;left ventricular mass index;,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Nov 30 2018 12:00AM,NA,Fei Ren,+86 010 66356729,NA
ChiCTR1900022488,http://www.chictr.org.cn/showproj.aspx?proj=37970,A randomized controlled study for puerarin regulates gut microbiota of patients with carotid atherosclerosis,Carotid atherosclerosis,"Puerarin group:Puerarin capsule (50mg/time), 3 times a day + Statins;Control group:Statins;",A randomized controlled study for puerarin regulates gut microbiota of patients with carotid atherosclerosis,ChiCTR,2019-04-13,2019-05-01,FALSE,Interventional study,Parallel,0,Puerarin group:10;Control group:10;,"Zhujiang Hospital, Southern Medical University",China,NA,NULL,2019-04-13,2019-05-01,ChiCTR,23 April 2019,NULL,Minsheng Chen,NA,"1023-1063 Shatai Road South, Baiyun District, Guangzhou",minshengsmu@163.com,+86 020 61648011,Southern Medical University,Zehua Li,NA,"253 Industrial Avenue, Haizhu District, Guangzhou",595814782@qq.com,+86 15626044340,"Zhujiang Hospital, Southern Medical University",Pending,NULL,"National Natural Science Foundation of China,U1501222",NA,NA,Both,"Inclusion criteria: 1. Patients (male/female) between 40 and 80 years of age;<br>2. The distance between the outer membrane interface of the common carotid artery and the endometrial interface (IMT) = 1.0 mm or at least one measurable plaque;<br>3. Dyslipidemia metabolism: TG >200 mg/dL, LDL-C>130 mg/dL, TC>200 mg/dL and HDL-C<40 mg/dL for men and <50 mg/dL for women;<br>4. Voluntarily participate in this clinical trial, understand and sign the informed consent form.","Exclusion criteria: 1. Patients with hepatic impairment (SGOT or SGPT levels > 3 Upper Limit of Normal (ULN)) or renal impairment (serum creatinine =2.0 mg/dl), patients with any other severe systemic illness such as malignancy, severe neuroendocrine system diseases and mental disease;<br>2. Patients who have taken any antibiotics or probiotics or prebiotic preparations within one month;<br>3. Patients who have taken any Chinese traditional patent Medicine or Chinese traditional medicine within one month;<br>4. Pregnancy or preparation for pregnancy and lactation women;<br>5. Allergic persons, or those known to be allergic to puerarin;<br>6. patients who are participating in another clinical trial within 1 month.",Plasma TMAO concentration;16S rRNA gene sequencing analysis of stool;Fecal TMA concentration;,NULL,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Feb  1 2019 12:00AM,NA,Tingting Zhang,NA,NA
ChiCTR1900026242,http://www.chictr.org.cn/showproj.aspx?proj=43382,Study for the therapeutic effect of heparin in the treatment of Pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome,hepatic sinusoidal obstruction syndrome,Experimental group:subcutaneous injection of low molecular weight heparin;Control group:Symptomatic supportive treatment of traditional hepatoprotective and diuretic therapy;,Study for the effect of heparin in the treatment of Pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome,ChiCTR,2019-09-28,2019-10-01,FALSE,Interventional study,Parallel,4,Experimental group:30;Control group:30;,"Division of Gastroenterology, Union Hosptial, Tongji Medical College, Huazhong University of Science and Technology",China,NA,NULL,2019-09-28,2019-10-01,ChiCTR,30 September 2019,NULL,Yuhu Song,NA,"1277 Jiefang Avenue, Wuhan, Hubei, China",yuhusong@163.com,+86 15007187581,NA,Yuhu Song,NA,"1277 Jiefang Avenue, Wuhan, Hubei, China",yuhusong@163.com,+86 15007187581,"Union Hosptial, Tongji Medical College, Huazhong University of Science and Technology",Pending,NULL,supported by ourselves,NA,NA,Both,Inclusion criteria: 1. Patients aged >=18 years;<br>2. Hepatic sinusoidal obstruction syndrome induced by Pyrrolidine alkaloids;<br>3. Medium or large amount of ascites;<br>4. T-Bil>34.2umol/L.,"Exclusion criteria: 1. Patients with active bleeding or coagulation system-related disease (such as haemophilia,aplastic anemia, etc);<br>2. Patients with a bleeding tendency: uncontrollable severe hypertension, intracranial hypertension, retinal vascular diseases, peptic ulcer in the active period,etc;<br>3. Prolonged prothrombin time ( PT) >10 s;<br>4. Allergy to low molecular weight heparin and its derivatives;<br>5. Previous medical history of thrombocytopenia associated with the use of low molecular weight heparin;<br>6. Severe renal dysfunction;<br>7. Children or pregnant woman; <br>8. Having a history of surgical operation in short term.",Liver function;Blood coagulation function;,Computed Tomography;Magnetic Resonance Imaging;,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Sep  4 2019 12:00AM,tongjilunli@163.com,Xiaoyan Yang,+86 027-83691785,tongjilunli@163.com
ChiCTR1900027146,http://www.chictr.org.cn/showproj.aspx?proj=45130,China Children's Leukemia Group (CCLG) - AML2019 study on pediatric acute myeloid leukemia,pediatic acute myeloid leukemia,Ara-c+6-TG:Ara-c+6-TG;ATRA+RIF:ATRA+RIF;,China Children's Leukemia Group (CCLG) - AML2019 study on pediatric acute myeloid leukemia,ChiCTR,2019-11-02,2019-11-01,FALSE,Interventional study,Parallel,4,Ara-c+6-TG:300;ATRA+RIF:300;,Capital Medical University Beijing Children's Hospital,China,NA,1,2019-11-02,2019-11-01,ChiCTR,4 November 2019,NULL,Zheng Huyong,NA,"56 South Lishi Road, Xicheng District, Beijing",zhenghuyong@vip.sina.com,+86 010-59617621,Capital Medical University Beijing Children's Hospital,Zhang Xixi,NA,"56 South Lishi Road, Xicheng District, Beijing",zhangxixi10@163.com,+86 010-59617629,Capital Medical University Beijing Children's Hospital,Recruiting,NULL,self-raised,0,18,Both,"Inclusion criteria: 1. Patients diagnosed of AML; 2. Patients younger than 18 years old; 3. Patients who haven't received pre-treatment, except for those who receive single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosis; 4. Patients who have signed the Informed Consent Form.","Exclusion criteria: 1. Acute Promyelocytic Leukemia; <br>2. Junior Myelomonocytic Leukemia; <br>3. AML secondary to Fanconi Anemia; <br>4. AML secondary to Kostmann Syndrome; <br>5. AML secondary to Shwachman Syndrome; <br>6. AML secondary to other Bone Marrow Failure; <br>7. Patients who fail to receive systematic choemotherapy according to the protocol;<br>8. Patients who received any anti-tumor treatment within 2 weeks, except for those who received single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosis and have recovered from the adverse drug reactions; <br>9. Uncontrolled infection of bacteria, fungi, virus or any other pathogens (infection-related symptoms and sign progress despite proper use of antibiotics or any other treatment); <br>10. Patients complicated with psychiatric disease or any other diseases that could affect their safety and compliance, participation, follow-up or interpretation of results.",Remission State of Bone Marrow;Three year's event free survival;,Minimal Residual Disease;Side effect of chemotherapy;,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Oct 29 2019 12:00AM,NA,Guo Chunyan,+86 010-59616083,NA
ChiCTR1900023825,http://www.chictr.org.cn/showproj.aspx?proj=39847,"Platelet inhibition in ACS patients after PCI by standard dose ticagrelor, low-dose ticagrelor and standard dual anti-platelet therapy after shortening the duration of dual anti-platelet therapy",acute coronary syndrome,Standard dual antibody group(A):Oral standard dose and time of dual antiplatelet drugs;Standard dose ticagrelor monoclonal antiplateletStandard dose tigrilol monoclonal antiplatelet:The duration of dual antiplatelet therapy was shortened to standard dose ticagrelor monoclonal antiplatelet therapy;Low dose ticagrelor monoclonal antiplatelet(C):The duration of dual antiplatelet therapy was shortened to low dose ticagrelor monoclonal antiplatelet therapy;,Platelet inhibition in ACS patients after PCI by shortening the duration of dual antiretroviral therapy and low-dose ticagrelor,ChiCTR,2019-06-13,2019-07-01,FALSE,Interventional study,Parallel,4,Standard dual antibody group(A):50;Standard dose ticagrelor monoclonal antiplateletStandard dose tigrilol monoclonal antiplatelet:50;Low dose ticagrelor monoclonal antiplatelet(C):50;,Tianjin Union Medical Center,China,NA,NULL,2019-06-13,2019-07-01,ChiCTR,17 June 2019,NULL,Zhuhua Yao,NA,"190 Jieyuan Road, Hongqiao District, Tianjin, China",1401596904@qq.com,+86 13902199877,Tianjin Union Medical Center,Wenting Li,NA,"190 Jieyuan Road, Hongqiao District, Tianjin, China",tjrmyyxnk@163.com,+86 15822105821,Tianjin Union Medical Center,Pending,NULL,self-raised funds,NA,NA,Both,"Inclusion criteria: 1) aged =18 years, regardless of gender;<br>2) patients clinically diagnosed with acute coronary syndrome (ACS) who were treated with dual-antibody therapy (aspirin 75-100mgqd + tigrilol 90mgBID) for 6-9 months after PCI;<br>3) able and willing to sign informed consent and abide by the research protocol.","Exclusion criteria: 1) patients with high risk of ischemia, such as patients with left main disease implanted with stents, patients with double-vessel disease implanted with stents, and patients with dual-antibody ischemia symptoms (chest tightness, chest pain, etc.) who persist 6-9 months after PCI and whose electrocardiogram indicates new ischemia manifestations;<br>2) patients allergic to aspirin or tigrilol;<br>3) any of the following is true: cardiac shock, chronic congestive heart failure NYHA class III or higher, ultrasonic cardiac graphic left ventricular ejection fraction < 35%, low blood pressure (< 90 MMHG systolic or diastolic blood pressure < 60 MMHG), severe arrhythmia (including height of atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, liver function is (not a heart disease caused the ALT and AST 3 times more than normal ceiling), severe renal insufficiency (eGFR < 30 ml/min), cirrhosis of the liver;<br>4) life expectancy of patients with other serious diseases <1 year;<br>5) patients with mental disorder or alcohol dependence who cannot have good compliance;<br>6) patients using thrombolytic or anticoagulant drugs;<br>7) inability to discontinue non-selective non-steroidal anti-inflammatory drugs (except aspirin) and prostacyclin or other drugs that may affect coagulation function;<br>8) positive pregnancy test results of women of reproductive age during screening;<br>9) women who have the intention to become pregnant or are breast-feeding in the study;<br>10) those who are receiving any experimental drugs or medical devices before screening;<br>11) patients who plan to undergo surgery in the past three months;<br>12) the patient is not willing to participate in this study.",Platelet aggregation rate;Urinary content of 11- dehydrothromboxane B2(11 dh - TXB2);,NULL,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,May 27 2019 12:00AM,NA,Lei Song,NA,NA
ChiCTR1900027678,http://www.chictr.org.cn/showproj.aspx?proj=44407,GC012F injection (BCMA/CD19 CAR-T) in the treatment of recurrent refractory BCMA+ multiple myeloma,BCMA+Multiple Myeloma,single arm:CD19/BCMA CAR-T therapy;,GC012F injection (BCMA/CD19 CAR-T) in the treatment of recurrent refractory BCMA+ multiple myeloma,ChiCTR,2019-11-23,2019-11-24,FALSE,Interventional study,Single arm,0,single arm:12;,The First Affiliated Hospital of Anhui Medical University,China,NA,NULL,2019-11-23,2019-11-24,ChiCTR,25 November 2019,NULL,Ge Jian,NA,"218 Jixi Road, Shushan District Hefei, Anhui, China",gejian52@163.com,+86 0551 62923653,The First Affiliated Hospital of Anhui Medical University,Ge Jian,NA,"218 Jixi Road, Shushan District, Hefei, Anhui, China",gejian52@163.com,+86 0551 62923653,The First Affiliated Hospital of Anhui Medical University,Recruiting,NULL,Gracell Biotechnology Ltd.,18,NA,Both,"Inclusion criteria: The patients must meet the following criteria for inclusion in the study:<br>1) Male or female, over the age of 18<br>2) Patients with refractory/recurrent MM diagnosed as BCMA positive;<br>3) Refractory/recurrent is defined as:<br>a) Multiple myeloma has been adequately treated with at least one regimen containing proteasome inhibitors (PI) and/or immunoregulatory agents (IMiD) (induction therapy with or without hematopoietic stem cell transplantation and maintenance therapy is considered the same regimen. That is: induction chemotherapy, stem cell transplantation and maintenance therapy, if there is no disease progression, then it is considered as a treatment regimen. At least 1 full cycle of treatment per regimen, unless the optimal response is disease progression (PD) or below. Or progression or recurrence during or after the most recent anticancer treatment.<br>b) The definition of disease progression and recurrence refer to the 2017 revision of Chinese guidelines for diagnosis and treatment of multiple myeloma.<br>4)ECOG <= 2;<br>5)Expected survival time >= 3 months;<br>6)The absolute count of neutrophils is more than 0.5 x 10^9/L.<br>7)Platelet count >= 30 x 10^9 / L<br>8)Adequate organ function reserve:<br>a)Glutamate transaminase/glutamate transaminase <= 2.5 x UNL (upper limit of normal value);<br>b)Creatinine clearance (Cockcroft-Gault method) >= 30mL/min;<br>c)Serum total bilirubin <= 1.5 x UNL;<br>d)The subjects were diagnosed with left ventricular ejection fraction (LVEF) >= 50% by transechocardiography and no pericardial effusion or clinically significant ecg abnormalities were observed.<br>e)Indoor natural air environment, the basic oxygen saturation > 92%.<br>9) The venous access needed for collection can be established, and there is no contraindication for white blood cell collection.<br>10) Women of childbearing age who failed a urine pregnancy test during the screening period and before starting the drug and who agreed to use effective contraception at least 100 days after the infusion; Male subjects whose partners are fertile must agree to use effective barrier contraception for at least 100 days after the infusion.<br>11) Sign informed consent.","Exclusion criteria: Any of the following points are used as the exclusion criteria for patients:<br>1)Patients with other invasive malignant tumors (malignant tumors that have received radical treatment, no known active diseases within >= 3 years before enrollment, or non-melanoma skin cancer, in-situ cervical cancer, bladder cancer, breast cancer and other diseases that have been fully treated without any evidence of disease);<br>2)Severe mental disorders;<br>3)Any issues that are not conducive to subjects receiving or tolerating planned treatment or understanding informed consent in the study center, or any condition in which participating in the study is not considered by the investigator to be in the best interest of the subjects (for example, to the detriment of health), or any condition that may prevent, limit or confuse the study protocol assessment;<br>4)Known active central nervous system involvement or multiple myeloma meningeal involvement clinical signs;<br>5)Patients with grade iii-iv heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina or other clinically significant heart disease within 6 months prior to enrollment;<br>6)History or existence of the central nervous system diseases such as epilepsy disease, cerebral ischemia/hemorrhage, dementia, cerebellum, disease, or any kind of autoimmune disease involving CNS;<br>7) Any of the following test results is positive: HIV; HCV. HBV DNA copy number; TPPA.<br>8)There are other serious active viruses, bacteria infections or uncontrolled systemic fungal infection, active autoimmune diseases or autoimmune disease inside 3 years;<br>9)There are other serious active viruses, bacteria infections or uncontrolled systemic fungal infection, active autoimmune diseases or autoimmune disease inside 3 years;<br>10)Once or patients with interstitial lung disease (such as pneumonia, pulmonary fibrosis);<br>11)Due to factors such as physical, family, society, geography to adherence is poor, cannot do research plan and follow-up planners;<br>12)Patients contraindicated with cyclophosphamide or fludarabine chemotherapy;<br>13)Major surgery was performed within 2 weeks before the operation, or surgery was planned during the study period or within 2 weeks after the treatment (except for patients planning local anesthesia surgery);<br>14)Subjects requiring systemic corticosteroid therapy ( >= 5mg/ d prednisone or equivalent dose of other corticosteroids) or other immunosuppressive drugs within 28 days after CART return, except for adverse events during the trial;<br>15 Any other conditions that the researchers considered inappropriate for inclusion.",Grade of Toxicities and Adverse Events;overall response rate;,NULL,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Aug 22 2019 12:00AM,NA,Zhou Tao,NA,NA
ChiCTR1900022351,http://www.chictr.org.cn/showproj.aspx?proj=35137,"A prospective, multi-center, randomized controlled clinical trial for perioperative optimal bridge strategy on antithrombotic therapy of patients with a recently implanted coronary drug-eluting stent undergoing non-cardiac surgery",coronary artery disease,GP IIb/IIIa group:tirofiban;LWMH group:enoxaparin;,"A prospective, multi-center, randomized controlled clinical trial for perioperative optimal bridge strategy on antithrombotic therapy of patients with a recently implanted coronary drug-eluting stent undergoing non-cardiac surgery",ChiCTR,2019-04-07,2019-05-01,FALSE,Interventional study,Parallel,4,GP IIb/IIIa group:800;LWMH group:800;,"Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine",China,NA,NULL,2019-04-07,2019-05-01,ChiCTR,8 April 2019,NULL,Yang Zhenkun,NA,"197 Second Ruijin Road, Huangpu District, Shanghai, China",yangzhenkun2002@hotmail.com,+86 13918878748,"Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine",Yang Zhenkun,NA,"197 Second Ruijin Road, Huangpu District, Shanghai, China",yangzhenkun2002@hotmail.com,+86 13918878748,"Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine",Pending,NULL,"Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine",18,NA,Both,Inclusion criteria: Aged >= 18 year old patients with recently (within previous 6-momth for stable coronary artery disease or within previous 12-month for acute coronary syndromes) drug-eluting stents (DESs) implantation who require dual antiplatelet therapy (DAPT) discontinuation due to undergoing selected middle or high risk of bleeding non-cardiac surgery. <br>All patients gave written informed consent.,"Exclusion criteria: 1. All urgent, and/or low risk of bleeding non-cardiac surgery; <br>2. PCIs history longer than 6 month for stable coronary artery disease or 12 month for acute coronary syndromes ;<br>3. ongoing severe bleeding due to other diseases;<br>4. those with blood Platelet count (PLT) < 60×10^9/L; <br>5. a stroke within the previous 30 days or a history of haemorrhagic stroke;<br>6. intracranial disease or bleeding diathesis; <br>7. contraindicated to use of GPIIb/IIIa receptor blocker or low-molecular-weight heparin;<br>8. during pregnancy and lactation;<br>9. those unwilling or unable to sign the informed consent form.",Blood routine;bleeding and coagulation function;liver function;kidney function;cardiac troponin;urine routine;fecal occult blood test;electrocardiogram;echocardiography;,NULL,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Mar  5 2019 12:00AM,NA,Yang Weiguo,+86 021 54661789,NA
ChiCTR1900025842,http://www.chictr.org.cn/showproj.aspx?proj=43207,"A randomized, double-blind, placebo parallel controlled, multi-center clinical study for Tongxinluo Capsule in the treatment of coronary vulnerable plaque",Acute coronary syndrome,"Esperimental group:Standardized treatment of acute coronary syndrome + Tongxinluo capsule 4 capsules / time, 3 times / day, oral;Control group:Standardized treatment of acute coronary syndrome + Tongxinluo capsule placebo 4 capsules / time, 3 times / day, oral;","A randomized, double-blind, placebo parallel controlled, multi-center clinical study for Tongxinluo Capsule in the treatment of coronary vulnerable plaque",ChiCTR,2019-09-10,2019-09-15,FALSE,Interventional study,Parallel,4,Esperimental group:110;Control group:110;,Qilu Hospital of Shandong University,China,NA,NULL,2019-09-10,2019-09-15,ChiCTR,16 September 2019,NULL,Peili Bu,NA,"107 Wenhua Road West, Lixia District, Jinan, Shandong",bupeili@medmail.com.cn,+86 0531-82169395,Qilu Hospital of Shandong University,Yun Ti,NA,"107 Wenhua Road West, Lixia District, Jinan, Shandong",tiyun0820@163.com,+86 0531-82169395,Qilu Hospital of Shandong University,Recruiting,NULL,"National Key Technologies R&D Program, Modernization of Traditional Chinese Medicine of Ministry of Science and Technogy of the People's Republic of China (Project No. 2017YFC1700500)",18,80,Both,"Inclusion criteria: 1. Male or female patients aged 18-80 years;<br>2. Meet with NSTE-ACS diagnostic criteria;<br>Coronary angiography confirmed the presence of stent-free stenosis, and the defined scope met one of the following criteria:<br>(1) Coronary artery stenosis with diameter less than 70% does not require stent implantation, which could be used as OCT observation target.<br>(2) Coronary artery stenosis with diameter more than 70%, stent implantation and other vessels without interventional treatment, which could be selected as the target of OCT observation.<br>(3) Coronary artery stenosis with diameter more than 70%, stent implantation during operation, and stenosis without interventional treatment in other parts of the same vessel, which is more than 5 mm away from the edge of the stent, could be used as the target of OCT observation.<br>3. The imaging results showed AS lesions in situ (not in stent or CABG).<br>4. The informed consent was signed by the patients themselves or their legal representatives before the study began.","Exclusion criteria: 1. Coronary angiography showed left main artery and/or right coronary artery opening lesions;<br>2. A history of myocardial infarction or stroke within one month.<br>3. Type 1 diabetes; familial hypercholesterolemia; patients requiring warfarin anticoagulation therapy;<br>4. Takayasu arteritis;<br>5. Pregnancy or lactation, or having fertility intention within one year, or failing to take effective contraceptive measures during childbearing age;<br>6. Liver dysfunction (3.0 times higher than the upper limit of normal value) and renal dysfunction (creatinine over 2 mg/dl);<br>7. Severe chronic obstructive pulmonary disease (COPD) or respiratory failure; a history of gastrointestinal, respiratory or other organ bleeding within the last month; severe infections; severe weakness, such as cachexia; malignant tumors; neuropsychiatric disorders;<br>8. Other pathophysiological conditions with a life expectancy of less than 1 year;<br>9. Allergic to the drug ingredients in this study; participating in other clinical studies;<br>10. With other diseases that are not suitable for clinical research.",Thickness of fibrous cap of target vessel plaque;,"To evaluate the incidence of fibrous plaque, calcified plaque, ruptured plaque and thrombus in patients NSTE-ACS treated with Tongxinluo Capsule after 1 year; to analyze the changes of lipid angle and length of plaque.;To evaluate the incidence of one-year composite endpoint events (including all-cause death, sudden cardiac death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for angina pectoris or heart failure, PCI or CABG for ACS) in patients with NSTE-ACS.;Severity of angina pectoris (Canadian Cardiovascular Society angina classification);Seattle Angina Questionnaire(SAQ);Levels of inflammatory factors (IL-1beta, IL-18, TNF-alpha);Clinical mechanism indicators of some research centers: changes of intestinal flora;",NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jul  4 2019 12:00AM,NA,Yanqing Li,NA,NA
ChiCTR1900026494,http://www.chictr.org.cn/showproj.aspx?proj=44030,A randomized controlled tiral for the effect of preoperative Vitamin D supplementation on the incidence of Post Operative Cognitive Dysfunction in old patients after surgery,Postoperative cognitive dysfunction,Experimental group:Vitmin D3;Control group:D-Cal calcium;,A randomized controlled tiral for the effect of preoperative Vitamin D supplementation on the incidence of Post Operative Cognitive Dysfunction in old patients after surgery,ChiCTR,2019-10-12,2019-10-14,FALSE,Interventional study,Parallel,0,Experimental group:60;Control group:60;,"Department of Anesthesiology, Peking University First Hospital",China,NA,NULL,2019-10-12,2019-10-14,ChiCTR,18 November 2019,NULL,Mu Dongliang,NA,"8 Xishiku Street, Xicheng District, Beijing, China",mudongliang@iCloud.com,+86 13810702725,NA,Mu Dongliang,NA,"8 Xishiku Street, Xicheng District, Beijing, China",mudongliang@iCloud.com,+86 13810702725,Peking  University First Hospital,Pending,NULL,National Key R&D Program,65,NA,Both,Inclusion criteria: 1. Patients of elective abdominal surgery in general anesthesia;<br>2. Expected surgery duration more than 2 hours;<br>3. Aged >=65 years;<br>4. vitamin D insufficiency.,"Exclusion criteria: 1. refused to participate;<br>2. vitamin D contraindication patients: hypercholesterolemia, hyperphosphatemia, chronic renal insufficiency (need dialysis patients), vitamin D allergy;<br>3. ASA>=4.",Incidence of cognitive impairment on day 5 after operation;,incidence of emergence delirium and  postoperative delirium within 5 days;postoperative 30-day compliations and mortality;postoperative hospital length of stay;expense during hospital stay;postoperative 30-day mortality;Questionnaire survey on quality of life 3 months after operation;Telephone Interview for Cognitive Status;,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Aug 19 2019 12:00AM,bdyyll@126.com,Ma Li,+86 010-66119025,bdyyll@126.com
NCT03958097,https://clinicaltrials.gov/show/NCT03958097,A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,Combination Product: NK cell and PD-1 antibody,A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer,CT.gov,2019-05-20,2019-05-17,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,20,First Hospital of Jilin University,China,NA,NULL,20/5/2019,"May 17, 2019",NCT039,3 June 2019,19K047-001,;,"Jiuwei Cui, M.D. Ph.D.;jiuwei Cui, M.D. Ph.D",NULL,applexiyu@126.com;applexiyu@126.com,043188783173;043188783173,NA,;,"Jiuwei Cui, M.D. Ph.D.;jiuwei Cui, M.D. Ph.D",NULL,applexiyu@126.com;applexiyu@126.com,043188783173;043188783173,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  (1) Age = 18 years old.<br><br>          -  (2) Locally advanced (IIIB/IIIC phase) or metastatic NSCLC (squamous or non-squamous)<br>             confirmed by histological examination.<br><br>          -  (3) Disease progression occurred after platinum-based chemotherapy in the previous<br>             line, and measurable lesions existed according to RECIST v1.1.<br><br>          -  (4) Patients must be able to provide fresh or archived tumor tissue and pathology<br>             reports. Non-squamous NSCLC must be able to provide a report that is confirmed to be<br>             wild-type EGFR by tissue-based assays.<br><br>          -  (5) ECOG PS = 1.<br><br>          -  (6) The vital organs are fully functional, and the following results are obtained for<br>             each laboratory indicator (accepting the results of the examinations made within = 28<br>             days before randomization):<br><br>               -  Cardiac ultrasound indicates a cardiac ejection fraction = 50%; blood oxygen<br>                  saturation = 90%;<br><br>               -  Absolute neutral cell count (ANC) = 1.5 x 109/L, platelet count = 100 x 109/L,<br>                  hemoglobin = 90g/dL;<br><br>               -  Creatinine (Cr) = 2.5 times normal range;<br><br>               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 times<br>                  normal range, total bilirubin (TBIL) = 1.5 times normal range.<br><br>          -  (7) No contraindications for apheresis and cell separation.<br><br>          -  (8) Male or female with fertility needs to agree to take effective contraceptive<br>             measures during the study period and at least 120 days after the end of medication.<br><br>          -  (9) A written informed consent can be provided and the research requirements are<br>             understood and followed.<br><br>        Exclusion Criteria:<br><br>          -  (1) Previously received immunological checkpoint inhibitors targeting PD-1, PD-L1 or<br>             CTLA-4 and other immunotherapies (including but not limited to interferon or IL-2,<br>             chimeric antigen receptor T Cells, vaccines, etc.).<br><br>          -  (2) NSCLC with EGFR gene mutation or ALK gene translocation.<br><br>          -  (3) The toxicity caused by previous anticancer treatment has not recovered to baseline<br>             level or returned to stability (except for hair loss, rash, pigmentation or specific<br>             laboratory abnormalities).<br><br>          -  (4) A history of severe allergic reactions to other monoclonal antibodies.<br><br>          -  (5) History of interstitial pneumonia, non-infectious pneumonia or uncontrolled<br>             systemic diseases, including diabetes, hypertension, and pulmonary fibrosis.<br><br>          -  (6) Clinically severe pericardial effusion.<br><br>          -  (7) Pleural effusion or ascites that is clinically uncontrolled and requires<br>             thoracentesis or abdominal puncture drainage within 2 weeks prior to randomization.<br><br>          -  (8) Active pia mater disease or unstable brain metastasis.<br><br>          -  (9) Major surgery, open biopsy or severe traumatic injury was performed = 28 days<br>             prior to randomization, or major surgical procedures were expected during the study.<br><br>          -  (10) Other malignant tumors other than NSCLC (except for surgically resected<br>             non-melanoma skin cancer, fully treated cervical carcinoma in situ, cured local<br>             prostate cancer, fully treated low-grade bladder cancer, Curatively treated breast<br>             ductal carcinoma in situ, or a malignant tumor diagnosed 2 years ago, but there is<br>             currently no evidence of disease in the absence of treatment = 2 years prior to<br>             randomization).<br><br>          -  (11) Severe chronic or active infections requiring systemic antibacterial, antifungal<br>             or antiviral treatment, including HIV, HBV, HCV infection.<br><br>          -  (12) Active autoimmune disease or a history of autoimmune disease but may recur.<br><br>          -  (13) Subjects who require systemic treatment with corticosteroids or other<br>             immunosuppressive agents within 14 days prior to randomization.<br><br>          -  (14) Those who have undergone organ transplantation or hematopoietic stem cell<br>             transplantation.<br><br>          -  (15) Any live vaccine against infectious diseases (eg, influenza, chickenpox, etc.)<br>             was used within 28 days prior to randomization.<br><br>          -  (16) Meet any of the following cardiovascular disease criteria:<br><br>               -  Evidence of acute or positive myocardial ischemia<br><br>               -  There are currently symptomatic pulmonary embolisms<br><br>               -  Acute myocardial infarction occurred within =6 months before randomization.<br><br>               -  Has reached the New York Heart Association grading standard (see Appendix 5) 3 or<br>                  4 before randomization = 6 months Grade of heart failure.<br><br>               -  A =2 grade ventricular arrhythmia occurred within =6 months before randomization.<br><br>               -  A cerebrovascular accident (CVA) or transient ischemic attack (TIA) occurred<br>                  within =6 months before randomization.<br><br>          -  (17) Pregnant and lactating women.<br><br>          -  (18) If the patient is unable to follow the study procedures, limitations, and<br>             requirements, the investigator believes that the patient is not allowed to participate<br>             in the study.<br>",NULL,Progression Free Survival(PFS),Overall Response Rate(ORR);Overall Survival(OS);Duration of Response(DoR),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04032171,https://clinicaltrials.gov/show/NCT04032171,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety",Relapsing-remitting Multiple Sclerosis,Drug: Evobrutinib;Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo;Drug: Placebo,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis,CT.gov,2019-07-23,2019-09-10,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,1,"EMD Serono Research & Development Institute, Inc.",United States;Germany;United States,NA,NULL,23/7/2019,"September 10, 2019",NCT040,16 July 2020,2018-004700-19;MS200527_0074,NA,Medical Responsible,NULL,NA,NA,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",NA,Medical Responsible,NULL,NA,NA,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Terminated,"Merck KGaA, Darmstadt, Germany",Please refer to primary and secondary sponsors,18 Years,55 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Participants diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or<br>             secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017<br>             Revised McDonald criteria (Thompson 2018).<br><br>          -  Participants with one or more documented relapses within the 2 years before Screening<br>             with either: a. one relapse which occurred within the last year prior to<br>             randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion<br>             within 6 months prior to randomization.<br><br>          -  Participants have EDSS score of 0 to 5.5 at Baseline. Participants with an EDSS score<br>             <= 2 at screening are only eligible for participation if their disease duration (time<br>             since onset of symptoms) is no more than 10 years.<br><br>          -  Participants are neurologically stable for >= 30 days prior to both screening and<br>             baseline.<br><br>          -  Female participants must be neither pregnant nor breast-feeding and must lack<br>             child-bearing potential, as defined by either: post-menopausal or surgically sterile<br>             or use an effective method of contraception for the duration of the study.<br><br>          -  Participants have given written informed consent prior to any study-related procedure.<br><br>          -  Other protocol defined inclusion criteria could apply<br><br>        Exclusion Criteria:<br><br>          -  Participants diagnosed with Progressive MS, in accordance with the 2017 Revised<br>             McDonald criteria as follows: a). Participants with Primary Progressive MS. b).<br>             Participants with secondary progressive MS without evidence of relapse.<br><br>          -  Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at<br>             screening.<br><br>          -  Immunologic disorder other than MS, or any other condition requiring oral, intravenous<br>             (IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of<br>             well-controlled Type 2 diabetes mellitus or well controlled thyroid disease.<br><br>          -  Other protocol defined exclusion criteria could apply.<br>",NULL,Annualized Relapse Rate (ARR),"Time to First Occurrence of 12-Week Confirmed Expanded Disability Status Scale (EDSS) Progression;Time to First Occurrence of 24-Week Confirmed Expanded Disability Status Scale (EDSS) Progression;Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Physical Function (PF) Short Form Score;Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Fatigue Short Form Score;Total Number of Gadolinium-Enhancing (Gd+) T1 Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans;Total Number of New or Enlarging T2 Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans;Number of Participants with Adverse Events (AEs) and Adverse Events of Special Interest (AESIs);Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings;Absolute Concentrations of Immunoglobulin (Ig) Levels;Change From Baseline in Immunoglobulin (Ig) Levels",NA,EUCTR2018-004700-19-BG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04082325,https://clinicaltrials.gov/show/NCT04082325,"Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-oral-dose Study Investigating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Properties of Lu AF88434 and Open-label Crossover Study to Investigate the Intra-individual Variability, Metabolic Profile, and Effect of Food on Lu AF88434 in Healthy Young Men",Healthy,Drug: Lu AF88434;Drug: Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434);Drug: Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434);Drug: Placebo,Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men,CT.gov,2019-09-05,2019-07-23,FALSE,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 1,66,H. Lundbeck A/S,Netherlands,NA,NULL,5/9/2019,"July 23, 2019",NCT040,2 March 2020,18144A,; ;,Email contact via H. Lundbeck A/S;Email contact via H. Lundbeck A/S;Email contact via H. Lundbeck A/S,NULL,;LundbeckClinicalTrials@Lundbeck.com;LundbeckClinicalTrials@Lundbeck.com,;+45 36301311;+45 36301311,LundbeckClinicalTrials@Lundbeck.com;,; ;,Email contact via H. Lundbeck A/S;Email contact via H. Lundbeck A/S;Email contact via H. Lundbeck A/S,NULL,;LundbeckClinicalTrials@Lundbeck.com;LundbeckClinicalTrials@Lundbeck.com,;+45 36301311;+45 36301311,LundbeckClinicalTrials@Lundbeck.com;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,45 Years,Male,"<br>        Inclusion Criteria:<br><br>        -Healthy young non-smoking men with a body mass index (BMI) =18.5kg/m2 and =30kg/m2 at the<br>        Screening Visit and Baseline Visit.<br><br>        Exclusion Criteria:<br><br>          -  The subject has or has had any clinically significant immunological, cardiovascular,<br>             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological,<br>             haematological, dermatological, venereal, neurological, or psychiatric disease or<br>             other major disorder.<br><br>          -  For Part B: The subject has received radiolabelled material <12 months prior to the<br>             Screening Visit.<br><br>        Other inclusion and exclusion criteria may apply<br>",NULL,"CL/F Lu AF88434;Cumulative recovery of radioactivity in urine, faeces, and total (urine+faeces) (% of administered dose);Total recovery of radioactivity in urine, faeces, and total (urine+faeces) (% of administered dose);AUC(0-inf) Lu AF88434;Cmax Lu AF88434;Number of participants with treatment-emergent adverse events",NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03966170,https://clinicaltrials.gov/show/NCT03966170,Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial,Pre-Term,Drug: Citicoline;Drug: Placebo oral tablet,Citicoline as Neuroprotector in Preterm,CT.gov,2019-05-24,2019-05-01,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,40,Sherief Abd-Elsalam,Egypt,NA,NULL,24/5/2019,"May 1, 2019",NCT039,11 June 2019,Citicoline,; ; ;,"May R Elsheikh, MD;Abeer Salamah, MD;Sherief Abd-Elsalam, ass. prof.;Sherief Abd-Elsalam",NULL,;;sheriefabdelsalam@yahoo.com;,;;00201147773440;,Tanta University - Faculty of Medicine;Kafr-Elsheikh University - Faculty of Medicine;,; ; ;,"May R Elsheikh, MD;Abeer Salamah, MD;Sherief Abd-Elsalam, ass. prof.;Sherief Abd-Elsalam",NULL,;;sheriefabdelsalam@yahoo.com;,;;00201147773440;,Tanta University - Faculty of Medicine;Kafr-Elsheikh University - Faculty of Medicine;,Recruiting,NULL,Please refer to primary and secondary sponsors,N/A,1 Month,All,<br>        Inclusion Criteria:<br><br>          -  Preterm on CPAP or ventilator<br><br>        Exclusion Criteria:<br><br>          -  Multiple congenital anomalies<br>,NULL,Number of children with affection of the brain,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03973177,https://clinicaltrials.gov/show/NCT03973177,"Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain Following Total Knee Arthroplasty: a Pilot Prospective, Randomized, Crossover Trial","Pain, Chronic",Drug: Phenol Injection;Drug: Methylprednisolone Injection,Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain,CT.gov,2019-05-28,2019-05-24,FALSE,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 4,40,Northwestern University,United States,NA,NULL,28/5/2019,"May 24, 2019",NCT039,16 July 2020,STU00209591,; ;,"David Walega, MD;David Walega, MD;David Walega, MD",NULL,;d-walega@northwestern.edu;d-walega@northwestern.edu,;312-695-2500;312-695-2500,Northwestern University;,; ;,"David Walega, MD;David Walega, MD;David Walega, MD",NULL,;d-walega@northwestern.edu;d-walega@northwestern.edu,;312-695-2500;312-695-2500,Northwestern University;,Recruiting,NULL,Please refer to primary and secondary sponsors,40 Years,95 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Ages 40-95 years<br><br>          -  Patients with knee pain, on average > 4 (NRS) persisting more than 6 months after TKA<br><br>          -  Willingness to undergo image guided diagnostic nerve block and the study intervention<br><br>        Exclusion Criteria:<br><br>          -  Pain score (NRS) < 4 at time of study enrollment<br><br>          -  Conditions that preclude the diagnostic block or the study intervention (e.g.,<br>             irreversible coagulopathy or bleeding disorder, allergic reaction/contraindication to<br>             local anesthetic, contrast dye, steroids, and/or phenol, pregnancy, severe or<br>             uncontrolled medical illness).<br><br>          -  Evidence of indolent infection of the knee prosthesis (elevated C-reactive protein<br>             assessed when clinically indicated)<br><br>          -  Inability to write, speak, or read in English<br><br>          -  Pregnancy<br>",NULL,Oxford Knee Score,Hospital Anxiety and Depression Scale;Hospital Anxiety and Depression Scale;Hospital Anxiety and Depression Scale;Oxford Knee Score;Oxford Knee Score;PROMIS Pain Interference Short Form 6b;PROMIS Pain Interference Short Form 6b;PROMIS Pain Interference Short Form 6b;PROMIS Sleep Disturbance Short Form 4a;PROMIS Sleep Disturbance Short Form 4a;PROMIS Sleep Disturbance Short Form 4a;PROMIS Pain Intensity Short Form 3a;PROMIS Pain Intensity Short Form 3a;PROMIS Pain Intensity Short Form 3a;Non-opioid analgesic use at 6 months;Non-opioid analgesic use at 3 months;Opioid analgesic use at 6 months;Opioid analgesic use at 3 months;Patients Global Impression of Change;Patients Global Impression of Change;Numeric Rating Scale Score;Numeric Rating Scale Score,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03803540,https://clinicaltrials.gov/show/NCT03803540,"Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis, a Pilot Study.",Non-Alcoholic Fatty Liver Disease;Non Alcoholic Steatohepatitis,Other: Fecal Microbiota Transplantation,Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis,CT.gov,2019-01-09,2019-05-01,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,15,Puerta de Hierro University Hospital,Spain,NA,NULL,9/1/2019,"May 1, 2019",NCT038,1 April 2019,FMT-NASH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Not yet recruiting,Hospital Universitario Marqués de Valdecilla,Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Body Mass Index > 30 Kg / m^2<br><br>          -  Histological evidence of NASH (by means of hepatic percutaneous biopsy obtained in the<br>             previous six months) defined as at least 1 point in each category of NAFLD Activity<br>             Score with a fibrosis stage between 0 and 3.<br><br>          -  Global NAFLD Activity Score >= 4 points<br><br>          -  For patients with fibrosis stage 0 or 1, NAFLD Activity Score should be >= 5 points<br>             and they should have one of the following comorbidities: Metabolic Syndrome, type 2<br>             diabetes mellitus or Homeostasis Model Assessment - Insulin Resistance (HOMA-IR) > 6.<br><br>        Exclusion Criteria:<br><br>          -  Patients unable or unwilling to give the informed consent<br><br>          -  Patients actively participating in another clinical trial or investigational protocol<br><br>          -  Cirrhosis of the liver: Transient elastography > 20 kilopascal or histological<br>             evidence of it (grade 4 fibrosis)<br><br>          -  Alcoholic consumption greater than 14 g / week in women or 21 g / week in men<br><br>          -  Any significant hepatic comorbidity: chronic active viral hepatitis, cholestatic<br>             disease, hemochromatosis or Wilson disease<br><br>          -  HIV infection<br><br>          -  Liver transplantation<br><br>          -  Hepatocellular carcinoma<br><br>          -  Women during pregnancy or breastfeeding<br><br>          -  Portal thrombosis<br><br>          -  Non-cirrhotic portal hypertension<br><br>          -  Gastroesophageal varices<br><br>          -  Previous gastrointestinal tract major surgery (excluding appendectomy and<br>             cholecystectomy)<br><br>          -  Previous Fecal Microbiota Transplantation<br><br>          -  Chronic significant kidney or heart disease<br><br>          -  Life expectancy lower than two years<br><br>          -  Chronic use of steatogenic drugs<br><br>          -  Chronic use of immunosuppressants<br>",NULL,Efficacy (Histological resolution of NASH defined as ballooning disappearance with or without persistence of minimal lobulillar inflammation and no progression of fibrosis stage),Microbiota composition (Changes in microbiota diversity profile related with Fecal Microbiota Transplantation via 16S rRNA analysis);Safety (Appearance of adverse events related with Fecal Microbiota Transplantation),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04126811,https://clinicaltrials.gov/show/NCT04126811,"Single-center, Open, Non-randomized, Phase II Prospective Study of Apatinib Combined With Chemotherapy in the Treatment of Unresectable Soft Tissue Sarcoma",Soft Tissue Sarcoma,"Drug: Apatinib Mesylate, Pirarubicin, Ifosfamide;Drug: Apatinib Mesylate;Drug: Pirarubicin, Ifosfamide",Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma,CT.gov,2019-09-30,2019-06-01,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,120,Tianjin Medical University Cancer Institute and Hospital,China,NA,NULL,30/9/2019,"June 1, 2019",NCT041,28 October 2019,E2019145,;,"Jilong Yang, M.D., Ph.D;Jilong Yang, M.D., Ph.D.",NULL,yangjilong@tjmuch.com;yangjilong@tjmuch.com,+8618622221626;+8618622221626,NA,;,"Jilong Yang, M.D., Ph.D;Jilong Yang, M.D., Ph.D.",NULL,yangjilong@tjmuch.com;yangjilong@tjmuch.com,+8618622221626;+8618622221626,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,14 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Patients voluntarily join the study, sign informed consent, and have good compliance;<br><br>          2. A distantly metastatic or locally advanced and soft tissue sarcoma subject determined<br>             by the investigator not suitable for surgical treatment (Confirmed by pathology or<br>             cytology, except for gastrointestinal stromal tumors, cartilage-bone tumors,<br>             embryonic/acinar rhabdomyosarcoma, Ewing's sarcoma, and distant metastatic soft tissue<br>             tumors such as dermatofibrosarcoma And inflammatory myofibroblastic sarcoma, clear<br>             cell sarcoma and alveolar soft tissue sarcoma, etc).<br><br>          3. The clinical staging is based on the TNM staging criteria of the American Joint<br>             Committee on Cancer Research (AJCC). At least one double-path measurable lesion<br>             according to CT or MR I;<br><br>          4. Patients who have not previously received chemotherapy for soft-tissue sarcoma; or who<br>             have benefited from chemotherapy and who have relapsed or metastasized more than 6<br>             months after discontinuation of the drug. The accumulated amount of anthracycline used<br>             in the past <450mg/m2.<br><br>          5. 14~75 years old, PS score: 0~1 (Amputation patient can be relaxed to 2 points); the<br>             expected survival time is more than 3 months;<br><br>          6. All acute toxic reactions caused by previous anti-tumor treatment or surgery are<br>             relieved to 0-1 before screening (according to NCI CTCAE version 4.03) or to the level<br>             specified by the enrollment/exclusion criteria (alopecia, etc. Except for toxicity<br>             that does not pose a safety risk to the subject);<br><br>          7. There are sufficient organ and bone marrow functions, defined as follows: Blood<br>             routine (no blood transfusion within 14 days before treatment, no use of G-CSF, no use<br>             of drugs to correct), Neutrophil count (ANC) = 1,500/mm3 (1.5 × 109/L), Platelet count<br>             (PLT) = 100,000/mm3 (100 × 109/L), Hemoglobin (Hb) = 9 g/dL (90 g/L); Blood chemistry,<br>             Serum creatinine (Cr) = 1.5 × upper limit of normal (ULN) or creatinine clearance<br>             (Cockroft-Gault formula) = 60 ml / min, Total bilirubin (TBIL) = 1.5 × ULN; Aspartate<br>             aminotransferase (AST) or alanine aminotransferase (ALT) levels = 2.5 × ULN, liver<br>             metastases should be = 5 × ULN; Coagulation, International normalized ratio (INR) =<br>             1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 ×<br>             ULN; Urine routine, Urine protein <2+; if urine protein = 2+, 24-hour urine protein<br>             quantitation shows that the protein must be = 1g; Thyroid function, Thyroid<br>             stimulating hormone (TSH) = ULN; if abnormalities should be considered T3 and T4<br>             levels, T3 and T4 levels can be selected;<br><br>          8. Female subjects of childbearing age must undergo a serum pregnancy test within 7 days<br>             prior to treatment and the results are negative, and are willing to use a medically<br>             recognized effective contraceptive measure during the study period and within 3 months<br>             after the last administration of the study drug (eg: Intrauterine devices,<br>             contraceptives or condoms; for male subjects whose partners are women of childbearing<br>             age, surgical sterilization is required, or an effective method of contraception is<br>             recommended during the study period and within 3 months after the last study<br>             administration;<br><br>          9. With my consent and signed informed consent, I am willing and able to follow planned<br>             visits, research treatments, laboratory tests and other testing procedures.<br><br>        Exclusion Criteria:<br><br>          1. The following treatments were received within 4 weeks of treatment: Radiotherapy,<br>             surgery, chemotherapy, immunization or molecular targeted therapy for tumors; Other<br>             clinical research drugs; Vaccination live attenuated vaccine;<br><br>          2. Patients with previous chemotherapy failure or who have received anti-angiogenic<br>             targeted drugs within the past 3 months, such as Anlotinib, Pazopanib, Sorafenib,<br>             Sunitinib, Bevacizumab, Imatinib, Crizotinib, Apatinib, Regorafenib and Drugs such as<br>             endostatin;<br><br>          3. Surgery and/or radiation therapy for soft tissue sarcomas is planned during the study<br>             (regardless of <5% of the bone marrow area);<br><br>          4. Imaging diagnosis of central nervous system tumors;<br><br>          5. Immune-suppressing drugs have been used within 14 days prior to initiation of<br>             treatment, excluding nasal and inhaled corticosteroids or physiological doses of<br>             systemic steroid hormones (That is, no more than 10 mg / day of prednisolone or<br>             equivalent physiological dose of other corticosteroids);<br><br>          6. There is any active autoimmune disease or a history of autoimmune disease (Including<br>             but not limited to: Autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,<br>             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism,<br>             hypothyroidism; Subjects with vitiligo or asthma that have been completely relieved in<br>             childhood and currently do not require medical intervention may be included, or a<br>             history of allogeneic organ transplantation or a history of allogeneic hematopoietic<br>             stem cell transplantation);<br><br>          7. Severe infections (such as intravenous infusion of antibiotics, antifungal or<br>             antiviral drugs) within 4 weeks prior to treatment, or unexplained fever >38.5 °C<br>             during screening/first administration;<br><br>          8. High blood pressure, and excellent control without antihypertensive medication<br>             (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg);<br><br>          9. There are significant clinically significant bleeding symptoms or clear bleeding<br>             tendency within 3 months before treatment, such as gastrointestinal bleeding,<br>             hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, vasculitis, etc.<br>             Or venous/venous thrombosis events occurring within 6 months prior to treatment, such<br>             as cerebrovascular accidents (including transient ischemic attacks, cerebral<br>             hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; or<br>             require long-term anticoagulant therapy with warfarin or heparin, or long-term<br>             antiplatelet therapy (aspirin = 300 mg / day or clopidogrel = 75 mg / day);<br><br>         10. There were active heart disease in the 6 months before treatment, including myocardial<br>             infarction, severe/unstable angina. Echocardiography left ventricular ejection<br>             fraction <50%, poorly controlled arrhythmia (including QTcF interval men > 450 ms,<br>             women > 470 ms);<br><br>         11. Any other malignant tumor was diagnosed within 3 years prior to treatment, except for<br>             adequately treated basal cells or squamous cell skin cancer or cervical carcinoma in<br>             situ;<br><br>         12. It is known to be allergic to the study drug or any of its excipients;<br><br>         13. Human immunodeficiency virus (HIV) infection, active hepatitis B (HBV-positive and HBV<br>",NULL,Progression-free survival (PFS),Disease control rate(DCR);Objective tumor response rate(ORR);Overall survival(OS),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04095936,https://clinicaltrials.gov/show/NCT04095936,A Phase 2/3 Study of AMG531 Combined With Ciclosporin A in Patients With Aplastic Anemia Previously Untreated With Immunosuppressive Therapy,Aplastic Anemia,Drug: Romiplostim,Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia,CT.gov,2019-09-18,2019-12-03,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2/Phase 3,24,"Kyowa Kirin Co., Ltd.",Japan,JPRN-JapicCTI-194962,NULL,18/9/2019,"December 3, 2019",NCT040,10 August 2020,531-004,NA,"Kyowa Kirin Co., Ltd.",NULL,clinical.info.jp@kyowakirin.com,+81-3-5205-7200,NA,NA,"Kyowa Kirin Co., Ltd.",NULL,clinical.info.jp@kyowakirin.com,+81-3-5205-7200,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,20 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Voluntary signed informed consent to participate in the study;<br><br>          2. A diagnosis of AA confirmed by blood and bone-marrow examinations, etc.;<br><br>          3. Considered to require new treatment with immunosuppressive therapy provided that NSAA<br>             must be platelet or erythrocyte transfusion-dependent.<br><br>          4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1at<br>             screening;<br><br>        Exclusion Criteria:<br><br>          1. Previously treated with Anti-human thymocyte immunoglobulin (ATG), CsA, or<br>             Alemtuzumab;<br><br>          2. Diagnosed as having congenital AA (Fanconi anemia, congenital dyskeratosis, etc.);<br><br>          3. Diagnosed as having acute myelocytic leukemia (AML) or chronic myelomonocytic<br>             leukemia;<br><br>          4. Concurrent thrombocytopenia of other etiologies (e.g., myelodysplastic syndrome (MDS),<br>             idiopathic thrombocytopenic purpura (ITP), cirrhosis);<br><br>          5. Concurrent active infection not adequately responding to appropriate therapy;<br><br>          6. Concurrent clinically significant illness(es) items which are deemed by the<br>             Investigator to be likely to affect the study conduct and assessments.<br><br>          7. Having active malignancies, or having a history of treatment of malignancies within 5<br>             years prior to informed consent.<br><br>          8. Concurrent paroxysmal nocturnal hemoglobinuria (PNH)<br><br>          9. Having Grade 2 or higher bone marrow reticulin based on Bone Marrow Pathology (2nd<br>             edition) ;<br><br>         10. History of chromosome aberrations discovered in bone marrow cells.<br><br>         11. Having blast cells > 2% in bone marrow;<br><br>         12. Positive for anti-human immunodeficiency virus (HIV) antibody;<br><br>         13. Receiving prophylactic or therapeutic treatment for hepatitis type B<br><br>         14. Having hepatitis C virus (HCV) infection confirmed by HCV-RNA or other tests at<br>             screening.<br><br>         15. Planned hematopoietic stem cell transplantation during the study;<br><br>         16. Systemic treatment with any of the following medication for the treatment of AA within<br>             4 weeks before Day 1:<br><br>               -  Anabolic steroids<br><br>               -  Corticosteroids;<br><br>         17. Pregnant or breastfeeding women, or women willing to become pregnant;<br><br>         18. Other conditions unsuitable for participation in the study in the opinion of the<br>             Investigator.<br>",NULL,Rate of achievement of complete response (CR) or partial response (PR),Rate of achievement of CR or PR;Rate of achievement of CR;The time to CR or PR;Reduction or independence of platelet and/or erythrocyte transfusion;Change from baseline in platelet count (/µL);Change from baseline in hemoglobin (Hb) concentration (g/dL);Change from baseline in neutrophil count (/µL);Change from baseline in reticulocyte count (/µL),child,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03835949,https://clinicaltrials.gov/show/NCT03835949,A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer,Solid Tumor;Metastatic Cancer,Drug: TJ004309;Drug: Atezolizumab,Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer,CT.gov,2019-02-05,2019-07-26,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,36,Tracon Pharmaceuticals Inc.,United States,NA,NULL,5/2/2019,"July 26, 2019",NCT038,24 August 2020,4309ST101,;,"Charles Theuer, MD, PhD;Charles Theuer, MD, PhD",NULL,;clinicaltrials@traconpharma.com,;(858) 251-3490,Medical Monitor;,;,"Charles Theuer, MD, PhD;Charles Theuer, MD, PhD",NULL,;clinicaltrials@traconpharma.com,;(858) 251-3490,Medical Monitor;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Histologically confirmed advanced or metastatic cancer in patients who are refractory<br>             to or intolerant to all available therapy.<br><br>          2. Measurable disease by iRECIST<br><br>          3. Formalin fixed, paraffin-embedded (FFPE) tumor tissue that permits the preparation of<br>             12 unstained slides of tumor sample- Biopsy must be excisional, incisional, or core.<br>             Needle aspiration is insufficient.<br><br>          4. Age = 18 years<br><br>          5. Eastern Cooperative Oncology Group (ECOG) performance status = 1<br><br>          6. Resolution of all acute adverse events resulting from prior cancer therapies to<br>             National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)<br>             Grade = 1 or baseline (except alopecia or neuropathy)<br><br>          7. Adequate organ function<br><br>          8. Willingness and ability to consent for self to participate in study<br><br>          9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory<br>             tests, and other study procedures<br><br>        Exclusion Criteria:<br><br>          1. Autoimmune disease requiring treatment within the past twelve months<br><br>          2. Condition requiring systemic treatment with either corticosteroids or other<br>             immunosuppressive medications within 14 days prior to study treatment<br><br>          3. History of or active interstitial lung disease<br><br>          4. Prior T-cell or NK cell therapy<br><br>          5. Current treatment on another therapeutic clinical trial<br><br>          6. Receipt of systemic anticancer therapy, including investigational agents, within 28<br>             days prior to study treatment<br><br>          7. Major surgical procedure or significant traumatic injury within 4 weeks prior to study<br>             treatment, and must have fully recovered from any such procedure; and no date of<br>             surgery (if applicable) or anticipated need for a major surgical procedure planned<br>             within the next 6 months<br><br>          8. Chest radiotherapy = 28 days, wide field radiotherapy = 28 days (defined as > 50% of<br>             volume of pelvic bones or equivalent), or limited field radiation for palliation = 14<br>             days prior to study treatment - such patients must have recovered adequately from any<br>             side effects of such therapy.<br><br>          9. Hypertension defined as blood pressure (BP) systolic > 150 or diastolic > 90 mm Hg<br><br>         10. Ascites or pericardial effusion that required intervention within 3 months prior to<br>             study treatment.<br><br>         11. Brain involvement with cancer, spinal cord compression, or carcinomatous meningitis,<br>             or new evidence of brain or leptomeningeal disease, unless the lesion(s) have been<br>             radiated or resected, are considered fully treated and inactive, are asymptomatic, and<br>             no steroids have been administered for CNS disease over the 7 days prior to study<br>             treatment<br><br>         12. Angina, myocardial infarction (MI), symptomatic congestive heart failure,<br>             cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary<br>             embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery<br>             bypass grafting (CABG) within 6 months prior to study treatment<br><br>         13. Thrombolytic use (except to maintain IV catheters) within 10 days prior study<br>             treatment<br><br>         14. Known active viral or nonviral hepatitis or cirrhosis, except patients with Hepatitis<br>             C infection and undetectable virus following treatment are eligible.<br><br>         15. Any active infection requiring systemic treatment<br><br>         16. History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months<br>             prior to study treatment<br><br>         17. Known human immunodeficiency virus (HIV) unless CD4+ T cell count > 350 cells/µL with<br>             an undetectable viral load.<br><br>         18. Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., = 6<br>             weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal<br>             ligation) or be postmenopausal for at least one year, or must agree to use effective<br>             contraception during the study and for 5 months following last dose of TJ004309. All<br>             female patients of reproductive potential must have a negative pregnancy test (serum<br>             or urine) within 7 days prior to study treatment. Male patients must be surgically<br>             sterile or must agree to use effective contraception during the study and for 5 months<br>             following last dose of TJ004309.<br><br>         19. Patients with any severe infection within 4 weeks prior to initiation of study<br>             treatment, including, but not limited to, hospitalization for complications of<br>             infections should not be enrolled in the trial. Patients who required IV antibiotics<br>             or were treated with antiviral medications within this 4 week period should be<br>             discussed with the TRACON prior to enrollment.<br><br>         20. Other severe acute or chronic medical or psychiatric condition or laboratory<br>             abnormality that may increase the risk associated with study participation or may<br>             interfere with the interpretation of study results and, in the judgment of the<br>             Investigator, would make the patient inappropriate for this study<br>",NULL,Maximum Tolerate Dose of TJ004309 plus Atezolizumab,Determine Phase 2 dose to TJ004309 as a single agent;Trough TJ004309 concentrations;Trough atezolizumab concentrations;Determine the Rate of TJ004309 Immunogenicity;Determine the Rate of Atezolizumab Immunogenicity;Assessment of antitumor activity,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03868423,https://clinicaltrials.gov/show/NCT03868423,Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes,Advanced Malignant Neoplasm;ALK Fusion Protein Expression;ALK Gene Amplification;ALK Gene Mutation;Locally Advanced Malignant Solid Neoplasm;Metastatic Malignant Neoplasm in the Brain;Metastatic Malignant Neoplasm in the Central Nervous System;Metastatic Malignant Solid Neoplasm;ROS1 Fusion Positive;ROS1 Gene Amplification;ROS1 Gene Mutation,Drug: Brigatinib;Other: Laboratory Biomarker Analysis;Other: Quality-of-Life Assessment;Other: Questionnaire Administration,Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers,CT.gov,2019-02-04,2019-03-20,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,20,Sameek Roychowdhury,United States,NA,NULL,4/2/2019,"March 20, 2019",NCT038,3 February 2020,NCI-2017-01394;P30CA016058;OSU-17060,; ;,"Sameek Roychowdhury, MD;The Ohio State University Comprehensive Cancer Center;Sameek Roychowdhury, MD",NULL,;OSUCCCClinicaltrials@osumc.edu;sameek.roychowdhury@osumc.edu,;800-293-5066;614-685-5841,Ohio State University Comprehensive Cancer Center;,; ;,"Sameek Roychowdhury, MD;The Ohio State University Comprehensive Cancer Center;Sameek Roychowdhury, MD",NULL,;OSUCCCClinicaltrials@osumc.edu;sameek.roychowdhury@osumc.edu,;800-293-5066;614-685-5841,Ohio State University Comprehensive Cancer Center;,Recruiting,National Cancer Institute (NCI),Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Patients with histologically or cytologically confirmed diagnosis of locally advanced<br>             or metastatic solid tumors<br><br>          -  Patients must have activating genomic alterations in ALK or ROS1 (mutations, fusions<br>             or amplifications) by any validated Clinical Laboratory Improvement Act<br>             (CLIA)-certified molecular testing (fluorescence in situ hybridization [FISH],<br>             polymerase chain reaction [PCR] or next-generation sequencing [NGS] data are<br>             acceptable); CLIA validated results from other institutions and commercial diagnostic<br>             labs (e.g. Foundation Medicine) are also acceptable<br><br>          -  Patients with progressive disease on any previous therapy including crizotinib and<br>             other ALK tyrosine kinase inhibitors (TKIs), chemotherapy or immunotherapy<br><br>          -  Patients with locally advanced or metastatic solid tumors who have received no<br>             previous therapy of any kind (i.e. first-line therapy) are eligible<br><br>          -  Patients with brain metastases or metastases elsewhere within the central nervous<br>             system (CNS) are eligible for study; patients must be neurologically stable and<br>             asymptomatic<br><br>          -  Patients with tumor suitable for biopsy (as assessed by trained specialists in<br>             interventional radiology) and medically fit to undergo a biopsy or surgical procedure<br>             will have mandatory pre-treatment tumor biopsy or sampling; however, if patients do<br>             not have a tumor suitable for biopsy but have another tissue (preferably progressive<br>             metastatic site) available for molecular evaluation this will be acceptable<br><br>          -  Patients with solid tumors must have at least 1 measurable lesion per Response<br>             Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1; Note: previously<br>             irradiated lesions may not be used for target lesions; unless there is unambiguous<br>             radiological progression after radiotherapy; brain lesions may not be used as target<br>             lesions if they were: 1) previously treated with whole brain radiation therapy (WBRT)<br>             within 3 months, or 2) previously treated by stereotactic radiosurgery (SRS) or<br>             surgical resection<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2<br><br>          -  Life expectancy of greater than 3 months<br><br>          -  Patients with multiple malignancies remain eligible<br><br>          -  Patients with an inherited cancer syndrome or a medical/family history suggestive of<br>             an inherited cancer syndrome remain eligible<br><br>          -  Women of child-bearing potential and men must agree to use adequate contraception<br>             (hormonal or barrier method of birth control; abstinence) prior to study entry and<br>             through 4 months after the end of treatment; for women of childbearing potential, a<br>             negative pregnancy test must be documented prior to registration<br><br>          -  Absolute neutrophil count >= 1,500/mcL<br><br>          -  Hemoglobin >= 10 g/dL<br><br>          -  Platelet count >= 75,000/mcL<br><br>          -  Total bilirubin =< 1.5 x upper limit of normal (ULN), unless due to Gilbert?s syndrome<br>             (< 5 if metastatic involvement of the liver)<br><br>          -  Serum lipase =< 1.5 x ULN<br><br>          -  Serum amylase =< 1.5 x ULN<br><br>          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/<br>             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x<br>             institutional ULN<br><br>          -  Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi-gated<br>             acquisition (MUGA)<br><br>          -  Normal QT interval on screening electrocardiogram (ECG), defined as QT interval<br>             corrected of =< 450 ms in males or =< 470 ms in females<br><br>          -  Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault<br>             formula) >= 60 mL/min OR 24-hour urine creatinine clearance >= 60 mL/min<br><br>          -  Ability to understand and the willingness to sign a written informed consent document<br><br>        Exclusion Criteria:<br><br>          -  Patients with hematological malignancies<br><br>          -  Patients with ALK positive (+) lung cancer<br><br>          -  Major surgery (e.g. thoracic, abdominal, vascular, neurosurgery) within 30 days prior<br>             to registration on study<br><br>          -  Pregnant women or mothers who are breastfeeding<br><br>          -  Patients who are incarcerated<br><br>          -  Patients who have a history or the presence at baseline of pulmonary interstitial<br>             disease or drug-related pneumonitis, or radiation pneumonitis<br><br>          -  Patients who have a known history of human immunodeficiency virus (HIV); testing not<br>             required in the absence of history<br><br>          -  Patients with history of clinically significant bleeding disorder or history of active<br>             significant gastrointestinal (GI) bleeding within 3 months of first dose of brigatinib<br><br>          -  Patients who have malabsorption syndrome or other GI illness or condition that could<br>             affect oral absorption of the study drug<br><br>          -  History of allergic or suspected hypersensitivity reactions attributed to compounds of<br>             similar chemical or biologic composition to brigatinib<br><br>          -  Patients with history of clinically significant atrial arrhythmias (requiring any<br>             anti-arrhythmic therapy or as determined by the treating physician) or any history of<br>             ventricular arrhythmias<br><br>          -  Patients who have significant, uncontrolled or active cardiovascular disease,<br>             including but not restricted to the following:<br><br>               -  Myocardial infarction (MI) within 6 months prior to first dose of brigatinib<br><br>               -  Unstable angina (UA) within 6 months prior to first use<br><br>               -  Decompensated congestive heart failure within 6 months prior to first dose<br><br>               -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months<br>                  prior to first dose<br><br>          -  Clinically significant, uncontrolled intercurrent illness including, but not limited<br>             to:<br><br>               -  Symptomatic or active infection requiring intravenous (IV) antibiotics<br><br>               -  Psychiatric illness and/or social situations that would limit compliance with<br>                  completion of study requirements<br><br>          -  Patients on medications known to be associated with torsades de pointes<br><br>          -  Patients who have uncontrolled hypertension; patients with hypertension should be<br>             under treatment on study entry to control blood pressure<br><br>          -  Patients who have received cytotoxic chemotherapy, investigational agents, or<br>             radiation within 14 days, except stereotactic radiosurgery (SRS) or stereotactic body<br>             radiosurgery<br><br>          -  Patients who have received monoclonal antibodies or had major surgery within 30 days<br>             of the first dose of brigatinib<br><br>          -  Patients who have not recovered (=< Common Terminology Criteria for Adverse Events<br>             [CTCAE] grade 1) from adverse events (with the exception of alopecia) due to agents<",NULL,Overall response rate assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,Confirmed objective response rate (ORR);Time to response;Duration of response;Time on treatment;Disease control rate;Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;Overall survival;Progression-free survival;Clinical benefit rate;Rate of participation of those screened and identified with the eligible genetic alterations;Rate of enrollment of those screened and identified with the eligible genetic alterations,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04144192,https://clinicaltrials.gov/show/NCT04144192,"Phase 1, Randomized, Comparative Pharmacokinetic Study of Bolus Intravenous Lidocaine 0.7 mg/kg, Lidocaine Patch 1.8%, and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects",Healthy,Drug: Lidocaine patch 1.8%;Drug: Lidocaine 5% patch;Drug: Lidocaine 2% Injectable Solution,Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects,CT.gov,2019-10-28,2014-04-28,FALSE,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).,Phase 1,58,"Scilex Pharmaceuticals, Inc.",NULL,NA,1,28/10/2019,"April 28, 2014",NCT041,4 November 2019,SCI-LIDO-PK-001,NA,"Phillip LaStella, MD",NULL,NA,NA,"TKL Research, Inc.",NA,"Phillip LaStella, MD",NULL,NA,NA,"TKL Research, Inc.",Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Must be healthy based on by medical history, laboratory work, and physical exam<br><br>          -  Be at least 18 years of age<br><br>          -  If childbearing potential, use of acceptable form of birth control<br><br>          -  In the case of females of childbearing potential, have a negative serum pregnancy test<br><br>        Exclusion Criteria:<br><br>          -  Use of a prescription medication within 14 days or over-the-counter products within 7<br>             days prior to administration of study medication<br><br>          -  Known hypersensitivity or allergy to any of the components of the lidocaine topical<br>             system formulation<br><br>          -  Any serious illness in the 4 weeks preceding the beginning of treatment that resulted<br>             in missed work or hospitalization<br>",NULL,Peak plasma concentration (Cmax) of lidocaine;Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time 48 hours;Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time Infinity,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03815929,https://clinicaltrials.gov/show/NCT03815929,Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women After Bilateral Oophorectomy: A Randomized Controlled Trial,Cardiovascular Risk Reduction,Drug: Estradiol 100 Micrograms Patch;Drug: Estradiol Patch,"Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women",CT.gov,2019-01-17,2019-03-15,FALSE,Interventional,Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 2,60,Mayo Clinic,United States,NA,NULL,17/1/2019,"March 15, 2019",NCT038,10 February 2020,18-007999,; ;,"Ekta Kapoor, MBBS;Shawn C Fokken, BS, CCRP;Shawn C Fokken",NULL,;fokken.shawn@mayo.edu;fokken.shawn@mayo.edu,;507-293-2740;507-293-2740,Mayo Clinic;,; ;,"Ekta Kapoor, MBBS;Shawn C Fokken, BS, CCRP;Shawn C Fokken",NULL,;fokken.shawn@mayo.edu;fokken.shawn@mayo.edu,;507-293-2740;507-293-2740,Mayo Clinic;,Recruiting,NULL,Please refer to primary and secondary sponsors,21 Years,45 Years,Female,"<br>        Inclusion Criteria:<br><br>          -  Premenopausal women undergoing (or completion of a) bilateral oophorectomy for<br>             non-malignant diagnoses at Mayo Clinic, Rochester; or premenopausal women not<br>             undergoing the procedure for the timed control group<br><br>          -  Currently between the ages of 21- 45 years<br><br>          -  Able to participate fully in all aspects of the study<br><br>          -  Able to understand and sign the informed consent.<br><br>        Exclusion Criteria:<br><br>          -  History of hepatic, renal, or hematological diseases<br><br>          -  History of venous thromboembolism; peripheral vascular disease; coronary artery<br>             disease; stroke/neurovascular disease<br><br>          -  Chemotherapy or radiation therapy in the preceding 3 months<br><br>          -  Current tobacco use<br><br>          -  Current use of medication that alters autonomic or vascular function (e.g. tricyclic<br>             antidepressants, a-blockers, ß-blockers, etc.) or aromatase inhibitor/tamoxifen<br>             therapy<br><br>          -  Contra-indication to estrogen use<br><br>          -  Current or previous diagnosis of breast and endometrial cancer<br><br>          -  For Timed Controls: Are currently pregnant or lactating, or are of child-bearing<br>             potential or are likely to become pregnant during the study and unwilling to use<br>             contraception; Acceptable forms include:Barrier methods (such as a condom or<br>             diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm), Copper<br>             Intra Uterine Device, Hysterectomy, Tubal ligation, Abstinence (no sex)<br><br>          -  Any condition or factor judged by the investigator to preclude participation in the<br>             study<br>",NULL,Change in Endothelial function;Change in cerebral vascular reactivity,Change in Arterial tonometry;Changes in maximal Voluntary Contraction of the non-dominant arm;Changes to the index of baroreflex sensitivity;Changes in measurements of whole body and regional fat and fat-free mass,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04003688,https://clinicaltrials.gov/show/NCT04003688,Strategy to Calculate Magnesium Sulfate Dose in Obese Patients. A Randomized and Blind Trial.,Magnesium Sulfate;Postoperative Pain;Obesity,Drug: Magnesium sulfate through real weight group;Drug: Placebo group;Drug: Magnesium sulfate through ideal corrected weight group,Magnesium Sulfate Dose in Obese Patients.,CT.gov,2019-06-24,2019-11-01,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",N/A,75,University of Sao Paulo General Hospital,Brazil,NA,NULL,24/6/2019,"November 1, 2019",NCT040,16 November 2020,CAAE 09006119.2.0000.5501,; ; ;,"Joaquim Vieira, Professor;Sebastião Silva Filho, Physician;Joaquim Vieira, Professor;joaquim vieira, MD",NULL,;;joaquimev@usp.br;joaquimve@usp.br,;;11 995038702;55-11-30618716,University of Sao Paulo School of Medicine;University of Sao Paulo School of Medicine;,; ; ;,"Joaquim Vieira, Professor;Sebastião Silva Filho, Physician;Joaquim Vieira, Professor;joaquim vieira, MD",NULL,;;joaquimev@usp.br;joaquimve@usp.br,;;11 995038702;55-11-30618716,University of Sao Paulo School of Medicine;University of Sao Paulo School of Medicine;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,60 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Patients aged 18 to 60 year-old<br><br>          -  body mass index > 30 kg/m²<br><br>          -  American Society of Anesthesiologists score < III.<br><br>        Exclusion Criteria:<br><br>          -  Allergy to any medications of the trial<br><br>          -  refusal to participate or sign the consent form<br><br>          -  any global diagnosed neuromuscular disorder<br><br>          -  cardiac conduction blockade higher than atrioventricular block II<br><br>          -  use of illicit drugs, use of calcium channel blockers<br><br>          -  creatinine > 2 mg/dl.<br>",NULL,Magnesium blood concentration at the preset timepoints.,Opioid consumption;Time to recovery from neuromuscular blockade,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03896685,https://clinicaltrials.gov/show/NCT03896685,Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q),"Tuberculosis, Multidrug-Resistant;Tuberculosis;Pulmonary Tuberculoses;Mycobacterial Infections;Bacterial Infections;Gram-Positive Bacterial Infections","Drug: Bedaquiline 100 MG;Drug: Delamanid 50 MG Oral Tablet;Drug: Clofazimine Pill;Drug: Linezolid Pill;Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines",Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q),CT.gov,2019-03-28,2020-04-06,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,324,"Médecins Sans Frontières, France",India;Kazakhstan;Lesotho;Pakistan;Peru;Vietnam;India;Kazakhstan;Lesotho;Pakistan;Peru;Vietnam;South Africa,CTRI/2020/06/025618,NULL,28/3/2019,"April 6, 2020",NCT038,14 September 2020,MSF ERB-1761,; ;,"Lorenzo Guglielmetti, MD;Carole Mitnick, Sc.D;Melchior Atger",NULL,;;endtb.clinicaltrial@paris.msf.org,;;+33 1 40 21 54 12,"Médecins Sans Frontières, France;Harvard Medical School;",; ;,"Lorenzo Guglielmetti, MD;Carole Mitnick, Sc.D;Melchior Atger",NULL,;;endtb.clinicaltrial@paris.msf.org,;;+33 1 40 21 54 12,"Médecins Sans Frontières, France;Harvard Medical School;",Recruiting,"Partners in Health;Harvard Medical School;Epicentre;Institute of Tropical Medicine, Belgium;Socios En Salud, Peru;Interactive Research and Development",Please refer to primary and secondary sponsors,15 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Has documented pulmonary tuberculosis due to strains of M. tuberculosis resistant to<br>             rifampin (RIF) and not susceptible to fluoroquinolones, according to a validated rapid<br>             molecular test.<br><br>          2. Is =15 years of age;<br><br>          3. Is willing to use effective contraception: pre-menopausal women or women whose last<br>             menstrual period was within the preceding year, who have not been sterilized must<br>             agree to use two methods of contraception (e.g., a hormonal method and a barrier<br>             method) unless their partner has had a vasectomy; men who have not had a vasectomy<br>             must agree to use condoms;<br><br>          4. Provides informed consent for study participation; additionally a legal representative<br>             of patients considered minor per local laws should also provide consent;<br><br>          5. Lives in a dwelling that can be located by study staff and expects to remain in the<br>             area for the duration of the study.<br><br>        Exclusion Criteria:<br><br>        1. Has known allergies or hypersensitivity to any of the investigational drugs; 2. Is known<br>        to be pregnant or is unwilling or unable to stop breastfeeding an infant; 3. Is unable to<br>        comply with treatment or follow-up schedule; 4. Has any condition (social or medical)<br>        which, in the opinion of the site principal investigator, would make study participant<br>        unsafe; 5. a. Has had exposure (intake of the drug for 30 days or more) in the past five<br>        years to bedaquiline, delamanid, linezolid, or clofazimine, or has proven or likely<br>        resistance to bedaquiline, delamanid, linezolid, or clofazimine (e.g., household contact of<br>        a DR-TB index case who died or experienced treatment failure after treatment containing<br>        bedaquiline, delamanid, linezolid, or clofazimine or had resistance to one of the listed<br>        drugs); exposure to other anti-TB drugs is not a reason for exclusion.<br><br>        b. Has received second-line drugs for 15 days or more prior to screening visit date in the<br>        current MDR/RR-TB treatment episode. Exceptions include:<br><br>          1. patients whose treatment has failed according to the WHO definition and who are being<br>             considered for a new treatment regimen;<br><br>          2. patients starting a new treatment regimen after having been lost to follow-up<br>             according to the WHO definition and,<br><br>          3. patients in whom treatment failure is suspected (but not confirmed according to WHO<br>             definition), who are being considered for a new treatment regimen, and for whom the<br>             Clinical Advisory Committee (CAC) consultation establishes eligibility.<br><br>        6. Has one or more of the following:<br><br>          -  Hemoglobin =7.9 g/dL;<br><br>          -  Uncorrectable electrolytes disorders:<br><br>               -  Total Calcium <7.0 mg/dL (1.75 mmol/L);<br><br>               -  Potassium <3.0 mEq/L (3.0 mmol/L) or =6.0 mEq/L (6.0 mmol/L);<br><br>               -  Magnesium <0.9 mEq/L (0.45 mmol/L);<br><br>          -  Serum creatinine >3 x ULN;<br><br>          -  Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) =3 x ULN;<br><br>          -  Total bilirubin =3 x ULN;<br><br>          -  Albumin <2.8 g/dL; Unless otherwise specified, Grade 4 result as defined by the MSF<br>             Severity Scale (Appendix 2) on any of the screening laboratory tests.<br><br>             7. Has cardiac risk factors defined as:<br><br>          -  An arithmetic average of the two ECGs with highest QTcF intervals of greater than or<br>             equal to 450 ms. Retesting to reassess eligibility will be allowed using an<br>             unscheduled visit during the screening phase;<br><br>          -  Evidence of ventricular pre-excitation (e.g., Wolff Parkinson White syndrome);<br><br>          -  Electrocardiographic evidence of either:<br><br>               -  Complete left bundle branch block or right bundle branch block; OR<br><br>               -  Incomplete left bundle branch block or right bundle branch block and QRS complex<br>                  duration >120 msec on at least one ECG;<br><br>          -  Having a pacemaker implant;<br><br>          -  Congestive heart failure;<br><br>          -  Evidence of second or third degree heart block;<br><br>          -  Bradycardia as defined by sinus rate less than 50 bpm;<br><br>          -  Personal or family history of Long QT Syndrome;<br><br>          -  Personal history of arrhythmic cardiac disease, with the exception of sinus<br>             arrhythmia;<br><br>          -  Personal history of syncope (i.e. cardiac syncope not including syncope due to<br>             vasovagal or epileptic causes).<br><br>             8. Is currently taking part in another trial of a medicinal product;<br><br>             9. Is taking any medication that is contraindicated with the medicines in the trial<br>             regimen which cannot be stopped (with or without replacement) or requires a wash-out<br>             period longer than 2 weeks.<br>",NULL,Week 73 Efficacy: Proportion of participants with favorable outcome at Week 73,Week 104 Efficacy: Proportion of participants with favorable outcome at Week 104;Early Treatment Response (culture conversion);Week 39 Efficacy: Proportion of participants with favorable outcome at Week 39;Week 24 Efficacy: Proportion of participants with favorable outcome at Week 24;Week 73 Failure/Relapse;Week 104 Failure/Relapse;Week 73 Survival;Week 104 Survival;Week 73 AEs and SAEs;Week 104 AEs and SAEs;Week 73 AESIs;Week 104 AESIs,parent,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04096911,https://clinicaltrials.gov/show/NCT04096911,"A Single-arm, Single-center, Phase II Clinical Study Evaluating Efficacy of PD-1 Monoclonal Antibody Combined With HPV Vaccine in the Patients With Cervical Cancer(CC)Who Fails in or Can Not Endure the Standard Treatment",Uterine Cervical Neoplasms;Cervical Cancer;Cervical Neoplasms;Cervix Cancer,Drug: Sintilimab;Drug: quadrivalent HPV vaccine,Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer,CT.gov,2019-09-18,2019-07-31,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,20,Buhai Wang,China,NA,NULL,18/9/2019,"July 31, 2019",NCT040,30 September 2019,WBH-7209,; ; ;,"Buhai Wang;Yuechao Wu;Buhai Wang;Buhai Wang, MD/PhD",NULL,;;wbhself@sina.com;wbhself@sina.com,;;18051062288;18051062288,People's hospital of northern jiangsu;People's hospital of northern jiangsu;,; ; ;,"Buhai Wang;Yuechao Wu;Buhai Wang;Buhai Wang, MD/PhD",NULL,;;wbhself@sina.com;wbhself@sina.com,;;18051062288;18051062288,People's hospital of northern jiangsu;People's hospital of northern jiangsu;,Recruiting,Innovent Biologics (Suzhou) Co. Ltd.,Please refer to primary and secondary sponsors,18 Years,N/A,Female,"<br>        Inclusion Criteria:<br><br>          1. Patients must have persistent, recurrent or metastatic squamous cell carcinoma,<br>             adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease<br>             progression (disease not amendable to curative therapy)<br><br>          2. All patents must have measurable disease as defined by RECIST 1.1; measurable disease<br>             is defined as at least one lesion that can be accurately measured in at least one<br>             dimension (longest diameter to be recorded); each lesion must be >= 10 mm when<br>             measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper<br>             measurement by clinical exam;lymph nodes must be >= 15 mm in short axis when measured<br>             by CT or MRI<br><br>          3. Patients must have at least one target lesion to be used to assess response on this<br>             protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be<br>             designated as non-target lesions unless progression is documented or a biopsy is<br>             obtained to confirm persistence at least 90 days following completion of radiation<br>             therapy<br><br>          4. In the state of HPV infection<br><br>          5. Appropriate for study entry based on the following diagnostic workup:<br><br>               -  History/physical examination within 28 days prior to registration<br><br>               -  Imaging of target lesion(s) within 28 days prior to registration<br><br>               -  Further protocol-specific assessments:<br><br>                    -  Recovery from adverse effects of recent surgery, radiotherapy or<br>                       chemotherapy<br><br>                    -  Any other prior therapy directed at the malignant tumor including<br>                       chemotherapy, biologic/targeted agents and immunologic agents must be<br>                       discontinued at least three weeks prior to registration Investigation agents<br>                       must be discontinued for at least 30 days prior to registration<br><br>                    -  Any prior radiation therapy must be completed at least 4 weeks prior to<br>                       registration<br><br>                    -  At least 4 weeks must have elapsed since any major surgery prior to<br>                       registration<br><br>          6. Patients must have had one prior systemic chemotherapeutic regimen for management of<br>             persistent, recurrent or metastatic carcinoma of the cervix (e.g.;<br>             paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered<br>             concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a<br>             systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of<br>             radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as<br>             a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles);<br>             NOTE: patients who have received more than one prior regimen are NOT eligible<br><br>          7. Have a performance status of 0 or 1 on the ECOG Performance Scale<br><br>          8. Absolute neutrophil count (ANC) >= 1,500/ul<br><br>          9. Platelets >= 100,000/ul<br><br>         10. Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance<br>             (CrCl) >= 40 mL/min using Cockcroft-Gault formula<br><br>         11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN<br><br>        Exclusion Criteria:<br><br>          1. Has disease which is amenable to radical treatment with surgery or radiation or a<br>             combination of treatments.<br><br>          2. Is currently participating in or has participated in a study of an investigational<br>             agent or using an investigational device within 4 weeks of the first dose of<br>             treatment.<br><br>          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any<br>             other form of immunosuppressive therapy within 7 days prior to the first dose of trial<br>             treatment.<br><br>          4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy<br>             within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at<br>             baseline) from adverse events due to a previously administered agent.<br><br>          5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy<br>             within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at<br>             baseline) from adverse events due to a previously administered agent.<br><br>               -  Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and<br>                  may qualify for the study.<br><br>               -  Note: If subject received major surgery, they must have recovered adequately from<br>                  the toxicity and/or complications from the intervention prior to starting<br>                  therapy.<br><br>          6. Has a known additional malignancy that is progressing or requires active treatment.<br><br>          7. Has known active central nervous system (CNS) metastases and/or carcinomatous<br>             meningitis. Subjects with previously treated brain metastases may participate provided<br>             they are stable (without evidence of progression by imaging for at least four weeks<br>             prior to the first dose of trial treatment and any neurologic symptoms have returned<br>             to baseline), have no evidence of new or enlarging brain metastases, and are not using<br>             steroids for at least 7 days prior to trial treatment.<br><br>          8. Has an active autoimmune disease requiring systemic treatment within the past 3 months<br>             or a documented history of clinically severe autoimmune disease, or a syndrome that<br>             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or<br>             resolved childhood asthma/atopy would be an exception to this rule. Subjects that<br>             require intermittent use of bronchodilators or local steroid injections would not be<br>             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or<br>             Sjorgen's syndrome will not be excluded from the study.<br><br>          9. Has an active infection requiring systemic therapy.<br><br>         10. Has a history or current evidence of any condition, therapy, or laboratory abnormality<br>             that might confound the results of the trial, interfere with the subject's<br>             participation for the full duration of the trial, or is not in the best interest of<br>             the subject to participate, in the opinion of the treating investigator.<br><br>         11. Has known hypersensitivity to Sintilimab or its formulation<br><br>         12. Has known psychiatric or substance abuse disorders that would interfere with<br>             cooperation with the requirements of the trial.<br><br>         13. Is pregnant or breastfeeding, or expecting to conceive or father children within the<br>             projected duration of the trial, starting with the pre-screening or screening visit<br>             through 120 days after the last dose of trial treatment.<br><br>         14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or<br>             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including<br>             ipilimumab or any other antibod",NULL,Objective Response Rate,Progression-free survival;Overall survival;Duration of Response,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03805568,https://clinicaltrials.gov/show/NCT03805568,The Effect of Dexmedetomidine and Remifentanil on the Postoperative Sore Throat After Thyroidectomy,Post Operative Sore Throat,Drug: dexmedetomidine infusion group;Drug: remifentanil infusion group,A Postoperative Sore Throat After Thyroidectomy,CT.gov,2019-01-07,2017-07-05,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).",N/A,74,Yeungnam University College of Medicine,"Korea, Republic of",NA,1,7/1/2019,"July 5, 2017",NCT038,28 January 2019,YUMC 2017-03-037,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,20 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Patients who scheduled primary thyroidectomy were enrolled and their physical status<br>             was American Society of Anesthesiologists (ASA) class 1 or 2<br><br>        Exclusion Criteria:<br><br>          -  Patients with respiratory tract disease, previous head, and neck surgery, preexisting<br>             steroid or non-steroidal anti-inflammatory drug use, and known or suspected difficult<br>             airway<br>",NULL,incidence of postoperative sore throat at rest;incidence of postoperative sore throat at swallowing;severity of postoperative sore throat at rest;severity of postoperative sore throat at swallowing,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03931135,https://clinicaltrials.gov/show/NCT03931135,Comparison Between Cyclizine and Dexamethasone for Prevention of Nausea and Vomiting After Intrathecal Morphine in Patients Undergoing Cesarean Section,Spinal Anesthetics Causing Adverse Effects in Therapeutic Use,Drug: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section,Cyclizine Vs. Dexamethasone for Nausea and Vomiting Following Intrathecal Morphine in Cases of Cesarean Section,CT.gov,2019-03-26,2019-09-01,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",N/A,160,Assiut University,NULL,NA,NULL,26/3/2019,"September 1, 2019",NCT039,6 May 2019,Cyclizine vs dexa for PONV,NA,"Mina Habib, Principal Investigator",NULL,micheale14@gmail.com,+201092644868,NA,NA,"Mina Habib, Principal Investigator",NULL,micheale14@gmail.com,+201092644868,NA,Not yet recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,45 Years,Female,<br>        Inclusion Criteria:<br><br>          -  Female<br><br>          -  18 to 45 years old<br><br>          -  Parturient<br><br>          -  ASA I-II<br><br>          -  Full Term<br><br>        Exclusion Criteria:<br><br>          -  Women who has obstetric complications.<br><br>          -  Women with evidence of foetal compromise.<br><br>          -  Patients who have gastro-intestinal diseases.<br><br>          -  Administration of anti-emetic drugs within 24 hours before operation.<br><br>          -  Patients who have hyperemesis gravidarium<br>,NULL,Change in Post operative nausea and vomiting after intrathecal morphine by using PONV intensity scale.,Change in postoperative pain (assessed by VAS ).,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03876210,https://clinicaltrials.gov/show/NCT03876210,"A Randomized, Open-label, Single Dose, 2x2 Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination or Loose Combination of PK101 in Healthy Volunteers",Arthritis,"Combination Product: PK101;Drug: PK101-001, PK101-002",Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs,CT.gov,2019-03-13,2019-07-12,FALSE,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,47,"PMG Pharm Co., Ltd","Korea, Republic of",NA,NULL,13/3/2019,"July 12, 2019",NCT038,7 October 2019,PK101_P102,NA,Jang-Hee Hong,NULL,NA,NA,"Clinical Trials Center, Chungnam National University Hospital",NA,Jang-Hee Hong,NULL,NA,NA,"Clinical Trials Center, Chungnam National University Hospital",Completed,NULL,Please refer to primary and secondary sponsors,19 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Healthy adults = 19 years of age (on the day of screening)<br><br>          -  Body weigth =50.0kg, 18.5Kg/(m)^2 = (BMI) =30.0Kg/(m)^2<br><br>          -  No congenital or chronic diseases and no abnormal signs determined by medical<br>             examinations<br><br>          -  Not abnormal or not clinical significant lab values<br><br>          -  Understand the requirements of the study and voluntarily consent to participate in the<br>             study.<br><br>        Exclusion Criteria:<br><br>          -  Clinically significant disease with liver, renal, neurologic, respiratory, digestive,<br>             endocrine, hemato-oncology, urologic, cardiovascular, musculoskeletal, psychiatric<br>             system<br><br>          -  Subjects who have hypersensitivity for investigational products<br><br>          -  AST or ALT > 2*ULN, r-GTP > 1.5*ULN, Blood creatinine > ULN (ULN, Upper Limit of<br>             Normal)<br><br>          -  SBP = 140 mmHg or< 90 mmHg, DBP = 90 mmHg or < 60 mmHg<br><br>          -  Subjects who were administered below medications within 30 days (barbiturates, drugs<br>             of induced or suppressive drug metabolizing enzyme, etc)<br><br>          -  Subjects who previously participated in other clinical trials or bioequivalence Test<br>             within 6 months<br><br>          -  Subjects with whole blood donation within 2 months or component blood donation within<br>             1 month or blood transfusion within 1 month prior to the first dosing.<br>",NULL,AUCt;Cmax,Tmax;AUCinf;t1/2;CL/F;AUCt/AUCinf,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04078386,https://clinicaltrials.gov/show/NCT04078386,"A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome",Primary Sjögren's Syndrome,Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg,A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome,CT.gov,2019-07-18,2019-06-28,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,30,RemeGen,China,NA,NULL,18/7/2019,"June 28, 2019",NCT040,16 September 2019,18C012,; ;,"Xiaofeng Zeng, M.D.;Binghua Xiao;wenxiang wang, M.D.",NULL,;Xiaobing.hua@remegen.cn;wenxiang.wang@remegen.cn,;86-010-58076833;+86-010-58075563,Peking Union Medical College Hospital;,; ;,"Xiaofeng Zeng, M.D.;Binghua Xiao;wenxiang wang, M.D.",NULL,;Xiaobing.hua@remegen.cn;wenxiang.wang@remegen.cn,;86-010-58076833;+86-010-58075563,Peking Union Medical College Hospital;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Voluntarily signed informed consent ;<br><br>          -  Patient with primary Sjögren's syndrome according to the European - American consensus<br>             group criteria.<br><br>          -  Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies<br><br>          -  ESSDAI score = 5.<br><br>        Exclusion Criteria:<br><br>          -  Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic<br>             lupus erythematosus, systemic sclerosis and other autoimmune diseases;<br><br>          -  Abnormal laboratory parameters need to be excluded, including but not limited to:<br><br>          -  Immunosuppressive agents were used within 4 weeks prior to randomization.;<br><br>          -  The use of hydroxychloroquine was allowed during the trial, and the pre-randomized<br>             drug regimen was stable for less than 12 weeks;<br><br>          -  Use of biological agents for targeted therapy in the first 6 months of randomization;<br><br>          -  Treatment of primary Sjogren's syndrome with traditional Chinese medicine and<br>             proprietary Chinese medicine within 4 weeks before randomization;<br><br>          -  The use of saliva-stimulating drugs within 7 days prior to randomization;<br><br>          -  Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of<br>             the randomized pre-medication scheme is less than 4 weeks;<br><br>          -  Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before<br>             randomization;<br><br>          -  Infection with herpes zoster or HIV and hepatitis C virus(HCV) antibody positive;<br><br>          -  Currently suffering from active hepatitis or severe liver lesions and history;<br><br>          -  Malignant tumor patients ;<br><br>          -  Combined with involvement of important organs or neuropathy;<br><br>          -  Have participated in any clinical trial in the first 28 days of the initial screening<br>             or 5 times half-life period of the study compound (taking the time for the shorter).<br><br>          -  Pregnant , lactating women and men or women who have birth plans during the research;<br><br>          -  Investigator considers candidates not appropriating for the study<br>",NULL,The amount of change of European League Against Rheumatism Sjögren's syndrome disease activity(ESSDAI) score compared to the baseline at week 24.,The amount of change of ESSDAI score compared to the baseline at week 12.;The amount of change of European League Against Rheumatism Sjögren'sSyndrome Patient Reported Index(ESSPRI) score compared to the baseline at week 12 and week 24;Doctors assess overall changes in disease activity relative to baseline at week 12 and week 24;Overall patient assessment of disease activity compared to baseline at week 12 and week 24;Changes in short form(SF)-36 relative to baseline at week 12 and week 24;Statistical Analysis of the variation of multidimensional fatigue inventory relative to baseline at week 12 and week 24,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03985995,https://clinicaltrials.gov/show/NCT03985995,"Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults",Pain Sensation;Hyperalgesia;Allodynia,Drug: CBD 800 mg p.o;Drug: Placebo p.o,"Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults",CT.gov,2019-06-11,2019-09-16,FALSE,Interventional,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).",N/A,20,"University Hospital, Basel, Switzerland",Switzerland,NA,NULL,11/6/2019,"September 16, 2019",NCT039,17 February 2020,2019-00839; qu18Ruppen2,NA,"Tobias Schneider, Dr. med",NULL,NA,NA,"Department of Anaesthesiology, University Hospital of Basel",NA,"Tobias Schneider, Dr. med",NULL,NA,NA,"Department of Anaesthesiology, University Hospital of Basel",Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Healthy adults<br><br>          -  BMI between 18.5 until 25 kg/m2<br><br>          -  Able to understand the study and the NRS scale<br><br>          -  Able to give informed consent<br><br>        Exclusion Criteria:<br><br>          -  Regular consumption of cannabinoids or other drugs / substances<br><br>          -  Regular intake of medications potentially interfering with pain sensation (analgesics,<br>             antihistamines, calcium and potassium channel blockers, serotonin / noradrenaline<br>             reuptake inhibitors, corticosteroids)<br><br>          -  Neuropathy<br><br>          -  Chronic pain<br><br>          -  Neuromuscular disease<br><br>          -  Psychiatric disease<br><br>          -  Known or suspected kidney or liver disease<br><br>          -  Pregnancy/ Lactation<br><br>          -  Allergy / hypersensitivity to cannabidiol<br>",NULL,Change in pain (numeric rating scale (NRS): 0 = no pain and 10 = maximum tolerable pain),Change in area of hyperalgesia (cm);Change in area of allodynia (cm),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04063267,https://clinicaltrials.gov/show/NCT04063267,Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder,Cigarette Smoking;Addiction;E Cig Use,Device: E cigarettes;Other: Nicotine Replacement Therapy,Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder,CT.gov,2019-08-19,2020-10-27,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,240,NYU Langone Health,United States,NA,NULL,19/8/2019,"October 27, 2020",NCT040,9 November 2020,18-00840,; ;,"Scott Sherman, MD;Meghan Durr, MPH;Meghan Durr, MPH",NULL,;meghan.durr@nyulangone.org;,;646-501-3571;,NYU Langone Health;,; ;,"Scott Sherman, MD;Meghan Durr, MPH;Meghan Durr, MPH",NULL,;meghan.durr@nyulangone.org;,;646-501-3571;,NYU Langone Health;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>          -  smokes at least 10 cigarettes per day<br><br>          -  meet DSM-V AUD and/or OUD within the past year, interested in reducing CPDs<br><br>          -  able to provide consent<br><br>          -  use a cell phone, are willing/able to receive and respond to daily text messages<br>             regarding their cigarette use and e-cigarette use on their cell phone<br><br>          -  provide one additional contact, and are willing to use an e-cigarette for 3 weeks.<br><br>        Exclusion Criteria:<br><br>          -  pregnant and/or breast feeding (self-reported)<br><br>          -  currently using smoking cessation medications (including other forms of NRT,<br>             buproprion, or varenicline)<br><br>          -  enrolled in a smoking cessation program or another cessation tria<br><br>          -  have used an e-cigarette in the past 14 days<br><br>          -  have used any other tobacco products (pipe, cigar, cigarillos, snuff, chewing tobacco,<br>             rolling tobacco, or hookah/shisha) in the past 30 days<br><br>          -  report having a history of asthma, other airways diseases, or heart disease.<br>",NULL,Proportion of participants who achieve 50% reduction in CPD at 3 weeks.,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03904199,https://clinicaltrials.gov/show/NCT03904199,A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia,Hyperglycemia,Drug: Insulin,Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia,CT.gov,2019-04-03,2019-04-04,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,Phase 4,576,H. Lee Moffitt Cancer Center and Research Institute,United States,NA,NULL,3/4/2019,"April 4, 2019",NCT039,20 July 2020,MCC-19637,;,"Smitha Pabbathi, MD;Cienna Wesley",NULL,;Cienna.Wesley@Moffitt.org,;813-745-3861,Moffitt Cancer Center,;,"Smitha Pabbathi, MD;Cienna Wesley",NULL,;Cienna.Wesley@Moffitt.org,;813-745-3861,Moffitt Cancer Center,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Provision of signed and dated informed consent form<br><br>          -  Stated willingness to comply with all study procedures and availability for the<br>             duration of the study<br><br>          -  Provide race and ethnicity information<br><br>          -  Male or female, aged 18 years or greater<br><br>          -  Diagnosed with cancer<br><br>          -  Hospitalized at MCC in the medical, hematologic, or bone marrow transplant units<br><br>          -  Having in-hospital hyperglycemia with or without a pre-existing diagnosis of DM, with<br>             2 measurements of BG > 180 mg/dL and/or 1 measurement of BG > 350mg/dL within the<br>             first 48 hours of hospitalization, detected by bedside point-of-care testing and/or<br>             basic metabolic panel laboratory data.<br><br>          -  Participants enrolled in other clinical trials are admissible to this trial.<br><br>        Exclusion Criteria:<br><br>          -  An individual who meets any of the following criteria will be excluded from<br>             participation in this study:<br><br>          -  Participants < 18 years of age<br><br>          -  Participants at the end of life and/or with limited life expectancies (< 6 months)<br><br>          -  Participants without cancer diagnoses<br><br>          -  Surgical patients and patients admitted directly to the intensive care unit, other<br>             than those in the Bone Marrow Transplant Unit, who are included<br><br>          -  Participants treated and discharged in outpatient settings (ie, direct referral<br>             center, infusion center, or clinical research unit) or those admitted for observation<br>             only (hospitalized less than 24 hours)<br><br>          -  Participants on total parenteral nutrition<br><br>          -  Participants on insulin pumps<br><br>          -  Participants admitted with diabetic ketoacidosis and hyperglycemic hyperosmolar<br>             syndrome<br><br>          -  Pregnant Participants based on medical history<br><br>          -  Participants being followed by endocrinology for hyperglycemia or hypoglycemia<br>",NULL,Proportion of blood glucose values within normal range,Proportion of high blood glucose levels;Proportion of low blood glucose levels;Duration of normal blood glucose level,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04061590,https://clinicaltrials.gov/show/NCT04061590,A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer,Lung Non-Small Cell Carcinoma;Stage I Lung Cancer AJCC v8;Stage IA1 Lung Cancer AJCC v8;Stage IA2 Lung Cancer AJCC v8;Stage IA3 Lung Cancer AJCC v8;Stage IB Lung Cancer AJCC v8;Stage II Lung Cancer AJCC v8;Stage IIA Lung Cancer AJCC v8;Stage IIB Lung Cancer AJCC v8;Stage IIIA Lung Cancer AJCC v8,Drug: Cisplatin;Biological: Pembrolizumab;Drug: Pemetrexed;Drug: Pemetrexed Disodium;Procedure: Therapeutic Conventional Surgery,Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer,CT.gov,2019-08-16,2019-12-21,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,84,"University of California, San Francisco",United States,NA,NULL,16/8/2019,"December 21, 2019",NCT040,2 September 2019,NCI-2019-04763;19702,;,Matthew A Gubens;Matthew A. Gubens,NULL,;matthew.gubens@ucsf.edu,;415-353-9674,UCSF Medical Center-Mount Zion,;,Matthew A Gubens;Matthew A. Gubens,NULL,;matthew.gubens@ucsf.edu,;415-353-9674,UCSF Medical Center-Mount Zion,Not yet recruiting,Merck Sharp & Dohme Corp.,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Histologically or cytologically confirmed NSCLC, performed on a biopsy that occurred<br>             within the last 60 days<br><br>          -  Computed tomography (CT) within the last 30 days showing radiographic stage I to IIIa<br>             lung cancer (mediastinal staging biopsy is allowed but not required) by the American<br>             Joint Committee on Cancer (AJCC) 8th edition<br><br>          -  Documentation that the patient is a candidate for surgical resection of their lung<br>             cancer by an American Board of Thoracic Surgery-certified surgeon<br><br>          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as<br>             assessed by the investigator<br><br>          -  Adequate tissue specimens for correlative biomarker analysis. The patient should be<br>             willing to provide tissue from a newly obtained core or excisional biopsy of a tumor<br>             lesion. Newly-obtained is defined as a specimen obtained up to 8 weeks (56 days) prior<br>             to initiation of treatment on day 1. Patients for whom newly-obtained samples cannot<br>             be provided (e.g. inaccessible or patient safety concern) may submit an archived<br>             specimen only upon agreement from the principal investigator<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1<br><br>          -  Resolution of all acute toxic effects of prior chemotherapy, radiotherapy or surgical<br>             procedures to NCI CTCAE version (v)5.0 grade 1<br><br>          -  Be willing and able to provide written informed consent for the trial<br><br>          -  Absolute neutrophil count (ANC) >= 1500 cells/ microlitre(uL) (within 10 days prior to<br>             the start of trial treatment)<br><br>          -  Platelets >= 100 000 cells/uL (within 10 days prior to the start of trial treatment)<br><br>          -  Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L (criteria must be met without erythropoietin<br>             dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks)<br>             (within 10 days prior to the start of trial treatment)<br><br>          -  Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine<br>             clearance, glomerular filtration rate (GFR) can also be used in place of creatinine or<br>             creatinine clearance (CrCl) >= 30 mL/min for patients with creatinine levels > 1.5 x<br>             institutional ULN (within 10 days prior to the start of trial treatment)<br><br>          -  Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for patients with total<br>             bilirubin levels > 1.5 x ULN (within 10 days prior to the start of trial treatment)<br><br>          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and<br>             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x<br>             ULN (=< 5 x ULN for patients with liver metastases) (within 10 days prior to the start<br>             of trial treatment)<br><br>          -  International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN unless<br>             patient is receiving anticoagulant therapy as long as PT or partial thromboplastin<br>             time (PTT) is within therapeutic range of intended use of anticoagulants (within 10<br>             days prior to the start of trial treatment)<br><br>          -  Activated partial thromboplastin time (aPTT)/PTT =< 1.5 x ULN unless patient is<br>             receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is<br>             within therapeutic range of intended use of anticoagulants (within 10 days prior to<br>             the start of trial treatment)<br><br>          -  Female patients of childbearing potential must have a negative urine or serum<br>             pregnancy test within 72 hours prior to receiving the first dose of trial medication.<br>             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy<br>             test will be required<br><br>          -  Male and female patients of childbearing potential must be willing to use an adequate<br>             method of contraception as outlined, for the course of the trial through 120 days<br>             after the last dose of trial drug<br><br>               -  Note: Abstinence is acceptable if this is the usual lifestyle and preferred<br>                  contraception for the patient<br><br>          -  Be willing to provide newly obtained tissue (core biopsy of tumor) for PD-L1 biomarker<br>             analysis and, based on the adequacy of the tissue sample quality for assessment of<br>             PD-L1 status, received permission for enrollment from the core laboratory. Repeat<br>             samples may be required if adequate tissue is not provided. Newly obtained biopsy<br>             specimens are preferable to archived samples, and formalin-fixed paraffin-embedded<br>             (FFPE) block specimens are preferred to slides. A post-treatment biopsy after<br>             pembrolizumab treatment is desirable if patient agrees<br><br>               -  Collection of an archived tissue sample will also be requested available) to<br>                  support evaluation of the clinical utility of PD-L1 assessment in newly obtained<br>                  versus (vs.) archived tissue samples; however, a patient will not be precluded<br>                  from participating in the study if an archived tissue sample is not available for<br>                  collection or is otherwise insufficient for analysis<br><br>        Exclusion Criteria:<br><br>          -  Is ineligible for an operation based on medical or oncologic contraindications to<br>             surgery<br><br>          -  Is currently participating in or has participated in a trial of an investigational<br>             agent or has used an investigational device within 4 weeks prior to the first dose of<br>             trial treatment<br><br>               -  Note: Patients who have entered the follow-up phase of an investigational trial<br>                  may participate as long as it has been 4 weeks after the last dose of the<br>                  previous investigational agent<br><br>          -  Has any component of small cell tumor in the specimen, e.g. mixed NSCLC/small cell<br><br>          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with<br>             an agent directed to another stimulatory or co-inhibitory T cell receptor (e.g.,<br>             CTLA-4, OX-40, CD137)<br><br>          -  Has severe hypersensitivity >= grade 3) to pembrolizumab and/or any of its excipients<br><br>          -  Has a history of (non-infectious) pneumonitis / interstitial lung disease that<br>             required treatment with steroids or has current pneumonitis / interstitial lung<br>             disease that requires steroids<br><br>          -  Has a known history of human immunodeficiency virus (HIV) infection<br><br>               -  Note: No HIV testing is required unless mandated by local health authority<br><br>          -  Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]<br>             reactive) or known active hepatitis C virus (HCV) (defined as HCV ribonucleic acid<br>             [RNA] [qualitative] is detected) infection<br><br>               -  Note: No testing for hepatitis B and hepatitis C is required unless mandated by<br>                  local health authority<br><br>          -  Has a known history of active tuberculosis (TB; Mycobacterium tuberculosis)<br><br>          -  Has received prior radiot",NULL,Proportion of patients with a >= 2-fold increase in the number of tumor-infiltrating immune cells (TIICs) in post- versus (vs.) pre-pembrolizumab treatment tumor specimens,Incidence of adverse events (AEs);Disease response;Clinical benefit rate;Pathologic response in resected tumor;Progression-free survival (PFS),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03926377,https://clinicaltrials.gov/show/NCT03926377,Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid,Osteoporosis;Bullous Pemphigoid,Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate,Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid,CT.gov,2019-04-15,2019-04-01,TRUE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 4,50,"Centre Hospitalier Universitaire, Amiens",NULL,NA,NULL,15/4/2019,April 2019,NCT039,6 May 2019,PI2018_843_0040,; ; ;,"Guillaume Chaby, MD;Catherine Lok, Pr;Pascal Joly, Pr;Benjamin Batteux, MD",NULL,;;;batteux.benjamin@chu-amiens.fr,;;;(33)322088370,CHU Amiens;CHU Amiens;CHU Amiens;,; ; ;,"Guillaume Chaby, MD;Catherine Lok, Pr;Pascal Joly, Pr;Benjamin Batteux, MD",NULL,;;;batteux.benjamin@chu-amiens.fr,;;;(33)322088370,CHU Amiens;CHU Amiens;CHU Amiens;,Not yet recruiting,"University Hospital, Rouen",Please refer to primary and secondary sponsors,18 Years,N/A,All,<br>        Inclusion Criteria:<br><br>          -  patients presenting a multi-bullous pemphigoid newly diagnosed or relapsed more than 3<br>             months after stopping corticosteroids and treated according to the national protocol<br>             for diagnosis and care issued by the reference center for autoimmune bullous diseases<br>             of April 2016<br><br>          -  patients having received written and oral information and signed informed consent<br><br>          -  patients covered by national health insurance<br><br>        Exclusion Criteria:<br><br>          -  Patients under tutorship or curatorship or inability to give informed consent<br><br>          -  Patients receiving an anti-osteoporotic treatment<br><br>          -  Patients requiring an anti-osteoporotic baseline treatment (T-score ? -3DS on at least<br>             1 site or FRAX score above the therapeutic intervention threshold)<br><br>          -  Patients with one or more major risk factors for osteoporosis<br><br>          -  Patients who have received topical corticosteroids in less than 3 months<br>,NULL,Variation of the bone mineral density (BMD) expressed in g/cm² at the lumbar spine between baseline and the theorical end of the treatment.,"Variation of the bone mineral density (BMD) expressed in g/cm² at the lumbar spine between baseline and the theorical end of the treatment of attack.;Variation of the bone mineral density (BMD) expressed in g/cm² at the hip between baseline and the theorical end of the treatment of attack.;Variation of the bone mineral density (BMD) expressed in g/cm² at the hip between baseline and the theorical end of the treatment.;Variation in plasma concentrations of corrected calcemia, phosphoremia, 25 OH vitamin D and cortisolemia between Baseline and the theorical end of the treatment of attack.;Variation in plasma concentrations of corrected calcemia, phosphoremia, 25 OH vitamin D and cortisolemia between Baseline and the theorical end of the treatment.;frequency of fractures (axial and , or peripheral)",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04121039,https://clinicaltrials.gov/show/NCT04121039,"A Randomized,Parallel Controlled,Multicentre,Phase II Study of Apatinib Plus POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) Versus POF in Patients With Advanced/Metastatic Bastric Cancer",Gastric Adenocarcinoma;Advanced Cancer,Drug: Apatinib;Drug: POF,Study of the Apatinib Combine With POF Versus POF in Gastric Cancer,CT.gov,2019-10-08,2019-12-01,TRUE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,116,Fujian Cancer Hospital,China,NA,NULL,8/10/2019,December 2019,NCT041,22 October 2019,FNF016,NA,Rongbo Lin,NULL,rongbo_lin@163.com,13705919382,NA,NA,Rongbo Lin,NULL,rongbo_lin@163.com,13705919382,NA,Not yet recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Patients with advanced unresectable, histologically confirmed adenocarcinoma of the<br>             gastric or gastroesophageal junction.<br><br>        No previous treatment with chemotherapy or radiation therapy. Ability to take medications<br>        orally. With measurable lesions. Patients must have a performance status of 0-1 on the<br>        Eastern Cooperative Oncology Group (ECOG) scale.<br><br>        Without serious system dysfunction and could tolerate chemotherapy. With normal marrow,<br>        liver and renal function: a hemoglobin (HGB) of =100g/L (without blood transfusion during<br>        14 days); a leucopenia count of =4.0×109/L; a platelet count of =100×109/L; a total<br>        bilirubin (TBil) of =1.5 upper normal limitation (UNL); a creatinine (Cr) of = 1.5 UNL; a<br>        creatinine clearance rate = 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT)<br>        and aspartate aminotransferase (ASAT) of =2.5 UNL or =5 UNL in case of liver metastasis.<br><br>        Life expectancy =3 months. With normal electrocardiogram results and no history of<br>        congestive heart failure.<br><br>        Without bleeding and thrombosis disease. With normal coagulation function: activated<br>        partial thromboplastin time (APTT), prothrombin time (PT) and INR, each = 1.5 x ULN.<br><br>        Female subjects of child-bearing potential must agree to use contraceptive measures<br>        starting 1 week before the administration of the first dose of apatinib until 8 weeks after<br>        discontinuing study drug. Male subjects must agree to use contraceptive measures during the<br>        study and 8 weeks after last dose of study drug With written informed consent signed<br>        voluntarily by patients themselves or their supervisors witted by doctors.<br><br>        With good compliance and agree to accept follow-up of disease progression and adverse<br>        events.<br><br>        Exclusion Criteria:<br><br>          -  Patients with a history of another neoplastic disease within the past three years,<br>             excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or<br>             nonmetastatic prostate cancer.<br><br>        Patients with brain or central nervous system metastases, including leptomeningeal disease.<br><br>        Pregnant (positive pregnancy test) or breast feeding. Serious, non-healing wound, ulcer, or<br>        bone fracture. Significant cardiac disease as defined as: unstable angina, New York Heart<br>        Association (NYHA) grade II or greater, congestive heart failure, history of myocardial<br>        infarction within 6 months Evidence of bleeding diathesis or coagulopathy.<br><br>        History of a stroke or CVA within 6 months. Clinically significant peripheral vascular<br>        disease. Inability to comply with study and/or follow-up procedures. Patients with any<br>        other medical condition or reason, in that investigator's opinion, makes the patient<br>        unstable to participate in a clinical trial.<br>",NULL,Progression-Free Survival (PFS) Rate at 6-month,Objective Overall Response Rate (ORR);Overall Survival (OS);Progression-Free Survival (PFS),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03915366,https://clinicaltrials.gov/show/NCT03915366,"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial",Pneumonia;HIV/AIDS;Tuberculosis;Cytomegalovirus Infections,Drug: Valganciclovir Oral Solution [Valcyte];Drug: Tuberculostatic Agents,Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia,CT.gov,2019-04-10,2020-01-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2/Phase 3,624,Hospital Universitario 12 de Octubre,Côte D'Ivoire;France;Italy;Malawi;Mozambique;Netherlands;Spain;Uganda;United Kingdom;Zambia;Zimbabwe;Côte D'Ivoire;France;Italy;Malawi;Mozambique;Netherlands;Spain;Uganda;United Kingdom;Zambia;Zimbabwe,NA,NULL,10/4/2019,"January 1, 2020",NCT039,23 April 2019,2019-001749-42;EDCTP RIA2017MC-2013EMPIRICAL;U1111-1231-4736;PACTR201904797961340;19/096,;,"Cinta Moraleda, MD, PhD;Alfredo Tagarro, MD, PhD",NULL,;alfredo.tagarro@salud.madrid.org,;+34917792621,Fundación para la Investigación Biomédica del Hospital 12 de Octubre;,;,"Cinta Moraleda, MD, PhD;Alfredo Tagarro, MD, PhD",NULL,;alfredo.tagarro@salud.madrid.org,;+34917792621,Fundación para la Investigación Biomédica del Hospital 12 de Octubre;,Not yet recruiting,"University Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;PENTA Foundation;Centre Hospitalier Cocody;Malawi-Liverpool-Wellcome Trust Clinical Research Programme;Eduardo Mondlane University;Centro de Investigação em Saúde de Manhiça;Stichting Katholieke Universiteit;Barcelona Institute for Global Health;University of Lincoln;Makerere University;University Teaching Hospital, Lusaka, Zambia;University of Zimbabwe",Please refer to primary and secondary sponsors,N/A,365 Days,All,"<br>        Inclusion Criteria:<br><br>          1. Age 28 days to 365 days of age<br><br>          2. Pneumonia defined as chest indrawing or fast breathing for age, for infants 28 to 60<br>             days of age =60 breaths per minute and for infants 61 to 365 days of age, =50 breaths<br>             per minute.<br><br>          3. Current hospitalization due to pneumonia with criteria for parenteral antibiotics (1<br>             or more criteria)<br><br>               1. Chest indrawing with HIV infection<br><br>               2. No improvement with oral treatment.<br><br>               3. One or more danger signs according to WHO 5,44,45<br><br>                    -  Central cyanosis or saturation of O2 <90%<br><br>                    -  Severe respiratory distress, e.g. grunting or very severe chest indrawing<br><br>                    -  Signs of pneumonia with a general danger sign:<br><br>                    -  Unable to drink or breastfeed<br><br>                    -  Persisting vomiting<br><br>                    -  Convulsions in the last 24 hours<br><br>                    -  Lethargic or unconscious<br><br>                    -  Stridor while calm<br><br>                    -  Severe malnutrition<br><br>          4. HIV-confirmed infection (with at least one molecular method: DNA polymerase chain<br>             reaction (PCR) or RNA PCR/viral load).<br><br>          5. Informed consent obtained<br><br>        Exclusion Criteria:<br><br>          1. Clinical TB (pulmonary or extrapulmonary) diagnosis, defined as the necessity of TB-T<br>             prescribed by a physician, at the moment of randomization<br><br>          2. Known bacteriologically confirmed TB case (at least one biological specimen positive<br>             by culture or Xpert MTB/RIF) at the moment of randomization<br><br>          3. Patient previously treated for TB or currently on treatment for TB<br><br>          4. Documented evidence of close TB exposure (household contact of a patient with<br>             documented TB during the lifetime of the child, or currently receiving TB-T)<br><br>          5. Pure wheezers defined as a clear clinical improvement after a bronchodilator test<br>             (give a challenge of rapid-acting inhaled bronchodilator for up to three times 15-20<br>             minutes apart. Count the breaths and look for chest indrawing again, and then<br>             re-classify)<br><br>          6. Active malignancies<br><br>          7. Systemic immunosuppressive medications. Steroids will be considered to be<br>             immunosuppressing only if >2 mg/kg of prednisone or equivalent during >15 days<br><br>          8. Evidence of condition other than HIV and pneumonia which precludes, to the judgment of<br>             the clinical researcher, enrollment in this trial due to risk for the patient. In case<br>             of doubt, the Trial Management Team will be contacted to assess eligibility<br><br>          9. Less than 2.5 kg of weight<br><br>         10. Hb <6 g/dL in the screening blood test or in a test done in the last 48 hours.<br>             Transfusion is permitted to achieve >6 g/dL if the patient's state allows it. In case<br>             a transfusion is administered, the patient can be enrolled<br><br>         11. Neutropenia <500 /mm3 in the screening blood test or in a test done in the last 48<br>             hours. Repeating the test is allowed to check eligibility<br>",NULL,Mortality,Days with oxygen therapy;Days of hospitalization;Serious Adverse Events;Adverse Reactions;Notable Adverse Events;Immune-reconstitution inflammatory syndrome;Baseline cytomegalovirus prevalence;Baseline tuberculosis prevalence;Tuberculosis incidence;Deaths attributable to tuberculosis;CMV prevalence in died participants;CMV Molecular response to treatment;TB-lipoarabinomannan (LAM) sensitivity and specificity;Quality-adjusted life expectancy;Per-patient cost,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03961334,https://clinicaltrials.gov/show/NCT03961334,"MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial","Stroke, Ischemic",Drug: Dabigatran;Drug: Apixaban;Drug: Edoxaban;Drug: Aspirin;Drug: Clopidogrel,MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention,CT.gov,2019-05-16,2019-12-05,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 3,590,University of Zurich,Germany;Norway;Spain;Switzerland;United Kingdom;Germany;Norway;Spain;Switzerland;United Kingdom;Greece,NA,NULL,16/5/2019,"December 5, 2019",NCT039,28 September 2020,MOSES,;,"Mira Katan, PD Dr. med.;Mira Katan, PD Dr. med.",NULL,;mira.katan@usz.ch,;+41 44 255 47 32,University of Zurich;,;,"Mira Katan, PD Dr. med.;Mira Katan, PD Dr. med.",NULL,;mira.katan@usz.ch,;+41 44 255 47 32,University of Zurich;,Recruiting,Swiss National Science Foundation,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Clinical diagnosis of ischemic stroke<br><br>          -  elevated MRproANP level within 24 hours from symptom onset<br><br>          -  Age = 18 years<br><br>          -  Signed informed consent<br><br>        Exclusion Criteria:<br><br>          -  History of AF, AF on 12-lead ECG on admission or any AF =30 seconds during<br>             heart-rhythm monitoring prior to randomization<br><br>          -  Other condition that require anticoagulant therapy (e.g., venous thromboembolism) as<br>             per Investigator's judgment including therapeutical dose of low-molecular-weight<br>             heparin or heparin<br><br>          -  Strong likelihood to be treated with prolonged (i.e. more than 30 days) dual<br>             antiplatelet therapy during the course of the trial (such as coronary stenting, etc.)<br><br>          -  Patients undergoing planned procedures where therapy with a DOAC is a contraindication<br>             (e.g. surgery)<br><br>          -  Previous intracranial hemorrhage in the last year<br><br>          -  Evidence of severe cerebral amyloid angiopathy if MRI scan performed<br><br>          -  Chronic kidney disease with creatinin clearance <30ml/min and or subject who requires<br>             haemodialysis or peritoneal dialysis<br><br>          -  Known bleeding diathesis (e.g. active peptic ulcer disease , platelet count <<br>             100'000/mm3 or haemoglobin < 9 g/dl or INR = 1.7, documented haemorrhagic tendencies<br>             or blood dyscrasias)<br><br>          -  Active infective endocarditis<br><br>          -  CT or MRI evidence of cerebral vasculitis<br><br>          -  Known allergy or intolerance to antiplatelets or DOACs<br><br>          -  Female who is pregnant or lactating or has a positive pregnancy test at time of<br>             admission<br><br>          -  Current participation in another drug trial<br>",NULL,Recurrent stroke of any type,"Composite of major bleeding, recurrent stroke and/or vascular death;Major bleeding, recurrent stroke and/or vascular death as single components",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04097080,https://clinicaltrials.gov/show/NCT04097080,"Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease",Parkinson Disease,Drug: NBTX-001;Drug: Standard of Care,"Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease",CT.gov,2019-09-18,2019-12-15,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,60,Nobilis Therapeutics Inc.,Russian Federation,NA,NULL,18/9/2019,"December 15, 2019",NCT040,16 March 2020,NBTX-009,NA,"Vlad Bogin, MD, FACP",NULL,vlad.bogin@nobilistx.com,971-229-1679,NA,NA,"Vlad Bogin, MD, FACP",NULL,vlad.bogin@nobilistx.com,971-229-1679,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  The patient must be male or female over the age of 18.<br><br>          -  The subject must have idiopathic Parkinson's disease.<br><br>          -  The subject has Stage III by Hoehn and Yahr in the on state on a screening visit<br><br>          -  Subjects suffering from anxiety, depression, cognitive dysfunction<br><br>          -  Dopaminergic drugs should be taken in a stable dosage for 28 days prior to<br>             registration, and throughout the study<br><br>          -  Patients who have signed an approved consent form and are consistent with both the<br>             clinical trial plan and follow-up.<br><br>        Exclusion Criteria:<br><br>          -  Patients have atypical parkinsonism (eg, neuroleptics, metoclopramide, flunarizin),<br>             metabolic neurodegenerative disorders (eg, Wilson's disease), encephalitis,<br>             cerebrovascular disease or degenerative disease (e.g. progressive supranuclear palsy)<br><br>          -  Patients who received deep brain stimulation<br><br>          -  Patients with cancer, HIV, kidney or liver disease.<br><br>          -  Patients taking new antipsychotic, antidepressant, anxiolytic or narcotic drugs for<br>             less than 3 months<br>",NULL,Unified Parkinson Disease Rating Scale (UPDRS),NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04019704,https://clinicaltrials.gov/show/NCT04019704,"AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder",Depression;Major Depressive Disorder,Drug: AXS-05;Drug: Placebo,A Trial of AXS-05 in Patients With Major Depressive Disorder,CT.gov,2019-07-11,2019-06-20,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,327,"Axsome Therapeutics, Inc.",United States,NA,NULL,11/7/2019,"June 20, 2019",NCT040,3 February 2020,AXS-05-MDD-301,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,65 Years,All,"<br>        Key Inclusion Criteria:<br><br>          -  Age 18 - 65<br><br>          -  Currently meets DSM-5 criteria for MDD<br><br>          -  Body Mass Index between 18 and 40 kg/m^2, inclusive<br><br>        Key Exclusion Criteria:<br><br>          -  Suicide risk<br><br>          -  History of treatment resistance in current depressive episode<br><br>          -  History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic<br>             stimulation or any experimental central nervous system treatment during the current<br>             episode or in the past 6 months<br><br>          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study<br>",NULL,Types and rates of adverse events;Montgomery-Åsberg Depression Rating Scale (MADRS),NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04049669,https://clinicaltrials.gov/show/NCT04049669,Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG,Glioblastoma;Medulloblastoma;Ependymoma;Diffuse Intrinsic Pontine Glioma,Drug: Indoximod;Radiation: Partial Radiation;Radiation: Full-dose Radiation;Drug: Indoximod;Drug: Temozolomide;Drug: Cyclophosphamide;Drug: Etoposide;Drug: Lomustine,Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG,CT.gov,2019-08-02,2019-10-02,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,140,Theodore S. Johnson,United States,NA,NULL,2/8/2019,"October 2, 2019",NCT040,3 August 2020,R01CA229646;GCC1949,;,"Theodore S Johnson, MD, PhD;Theodore S Johnson, MD, PhD",NULL,;thjohnson@augusta.edu,;706-721-4962,Augusta University;,;,"Theodore S Johnson, MD, PhD;Theodore S Johnson, MD, PhD",NULL,;thjohnson@augusta.edu,;706-721-4962,Augusta University;,Recruiting,National Cancer Institute (NCI);Augusta University;Emory University,Please refer to primary and secondary sponsors,3 Years,21 Years,All,"<br>        Inclusion Criteria:<br><br>        Diagnosis:<br><br>          -  Progressive disease with histologically proven initial diagnosis of glioblastoma,<br>             medulloblastoma, or ependymoma; With confirmation of progression by either MRI or CSF<br>             analysis; Measureable disease is not required for study entry; Patients with<br>             progressive disease must have been previously treated with therapeutic radiation as<br>             part of treatment for the initial brain cancer diagnosis or for a prior relapse.<br><br>          -  Newly diagnosed DIPG (diffuse intrinsic pontine glioma) with no prior therapy<br>             (including no prior radiation); Biopsy is not required for DIPG.<br><br>          -  Central review of tissue diagnosis is required, except non-biopsied DIPG; Archival<br>             tumor tissue must be located and available prior to study entry.<br><br>          -  Patients with metastatic disease are eligible.<br><br>        Lansky or Karnofsky performance status score must be = 50%.<br><br>        Adequate renal function: creatinine = 1.5-times upper limit of age-adjusted normal.<br><br>        Adequate liver function:<br><br>          -  ALT = 5-times upper limit of normal.<br><br>          -  Total bilirubin = 1.5-times upper limit of normal.<br><br>        Adequate Bone marrow function:<br><br>          -  Absolute neutrophil count (ANC) = 750/mcL.<br><br>          -  Platelets = 75,000/mcL (transfusion independent).<br><br>          -  Hemoglobin = 8 g/dL (transfusion independent).<br><br>        Central nervous system: seizure disorders must be well controlled on antiepileptic<br>        medication.<br><br>        Prior therapy<br><br>          -  DIPG patients must not have been treated with any prior radiation or medical therapy.<br><br>          -  Patients previously treated with indoximod are excluded.<br><br>          -  Patients previously treated with any other immunotherapy agent, including other<br>             IDO-targeted drugs, are eligible for enrollment.<br><br>          -  Patients previously treated with chemotherapy drugs included in this protocol are<br>             eligible for enrollment.<br><br>        Patients must be 14 days from the administration of any investigational agent or prior<br>        cytotoxic therapy with the following exceptions:<br><br>          -  Temozolomide dosed at or above 150 mg/m2 (allowed, but must be at least 21 days from<br>             the last dose of temozolomide).<br><br>          -  Must be 28 days from administration of antibody-based therapies (e.g., bevacizumab),<br>             tumor-directed vaccines, or cellular immune therapies (e.g., T cells, NK cells, etc).<br><br>          -  Must be 56 days from administration of tumor-directed therapies using infectious<br>             agents (e.g., viruses, bacteria, etc).<br><br>        Pregnant women are excluded from this study, where pregnancy is confirmed by a positive<br>        urine or serum hCG laboratory test.<br><br>        Patients must be able to swallow pills.<br><br>        .<br><br>        Exclusion Criteria:<br><br>        Patients who cannot swallow indoximod pills are excluded.<br><br>        Patients previously treated with indoximod are excluded.<br><br>        Patients with DIPG who have been treated with any prior radiation or medical therapy are<br>        excluded.<br><br>        Midline glioma that does not include significant brain stem involvement is not considered<br>        DIPG for enrollment purposes, and is excluded.<br><br>        Patients with active systemic infection requiring treatment, including any HIV infection or<br>        toxoplasmosis, are excluded.<br><br>        Patients with active autoimmune disease that requires systemic therapy are excluded.<br><br>        Pregnant women are excluded<br>",NULL,"8-month iRANO-PFS (Progression-Free Survival, defined by immune-adapted iRANO criteria);12-month Overall Survival (OS)","Overall Survival (OS);iRANO-PFS (Progression-Free Survival, defined by immune-adapted iRANO criteria);Time to Regimen Failure (TTRF)",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03813121,https://clinicaltrials.gov/show/NCT03813121,The Effects of Sedatives on Tobacco Use Disorder,Tobacco Use Disorder,Drug: midazolam intravenous infusion;Drug: placebo intravenous infusion;Drug: ketamine intravenous infusion,The Effects of Sedatives on Tobacco Use Disorder,CT.gov,2019-01-18,2019-06-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Single (Participant).,Phase 1/Phase 2,20,University of Arkansas,United States,NA,NULL,18/1/2019,"June 1, 2019",NCT038,3 August 2020,229077,; ;,"Merideth Addicott, PhD;Merideth Addicott, PhD;Merideth Addicott, PhD",NULL,;MAddicott@uams.edu;maddicott@uams.edu,;5015268436;501-526-8436,University of Arkansas;,; ;,"Merideth Addicott, PhD;Merideth Addicott, PhD;Merideth Addicott, PhD",NULL,;MAddicott@uams.edu;maddicott@uams.edu,;5015268436;501-526-8436,University of Arkansas;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,55 Years,All,"<br>        Inclusion Criteria:<br><br>          -  smoke at least 15 cigarettes per day<br><br>          -  smoked at least 2 years<br><br>          -  negative urine drug screen for psychoactive drugs and negative breath alcohol<br>             concentration<br><br>          -  live in Little Rock AR or surrounding area<br><br>        Exclusion Criteria:<br><br>          -  unstable or stable medical condition that would interact with study medication or<br>             participation<br><br>          -  serious head trauma or neurological disorder<br><br>          -  hypertension, abnormal ECG or metabolic blood results<br><br>          -  meet criteria for psychosis, schizophrenia, major depressive disorder, or bipolar<br>             disorder<br><br>          -  use of psychoactive drugs or medications<br><br>          -  BMI > 40<br><br>          -  among women, pregnancy or breastfeeding<br>",NULL,side effects,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04170023,https://clinicaltrials.gov/show/NCT04170023,"A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy and With an Approved C5 Inhibitor as Background Therapy",Paroxysmal Nocturnal Hemoglobinuria (PNH),Drug: ALXN2050;Drug: C5 inhibitor background therapy,Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH),CT.gov,2019-11-06,2019-12-16,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,26,Alexion Pharmaceuticals,"United States;Italy;Korea, Republic of;New Zealand;United Kingdom;Italy;Korea, Republic of;New Zealand;United Kingdom;United States",NA,NULL,6/11/2019,"December 16, 2019",NCT041,9 July 2020,ACH228-110,NA,Alexion Pharmaceuticals Inc.,NULL,clinicaltrials@alexion.com,855-752-2356,NA,NA,Alexion Pharmaceuticals Inc.,NULL,clinicaltrials@alexion.com,855-752-2356,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Key Inclusion Criteria:<br><br>        Documentation of vaccination for N. meningitidis: all participants must be vaccinated<br>        against meningococcal infections within 3 years prior to, or at the time of, initiating<br>        study drug.<br><br>        Participants currently receiving danicopan in Study ACH471-101 or Study ACH471-103 will<br>        have abbreviated eligibility criteria including:<br><br>          -  Female participants of childbearing potential must agree to use an acceptable method<br>             of contraception from the date of signing the informed consent to the first day of<br>             dosing (baseline) and must agree to use a highly effective method of contraception<br>             from the first day of dosing to 30 days after their last dose of study drug. Female<br>             participants of childbearing potential must also have a negative urine pregnancy test<br>             at the Baseline visit prior to administration of the first dose.<br><br>          -  Non-sterile male participants must agree to use a highly effective method of<br>             contraception with their partner(s) of childbearing potential from the first day of<br>             dosing to 90 days after their last dose of study medication.<br><br>          -  Males must agree not to donate sperm while enrolled in this study and for 90 days<br>             after their last dose of study medication.<br><br>        Participants not currently receiving danicopan must meet the following criteria:<br><br>          -  Newly-identified participants with PNH must meet one of the following conditions:<br><br>               -  PNH Type III erythrocyte and/or granulocyte clone size =10% with adequate<br>                  reticulocytosis (absolute reticulocyte count =100×10^9/liter [L]).<br><br>               -  Anemia (Hgb <10.5 grams/deciliter [g/dL]).<br><br>               -  LDH =1.5× upper limit of normal.<br><br>               -  Platelet count =30,000/microliter (µL) without the need for platelet<br>                  transfusions.<br><br>               -  Absolute neutrophil count (ANC) =750/ µL.<br><br>          -  Newly-identified participants with PNH on a background therapy with an approved C5<br>             inhibitor must have:<br><br>               -  Stable background regimen of an approved C5 inhibitor (at least 24 weeks for<br>                  eculizumab, or at least 2 doses for ravulizumab), without change in dose or<br>                  interval for at least the past 8 weeks.<br><br>               -  Anemia (Hgb <10 g/dL).<br><br>               -  Adequate reticulocytosis (absolute reticulocyte count =100×10^9/L).<br><br>               -  Platelet count =30,000/µL without the need for platelet transfusions.<br><br>               -  ANC =750/ µL.<br><br>        Key Exclusion Criteria:<br><br>          -  Estimated glomerular filtration rate <30 milliliters/minute/1.73 meters squared and/or<br>             are on dialysis.<br><br>          -  History of a major organ transplant (for example, heart, lung, kidney, liver) or<br>             hematopoietic stem cell/marrow transplant ([HSCT] unless HSCT engraftment has failed).<br><br>          -  History of dosing with an investigational agent other than danicopan within 30 days or<br>             5 half-lives of the investigational agent prior to ALXN2050 administration, whichever<br>             is greater.<br><br>          -  New participants in the monotherapy group with a history of dosing with eculizumab at<br>             any dose or interval within the past 75 days before study medication administration or<br>             300 days for ravulizumab.<br><br>          -  Known or suspected complement deficiency.<br><br>          -  Contraindication to one or more of the vaccinations that may be used in the study.<br><br>          -  History of seizure disorder unless seizure free without the use of antiepileptic<br>             medications for the past 5 years prior to screening.<br><br>          -  Evidence of human immunodeficiency virus (HIV), hepatitis B infection, or active<br>             hepatitis C infection at screening.<br>",NULL,Change From Baseline In Hemoglobin At Week 12,Change From Baseline In C3 Complement Protein Fragment Deposition On PNH RBCs At Week 12;Change From Baseline In PNH RBC Clone Size At Week 12;Change From Baseline In Total Bilirubin At Week 12;Change From Baseline In Direct Bilirubin At Week 12;Change From Baseline In Absolute Reticulocyte Count At Week 12;Change From Baseline In LDH At Week 12;Change In Transfusion Requirements;Number Of Participants Who Are Red Blood Cell (RBC) Transfusion-independent During 12 Weeks of Treatment,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03904836,https://clinicaltrials.gov/show/NCT03904836,Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session,"Renal Dialysis;Renal Failure, Chronic",Drug: Tobramycin,Tobramycin Administered at the Beginning of Dialysis,CT.gov,2019-02-08,2019-01-31,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 1,12,Maisonneuve-Rosemont Hospital,Canada,NA,NULL,8/2/2019,"January 31, 2019",NCT039,15 April 2019,2019-1619,; ;,"Jean-Philippe Lafrance, MD;Laurence Lepage, M.Sc.;Laurence Lepage",NULL,;llepage.hmr@ssss.gouv.qc.ca;llepage.hmr@ssss.gouv.qc.ca,;514-252-3400;514-252-3400,Maisonneuve-Rosemont Hospital;,; ;,"Jean-Philippe Lafrance, MD;Laurence Lepage, M.Sc.;Laurence Lepage",NULL,;llepage.hmr@ssss.gouv.qc.ca;llepage.hmr@ssss.gouv.qc.ca,;514-252-3400;514-252-3400,Maisonneuve-Rosemont Hospital;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Subjects aged 18 and over;<br><br>          -  Subjects with end-stage renal disease who are on an intermittent hemodialysis program<br>             (three times a week, 3-4 hours) at the Hôpital Maisonneuve-Rosemont hemodialysis unit<br>             for at least one month;<br><br>          -  Subjects with suspicion or diagnosis of Gram-negative rod-type bacteria infection for<br>             which an antibiotic is prescribed;<br><br>          -  Subjects able to consent to the study (consent form read and signed by the subject).<br><br>        Exclusion Criteria:<br><br>          -  Contraindication or possible medical hazard related to the administration of<br>             tobramycin or to any ingredient in the formulation (e.g. sulphites), such as severe<br>             allergies or aminoglycoside-reported previous intolerances;<br><br>          -  Variable residual renal function (e.g. acute or transient renal failure requiring<br>             occasional hemodialysis sessions, post-renal transplantation);<br><br>          -  Conditions sensitive to the side effects of tobramycin (e.g. history of myasthenia<br>             gravis, Parkinson's disease, vestibular or auditory disorder);<br><br>          -  Subjects with impaired volume of distribution (ie, severe burns [> 20%], significant<br>             ascites, decompensation for acute heart failure requiring hospitalization, admission<br>             to the critical care unit, cystic fibrosis, morbid obesity [dry weight greater than<br>             50% of ideal weight]);<br><br>          -  Pregnant or breastfeeding women;<br><br>          -  Unstable hemodynamic status (risk of not tolerating / completing a 3-4 hour dialysis<br>             session);<br><br>          -  Recent treatment with an aminoglycoside (<1 month);<br><br>          -  Participation in another research protocol;<br><br>          -  Inability to give free and informed consent.<br>",NULL,Ratio of maximum tobramycin concentration to minimal inhibitory concentration,Tobramycin concentration;Area under the curve between 0 to 24h after administration;Total area under the curve;Volume of distribution;Clearance associated with hemodialysis;Residual clearance;Tobramycin trough level,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03913130,https://clinicaltrials.gov/show/NCT03913130,"An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene","Leber Congenital Amaurosis 10;Blindness;Leber Congenital Amaurosis;Vision Disorders;Sensation Disorders;Neurologic Manifestations;Eye Diseases;Eye Diseases, Hereditary;Eye Disorders Congenital;Retinal Disease",Drug: QR-110,Extension Study to Study PQ-110-001 (NCT03140969),CT.gov,2019-02-21,2019-05-13,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1/Phase 2,11,ProQR Therapeutics,United States;Belgium;United States,NA,NULL,21/2/2019,"May 13, 2019",NCT039,3 February 2020,PQ-110-002,NA,ProQR Medical Monitor,NULL,NA,NA,ProQR Therapeutics,NA,ProQR Medical Monitor,NULL,NA,NA,ProQR Therapeutics,"Active, not recruiting",NULL,Please refer to primary and secondary sponsors,6 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Subjects who completed participation in the study PQ-110-001 and who may derive<br>             benefit from continued treatment with QR 110, as assessed by the Investigator, in<br>             consultation with the Medical Monitor<br><br>          -  Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the<br>             opinion of the Investigator, as determined by OCT.<br><br>          -  Clear ocular media and adequate pupillary dilation to permit good quality retinal<br>             imaging, as assessed by the Investigator.<br><br>          -  An adult (= 18 years) willing and able to provide informed consent for participation<br>             OR a minor (6 to < 18 years) with a parent or legal guardian willing and able to<br>             provide written permission for the subject's participation prior to performing any<br>             study related procedures, and pediatric subjects able to provide age-appropriate<br>             assent for study participation.<br><br>          -  Female subjects who have reached menarche and male subjects must either practice true<br>             abstinence in accordance with their preferred and usual lifestyle, or agree to use<br>             acceptable, highly effective methods of contraception for up to 3 months following<br>             their last dose QR-110. Acceptable methods of contraception are defined in the<br>             protocol. Women of non-childbearing potential may be included without the use of<br>             adequate birth control, provided they meet the criteria in the protocol.<br><br>        Exclusion Criteria:<br><br>          -  Any contraindication to IVT injection according to the Investigator's clinical<br>             judgment and international guidelines (Avery 2014).<br><br>          -  Safety issue during study PQ-110-001 that may compromise subject safety when continued<br>             dosing, as determined by the Investigator, and in consultation with the Medical<br>             Monitor.<br><br>          -  Any ocular or systemic disease or condition (including medications and laboratory test<br>             abnormalities) that could compromise subject safety or interfere with assessment of<br>             efficacy and safety, as determined by the Investigator and in consultation with the<br>             Medical Monitor.<br><br>          -  Pregnant or breast-feeding female.<br>",NULL,Frequency of ocular AEs;Frequency of non-ocular AEs,Change in BCVA;Change in Mobility course score;Change in photoreceptor outer segment layer thickness;Change in OCI;Change in FST blue;Change in FST red;Change in VFQ-25;Change in CVAQ;Change in PLR;Change in NIRAF,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03841110,https://clinicaltrials.gov/show/NCT03841110,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1),Advanced Solid Tumors;Lymphoma;Gastric Cancer;Colorectal Cancer;Head and Neck Cancer;Squamous Cell Carcinoma;EGFR Positive Solid Tumor;HER2-positive Breast Cancer;Hepatocellular Carcinoma;Small Cell Lung Cancer;Renal Cell Carcinoma;Pancreas Cancer;Melanoma;NSCLC;Urothelial Carcinoma;Cervical Cancer;Microsatellite Instability;Merkel Cell Carcinoma,Drug: FT500;Drug: Nivolumab;Drug: Pembrolizumab;Drug: Atezolizumab;Drug: Cyclophosphamide;Drug: Fludarabine;Drug: IL-2,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,CT.gov,2019-02-12,2019-02-15,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,76,Fate Therapeutics,United States,NA,NULL,12/2/2019,"February 15, 2019",NCT038,9 November 2020,FT500-101,;,"Jeff Chou, MD;Kimberly Musni",NULL,;clinical@fatetherapeutics.com,;858-875-1800,Fate Therapeutics;,;,"Jeff Chou, MD;Kimberly Musni",NULL,;clinical@fatetherapeutics.com,;858-875-1800,Fate Therapeutics;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>        1. Diagnosis of the following, as per Regimen Cohort:<br><br>        1A. Regimen A: FT500 Monotherapy (Dose Escalation and Expansion): An advanced solid tumor<br>        malignancy, including lymphoma, in a subject who has failed or refused available<br>        FDA-approved therapies and is now a candidate for salvage therapy.<br><br>        1B. Regimen B: FT500 + ICI (Dose Escalation): An advanced solid tumor malignancy, including<br>        lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab,<br>        pembrolizumab or atezolizumab), in a subject who has also failed or refused other available<br>        approved therapies and is now a candidate for salvage therapy.<br><br>        1C. Regimen B: FT500 + ICI (Dose Expansion): An advanced solid tumor malignancy, including<br>        lymphomas, in a subject who is currently receiving nivolumab, pembrolizumab or atezolizumab<br>        per USPI, with disease progression on the ICI.<br><br>        2. Provision of signed and dated ICF.<br><br>        3. Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start<br>        of lympho-conditioning and within 28 days prior to Day 1.<br><br>        4. Stated willingness to comply with study procedures and duration. 5. Provision of signed<br>        and dated ICF to agree to participate, at time of withdrawal or completion of this study,<br>        in Fate Therapeutics' long-term, non-interventional, observation study, FT-003.<br><br>        Exclusion Criteria:<br><br>        All Subjects:<br><br>          1. Females of reproductive potential who are pregnant or lactating, and males or females<br>             not willing to use a highly effective form of contraception from Screening through the<br>             end of the study.<br><br>          2. ECOG performance status = 2.<br><br>          3. Evidence of insufficient organ function as determined by any one of the following:<br><br>               1. Neutrophils <1000/µL or platelets <75,000/µL.<br><br>               2. Estimated creatinine clearance <50 mL/minute (Cockcroft-gault).<br><br>               3. Total bilirubin >2 x upper limit normal (ULN) with the exception of subjects with<br>                  Gilbert's Syndrome or known liver metastases.<br><br>               4. Aspartate aminotransferase (AST) >3 x ULN, or alanine aminotransferase (ALT) >3 x<br>                  ULN. For subjects with known liver metastases, AST or ALT >5 x ULN.<br><br>               5. Oxygen saturation <90% on room air; pulmonary function tests (PFTs) required if<br>                  symptomatic or prior known impairment - subject will be excluded if diffusing<br>                  capacity of the lungs for carbon monoxide (DLCO) or forced expiratory volume 1<br>                  (FEV1) is <50% of predicted for height and age.<br><br>               6. Left ventricular ejection fraction (LVEF) <40% (eg by echocardiogram (ECHO) or<br>                  multi-gated acquisition (MUGA) scan).<br><br>          4. Receipt of any biological therapy, chemotherapy, or radiation (except palliative<br>             radiation) within 2 weeks prior to Day 1. Subjects in Regimen B currently taking an<br>             ICI must interrupt ICI dosing at least 2 weeks prior to Day 1.<br><br>          5. CNS metastases that have not been treated; or treated CNS metastases that have not<br>             been stable for at least 6 months.<br><br>          6. Clinically significant cardiovascular disease, including stroke or myocardial<br>             infarction within 6 months prior to first study medication; or the presence of<br>             unstable angina or congestive heart failure of New York Heart Association grade 2 or<br>             higher.<br><br>          7. Currently receiving or likely to require systemic immunosuppressive therapy (eg,<br>             prednisone >5 mg daily) for any reason from Day -7 to Day 29.<br><br>          8. Uncontrolled infections.<br><br>          9. Known allergy to the following FT500 components: Albumin (Human) or DMSO.<br><br>         10. Presence of any medical or social issues that are likely to interfere with study<br>             conduct, or may cause increased risk to subject.<br><br>             Additional Exclusion Criteria for Regimen B: FT500 + ICI:<br><br>         11. Subjects who experienced an ICI-related adverse reaction that resulted in<br>             discontinuation of the ICI.<br><br>         12. Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid<br>             arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's<br>             disease, ulcerative colitis), except for subjects with isolated vitiligo, atopic<br>             dermatitis, controlled hypoadrenalism or hypopituitarism, and controlled thyroid<br>             disease.<br><br>         13. Subjects who have received an allograft organ transplant.<br>",NULL,The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.,Objective-response rate (ORR);Duration of FT500 persistence,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03856164,https://clinicaltrials.gov/show/NCT03856164,Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,Post Partum Hemorrhage;Fibrinolysis; Hemorrhage;Blood Loss,Drug: Tranexamic Acid;Drug: Placebo,Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,CT.gov,2019-02-21,2019-06-17,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Phase 2/Phase 3,110,University of Texas Southwestern Medical Center,United States,NA,NULL,21/2/2019,"June 17, 2019",NCT038,19 October 2020,STU-2018-0315,NA,"Olutoyosi Ogunkua, M.D.",NULL,NA,NA,UT Southwestern,NA,"Olutoyosi Ogunkua, M.D.",NULL,NA,NA,UT Southwestern,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,Female,"<br>        Inclusion Criteria:<br><br>          1. Intrauterine pregnancy<br><br>          2. Age = 18<br><br>          3. Gestation age = 37 weeks 0 days<br><br>          4. Scheduled cesarean delivery<br><br>          5. Second or third cesarean delivery<br><br>          6. Singleton pregnancy<br><br>        Exclusion Criteria:<br><br>          1. First cesarean delivery<br><br>          2. Four or more cesarean deliveries<br><br>          3. Intrauterine fetal death<br><br>          4. Fetal anomalies<br><br>          5. Documented coagulopathy (Elevated Prothrombin Time (PT), Elevated Partial<br>             Thromboplastin Time (PTT), Elevated International Normalized Ratio (INR))<br><br>          6. Thrombocytopenia (Platelet count < 100k)<br><br>          7. Internal bleeding, external bleeding, easy bruising<br><br>          8. History of thrombotic event<br><br>          9. Hypertension<br><br>         10. Diagnosis of renal insufficiency (Creatinine> 1 mg/dL)<br><br>         11. Insulin-treated diabetes<br><br>         12. Suspected morbidly adherent placenta<br><br>         13. Placenta previa<br><br>         14. Multiple Gestations<br><br>         15. BMI = 50<br><br>         16. Hematocrit = 25<br><br>         17. Blood transfusion within 24 hours prior to cesarean delivery<br><br>         18. History of abnormal bleeding or blood disorder<br><br>         19. Planned general anesthesia<br>",NULL,Blood volume loss,Fibrinogen (mg/dL);D-Dimer (mcg/mL fibrinogen equivalent units);Tissue Plasminogen Activator Antigen (ng/mL);Plasminogen Activator Inhibitor-Type-1 (Units/mL);Rotational Thromboelastometry (ROTEM) Values,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04061876,https://clinicaltrials.gov/show/NCT04061876,Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease,aGVHD;Stem Cell Transplant Complications,Drug: Ruxolitinib;Drug: Corticosteroid,First Line Therapy for High Risk Acute GVHD,CT.gov,2019-08-17,2019-06-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,198,Chinese PLA General Hospital,China,NA,NULL,17/8/2019,"June 1, 2019",NCT040,5 October 2020,S2019-177-01,; ;,Daihong Liu;Daihong Liu;Nan Bai,NULL,;daihongrm@163.com;301irb@sina.com,;86-13681171597;86-13810535576,Chines PLA General Hospital;,; ;,Daihong Liu;Daihong Liu;Nan Bai,NULL,;daihongrm@163.com;301irb@sina.com,;86-13681171597;86-13810535576,Chines PLA General Hospital;,Recruiting,LU DAOPEI MEDICAL;960th Hospital of PLA;The Second Hospital of Hebei Medical University,Please refer to primary and secondary sponsors,14 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>          1. diagnosed with hematological diseases.<br><br>          2. Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT)<br>             from any donor source using bone marrow, peripheral blood stem cells, or cord blood<br>             for hematologic malignancies.<br><br>          3. new onset of grade II~IV aGVHD or intermediate or high risk aGVHD (based on ST2,<br>             REG3a, other experimental objects) within 100 days post-transplantation.<br><br>        Exclusion Criteria:<br><br>          1. recipients of second allogeneic stem cell transplant.<br><br>          2. acute GVHD induced by donor lymphocyte infusion, interferon.<br><br>          3. received first line aGVHD treatment before enrollment.<br><br>          4. overlap GVHD syndrome.<br><br>          5. pregnant or breast-feeding women.<br><br>          6. absolute neutrophil count (ANC) <0.5×10e9/L or platelet count (PLT) < 20×10e9/L<br><br>          7. Serum creatinine > 2.0 mg/dL or creatinine clearance < 40 mL/min measured or<br>             calculated by Cockroft-Gault equation.<br><br>          8. uncontrolled infection<br><br>          9. human immunodeficiency virus infection<br><br>         10. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.<br><br>         11. Subjects with evidence of relapsed primary disease, or subjects who have been treated<br>             for relapse after the allo-HSCT was performed, or graft rejection.<br><br>         12. allergic history to Janus kinase inhibitors.<br><br>         13. Severe organ dysfunction unrelated to underlying GVHD, including:<br><br>             Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as<br>             persistent bilirubin abnormalities not attributable to GVHD and ongoing organ<br>             dysfunction).<br><br>             Clinically significant or uncontrolled cardiac disease including unstable angina,<br>             acute myocardial infarction within 6 months from Day 1 of study drug administration,<br>             New York Heart Association Class III or IV congestive heart failure, circulatory<br>             collapse requiring vasopressor or inotropic support, or arrhythmia that requires<br>             therapy.<br><br>             Clinically significant respiratory disease that requires mechanical ventilation<br>             support or 50% oxygen.<br><br>         14. Received Janus kinase inhibitor therapy after allo-HSCT for any indication.<br><br>         15. Any condition that would, in the investigator's judgment, interfere with full<br>             participation in the study, including administration of study drug and attending<br>             required study visits; pose a significant risk to the subject; or interfere with<br>             interpretation of study data.<br>",NULL,Overall response rate (ORR) at Day 28,Six-month duration of response;Duration of response;Nonrelapse mortality (NRM);Relapse rate;Disease-free survival (DFS);Overall survival (OS);GVHD-free and relapse-free survival (GRFS);recurrence of aGVHD,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03905109,https://clinicaltrials.gov/show/NCT03905109,"A Phase 2a, Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety of ABX464 Compared With Placebo in Patients With Moderate to Severe Active Crohn's Disease Who Have Inadequate Response, Loss of Response, or Intolerance to Prior Amino-salicylates, Immunosuppressant Treatment, Biologics, and/or Corticosteroid Treatment",Crohn Disease,Drug: ABX464;Drug: Placebo,Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease,CT.gov,2019-04-03,2020-04-15,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,30,Abivax S.A.,Belgium,NA,NULL,3/4/2019,"April 15, 2020",NCT039,6 January 2020,ABX464-201,NA,"Paul GINESTE, PhD",NULL,paul.gineste@abivax.com,+33 1 53 83 09 61,NA,NA,"Paul GINESTE, PhD",NULL,paul.gineste@abivax.com,+33 1 53 83 09 61,NA,Not yet recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Men or women age 18-75 years;<br><br>          -  Patients must have a documented diagnosis (endoscopic with histology) of CD for = 3<br>             months before screening;<br><br>          -  Patients must have active moderate to severe ileal, ileocolic, or colonic CD at<br>             baseline as defined by 220 = CDAI > 450,<br><br>          -  Patients must have a SES-CD score > 6 (=4 if isolated ileal disease) at screening,<br>             assessed by ileocolonoscopy and confirmed by a central reading.<br><br>          -  Patients must be willing and able to undergo endoscopy during screening after all<br>             other inclusion criteria have been met and at the end of Week 16.<br><br>          -  Patients must have had either a documented inadequate response, no response, a loss of<br>             response, or an intolerance (defined as the occurrence of at least one Adverse<br>             Reaction leading to treatment discontinuation) to either amino-salicylates,<br>             immunosuppressant treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate,<br>             biologics (i.e. tumor necrosis factor inhibitors, vedolizumab, ustekinumab), and/or<br>             corticosteroid treatment.<br><br>          -  Patients should be able and willing to comply with study visits and procedures as per<br>             protocol;<br><br>          -  Patients should understand, sign and date the written voluntary informed consent form<br>             at the screening visit prior to any protocol-specific procedures being performed;<br><br>          -  Patients should be affiliated to a social security regimen (for French sites only);<br><br>          -  Females and males receiving the study treatment and their partners must agree to use a<br>             highly effective contraceptive method during the study and for 3 months after end of<br>             study or early termination.<br><br>        Exclusion Criteria:<br><br>          -  Patients with indeterminate colitis, microscopic colitis, ischemic colitis, infectious<br>             colitis, radiation colitis or clinical/histologic findings suggestive of ulcerative<br>             colitis;<br><br>          -  Patients with colonic dysplasia or neoplasia or adenomatous colonic polyp;<br><br>          -  Patients with presence of fistulae;<br><br>          -  Patients with current symptomatic diverticulitis or diverticulosis;<br><br>          -  Patients with obstructive colonic stricture/stenosis, past medical history of colonic<br>             resection, a history of bowel surgery within 6 months before screening, or who are<br>             likely to require surgery for CD during the treatment period;<br><br>          -  Patients with past medical history of clinically significant short bowel syndrome;<br><br>          -  Patients requiring parenteral nutrition;<br><br>          -  Patients with past medical history of bowel surgery resulting in an existing or<br>             current stoma;<br><br>          -  Patients with active infections at screening such as infected abdominal abscess,<br>             Clostridium difficile (stool antigen and toxin required), cytomegalovirus, tuberculous<br>             colitis and recent infectious hospitalization;<br><br>          -  Acute, chronic or history of clinically relevant pulmonary, cardiovascular, hepatic,<br>             pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable<br>             central nervous system pathology such as seizure disorder, angina or cardiac<br>             arrhythmias, or any other clinically significant medical problems as determined by<br>             physical examination and/or laboratory screening tests and/or medical history;<br><br>          -  Acute, chronic or history of immunodeficiency or autoimmune disease;<br><br>          -  History of malignancy excluding patients considered cure (5 years disease free<br>             survivors);<br><br>          -  Active malignancy that may require chemotherapy or radiation therapy;<br><br>          -  Serious illness requiring systemic treatment and/or hospitalization within 3 Weeks<br>             prior to baseline;<br><br>          -  Pregnant or breast-feeding woman;<br><br>          -  Illicit drug or alcohol abuse or dependence;<br><br>          -  Use of any investigational or non-registered product within 3 months or within 5<br>             half-lives preceding baseline, whichever is longer;<br><br>          -  Any condition, which in the opinion of the investigator, could compromise the<br>             patient's safety or adherence to the study protocol.<br>",NULL,Incidence of Treatment-Emergent Adverse Events of ABX464,Proportion of patients with a clinical response;Proportion of patients with a clinical remission;Time to clinical response;Time to clinical remission;Evaluation of the effect of ABX464 50mg on Clinical Response and Remission assessed by 2-item Patient Reporting Outcome versus placebo;;Proportion of patients with endoscopic response;Proportion of patients with endoscopic remission;Evaluation of the effect of ABX464 on the histopathology of the Crohn's disease;Proportion of patients with both clinical response and endoscopic response;Evaluation of the effect of ABX464 50mg on C-reactive protein levels and fecal calprotectin at week 8 and week 16 versus placebo;;Evaluation of the effect of ABX464 50mg on patients' quality of life measured by Inflammatory Bowel Disease Questionnaire;Evaluation of treatment-emergent serious adverse events;Evaluation of adverse events leading to investigational product discontinuation;Change from baseline of the micro RNA-124 expression in whole blood and in tissue in the ABX464 treatment group vs placebo;;Assessment of ABX464 pharmacokinetics and its main active metabolite N-Glu-ABX464 after oral administration of a 50 mg dose of ABX464,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04082910,https://clinicaltrials.gov/show/NCT04082910,Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells,Solid Tumor;Hematologial Malignancy,Drug: Metoprolol;Drug: anti-TNFa antibody,Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells,CT.gov,2019-09-04,2019-09-15,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1/Phase 2,30,Chinese PLA General Hospital,China,NA,NULL,4/9/2019,"September 15, 2019",NCT040,11 November 2019,CHN-PLAGH-BT-044,;,"Weidong Han, M.D.;Weidong Han, M.D",NULL,hanwdrsw@sina.com;hanwdrsw@sina.com,+861055499341;+861055499341,NA,;,"Weidong Han, M.D.;Weidong Han, M.D",NULL,hanwdrsw@sina.com;hanwdrsw@sina.com,+861055499341;+861055499341,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,70 Years,All,<br>        Inclusion Criteria:<br><br>          -  Male or female participant 18 Years to 70 Years Patients with malignant tumors who<br>             received the treatment of CART cells. Estimated life expectancy = 12 weeks (according<br>             to investigator's judgement) Eastern Cooperative Oncology Group (ECOG) performance<br>             status = 2 Adequate organ function<br><br>        Exclusion Criteria:<br><br>          -  Significant bradycardia (heart rate < 45/min) cardiogenic shock severe or acute heart<br>             failure poor peripheral circulation perfusion degree II or III atrioventricular block<br>             sick sinus syndrome severe peripheral vascular disease<br>,NULL,Efficacy of Metoprolol on CRS,The change of IL-6 after Metoprolol,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03998085,https://clinicaltrials.gov/show/NCT03998085,Study of Anlotinib Single Drug as the Maintenance Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Drug: Anlotinib Hydrochloride,Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC,CT.gov,2019-06-23,2019-03-05,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,N/A,40,First Hospital of Jilin University,China,NA,NULL,23/6/2019,"March 5, 2019",NCT039,10 August 2020,ALTER-L011;K2018065,NA,"jiuwei cui, M.D. Ph.D.",NULL,cuijiuwei@vip.qq.com,043188783173,NULL,NA,"jiuwei cui, M.D. Ph.D.",NULL,cuijiuwei@vip.qq.com,043188783173,NULL,Recruiting,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          -  a.NSCLC was diagnosed by cytology or histology, and patients with stage IIIB,IIIC or<br>             IV and no sensitive mutation of EGFR/ALK were diagnosed according to UICC Staging<br>             Standard of the 8th edition of 2017; b. Patients with disease recurrence or<br>             progression 1 year after radical operation with platinum-assisted chemotherapy;<br><br>          -  Those who had received platinum-containing two-drug combination chemotherapy for 4-6<br>             cycles were judged as complete remission (CR), partial remission (PR) and<br>             stabilization (SD) according to RECIST 1.1 standard;<br><br>          -  Patients should be enrolled after the end of the last first-line chemotherapy cycle<br>             with platinum containing drugs =6 weeks (42 days)<br><br>          -  Age: 18 to 75 years old<br><br>          -  PS<2(ECOG) ;<br><br>          -  The life expectancy is more than 3 months;<br><br>          -  According to RECIST 1.1 criteria, patients have at least one imaging (CT, MRI) lesion<br>             that can be measured or evaluated; the lesion was not previously treated by<br>             radiotherapy. The longest diameter of the target lesion should be greater than or<br>             equal to 10 mm (the short axis of lymph node is greater than or equal to 15 mm);<br>             Patients with brain metastasis at baseline should be single intracranial metastasis,<br>             asymptomatic or asymptomatic after treatment;<br><br>          -  Women: For all women who may be pregnant, pregnancy tests must be performed within 72<br>             hours before starting treatment, or medically approved contraceptive methods must be<br>             used within three months after the treatment and during the period after the end of<br>             treatment; serum or urine pregnancy tests must be negative and must be non-lactating;<br>             Male: Contraceptive measures were taken during and within 3 months after surgical<br>             sterilization or treatment;<br><br>          -  The functional level of organs must meet the following requirements:<br><br>        Routine blood test ANC=1.5 x 109/L; PLT=100 x 109/L; Hb=90g/L Blood biochemistry TBIL=1.5 x<br>        ULN ALT and AST=2 x ULN; for patients with liver metastases, ALT and AST =5 x ULN; BUN and<br>        Cr=1.5 x ULN and creatinine clearance=50 ml/min;LVEF=50%; 12 lead electrocardiogram The<br>        Fridericia-corrected QTcF was < 450 ms for males and < 470 MS for females.<br><br>          -  Subjects who have the ability to understand and sign the informed consent must sign<br>             the informed consent before any screening evaluation.<br><br>        Exclusion Criteria:<br><br>          -  Small cell lung cancer (including mixed small cell lung cancer and non-small cell lung<br>             cancer);Central squamous cell carcinoma, or non-small cell lung cancer with hemoptysis<br>             (> 50ml/d) or risk of massive bleeding;<br><br>          -  Imaging (CT or MRI) shows that the distance between tumor lesion and the large blood<br>             vessel is = 5 mm, or there is a central tumor that invades the local large blood<br>             vessel; or there is a significant pulmonary cavity or necrotizing tumor;<br><br>          -  Medical history and combined history<br><br>               1. Active brain metastases, cancerous meningitis, spinal cord compression, or<br>                  imaging CT or MRI screening for brain or pia mater disease;<br><br>               2. The patient is participating in other clinical studies or completing the previous<br>                  clinical study in less than 4 weeks;<br><br>               3. Patients with hypertension who could not be well controlled by antihypertensive<br>                  drug (systolic pressure > 150 mmHg, diastolic pressure > 100 mmHg);<br><br>               4. Had malignant tumors except NSCLC within 5 years before enrollment(except for<br>                  patients with cervical carcinoma in situ , basal cell or squamous cell skin<br>                  cancer who have undergone a curative treatment, local prostate cancer after<br>                  radical resection, ductal carcinoma in situ or papillary thyroid cancer after<br>                  radical resection);<br><br>               5. Researchers judged that they had not recovered from previous adverse events<br>                  before taking the drug for the first time (NCI-CTCAE Version 4.0 Grade > Grade<br>                  1);<br><br>               6. Abnormal blood coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds<br>                  or APTT > 1.5 ULN), with bleeding tendency or undergoing thrombolytic or<br>                  anticoagulant therapy;Note: Under the premise of prothrombin time international<br>                  normalized ratio (INR) = 1.5, low-dose heparin (adult daily dose of 0.6 million<br>                  to 12,000 U) or low-dose aspirin (daily dosage = 100 mg) is allowed for<br>                  preventive purposes;<br><br>               7. Renal insufficiency: urine routine indicates urinary protein = ++, or confirmed<br>                  24-hour urine protein = 1.0g;<br><br>               8. The effects of surgery or trauma have been eliminated for less than 14 days<br>                  before enrollment in subjects who have undergone major surgery or have severe<br>                  trauma;<br><br>               9. Severe acute or chronic infections requiring systemic treatment;<br><br>              10. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial<br>                  infarction above grade II, poorly controlled arrhythmias (including men with QTc<br>                  interval = 450 ms, women = 470 ms); according to NYHA criteria, grades III to IV<br>                  Insufficient function, or cardiac color Doppler ultrasound examination indicates<br>                  left ventricular ejection fraction (LVEF) <50%;<br><br>              11. There is currently a peripheral neuropathy of =CTCAE 2 degrees, except for<br>                  trauma;<br><br>              12. Respiratory syndrome (=CTC AE grade 2 dyspnea), serous effusion (including<br>                  pleural effusion, ascites, pericardial effusion) requiring surgical treatment;<br><br>              13. There was a history of bleeding. Within 4 weeks before screening, any bleeding<br>                  events with a severe grade of 3 or more in CTCAE 4.0 occurred;<br><br>              14. Decompensated diabetes or other ailments treated with high doses of<br>                  glucocorticoids;<br><br>              15. Factors that have a significant impact on oral drug absorption, such as inability<br>                  to swallow, chronic diarrhea, and intestinal obstruction;<br><br>              16. Clinically significant hemoptysis (daily hemoptysis greater than 50ml) within 3<br>                  months prior to enrollment; or significant clinically significant bleeding<br>                  symptoms or defined bleeding tendency, such as gastrointestinal bleeding,<br>                  hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, or suffering<br>                  from vasculitis;<br><br>              17. Events of venous/venous thrombosis occurring within the first 6 months prior to<br>                  enrollment, such as cerebrovascular accidents (including transient ischemic<br>                  attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and<br>                  pulmonary embolism;<br><br>              18. Participated in clinical trials of other anti-tumor drugs during the first 4<br>                  weeks of enrollment or planned sys",NULL,PFS,OS,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03991520,https://clinicaltrials.gov/show/NCT03991520,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,Endometriosis;Anakinra;Markers of Inflammation,Drug: Anakinra 100Mg/0.67Ml Inj Syringe;Drug: Placebo,Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms,CT.gov,2019-05-27,2020-04-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Early Phase 1,20,"University of California, San Diego",United States,NA,NULL,27/5/2019,April 2020,NCT039,20 April 2020,182006,; ;,"Sanjay K Agarwal, MD;Celestine Magallanes, BS;Celestine Magallanes, BS",NULL,;cgmagall@health.ucsd.edu;cgmagall@health.ucsd.edu,;8582495419;858-249-5419,UC San Diego;,; ;,"Sanjay K Agarwal, MD;Celestine Magallanes, BS;Celestine Magallanes, BS",NULL,;cgmagall@health.ucsd.edu;cgmagall@health.ucsd.edu,;8582495419;858-249-5419,UC San Diego;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,40 Years,Female,"<br>        Inclusion Criteria:<br><br>          -  Women aged 18-40 with regular menstrual periods every 24-32 days and not lasting more<br>             than 6 days per month<br><br>          -  Laparoscopically proven endometriosis.<br><br>          -  At least a moderate level of menstrual pain based on the patient reported parameters<br>             of the B&B pain scale (>4/9) with dysmenorrhea being scored at least 2/3.<br><br>          -  Willing to remain on your current method of hormone therapy for duration of study<br><br>        Exclusion Criteria:<br><br>          -  History of hysterectomy or oophorectomy.<br><br>          -  Non-response to GnRH agonist/antagonist, DMPA, aromatase inhibitors or danazol.<br><br>          -  Currently pregnant or attempting pregnancy.<br><br>          -  Contraindication to anakinra.<br><br>          -  Chronic kidney disease stage 4 and 5 or creatinine clearance <30mL/min/1.73m2.<br><br>          -  Abnormal LFTs, CBC or serum electrolytes including estimated GFR.<br><br>          -  Patient refusal.<br><br>          -  Plan to receive a live vaccine<br>",NULL,Comparison of the impact of anakinra versus placebo on menstrual pain (dysmenorrhea) using the modified Biberoglu and Behrman scale.,"Comparison of the impact of anakinra versus placebo on dyspareunia and non menstrual pelvic pain using the modified Biberoglu and Behrman scale.;Comparison of serum inflammatory markers before and after anakinra administration.;Comparison of the impact of anakinra versus placebo on the quality of life using the Endometriosis Health Profile 30 questionnaire (EHP-30), conducted after each course of study medication administration.",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04026438,https://clinicaltrials.gov/show/NCT04026438,Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT),"Complication, Postoperative;Regeneration Liver",Drug: Potassium Phosphate Injection,Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT),CT.gov,2019-07-11,2018-12-12,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,Phase 4,140,"Institute of Liver and Biliary Sciences, India",India,NA,1,11/7/2019,"December 12, 2018",NCT040,29 July 2019,ILBS-livertransplant,; ;,"Viniyendra Pamecha, Professor;Vivek Senior Resident;Senior Resident",NULL,;vvkhere@gmail.com;,;+918800984217;,"Professor and Head, Department of HPB surgery and Liver transplantation, ILBS, New Delhi.;",; ;,"Viniyendra Pamecha, Professor;Vivek Senior Resident;Senior Resident",NULL,;vvkhere@gmail.com;,;+918800984217;,"Professor and Head, Department of HPB surgery and Liver transplantation, ILBS, New Delhi.;",Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,50 Years,All,<br>        Inclusion Criteria:<br><br>          -  All donors evaluated as per institutional protocol for donor hepatectomy and found fit<br><br>          -  Those who consent.<br><br>        Exclusion Criteria:<br><br>          -  Patients refusing to consent for inclusion in the study.<br><br>          -  Minor hepatectomy<br><br>          -  Those who develop profound hypophosphatemia in the control group<br>,NULL,Post operative complications,"Effect on liver regeneration;Trend of serum phosphorous levels;Trends in post-operative liver function tests;Duration of hospital, ICU stay",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03961308,https://clinicaltrials.gov/show/NCT03961308,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",Healthy Volunteers,Drug: Vedolizumab SC,A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants,CT.gov,2019-05-22,2018-03-12,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).,Phase 1,204,Takeda,United States,NA,1,22/5/2019,"March 12, 2018",NCT039,3 June 2019,U1111-1205-7175;VedolizumabSC-1022,NA,Medical Director,NULL,NA,NA,Takeda,NA,Medical Director,NULL,NA,NA,Takeda,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>        1. Weighs greater than (>) 50 kilogram (kg) and less than (<) 90 kg or has a body mass<br>        index (BMI) from 18 to 28 kilogram per square meter (kg/m^2), inclusive, at the time of<br>        informed consent.<br><br>        Exclusion Criteria:<br><br>          1. Has had previous exposure to approved or investigational anti-integrins (example,<br>             natalizumab, efalizumab, etrolizumab, AMG 181) or anti-mucosal addressin cell adhesion<br>             molecule-1 (anti-MAdCAM-1) antibodies or rituximab.<br><br>          2. Has 1 or more positive responses on the PML subjective symptom checklist at screening<br>             or before dosing on Day 1.<br><br>          3. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol<br>             abuse within 1 year before the Screening Visit or is unwilling to agree to abstain<br>             from alcohol for 7 days before Day -1 throughout confinement and for 48 hours before<br>             each clinic visit; and drugs throughout the study.<br><br>          4. Has evidence of an active infection during the Screening Period.<br><br>          5. Has received any live vaccinations within 30 days before Screening.<br><br>          6. Has active or latent tuberculosis (TB) as evidenced by the following:<br><br>             o A diagnostic TB test performed within 30 days of Screening or during the Screening<br>             Period that is positive, defined as:<br><br>               1. Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR<br><br>               2. A TB skin test reaction greater than or equal to (>=) 5 millimeter (mm). NOTE: If<br>                  participants have received Bacillus Calmette-Gueri (BCG) vaccine then a<br>                  QuantiFERON TB Gold test should be performed instead of the TB skin test.<br><br>             Note: Participants with documented previously treated TB with a negative QuantiFERON<br>             test can be included in the study.<br><br>          7. Has poor peripheral venous access.<br><br>          8. Is unable to attend all the study visits or comply with study procedures.<br><br>          9. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including<br>             serum pheresis), or had a transfusion of any blood product within 45 days before Day<br>             1.<br>",NULL,Cmax: Maximum Observed Serum Concentration for Vedolizumab SC;AUClast: Area Under the Serum Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC;AUC8: Area Under the Serum Concentration-time Curve from Time 0 to Infinity for Vedolizumab SC,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03913559,https://clinicaltrials.gov/show/NCT03913559,Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Drug: Inotuzumab ozogamicin;Drug: Methotrexate;Drug: Hydrocortisone;Drug: Cytarabine;Drug: Diphenhydramine;Drug: Acetaminophen;Drug: Methylprednisolone,Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia,CT.gov,2019-04-09,2019-05-14,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,32,St. Jude Children's Research Hospital,United States,NA,NULL,9/4/2019,"May 14, 2019",NCT039,13 July 2020,NCI-2019-01062;INOMRD,; ;,"Sima Jeha, MD;Sima Jeha, MD;Sima Jeha, MD",NULL,;referralinfo@stjude.org;referralinfo@stjude.org,;866-278-5833;866-278-5833,St. Jude Children's Research Hospital;,; ;,"Sima Jeha, MD;Sima Jeha, MD;Sima Jeha, MD",NULL,;referralinfo@stjude.org;referralinfo@stjude.org,;866-278-5833;866-278-5833,St. Jude Children's Research Hospital;,Recruiting,Pfizer,Please refer to primary and secondary sponsors,N/A,21 Years,All,"<br>        Inclusion Criteria:<br><br>        Age<br><br>          -  Participants must be < 22 years of age.<br><br>        Diagnosis<br><br>          -  Participants must have B-ALL with persistent or rising MRD between 0.1 and 4.99%<br>             without extramedullary disease following at least two prior induction attempts,<br>             relapse or after hematopoietic stem cell transplant<br><br>          -  Leukemia blasts demonstrating surface expression of CD22<br><br>        Performance Level<br><br>          -  Karnofsky or Lansky performance score = 50% (corresponding to ECOG Score of = 2). The<br>             Lansky performance score should be used for participants < 16 years and the Karnofsky<br>             performance score for participants = 16 years.<br><br>        Prior Therapy<br><br>          -  Patients must have fully recovered from the acute toxic effects of all prior<br>             anticancer therapy, defined as resolution of all such toxicities to = Grade 2 or lower<br>             per the inclusion/exclusion criteria prior to entering this study.<br><br>          -  At least 14 days must have elapsed since the completion of cytotoxic therapy, with the<br>             exception of standard maintenance therapy and steroids.<br><br>          -  At least 7 days must have elapsed since completion of therapy with a biologic agent.<br>             For agents that have known adverse events occurring beyond 7 days after<br>             administration, this period prior to enrollment must be extended beyond the time<br>             during which adverse events are known to occur.<br><br>          -  At least 3 half-lives must have elapsed since prior therapy that included a monoclonal<br>             antibody with the exception of blinatumomab. Patients must have been off blinatumomab<br>             infusion for at least 7 days and all drug related toxicity must have resolved to Grade<br>             2 or lower as outlined in the inclusion/exclusion criteria.<br><br>          -  At least 42 days must have elapsed since CAR-T cell therapy.<br><br>          -  Participant has received = 1 prior bone marrow transplant.<br><br>          -  At least 90 days have elapsed since bone marrow transplant and participant is off<br>             immune suppression for = 2 weeks, if applicable with no evidence of active GVHD.<br><br>          -  At least 2 weeks must have elapsed since local XRT (small port); = 3 months must have<br>             elapsed if prior cranial or craniospinal XRT was received, if = 50% of the pelvis was<br>             irradiated, or if TBI was received; = 6 weeks must have elapsed if other substantial<br>             bone marrow irradiation was given.<br><br>        Organ Function Requirements<br><br>          -  Adequate renal function defined as glomerular filtration rate = 60 cc/min/1.73m2 or<br>             serum creatinine based on age as follows:<br><br>               -  Age: <6 months; maximum serum creatinine (mg/dL): 0.4 (male, female); Age: 6<br>                  months to <1 year; maximum serum creatinine (mg/dL): 0.5 (male, female); Age: 1<br>                  to < 2 years; maximum serum creatinine (mg/dL): 0.6 (male, female); Age: 2 to < 6<br>                  years; maximum serum creatinine (mg/dL): 0.8 (male, female); Age: 6 to <10 years;<br>                  maximum serum creatinine (mg/ dL): 1 (male, female); Age: 10 to <13 years;<br>                  maximum serum creatinine (mg/dL): 1.2 (male, female); Age: 13 to <16 years;<br>                  maximum serum creatinine (mg/dL): 1.5 (male), 1.4 (female); Age: = 16 years;<br>                  maximum serum creatinine (mg/dL): 1.7 (male), 1.4 (female)<br><br>          -  Adequate hepatic function defined as:<br><br>               -  Direct bilirubin = 1.4 mg/dL (if total bilirubin > 1.4 mg/dL) and<br><br>               -  AST or ALT = 3 x ULN for age.<br><br>          -  Adequate cardiac function defined as shortening fraction of = 27% or ejection fraction<br>             = 45%.<br><br>        Exclusion Criteria:<br><br>          -  History of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) of any<br>             severity.<br><br>          -  Concurrent chemotherapy or targeted anti-cancer agents, other than intrathecal<br>             therapy.<br><br>          -  Patient with concurrent severe and/or uncontrolled medical conditions that, in the<br>             opinion of the investigator, may impair participation in the study or the evaluation<br>             of safety and/or efficacy.<br><br>          -  Known HIV infection or active hepatitis B (defined as hepatitis B surface<br>             antigen-positive) or C (defined as hepatitis C antibody-positive).<br><br>          -  Pregnant or lactating (female participant of childbearing potential must have negative<br>             serum or urine pregnancy test required within 7 days prior to start of treatment).<br><br>          -  Male or female participant of reproductive potential must agree to use appropriate<br>             methods of contraception for the duration of study treatment and for at least 30 days<br>             after last dose of protocol treatment.<br><br>          -  Inability or unwillingness of research participant or legal guardian/representative to<br>             give written informed consent.<br>",NULL,Treatment response Cycle1 - count;Treatment Response Cycle 1 - percentage;Treatment Response Cycle 2 - count;Treatment Response Cycle 2 - percentage,Occurrence of Veno-occlusive disease (VOD) - percentage;Occurrence of Veno-occlusive disease (VOD) - count;Occurrence of death - percentage;Occurrence of death - count,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03829332,https://clinicaltrials.gov/show/NCT03829332,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)",Non-small Cell Lung Cancer,Biological: Pembrolizumab;Drug: Lenvatinib;Drug: Placebo for lenvatinib,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007),CT.gov,2019-02-01,2019-03-13,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Phase 3,620,Merck Sharp & Dohme Corp.,"United States;Australia;Canada;China;Colombia;Estonia;France;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Turkey;Ukraine;Australia;Canada;China;Colombia;Estonia;France;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Taiwan;Turkey;Ukraine;United States",NA,NULL,1/2/2019,"March 13, 2019",NCT038,16 November 2020,MK-7902-007;E7080-G000-314;LEAP-007;2018-003794-98;194670;7902-007,;,Medical Director;Toll Free Number,NULL,;Trialsites@merck.com,;1-888-577-8839,Merck Sharp & Dohme Corp.;,;,Medical Director;Toll Free Number,NULL,;Trialsites@merck.com,;1-888-577-8839,Merck Sharp & Dohme Corp.;,Recruiting,Eisai Inc.,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Has a histologically or cytologically confirmed diagnosis of NSCLC.<br><br>          -  Has Stage IV NSCLC (American Joint Committee on Cancer [AJCC]).<br><br>          -  Has measurable disease based on RECIST 1.1.<br><br>          -  Has tumor tissue that demonstrates programmed cell death-ligand 1 (PD-L1) expression<br>             in =1% of tumor cells (Tumor Proportion Score [TPS] =1%) as assessed by<br>             immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central<br>             laboratory.<br><br>          -  Has a life expectancy of =3 months.<br><br>          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7<br>             days before the first dose of study treatment but before randomization.<br><br>          -  Male participants must agree to the following during the treatment period and for =30<br>             days after the last dose of lenvatinib/matching placebo: 1) Be abstinent from<br>             heterosexual intercourse as their preferred and usual lifestyle and agree to remain<br>             abstinent, OR 2) Must agree to use contraception unless confirmed to be azoospermic<br>             (vasectomized or secondary to medical cause).<br><br>          -  Female participants are eligible to participate if not pregnant or breastfeeding, and<br>             =1 of the following applies: 1) Is not a woman of child-bearing potential (WOCBP), OR<br>             2) Is a WOCBP and is using a highly effective contraceptive method that has a low user<br>             dependency, or be abstinent from heterosexual intercourse as their preferred and usual<br>             lifestyle during the treatment period and for =120 days post pembrolizumab or =30 days<br>             post lenvatinib/matching placebo, whichever occurs last.<br><br>          -  Has adequately controlled blood pressure (BP) with or without antihypertensive<br>             medications, defined as BP =150/90 mm Hg and no change in antihypertensive medications<br>             within 1 week before randomization.<br><br>          -  Has adequate organ function.<br><br>        Exclusion Criteria:<br><br>          -  Has known untreated central nervous system metastases and/or carcinomatous meningitis.<br><br>          -  Has a known history of an additional malignancy, except if the participant has<br>             undergone potentially curative therapy with no evidence of that disease recurrence for<br>             =3 years since initiation of that therapy. (Note: The time requirement does not apply<br>             to participants who underwent successful definitive resection of basal cell carcinoma<br>             of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ<br>             cervical cancer, or other in situ cancers.)<br><br>          -  Has an active autoimmune disease that has required systemic treatment in the past 2<br>             years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid<br>             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a<br>             form of systemic treatment and is allowed.<br><br>          -  Has had an allogeneic tissue/solid organ transplant.<br><br>          -  Has a known history of human immunodeficiency virus (HIV) infection.<br><br>          -  Has a history of (noninfectious) pneumonitis that required systemic steroids or<br>             current pneumonitis/interstitial lung disease.<br><br>          -  Has a known history of hepatitis B or known active hepatitis C virus infection.<br><br>          -  Has a history of a gastrointestinal condition or procedure that in the opinion of the<br>             investigator may affect oral study drug absorption.<br><br>          -  Has significant cardiovascular impairment within 12 months of the first dose of study<br>             treatment, such as a history of congestive heart failure greater than New York Heart<br>             Association Class II, unstable angina, myocardial infarction, cerebrovascular<br>             accident/stroke, or cardiac arrhythmia associated with hemodynamic instability.<br><br>          -  Has not recovered adequately from any toxicity and/or complications from major surgery<br>             before starting study treatment.<br><br>          -  Has a known history of active tuberculosis (TB).<br><br>          -  Has an active infection requiring systemic therapy.<br><br>          -  Has previously had a severe hypersensitivity reaction to treatment with a monoclonal<br>             antibody or has a known sensitivity or intolerance to any component of lenvatinib or<br>             pembrolizumab.<br><br>          -  Is pregnant or breastfeeding or expecting to conceive or father children within the<br>             projected duration of the study, starting with the screening visit through 120 days<br>             after the last dose of study treatment.<br><br>          -  Has received prior systemic chemotherapy or other targeted or biological<br>             antineoplastic therapy for their metastatic NSCLC.<br><br>          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with<br>             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.<br>             cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor<br>             superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9<br>             [CD137]) or has received lenvatinib as monotherapy or in combination with anti-<br>             programmed cell death protein (anti-PD-1) agents.<br><br>          -  Has received radiotherapy within 14 days before the first dose of study treatment or<br>             received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose<br>             of study treatment. (Note: Participants must have recovered from all radiation-related<br>             toxicities to =Grade 1, not require corticosteroids, and not have had radiation<br>             pneumonitis.)<br><br>          -  Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive<br>             therapy within 7 days before the first dose of study treatment.<br><br>          -  Is receiving systemic steroid therapy (doses >10 mg daily of prednisone equivalent)<br>             within 7 days before the first dose of study treatment.<br><br>          -  Has received a live vaccine within 30 days before the first dose of study treatment.<br><br>          -  Has had major surgery within 3 weeks prior to first dose of study treatment<br><br>          -  Has pre-existing =Grade 3 gastrointestinal or non-gastrointestinal fistula.<br>",NULL,Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1);Overall Survival (OS),Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1);Number of Participants Who Experience an Adverse Event (AE);Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE);Change from Baseline in Global Health Status (GHS)(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] Item 29) Score;Change from Baseline in Quality of Life (QoL)(EORTC QLQ-C30 Item 30) Score;Change from Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score;Change from Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score;Change from Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score;Change from Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score;Time to True Deterioration (TTD) Based on Change from Baseline in Global Health Status (GHS)(EORTC QLQ-C30 Item 29) Score;Time to True Deterioration (TTD) Based on Change from Baseline in Quality of Life (QoL)(EORTC QLQ-C30 Item 30) Score;Time to True Deterioration (TTD) Based on Change from Baseline in the Composite Endpoint of Cough & Chest Pain (EORTC QLQ-LC13 Items 31 & 40) or Dyspnea (EORTC QLQ-C30 Item 8);Time to True Deterioration (TTD) Based on Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03927781,https://clinicaltrials.gov/show/NCT03927781,Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot,"Nephrolithiasis;Urolithiasis;Perioperative/Postoperative Complications;Pain, Postoperative;Pain, Acute;Anesthesia;Urologic Diseases;Anesthesia Morbidity",Drug: Pregabalin 300mg,Perioperative Pregabalin in Ureteroscopy: a Pilot,CT.gov,2019-04-22,2019-04-01,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,10,University of Missouri-Columbia,United States,NA,NULL,22/4/2019,"April 1, 2019",NCT039,14 October 2019,2013680,NA,"Katie Murray, DO",NULL,NA,NA,Assistant Professor,NA,"Katie Murray, DO",NULL,NA,NA,Assistant Professor,Enrolling by invitation,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,<br>        Subject Population Undergoing elective ureteroscopy with stent placement by Dr. Murray at<br>        University of Missouri Hospital and affiliated facilities<br><br>        Subject Inclusion<br><br>        Age >= 18 years<br><br>        Subject Exclusion<br><br>          -  Renal insufficiency (eGFR < 30 mL/minute/1.73 m2)<br><br>          -  Chronic indwelling ureteral stent<br><br>          -  Chronic opioid use<br><br>          -  History of opioid abuse<br><br>          -  Chronic gabapentinoid use<br><br>          -  Plan for inpatient hospitalization<br><br>          -  Pregnancy<br><br>          -  Inability of the patient to consent for themselves in English<br><br>          -  Allergy to gabapentinoid<br><br>          -  Liver failure or hepatic dysfunction<br>,NULL,Adverse events related to study drug;Administration of study drug;Respondent reported usability of instruments,Early post-op stent related symptoms;Early post-op opioid needs;Opioid use;Amount of opioid use;Unplanned healthcare contacts;Patient satisfaction,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04209959,https://clinicaltrials.gov/show/NCT04209959,Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation:a Single-center Randomized Controlled Trial,Atrial Fibrillation,Drug: nifekalant,Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation,CT.gov,2019-12-03,2019-01-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator).,Phase 4,300,Second Affiliated Hospital of Nanchang University,China,NA,NULL,3/12/2019,"January 1, 2019",NCT042,6 January 2020,2014[023],NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Enrolling by invitation,NULL,Please refer to primary and secondary sponsors,18 Years,85 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Documented symptomatic persistent or longstanding persistent AF<br><br>          -  An absence of response to, unacceptable side effects from, or unwillingness to take<br>             antiarrhythmic agents<br><br>          -  Willingness to receive combined ablation strategy, including bilateral circumferential<br>             pulmonary vein isolation and linear ablation<br><br>          -  Failure to terminate AF to after combined ablation strategy<br><br>          -  Willingness to receive intravenous treatment with nifekalant during the procedure<br><br>        Exclusion Criteria:<br><br>          -  A history of nontraumatic intracerebral hemorrhage at any time<br><br>          -  Gastrointestinal bleeding within the past six months<br><br>          -  Major surgery within thirty days<br><br>          -  A known bleeding diathesis or coagulation disorder<br><br>          -  A confirmed thrombus in the left atrium by esophageal ultrasound<br><br>          -  Renal failure requiring dialysis<br><br>          -  Pregnant or lactating<br><br>          -  A left ventricular ejection fraction (LVEF) of 30% or less<br><br>          -  Ventricular tachycardia with prolonged QT interval<br><br>          -  Patients with QTc interval of more than 500 ms<br><br>          -  Torsades de pointes (Tdp), or Brugada syndrome<br>",NULL,"Comparison of the successful rates of different doses of nifekalant instant cardioversion of persistent atrial fibrillation after radiofrequency ablation;The occurrence of adverse events, including sinus bradycardia, cardiac arrest, Torsade de points and ventricular fibrillation confirmed in standard 12-lead ECGs and intracardiac electrograms within 30 minutes among different treatment groups.",NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03863938,https://clinicaltrials.gov/show/NCT03863938,"A Randomized, Open-label, Single-dose Phase 1 Clinical Trial to Compare the Effect of Timing of Food on the Pharmacokinetics and Pharmacodynamics of K-CAB (Tegoprazan) in Healthy Male Subjects",Healthy,Drug: Tegoprazan 50mg,Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects,CT.gov,2019-02-28,2019-03-27,FALSE,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,12,CJ HealthCare Corporation,"Korea, Republic of",NA,NULL,28/2/2019,"March 27, 2019",NCT038,2 September 2019,CJ_APA_112,NA,"In-Jin Jang, MD, PhD",NULL,NA,NA,"Seoul National University Hospital, Dept. of Clinical Pharmacology",NA,"In-Jin Jang, MD, PhD",NULL,NA,NA,"Seoul National University Hospital, Dept. of Clinical Pharmacology",Completed,NULL,Please refer to primary and secondary sponsors,19 Years,50 Years,Male,"<br>        Inclusion Criteria:<br><br>          -  Healthy adult males aged = 19 years and = 50 years<br><br>          -  Body weight of = 55.0 kg and = 90.0 kg, with body mass index (BMI) of = 18.0 kg/m2 and<br>             = 27.0 kg/m2 at the time of screening<br><br>          -  Helicobacter pylori negative<br><br>        Exclusion Criteria:<br><br>          -  Presence or history of clinically significant diseases<br><br>          -  Presence or history of gastrointestinal disorder (gastric ulcer, GERD, Crohn's<br>             disease, etc.)<br><br>          -  Hypersensitivity to drugs containing study drug or proton pump inhibitor and other<br>             drugs (aspirin, antibiotics, etc.) or history of clinically significant<br>             hypersensitivity<br><br>          -  Serologic test positive<br><br>          -  Abnormal obstacle to insertion and maintenance of pH meter catheter<br><br>          -  History of drug abuse<br><br>          -  Excessive caffeine intake or persistent alcohol intake<br><br>          -  Not use of a medically acceptable method of contraception<br>",NULL,AUClast of tegaprazan;Cmax of tegaprazan;Gastric pH,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03884465,https://clinicaltrials.gov/show/NCT03884465,"A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Subjects",Pulmonary Arterial Hypertension,Drug: Inhaled dry powder treprostinil (LIQ861),Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil,CT.gov,2019-03-04,2019-11-11,FALSE,Interventional,Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,32,"Liquidia Technologies, Inc.",France;Germany;France;Germany,NA,NULL,4/3/2019,"November 11, 2019",NCT038,16 November 2020,2018-003414-40;LTI-201,;,"Ardeschir Ghofrani, Prof. MD.;Clinical Study Manager Clinical Operations",NULL,;clinicaltrials@liquidia.com,;19193284400,Universitatskinikum Giessen und Marburg GmbH;,;,"Ardeschir Ghofrani, Prof. MD.;Clinical Study Manager Clinical Operations",NULL,;clinicaltrials@liquidia.com,;19193284400,Universitatskinikum Giessen und Marburg GmbH;,Recruiting,FGK Clinical Research GmbH,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria (A subject will be eligible for inclusion in this study only if all of<br>        the following criteria are met):<br><br>          1. An Institutional Review Board (IRB) approved informed consent is signed and dated by<br>             the subject prior to any study related activities.<br><br>          2. The subject is 18 years of age or older.<br><br>          3. If the subject is a female of childbearing potential, then the subject has a negative<br>             pregnancy test at the Day 1 Visit (tests performed within 2 days before Day 1 are<br>             accepted) and agrees to practice a highly effective (failure rate of less than 1% per<br>             year when used consistently and correctly) method of birth control until 24 hours<br>             after completion of all study assessments defined in Appendix 1. If the subject is<br>             postmenopausal or has documented surgical sterilization, a pregnancy test and birth<br>             control is not necessary. It is the Investigator's responsibility for determining<br>             whether the subject has adequate birth control for study participation.<br><br>          4. The subject has been diagnosed with PAH belonging to one of the following subgroups of<br>             the updated Nice Clinical Classification Group 1, which includes:<br><br>               1. Idiopathic PAH (1.1), or<br><br>               2. Heritable PAH (1.2), or<br><br>               3. Drug and toxin induced PAH (1.3), or<br><br>               4. PAH associated with connective tissue disease (1.4.1), HIV infection (1.4.2), or<br>                  congenital heart disease (1.4.4) with simple systemic-to-pulmonary shunt at least<br>                  1 year after surgical repair<br><br>          5. The subject is NYHA Functional Class II - IV at Screening and:<br><br>               1. has not previously been treated for PAH, or<br><br>               2. has documented stable doses of no more than 2 approved non prostacyclin<br>                  PAH-disease specific therapies for at least 3 months prior to Screening, is<br>                  willing and able to add LIQ861 to their treatment regimen and is willing to hold<br>                  the dosing of these therapies for at least 12 hours prior to study-mandated right<br>                  heart catheterization procedures.<br><br>          6. The subject can complete a baseline six-minute walk distance (6MWD) =150 m.<br><br>          7. The subject has had evidence of Forced Expiratory Volume in 1 Second (FEV1) and Forced<br>             Vital Capacity (FVC) =60% of predicted values and FEV1/FVC ratio =60% during the 6<br>             month period prior to consent.<br><br>        Exclusion Criteria (A subject is not eligible for inclusion in the study if any of the<br>        following criteria apply):<br><br>          1. The subject's clinical condition is such that, in the opinion of the Investigator,<br>             they are not expected to remain clinically stable for the duration of the study.<br><br>          2. Subjects with pulmonary hypertension (PH) in the Updated Nice Classification Groups<br>             2-5, or PAH Group 1 subgroups not covered by the inclusion criteria (e.g., associated<br>             with portal hypertension [1.4.3] or with schistosomiasis [1.4.5]).<br><br>          3. The subject is currently taking prostacyclin analogues or agonists, including<br>             treprostinil, iloprost, epoprostenol or selexipag.<br><br>          4. The subject has discontinued any medication (except for anticoagulants, but otherwise<br>             including but not limited to oxygen, a different class of vasodilator, diuretic,<br>             digoxin, and digitalis) for pulmonary hypertension within 14 days prior to Day 1.<br><br>          5. The subject has had a new type of therapy (including but not limited to oxygen, a<br>             different class of vasodilator, diuretic, digoxin, and digitalis) for pulmonary<br>             hypertension added within 30 days prior to Day 1.<br><br>          6. The subject has uncontrolled systemic hypertension as evidenced by systolic blood<br>             pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg at<br>             the time of screening.<br><br>          7. The subject has a history of hemodynamically significant left-sided heart disease<br>             including, but not limited to: aortic or mitral valve disease, pericardial<br>             constriction, restrictive or congestive cardiomyopathy, or symptomatic coronary artery<br>             disease (CAD).<br><br>          8. The subject has had an atrial septostomy.<br><br>          9. The subject has a history of prolongation of QT interval on ECG as follows: Male<br>             subjects with a corrected QT interval using Fridericia's formula (QTcF) >450 msec and<br>             female subjects with QTcF >470 msec.<br><br>         10. The subject has any serious or life-threatening disease other than conditions<br>             associated with PAH.<br><br>         11. The subject is taking any excluded medications listed in the Investigator's Brochure,<br>             namely inhibitors and inducers of CYP2C8 (see Appendix 3).<br><br>         12. The subject has a hypersensitivity or allergy to any of the ingredients of LIQ861, NO,<br>             or other clinically relevant allergies (clinical relevance per Investigator judgment).<br><br>         13. The subject has had an acute pulmonary embolus within 6 months prior to Baseline.<br><br>         14. The subject has had a stroke or transient ischemic attack within 6 months prior to<br>             Baseline.<br><br>         15. The subject has evidence of an active uncontrolled sepsis or systemic infection in the<br>             period after informed consent up to Baseline.<br><br>         16. The subject is pregnant or lactating.<br><br>         17. The subject has any musculoskeletal disease or any other disease that limits<br>             evaluation of 6MWD.<br><br>         18. The subject has participated in an investigational product or device study within the<br>             30 days prior to Baseline.<br><br>         19. The subject has current evidence of drug abuse in the opinion of the Investigator.<br><br>         20. The subject has severe hepatic impairment as evidenced by any history of ascites AND<br>             encephalopathy.<br><br>         21. The subject has severe renal impairment (estimated glomerular filtration rate [eGFR]<br>             <35 mL/min utilizing the Modification of Diet in Renal Disease (MDRD) study equation<br>             or requires dialytic support.<br><br>         22. The subject is an employee or an immediate family member to an employee of the Sponsor<br>             or the Investigator.<br><br>         23. The subject is not a member or beneficiary of a social security scheme.<br><br>         24. The subject lacks a legal protection measure.<br><br>         25. The subject has been deprived of their liberty by a judicial or administrative<br>             decision.<br><br>         26. The subject has a known Hepatitis B or Hepatitis C infection with active viral<br>             replication.<br><br>         27. The subject has a known HIV infection with CD4 count less than 200 and more than<br>             undetectable viral load, defined as less than 50 copies /mL.<br><br>         28. The subject required use of intravenous inotropes including, but not limited to,<br>             Levosimendan, Dopamine, Dobutamine, Dopexamine, Epinephrine, Isoprenaline<br>             (isoproterenol), Norepinephrine (noradrenaline), Milrinone, or Amrinone, within 30<br>             days prior to Baseline.<br><br>         29. The subject required intravenous diuretic th",NULL,Change in Pulmonary Vascular Resistance (PVR);Change in Pulmonary Artery Pressure (PAP);Change in Cardiac Output (CO);Change in Pulmonary Artery Oxygen Saturation (PAO2%),Number of participants with treatment emergent adverse events (AEs),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04114747,https://clinicaltrials.gov/show/NCT04114747,"Impact of Continuous Renal Replacement Therapy on Renal Oxygenation, Blood Flow and Function",AKI;Continuous Renal Replacement Therapy;Dialysis;Intensive Care;Renal Blood Flow;Renal Failure;Blood Pressure,Other: Starting at high or low blood pressure,Renal Physiology During Continuous Renal Replacement Therapy,CT.gov,2019-09-23,2020-08-31,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,N/A,20,"Sahlgrenska University Hospital, Sweden",Sweden,NA,NULL,23/9/2019,"August 31, 2020",NCT041,7 September 2020,Kidney and dialysis,; ;,"Kristina Svennerholm, MD PhD;Kristina Svennerholm, MD PhD;Kristina Svennerholm, MD PhD",NULL,;kristina.svennerholm@vgregion.se;kristina.svennerholm@vgregion.se,;+46313429336;+46313429336,;,; ;,"Kristina Svennerholm, MD PhD;Kristina Svennerholm, MD PhD;Kristina Svennerholm, MD PhD",NULL,;kristina.svennerholm@vgregion.se;kristina.svennerholm@vgregion.se,;+46313429336;+46313429336,;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,90 Years,All,"<br>        Inclusion Criteria:<br><br>        AKI, according to KDIGO, stage 2 or 3 but with preserved urine production. Treated in the<br>        ICU at Sahlgrenska University Hospital Written, signed informed consent Male and female<br>        subjects =18 years<br><br>        Exclusion Criteria:<br><br>        Emergency need for dialysis Allergy to contrast media (used for CEUS)<br>",NULL,Renal blood flow and CRRT;Renal blood flow and blood pressure;Glomerular filtration rate (GFR) and blood pressure;Glomerular filtration rate (GFR) and CRRT;Renal oxygenation during CRRT;Renal oxygenation and blood pressure,Contrast enhanced renal ultrasound (CEUS);atrial natriuretic peptide (ANP),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04014556,https://clinicaltrials.gov/show/NCT04014556,Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema. One Year Results of a Randomized Clinical Trial,Diabetic Macular Edema,Device: micropulse laser;Drug: Aflibercept,Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema,CT.gov,2019-07-05,2016-04-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,N/A,40,University of Alexandria,NULL,NA,1,5/7/2019,"April 1, 2016",NCT040,22 July 2019,31181,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  patients were older than 18 with the clinical diagnosis of previously untreated centre<br>             involved DME documented by fluorescein angiography and central macular thickness (CMT)<br>             = 300 µm on the spectral-domain OCT Best corrected visual acuity was better than 3/60<br>             with Hb A1C less than 10%.<br><br>        Exclusion Criteria:<br><br>          -  any previous treatment for DME, proliferative diabetic retinopathy, macular ischemia<br>             on fluorescein angiography, epiretinal membrane or tractional maculopathy on OCT,<br>             media opacity and any previous intraocular surgery with the exception of uneventful<br>             cataract surgery more than 6 months before the beginning of the study.<br>",NULL,The number of Aflibercept injections in both groups,The changes in visual acuity in both groups.;The changes in central macular thickness in both groups.,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03862807,https://clinicaltrials.gov/show/NCT03862807,"An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant","Amyloidosis, Familial;Transthyretin Amyloidosis",Drug: Patisiran,Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant,CT.gov,2019-02-28,2019-03-27,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,20,Alnylam Pharmaceuticals,France;Germany;Italy;Portugal;Spain;Sweden;United Kingdom;France;Germany;Italy;Portugal;Spain;Sweden;United Kingdom,NA,NULL,28/2/2019,"March 27, 2019",NCT038,26 October 2020,2018-003519-24;ALN-TTR02-008,NA,"Jing Jing Wang, MD",NULL,NA,NA,Alnylam Pharmaceuticals,NA,"Jing Jing Wang, MD",NULL,NA,NA,Alnylam Pharmaceuticals,"Active, not recruiting",NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Received liver transplant for treatment of hATTR amyloidosis =12 months before study<br>             start<br><br>          -  Has increase in polyneuropathy disability (PND) score after liver transplant<br><br>          -  Has received stable immunosuppressive regimen with =10 mg/day of prednisone for at<br>             least 3 months before study start<br><br>          -  Has Karnofsky Performance Status (KPS) of =70%<br><br>          -  Has vitamin A level greater than or equal to lower limit of normal<br><br>        Exclusion Criteria:<br><br>          -  Has previously received inotersen or patisiran<br><br>          -  Has clinically significant liver function test abnormalities<br><br>          -  Has known portal hypertension with ascites<br><br>          -  Has estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m^2<br><br>          -  Has known leptomeningeal amyloidosis<br><br>          -  Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)<br><br>          -  Has New York Heart Association heart failure classification of >2<br><br>          -  Is wheelchair bound or bedridden<br><br>          -  Has received organ transplants other than liver transplant<br><br>          -  Will be using an other tetramer stabilizer during the study<br>",NULL,Average of Month 6 and Month 12 Percentage Reduction from Baseline in Serum Transthyretin (TTR),Change from Baseline in the Neuropathy Impairment Score (NIS) at Month 12;Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Score at Month 12;Change from Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Month 12;Change from Baseline in the Composite Autonomic Symptom Score (COMPASS-31) at Month 12;Change from Baseline in the Modified Body Mass Index (mBMI) at Month 12;Percentage of Participants With Adverse Events,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03993379,https://clinicaltrials.gov/show/NCT03993379,"A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors",Solid Tumor;Unresectable or Metastatic Melanoma,Drug: CX-072;Drug: Ipilimumab,PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors,CT.gov,2019-05-14,2019-11-20,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,3,CytomX Therapeutics,"United States;Australia;Korea, Republic of;Netherlands;Spain;Australia;Korea, Republic of;Netherlands;Spain;United States",NA,NULL,14/5/2019,"November 20, 2019",NCT039,3 August 2020,CTMX-M-072-002,NA,"Lawrence Lu, MD",NULL,NA,NA,CytomX Therapeutics,NA,"Lawrence Lu, MD",NULL,NA,NA,CytomX Therapeutics,Terminated,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. At least 18 years of age<br><br>          2. Measurable disease as defined by RECIST v1.1<br><br>          3. Eastern Cooperative Oncology Group (ECOG) performance status of =1<br><br>          4. Agree to provide tumor tissue and blood samples for biomarker assessment<br><br>        Exclusion Criteria:<br><br>          1. Treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or<br>             any investigational agent within 28 days prior to the first dose of study treatment.<br><br>          2. Prior therapy with a chimeric antigen receptor T cell-containing regimen<br><br>          3. History of active autoimmune disease(s) including but not limited to inflammatory<br>             bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis,<br>             systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune<br>             neuropathies, type 1 insulin-dependent diabetes mellitus<br><br>          4. History of myocarditis regardless of the cause<br><br>          5. History of intolerance to prior checkpoint inhibitor therapy defined as the need to<br>             discontinue treatment due to an irAE<br><br>          6. History of any syndrome or medical condition that required treatment with systemic<br>             steroids (=10 mg daily prednisone equivalents) or immunosuppressive medications.<br><br>          7. History of severe allergic or anaphylactic reactions to human mAb therapy or known<br>             hypersensitivity to any Probody therapeutic<br>",NULL,"Overall response rate by RECIST v 1,1",The percentage of patients experiencing Treatment Related Adverse Events;The numbers of patients experiencing anti-tumor activity by irRECIST,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
CTRI/2019/02/017575,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31281,"A double blind randomized study on comparision of safety and efficacy of caudal,thoracic epidural and intravenous analgesia in paediatric cardiac surgery","Health Condition 1: Q214- Aortopulmonary septal defectHealth Condition 2: Q211- Atrial septal defectHealth Condition 3: Q212- Atrioventricular septal defectHealth Condition 4: Q251- Coarctation of aortaHealth Condition 5: Q209- Congenital malformation of cardiacchambers and connections, unspecifiedHealth Condition 6: Q233- Congenital mitral insufficiencyHealth Condition 7: Q205- Discordant atrioventricular connectionHealth Condition 8: Q203- Discordant ventriculoarterial connectionHealth Condition 9: Q202- Double outlet left ventricleHealth Condition 10: Q201- Double outlet right ventricleHealth Condition 11: Q225- Ebsteins anomalyHealth Condition 12: Q234- Hypoplastic left heart syndromeHealth Condition 13: Q226- Hypoplastic right heart syndromeHealth Condition 14: Q263- Partial anomalous pulmonary venousconnectionHealth Condition 15: Q250- Patent ductus arteriosusHealth Condition 16: Q213- Tetralogy of FallotHealth Condition 17: Q262- Total anomalous pulmonary venous connectionHealth Condition 18: Q210- Ventricular septal defect",Intervention1: caudal analgesia: inj bupivacaine local anesthetic agent along with inj morphine 50 mcg/kg given in caudal epidural space as analgesia<br>Intervention2: thoracic epidural analgesia: with 20 g needle  24 g catheter insertedin T5-T7 epidural space.inj bupivacaine with inj fentanyl 3 mcg/kg/hr as infusion intra op and post operatively<br>Control Intervention1: intravenous analgesia: inj fentanyl infusion 2 mcg/kg.hr<br>,Comparative study of various analgesic methods in Pediatric cardiac surgery,CTRI,2019-02-11,2019-02-12,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded",N/A,90,vrajesh kumar kodali,India,NA,NULL,11-02-2019,12-02-2019,CTRI/2,4 November 2020,NIL,V Rajesh kumar kodali,NA,Department of AnesthesiologyPorurChennai SriRamachandra institute of Higher education and Research F6 Cardio thoracic ICU    Porur                           Chennai,vrajesh.kodali@gmail.com,9444230150,SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH,V Rajesh kumar kodali,NA,Department of Anesthesiology  Sri Ramachandra Institute of Higher Education and Research   SriRamachandra institute of Higher education and ResearchF6 cardiothoracic ICU      Porur                           Chennai,vrajesh.kodali@gmail.com,9444230150,SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH,Closed to Recruitment of Participants,NULL,"Sri ramachandra medical college ,Porur, Chennai",NA,NA,NA,"Inclusion criteria: all elective paediatric cardiac surgeries,RACHS score 1-4","Exclusion criteria: emergency paediatric cardiac surgeries ,RACHS score more than or equal to 5,coagulation abnormality,spinal cord anomaly","Post operative pain scoresTimepoint: Post operative pain scores 2hr ,4 hrs,6 hrs,12 hrs after shifting to icu","Duration of ventilation <br/ ><br>Duration of intensive care unit stayTimepoint: Duration of ventilation is noted in terms of no of hours on ventilator like 1 hour,2 hour ,Duration of icu stay noted in terms of days like 2-3 days",NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan 21 2019 12:00AM,NA,institutional ethics committee sri ramachandra university,NA,NA
CTRI/2019/02/017505,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31033,Evaluation of efficacy of optimized natural killer cells as an adjunct to allogeneic stem cell transplantation in the treatment of refractory acute myeloid leukemia - ONKAML,Health Condition 1: C920- Acute myeloblastic leukemia,"Intervention1: Natural Killer cells: Single Infusion of optimized natural killer cells derived from haplo- identical family donors.<br>With unstimulated apheresis, we would expect about 109 to 1010 mononuclear cells being separated. Of these, about 10% would constitute NK cells. Thus after CD3 depletion and CD56 positive selection, we would have about 108 to 109 NK cells. The isolated NK cells (to a final concentration of not less than 2Ã?106/mL) will be suspended overnight in plasmalyte (50 to 100 mL) supplemented with 20% autologous plasma, 500 U/mL interleukin (IL)-2 (Aldesleuchina, ProleukinÂ®) and 1 Î¼M arsenic trioxide (ATO) at 37 Â°C<br>Control Intervention1: Not applicable: Not applicable<br>",Natural killer cell treament for Blood cancer,CTRI,2019-02-06,2019-02-11,FALSE,Interventional,Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable,Phase 2,21,Department of Biotechnology India,India,NA,NULL,06-02-2019,11-02-2019,CTRI/2,4 November 2020,Not applicable,Vikram Mathews,NA,"Room no: 4, First floor,Department of Haematology, Christian Medical College, Vellore â?? 632004 Room no: 4, First floor,Department of Haematology, Christian Medical College, Vellore â?? 632004",vikram@cmcvellore.ac.in,04162282352,"Christian Medical College, Vellore",Vikram Mathews,NA,"Room no: 4, First floor,Department of Haematology, Christian Medical College, Vellore â?? 632004 Room no: 4, First floor,Department of Haematology, Christian Medical College, Vellore â?? 632004",vikram@cmcvellore.ac.in,04162282352,"Christian Medical College, Vellore",Not Yet Recruiting,NULL,"Department of Biotechnology, India, 6th-8th Floor, Block 2CGO Complex, Lodhi RoadNew Delhi - 110 003.",NA,NA,NA,Inclusion criteria: Signed and dated written informed consent by start date of Screening visit in accordance with GCP and local legislation <br/ ><br>Patients with refractory acute myeloid leukemia planned for allogeneic stem cell transplantation <br/ ><br>Any Age <br/ ><br>Eastern Cooperative Oncology Group (ECOG) performance score  <2 at screening <br/ ><br>Life expectancy of 4 â?? 6 weeks,Exclusion criteria: Hypersensitivity to chemo drugs <br/ ><br>Total bilirubin or liver enzymes greater than 3 times the upper limit of normal <br/ ><br>HIV infection <br/ ><br>,1-year relapse free survivalTimepoint: At 1 year,"Incidence of acute and chronic graft versus host disease and 1-year overall survivalTimepoint: 30 days, 100 days and at 1 year",NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan 15 2018 12:00AM,NA,Ethics Committee Silver,NA,NA
CTRI/2019/08/020943,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27713,"A Phase 2, randomized, prospective, double-masked, vehicle controlled study to assess the efficacy and safety of NexagonÂ® (NEXAGON) applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries. - EXPEDE",Health Condition 1: H160- Corneal ulcer,"Intervention1: 1. NEXAGON High Dose Concentration<br>Other Name: CODA001<br><br>2. NEXAGON Low Dose Concentration<br>Other Name: CODA001: Applied under a bandage contact lens and to the fornices of the eye on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.<br>NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED.<br><br><br>Intervention2: 2. NEXAGON Low Dose Concentration<br>Other Name: CODA001<br>: Applied under a bandage contact lens and to the fornices of the eye on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.<br>NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED.<br><br>Control Intervention1: NEXAGON Vehicle (placebo): Applied under a bandage contact lens and to the fornices of the eye on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.<br>NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED.<br><br>",To study the efficacy and safety of NexagonÂ® (NEXAGON) applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries.,CTRI,2019-08-28,2020-05-15,FALSE,Interventional,Other<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Double Blind Double Dummy,Phase 2,108,OcuNexus Therapeutics Inc,India;United States of America,NA,NULL,28-08-2019,15-05-2020,CTRI/2,4 November 2020,NEX-PED-005 version 3  01-Aug-2019,Dr Saurendra Das,NA,"Assotech Business Cresterra, Tower-2, 9th Floor, Units 909-913, Plot No 22, Sector 135",sauren@excellifesciences.com,01206280200,Excel Life Sciences Pvt. Ltd.,Dr Saurendra Das,NA,"Assotech Business Cresterra, Tower-2, 9th Floor, Units 909-913, Plot No 22, Sector 135",sauren@excellifesciences.com,01206280200,Excel Life Sciences Pvt. Ltd.,Open to Recruitment,NULL,"OcuNexus Therapeutics, Inc.12481 High Bluff Drive, Suite 150, San Diego, CA 92130 USA.",NA,NA,NA,"Inclusion criteria: 1.Male and female of any age. <br/ ><br>2.The presence of a non-infected, corneal persistent epithelial defect (PED) which has resulted from a severe chemical and/or thermal (burn) injury to one or both eyes. <br/ ><br>3.The PED is non-responsive to current standard of care for at least 14 days from injury. <br/ ><br>4.The PED measures at least 2 mm along the largest diameter at Day 1 of the Treatment Period. <br/ ><br>5.Providing written informed consent and ability to comply with the visit and dosing schedule. <br/ ><br>","Exclusion criteria: 1.Subjects who will be unlikely to tolerate the wearing of a Bandage Contact Lens. <br/ ><br>2.Have active ocular infection. <br/ ><br>3.Subjects with corneal perforation or impending corneal perforation. <br/ ><br>4.Subjects receiving systemic corticosteroids (equivalent to GREATER THAN 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents unless the dose has remained unchanged for 30 days and will remain unchanged during the study. <br/ ><br>5.Subjects with severe lid abnormalities or ocular conditions that contribute to the persistence of the epithelial defect. <br/ ><br>6.Female subjects of childbearing potential who are pregnant, nursing, planning a pregnancy or not using an adequate and medically acceptable form of birth control. <br/ ><br>7.Subjects who have participated in an interventional clinical trial within 30 days prior to Day 1. <br/ ><br>","Corneal epithelial recovery, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least 28 days after initial re-epithelialization first recorded, as assessed by the investigator.Timepoint: Upto 56 days","1.Time to corneal epithelial recovery, defined as the time from randomization to the time of the initial corneal re-epithelialization. <br/ ><br>2.Improvement of visual acuity from baseline over the course of the study period <br/ ><br>3.Number of NEXAGON treatment doses required for recovery of the corneal epithelium  <br/ ><br>Timepoint: 1.Within 42 days <br/ ><br>2.Up to 98 days (plus 2 days) <br/ ><br>3.Within 42 days <br/ ><br>",NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved,Dec 31 2019 12:00AM;Feb 20 2020 12:00AM;Feb 25 2020 12:00AM;May 14 2019 12:00AM;Apr 18 2019 12:00AM;Dec 31 2018 12:00AM;Aug 23 2019 12:00AM;Feb 11 2019 12:00AM;Jan  7 2020 12:00AM;Dec 31 2019 12:00AM;Jun  7 2019 12:00AM;Apr 26 2019 12:00AM;Dec 24 2019 12:00AM;Jan 25 2020 12:00AM,;;;;;;;;;;;;;,"All India Institute of Medical Sciences, New Delhi.;B.J. Medical College & Civil Hospital, Ahmedabad-380016, Gujarat;Dr. Shroffâ??s Charity Eye Hospital, Ethics Committee at Dr. Shroffâ??s Charity Eye Hospital, 5027, Kedarnath Road, Daryaganj, New Delhi-110002;Ethics Committee situated at L. V. Prasad Eye Institute Kallam Anji Reddy Campus,  LV Prasad Marg, Road No. 2 Banjara Hills Hyderabad-500034;Ethics Committee, L V Prasad Eye Institute Situated at Patia, Bhubaneshwar-751024, Odisha;Indira Gandhi Institute of Medical Sciences IGMS Sheikhpura, Patna-800014 Bihar;Institutional Ethics Committee of Topiwala National Medical College and BYL Nair Charitable Hospital, G Building Ground Floor, Dr A.L Nair Road,Mumbai-400008, Maharashtra;Institutional Ethics Committee situated at Disha Eye Hospital Pvt Ltd 88 (63A) Ghosh Para road Barrackpore Kolkata-700120, West Bengal;Institutional Ethics Committee, PBMS H.V Desai Eye Hospital, S.No.93 Taravade Vasti, Mohammadwadi, Hadapsar Pune-411060, Maharashtra;Kanpur Medical Ethics Committee at JL Rohatgi Hospital 117/52 Sarvodaya Nagar, kanpur-208005, Uttar Pradesh;L V Prasad Eye Institute Ethics Committee, GMR Varalakshmi Campus, Hanumanthawaka Junction, Visakhapatnam-530040, Andhra Pradesh;Maulana Azad medical College 3rd Floor Room No. 306B Bahadur Shah Zagar Marg, New Delhi;Sankara Eye Care Institute sathy Road Sivanandapuram Coimbatore-641035, Tamil Nadu;SMS Medical College and Attached Hospitals Jaipur 1st Floor Dhanvantri OPD block SMS Hospital, JLN Marg Jaipur-302004, Rajasthan",;;;;;;;;;;;;;,;;;;;;;;;;;;;
CTRI/2019/01/017332,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30522,An open label single arm non-comparativeStudy to assess effectiveness and safety ofZolpidem Tartrate in patients of insomniaWith Diabetes Mellitus,Health Condition 1: G470- Insomnia,"Intervention1: Zolpidem Tartrate: Zolpidem is indicated for the short-term treatment of insomnia. The treatment should be taken in a single intake and not be re-administered during the same night. The recommended daily dose for adults is 10 mg to be taken orally immediately at bedtime. The lowest effective daily dose of Zolpidem tartrate should be used and must not exceed 10 mg. The duration of treatment should usually vary from a few days to two weeks with a maximum of four weeks including tapering off where clinically appropriate. As with all hypnotics, long-term use is not recommended.<br>Dose : Daily 1 tablet orally in Night <br>Duration : 3 Weeks treatment/patient<br>Control Intervention1: Not Applicable: Not Applicable<br>",A scientific study to check how much the drug Zolpidem tartrate is effective and safe in the patients of Insomnia (slip disorder) with Diabetes Mellitus,CTRI,2019-01-31,2019-02-01,FALSE,Interventional,Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label,Phase 4,50,Dr Faraz Farishta,India,NA,NULL,31-01-2019,01-02-2019,CTRI/2,4 November 2020,ZOLTD003 Version 1.0 Dated 05 Aug 2019,Dr Faraz Farishta,NA,"Room No. 1, Opposite Indo English High School, Santosh Nagar Main Rd, Santosh Nagar, Hyderabad, Telangana 500059",drfarazfarishta@gmail.com,9885035977,F S Endocrinology & Diabetic Centers,Dr Faraz Farishta,NA,"Room No.1, Opposite Indo English High School, Santosh Nagar Main Rd, Santosh Nagar, Hyderabad, Telangana 500059",drfarazfarishta@gmail.com,9885035977,F S Endocrinology & Diabetic Centers,Open to Recruitment,NULL,"Dr. Faraz Farishta, Opposite Indo English High School, Santosh Nagar Main Rd, Santosh Nagar, Hyderabad, Telangana 500059",NA,NA,NA,"Inclusion criteria: 1. Healthy adult patients (both male and female) who are 18 to  < 65 years of age. <br/ ><br>2. Must experience sleep disturbances (difficulty in sleep initiation or middle of the night awakening or early morning awakening or poor quality of sleep) for at least 3 nights/week, based on historical data. <br/ ><br>3. Insomnia Severity Index score of â?¥ 8 at screening. <br/ ><br>4. Patients with a clinical diagnosis of Diabetes Mellitus on treatment with anti diabetic agents. (At least one year prior to screening). <br/ ><br>5. Patient willing to sign informed consent form.","Exclusion criteria: 1. Currently using prescription and non-prescription sedative drugs given for more than 2 days for the purpose of sleep disturbances or to relieve jet lag with the last 28 days proceeding to enrolment. <br/ ><br>2. Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous 28 days. <br/ ><br>3. Evidence of any medical condition as revealed by history, physical examination or laboratory assessment which may interfere with administration or assessment of study medication. <br/ ><br>4. History of current Hypertension. <br/ ><br>5. Current alcohol or drug abuse. <br/ ><br>6. Patients viewed by the investigator as not being able to complete the study. <br/ ><br>7. History of obstructive sleep apnoea or restless leg syndrome <br/ ><br>8. History of myasthenia gravis <br/ ><br>9. History of hepatic insufficiency <br/ ><br>10. History of respiratory depression <br/ ><br>11. Patients with a known history of hypersensitivity to Zolpidem tartrate or any of the inactive ingredients <br/ ><br>12. The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebro vascular disease or malignancy. <br/ ><br>13. Patients with history of severe cardiac, hepatic, neurological and renal diseases within 6 months prior of screening. <br/ ><br>14. Pregnant or breastfeeding. <br/ ><br>15. Patient having participated in a clinical trial in the month before. <br/ ><br>16. Patients with history of bipolar disorder, psychosis, major depression, unstable anxiety disorders/panic attacks. <br/ ><br>17. Patients with cognitive impairment <br/ ><br>18. Elderly patients having symptoms of urinary obstructions <br/ ><br>19. Patients with symptoms of chronic/ incapacitating pain <br/ ><br>20. Patients with diabetic neuropathy <br/ ><br>21. Patients with any other serious disease or condition at screening that might affect the <br/ ><br>normal sleep pattern. <br/ ><br>22. Known history of other sleep disorders (i.e. narcolepsy; hypersomnia; parasomnias <br/ ><br>such as sleep walking, night terrors, recurring nightmares; circadian rhythm sleep <br/ ><br>disorder) <br/ ><br>23. Patients who are taking other CNS depressants drugs like antipsychotics <br/ ><br>(neuroleptics), hypnotics, anxiolytics/sedatives, antidepressant agents, narcotic analgesics, antiepileptic drugs, anaesthetics and sedative antihistamines or CYP 3A4 or CYP 1A2 inducers or inhibitors.",To measure the change in Insomnia severity index (ISI)ScoreTimepoint: Baseline visit to Day 21 Visit,To measure the change in HbA1c ScoreTimepoint: Baseline visit to Day 90;To measure the change in HRQoL ScoreTimepoint: Baseline visit to Day 21 Visit,NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Aug 19 2019 12:00AM,NA,Thumbey Hospital India Pvt Ltd,NA,NA
CTRI/2019/04/018410,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31674,EVALUATION OF DIFFERENT CONCENTRATION OF BHRINGRAJ TAILA ON PALITYA,Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere,Intervention1: group A: Nasya with bhringraj taila for a period of 45 days.<br>Dose: 6-8 drops Marsha<br>1-2 Drops Pratimarsha<br>In B/W the sitting of marsha pratimarsha will be given<br>Control Intervention1: group B: Nasya with double concentration bhringraj taila<br>,Effect of Bhringraj Tail In Premature Graying of Hair,CTRI,2019-04-03,2019-04-12,FALSE,Interventional,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",N/A,30,Rishikul campus,India,NA,NULL,03-04-2019,12-04-2019,CTRI/2,4 November 2020,NIL,Dr Sushma Rawat,NA,"Rishikul Campus,UAU,Haridwar",sushmarawat27@gmail.com,7617410346,"Rishikul campus,UAU,Haridwar",Dr Sushma Rawat,NA,"Rishikul Campus,UAU,Haridwar",sushmarawat27@gmail.com,7617410346,"Rishikul campus,UAU,Haridwar",Not Yet Recruiting,NULL,"Department of Rasa-shastra & Bhaishajya kalpana,Rishikul campus, u.a.u., haridwar",NA,NA,NA,"Inclusion criteria: 1.Patient presenting with premature graying of hair will be selected irrespective of their gender ,caste &greed. <br/ ><br>2. Age group below 30 years.","Exclusion criteria: 1.Pitta prakriti subjects. <br/ ><br>2.Patient suffering from albinism,vitiligo,throid disorders,liverdisorders, renal impairment. <br/ ><br>3.Nutritional deficiency like pernicious anemia. <br/ ><br>",1.A thorough history of the entire patient will be taken. <br/ ><br>2.Overall assessment will be done the basis of improvement of sign and  symptoms of palitya. <br/ ><br>.cured:90% relief in sign & symptoms. <br/ ><br>.Markedly improvement: 76-90% relief in sign & symptoms. <br/ ><br>.Moderate improvement:51-75% relief in sign& symptoms. <br/ ><br>Mild improvement:26-50% relief in sign& symptoms. <br/ ><br>.unchanged or no improvement:25% relief in sign & symptoms.Timepoint: 1st day 21st day & 45th day,Excaberation in Signs and SymptomsTimepoint: 2 months,NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Oct 30 2018 12:00AM,NA,Institutional ethical committee,NA,NA
CTRI/2019/02/017661,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31293,A Comparative Clinical Study of Arka And Apamarga Pratisaraneeya Kshara In The Management of Arsha,Health Condition 1: K641- Second degree hemorrhoids,"Intervention1: arka pratisaraneeya kshara: the whole plant of arka (calotropis procera)are burnt, the ash is collected and added water and reduced by heating and sankh nabhi, etc were mixed and final form of drug was obtained.<br>Control Intervention1: apamarga pratisaraneeya kshara: the whole plant of apamarga (achyranthes aspera linn.)are burnt, the ash is collected and added water and reduced by heating and sankh nabhi, etc were mixed and final form of drug was obtained.<br>",management of ano rectal piles with kshara,CTRI,2019-02-14,2019-03-01,FALSE,Interventional,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Outcome Assessor Blinded",Phase 2/ Phase 3,40,Department of Shalya Tantra,India,NA,NULL,14-02-2019,01-03-2019,CTRI/2,4 November 2020,NIL,Pratik Kumar Keshari,NA,"opd no 116, shalya department, parul ayurved hospital, parul university, vadodara",vivekkullolli@rediffmail.com,9945079276,parul institute of ayurveda,Dr Vivekanand Kullolli,NA,"opd no 116, shalya department, parul ayurved hospital, parul university, vadodara",vivekkullolli@rediffmail.com,9945079276,parul institute of ayurveda,Not Yet Recruiting,NULL,"parul institute of ayurveda, Vadodara, Gujrat",NA,NA,NA,"Inclusion criteria: 1.diagnosed cases of raktaja, pittaja and raktajpittaja arsha <br/ ><br>2. 1 and 2 degree haemorrhoids <br/ ><br>","Exclusion criteria: 1. vataja and kaphaja arsha <br/ ><br>2. ayogya for kshara prayoga <br/ ><br>3. pregnancy, hiv etc",reduction in  size of pile massTimepoint: on 1 day,reduction in  size of pile massTimepoint: 1 month,NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan  4 2019 12:00AM,NA,institutional ethical committe,NA,NA
CTRI/2019/05/018959,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32290,"Phase 3, Randomized, Open-label, Controlled,Multiple-Dose, Efficacy, Safety,Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to lesser than 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",Health Condition 1: N258- Other disorders resulting from impaired renal tubular function,Intervention1: Etelcalcetide (AMG 416): Etelcalcetide (AMG 416) IV TIW  (3 times per week)<br>Control Intervention1: Not Applicable: Not Applicable<br>,A Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis,CTRI,2019-05-06,2019-06-30,FALSE,Interventional,Other<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label,Phase 3,56,Amgen Technology Pvt Ltd,Argentina;India;Republic of Korea;Russian Federation;Singapore;Taiwan;Turkey;Ukraine;United States of America;Malaysia,NA,NULL,06-05-2019,30-06-2019,CTRI/2,4 November 2020,"20140315, Amendment 3.0 dated 9 Oct 2019;NCT03633708",Himani Parikh,NA,"Dynasty Business Park, A Wing, Level 4,Andheri-Kurla Road,Andheri (E)",hparikh@amgen.com,022677879304,Amgen Technology Private Limited,Himani Parikh,NA,"Amgen Technology Private Limited, Dynasty Business Park, A Wing, Level 4, Andheri Kurla Road,Andheri East",hparikh@amgen.com,022677879304,Amgen Technology Private Limited,Open to Recruitment,NULL,"Amgen Technology Pvt. Ltd, Dynasty Business Park, A Wing, Level 4, Andheri Kurla Road, Andheri (E), Mumbai - Maharashtra - 400059",NA,NA,NA,"Inclusion criteria: 1. Subjectâ??s legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated. <br/ ><br>2. Male or female subjects 28 days to  < 18 years of age at the time of enrollment. <br/ ><br>3. Dry weight â?¥ 7 kg during screening. <br/ ><br>4. Diagnosed with CKD and SHPT undergoing hemodialysis at the time of screening (subjects 6 months or older should have been receiving hemodialysis for â?¥ 1 month) no specific duration of current hemodialysis history is required for subjects 28 days to  < 6 months of age â?? only need to be undergoing hemodialysis at time of screening <br/ ><br>5. Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values â?¥ 400 pg/mL (42 pmol/L) during screening, on separate days and within 2 weeks of enrollment obtained from the central laboratory during screening. <br/ ><br>6. Serum cCa value â?¥ 9.0 mg/dL (2.25 mmol/L) for subjects â?¥ 2 years of age and older and serum cCa value â?¥ 9.6 mg/dL (2.4 mmol/L) for subjects 28 days to  < 2 years of age obtained from the central laboratory during screening. <br/ ><br>7. Dialysate Ca level â?¥ 2.5 mEq/L during screening. <br/ ><br>8. Subject receiving active vitamin D sterols must have had a stable dose within the 2 weeks prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable doses for the duration of the study, except for adjustments allowed per protocol                                                  9. Subject receiving phosphate binders must have had a stable dose within the 2 weeks prior to screening laboratory assessments, remain stable through <br/ ><br>randomization, and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol. <br/ ><br>10. Subject receiving Ca supplements must have had a stable dose within the 2 weeks prior to screening laboratory assessments and remain stable through randomization and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol. <br/ ><br>11. SHPT not due to vitamin D deficiency, per investigator assessment","Exclusion criteria: Disease Related <br/ ><br>1. History of congenital long QT syndrome, second or third degree heart block, <br/ ><br>ventricular tachyarrhythmiaâ??s or other conditions associated with prolonged QT <br/ ><br>interval. <br/ ><br>2. Anticipated or scheduled parathyroidectomy during the study period. <br/ ><br>3. Anticipated or scheduled kidney transplant during the study period. <br/ ><br>4. Subject has received a parathyroidectomy within 6 months prior to <br/ ><br>randomization. <br/ ><br>Other Medical Conditions <br/ ><br>5. History of other malignancy, except non-melanoma skin cancers, cervical or <br/ ><br>breast ductal carcinoma in situ within the last 5 years. <br/ ><br>Prior/Concomitant Therapy <br/ ><br>6. Use of concomitant medications that may prolong the corrected QT interval <br/ ><br>(eg, ondansetron, albuterol, sotalol, amiodarone, erythromycin, or <br/ ><br>clarithromycin). Refer to CredibleMeds.org for guidance. <br/ ><br>7. Receipt of cinacalcet therapy within 30 days prior to screening assessments <br/ ><br>and through randomization. <br/ ><br>8. Receipt of etelcalcetide within 6 months prior to screening assessments and <br/ ><br>through randomization. <br/ ><br>9. All herbal medicines (eg, St. Johnâ??s wort), vitamins, and supplements <br/ ><br>consumed by the subject within the 30 days prior to randomization, and <br/ ><br>continuing use if applicable, will be reviewed by the Principal Investigator and <br/ ><br>the Amgen Medical Monitor. Written documentation of the review and Amgen <br/ ><br>acknowledgment is required for subject participation. <br/ ><br>10. Use of any over-the-counter or prescription medications within the 14 days or <br/ ><br>5 half-lives (whichever is longer) prior to randomization that are not <br/ ><br>established therapies for subjects with renal disease or other conditions <br/ ><br>secondary to renal disease will be reviewed by the Principal Investigator and <br/ ><br>the Amgen Medical Monitor. Written documentation of the review and Amgen <br/ ><br>acknowledgment is required for subject participation. Paracetamol (up to <br/ ><br>2 g per day) for analgesia will be allowed. <br/ ><br>Prior/Concurrent Clinical Study Experience <br/ ><br>11. Currently receiving treatment in another investigational device or drug study, <br/ ><br>or less than 30 days or 5 half-lives (whichever is longer) since ending <br/ ><br>treatment on another investigational device or drug study(ies). Other <br/ ><br>investigational procedures while participating in this study are excluded. <br/ ><br>Diagnostic Assessments During Screening <br/ ><br>12. Subject has significant abnormalities on the most recent central laboratory test <br/ ><br>during the screening period prior to enrollment per the Investigator including <br/ ><br>but not limited to the following: <br/ ><br>a. Serum transaminase (alanine aminotransaminase [ALT] or serum <br/ ><br>glutamic pyruvic transaminase [SGPT], aspartate aminotransferase <br/ ><br>[AST] or serum glutamic oxaloacetic transaminase [SGOT]) <br/ ><br> > 2.0 times the upper limit of normal (ULN). <br/ ><br>13. Corrected QT interval (QTc)  > 500 ms, using Bazettâ??s formula. <br/ ><br>14. QTc â?¥450 to â?¤ 500ms using Bazettâ??s formula, unless writted permission to <br/ ><br>enroll is provided by the investigator after consultation with a pediatric <br/ ><br>cardiologist. <br/ ><br>15. Subject has a clinically significant electrocardiogram (ECG) abnormality during <br/ ><br>screening that, in the opinion of the investigator, could pose a risk to subject <br/ ><br>safety or interfere with the study evaluation. <br/ ><br>Within the 60 days pr",To evaluate the efficacy of etelcalcetide in reducing the intact parathyroid hormone level (iPTH) by  30% in children ages 28 days to  18 years with secondary hyperparathyroidism (SHPT) receiving maintenance hemodialysisTimepoint: Achievement of at least a 30% reduction from baseline in mean iPTH during the efficacy assessment phase (EAP),"1. To characterize PK of etelcalcetide treatment:Cmax and Cmin <br/ ><br>2. To characterize the safety of etelcalcetide treatment <br/ ><br>3. To characterize change in laboratory markers of CKD following etelcalcetide treatmentTimepoint: Nature,frequency,severity & relationship to treatment of all adverse events, incld. those of special interest reported during study,Frequency of hypocalcemia,Occurrence of corrected serum Ca levels during the study,Changes in laboratory parameters at scheduled visits. <br/ ><br>Percent change from baseline in predialysis iPTH during the EAP & Percent change in corrected total serum Ca and serum phosphorus from baseline during the EAP",NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved;Approved;Approved;Approved;Approved;Approved,Dec 19 2018 12:00AM;Dec 11 2019 12:00AM;Jul  1 2019 12:00AM;Jun  3 2019 12:00AM;Oct  9 2019 12:00AM;Jul 30 2019 12:00AM,;;;;;,"Ethics Committee for Research, Fortis Flt. Lt. Rajan Dhall Hospital, Dr. Sanjeev Gulati;Ethics Committee, Manipal Hospitals, Dr. Vishwanath Siddini;Ethics Committee, N.R.S Medical College, Dr. Biswanath Basu;Ethics Committee, Sir Ganga Ram Hospital, Dr. Kanav Anand;Institute Ethics Committee, All India Institute of Medical Sciences, Dr. Aditi Sinha;Institutional Ethics Committee, KLEs Dr Prabhakar kore Hospital, Dr. Mahantesh Patil",;;;;;,;;;;;
CTRI/2019/04/018467,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32630,Effectiveness of Anti-neuropathic medicines(Gabapentin andAmitryptiline) in Rheumatoid Arthritis patients for pain relief. - NIL,Health Condition 1: M05- Rheumatoid arthritis with rheumatoid factor,"Intervention1: Gabapentin and Amitryptiline,in addition to<br>conventional DMARDs: Gabapentin will be administered<br>starting with a dose of 300mg once daily for 5 days followed by 300mg twice daily for 5 days and<br>finally 300mg three times daily to continue for 16 weeks till end of study. <br>Amitryptiline will be given in a dose of<br>10 mg daily at 8.00p.m. for 16 weeks till end of study.<br>Control Intervention1: continue only with Disease Modifying Anti Rheumatic Drugs: Methotraxate, Sulfasalazine, Hydroxychloroquine in recommended dose either singly or in combination<br>",Effects of Gabapentin and Amitryptiline for pain management in Rheumatoid Arthritis patients.,CTRI,2019-04-08,2019-04-08,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Random Number Table  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant Blinded",Phase 4,30,ESI Institute of Pain Management,India,NA,NULL,08-04-2019,08-04-2019,CTRI/2,4 November 2020,NIL,Dr Subrata Goswami,NA,"ESI Institute of Pain Management, Department of Pain Management, ESI Hospital, Sealdah. 301/3 APC Road, Kolkata 700009.",drsgoswami@gmail.com,09830430430,ESI Institute of Pain Management,Dr Subrata Goswami,NA,"ESI Institute of Pain Management, Department of Pain Management, ESI Hospital, Sealdah. 301/3 APC Road, Kolkata 700009.",drsgoswami@gmail.com,09830430430,ESI Institute of Pain Management,Not Yet Recruiting,NULL,"ESI Hospital, Sealdah301/3 APC Road, Kolkata 700009",NA,NA,NA,"Inclusion criteria: 2.Seropositivityie. rheumatoid factor positive <br/ ><br>3.On DMARDs[single or combination] for more than 3 months <br/ ><br>4.Pain Score ie.NRS more than 4/10 <br/ ><br>5.Presence of neuropathic components like complaints of burning ,tingling nature of pain, <br/ ><br>numbness, hyperaesthesia, distant pain, pain experienced in areas outside the affected joints etc.","Exclusion criteria: 1.Acute flare <br/ ><br>2.Seronegativity <br/ ><br>3.History of mental illness like MDP ,Schizophrenia or other psychoses <br/ ><br>4.History of IHD, Ventricular conduction defects, Stroke, Liver disease, seizure disorders <br/ ><br>5.Pregnancy","Pain in Numeric Rating ScaleTimepoint: Day 0, At 4 weeks, 8 weeks, 12 weeks, and 16 weeks.",NILTimepoint: NA,NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan 19 2019 12:00AM,NA,"Institutional Ethics Committee, ESI Institute of Pain management",NA,NA
CTRI/2019/04/018681,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30558,Randomised control study on association between timing of zoledronic acid infusion and hip fracture healing in patients more than 50 years of age,Health Condition 1: M810- Age-related osteoporosis without current pathological fracture,"Intervention1: Inj zoledronic acid infusion at 1st week: Injection Zoledronic acid 5mg/100ml i.v. slowly over 1 hour at first week of fracture, dosage is once in a year<br>Control Intervention1: Inj Zoledrinic acid infusion at 6 weeks: Injection Zoledronic acid 5mg/100ml i.v. slowly over 1 hour at 6 weeks of fracture,dosage is once in a year<br>Control Intervention2: No Inj Zoledronic acid infusion: No Inj Zoledronic acid infusion to patients<br>",Association between timing of zoledronic acid infusion    and hip fracture healing in elderly patients.,CTRI,2019-04-22,2019-04-25,FALSE,Interventional,Cluster Randomized Trial<br>  Method of generating randomization sequence:Other  Method of allocation concealment:Other  Blinding and masking:Outcome Assessor Blinded,Post Marketing Surveillance,300,Dr Harsh Jalan,India,NA,NULL,22-04-2019,25-04-2019,CTRI/2,4 November 2020,NIL,Dr Harsh Jalan,NA,"Department of orthopedics,Ganga Hospital313, Mettupalayam Road, coimbatore Ganga Hospital313, Mettupalayam Road, coimbatore",orthoram@gmail.com,6001732851,Ganga Medical Centre and Hospital,Dr Ramesh Perumal,NA,"Department of orthopedicsGanga Hospital313, Mettupalayam Road, coimbatore Ganga Hospital313, Mettupalayam Road",orthoram@gmail.com,6001732851,Ganga Medical Centre and Hospital,Not Yet Recruiting,NULL,"313, Ganga Medical Centre and Hospital, Mettupalayam road, coimbatore-641043, Tamil Nadu",NA,NA,NA,Inclusion criteria: All patients greater then 50yrs age coming to our hospital with inter-trochanteric femur fracture and treated with closed reduction and nailing of femur,Exclusion criteria: patients with hepatic or renal failure <br/ ><br>patients with history of chronic steroid intake <br/ ><br>patient with history of malignancy <br/ ><br>patients with pathological fracture,Assessment of fracture healingTimepoint: outcome assessed at end of one year,To assess the morbidity and mortality associated with Inj. Zoledronic AcidTimepoint: % of complication in 1 year follow-up,NA,NULL,NA,0,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Nov  3 2018 12:00AM,NA,Institutional Review Board,NA,NA
EUCTR2019-004010-34-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004010-34,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study - ClaTBI/2019","Accute myeloid leukemia <br>MedDRA version: 21.0Level: LLTClassification code 10028557Term: Myeloid leukemia, acuteSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]",<br>Product Name: Cladribine<br>Pharmaceutical Form: Infusion<br><br>,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study",EUCTR,2019-11-05,2020-05-18,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,16,"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Oddzial w Gliwicach",Poland,NA,NULL,05/11/2019,18/05/2020,EUCTR2,25 May 2020,ClaTBI/2019,COI Centrala,NA,ul. Wybrzeze Armii Krajowej 15,onkologia@io.gliwice.pl,(32)2788886,"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Oddzial w Gliwicach",COI Centrala,NA,ul. Wybrzeze Armii Krajowej 15,onkologia@io.gliwice.pl,(32)2788886,"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Oddzial w Gliwicach",Authorised-recruitment may be ongoing or finished,NULL,"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Oddzial w Gliwicach",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>-patients with acute myeloid leukemia diagnosed with complete remission,<br>- low-risk disease with positive residual disease or intermediate and high risk disease regardless of residual disease status (according to ELN),<br>- demonstrated chemosensitivity after induction treatment with cladribine,<br>- age 18 to 60 years old,<br>- clinical condition according to WHO 0-1,<br>- planned transplantation from a HLA compatible or unrelated family HLA compatible donor,<br>- a negative result towards the active replication of HBV, HCV and HIV,<br>- organ capacity assessment on a WHO scale <3,<br>- signed informed consent to participate in the study.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 16<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>- patients with known low-risk acute myeloid leukemia with negative residual disease (according to ELN),<br>- demonstration of no chemosensitivity in case of induction treatment with cladribine,<br>- positive pregnancy result, lactation period,<br>- coexistence of another cancer disease,<br>- current severe active infection,<br>- previous hematopoietic cell allotransplantation from the same or different donor.<br><br>",Main Objective: Evaluation and safety of conditioning treatment with cladribine and TBI at a dose of 12 Gy.;Secondary Objective: ;Primary end point(s): • Relapse-free survival (RFS)<br>• Overall survival (OS)<br>• Relapse probability (RI)<br>• Non-relapse mortality (NRM)<br>• Presence of graft versus host disease (GvHD) - acute and chronic<br>• Time to get the implant<br>• Relapse-free and GvHD (GRFS) survival<br>• The frequency of individual side effects;Timepoint(s) of evaluation of this end point: From inclusion in the study to completion of the observation.,NULL,NA,NULL,Date trial authorised,NA,NA,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Dec 19 2019 12:00AM,NA,NA,NA,NA
EUCTR2019-001854-24-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001854-24,Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus.                Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study. - TACmono long-term.,kidney transplantation                vaccination responses;Therapeutic area: Body processes [G] - Immune system processes [G12],<br>                Trade Name: Pneumovax23<br>                Product Name: Pneumovax23<br>                Pharmaceutical Form: Injection<br><br>,Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus.                Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study.,EUCTR,2019-07-17,2019-08-07,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: no<br>                Randomised: no<br>                Open: no<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: no<br>                Other: no<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,76,Erasmus Medical Center,Netherlands,NA,NULL,17/07/2019,07/08/2019,EUCTR2,10 December 2019,NL67751.078.18,AE de Weerd,NA,dr Molewaterplein 40,a.deweerd@erasmusmc.nl,00310618834197,Erasmus Medical Center,AE de Weerd,NA,dr Molewaterplein 40,a.deweerd@erasmusmc.nl,00310618834197,Erasmus Medical Center,Authorised-recruitment may be ongoing or finished,NULL,ERasmus Medical Center,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                In order to be eligible to participate in this study, a subject must meet all of the following criteria:<br>                -recipient of a kidney transplant who has participated in the study: ‘Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study’, NL46834.078.14.<br>                -able to give written informed consent<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) no<br>                F.1.2.1 Number of subjects for this age range 36<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 40<br>",Exclusion criteria: <br>                A potential subject who is unable to give written informed consent will be excluded from participation in this study.<br><br><br>,<br>                Main Objective: 1.To compare long-term outcomes  in low-risk kidney transplant recipients on tacrolimus monotherapy versus dual regimen with tacrolimus and mycophenolate mofetil (TAC vs TAC/MMF).<br>                a.Renal function and proteinuria.<br>                b.Patient survival.<br>                c.Rejection episodes.<br>                d.Infectious complications.<br>                e.Malignancy (Skin and Non-skin).<br>            ;<br>                Secondary Objective: 1.To investigate the incidence and course of donor-specific antibodies in low-risk kidney transplant recipients beyond one year after transplantation (TAC vs TAC/MMF comparison).<br><br>                2.To investigate protective antibody responses after pneumococcal vaccination in patients using tacrolimus versus tacrolimus/ mycophenolate mofetil (TAC vs TAC/MMF comparison).<br>            ;<br>                Primary end point(s): 1.Long-term outcomes  in low-risk kidney transplant recipients on tacrolimus monotherapy versus dual regimen with tacrolimus and mycophenolate mofetil (TAC vs TAC/MMF).<br>                a.Renal function and proteinuria.<br>                b.Patient survival.<br>                c.Rejection episodes.<br>                d.Infectious complications.<br>                e.Malignancy (Skin and Non-skin).<br>            ;Timepoint(s) of evaluation of this end point: From inclusion 4 years after kidney transplantation till six years after kidney transplantation.,Timepoint(s) of evaluation of this end point: From inclusion 4 years after kidney transplantation till six years after kidney transplantation.;<br>                Secondary end point(s): 1.The incidence and course of donor-specific antibodies in low-risk kidney transplant recipients beyond one year after transplantation (TAC vs TAC/MMF comparison).<br><br>                2.The protective antibody responses after pneumococcal vaccination in patients using tacrolimus versus tacrolimus/ mycophenolate mofetil (TAC vs TAC/MMF comparison).<br>,NA,NULL,Date trial authorised,NA,NA,Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus.                 Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study.,NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2018-003012-51-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003012-51,"A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib - SAVANNAH","EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer <br>MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]",<br>Trade Name: TAGRISSO<br>Product Name: osimertinib<br>Product Code: AZD9291<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Osimertinib<br>CAS Number: 1421373-66-1<br>Current Sponsor code: AZD9291<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 80-<br><br>Trade Name: TAGRISSO<br>Product Name: osimertinib<br>Product Code: AZD9291<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Osimertinib<br>CAS Number: 1421373-66-1<br>Current Sponsor code: AZD9291<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br><br>Product Name: Savolitinib<br>Product Code: AZD6094<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Savolitinib<br>CAS Number: 1313725-88-0<br>Other descriptive name: SAVOLITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-200<br><br>Product Name: Savolitinib<br>Product Code: AZD6094<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Savolitinib<br>CAS Number: 1313725-88-0<br>Other descriptive name: SAVOLITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-100<br><br>,Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib,EUCTR,2019-03-21,2019-05-15,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 1<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,197,AstraZeneca AB,"United States;Taiwan;Spain;Chile;Israel;Italy;Vietnam;India;France;Canada;Brazil;Denmark;Japan;Korea, Republic of",NCT03778229,NULL,21/03/2019,15/05/2019,EUCTR2,10 August 2020,D5084C00007;NCT03778229,Information Centre,NA,Not applicable,informationcentre@astrazeneca.com,NA,AstraZeneca,Information Centre,NA,Not applicable,informationcentre@astrazeneca.com,NA,AstraZeneca,Authorised-recruitment may be ongoing or finished,NULL,AstraZeneca AB,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>- Patients must be =18 years of age (=20 years of age in Japan).  All genders are permitted.<br><br>- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.<br><br>- Documented radiologic disease progression following treatment with osimertinib (osimertinib does not need to be the most recent therapy).<br><br>- MET amplification/high expression as determined by FISH (central), IHC (central) or NGS (pre-existing) testing on tumour tissue collected following progression on prior osimertinib treatment.<br><br>- Available tissue from a biopsy for central MET FISH and ICH analysis or willingness to collect additional tissue for central testing which fulfils the following requirements: obtained within 2 years of submission for MET analysis; sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual. <br><br>- At least 1 lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as =10 mm in the longest diameter (except lymph nodes which must have short axis =15 mm) with CT or MRI which is suitable for accurate repeated measurements.  <br><br>- Received at least 1 but no more than 3 prior lines of therapy (may include investigational therapy) in the locally advanced/metastatic setting.<br>- No more than one prior line of chemotherapy regimen<br>- A chemotherapy regimen including a programmed cell death-1 (PD1) or a PD1 ligand 1 (PD L1) agent is acceptable, provided it was not the most recent line of therapy.<br>- No more than 2 prior lines of therapy containing EGFR TKI are acceptable<br><br>- Adequate haematological function defined as:<br>- Absolute neutrophil count =1500/µL<br>- Haemoglobin =9 g/dL (no transfusion in the past 2 weeks) <br>- Platelets =100,000/µL (no transfusion in the past 10 days)<br><br>- Adequate liver function<br>        - ALT, AST =2.5 x ULN with total bilirubin = ULN<br>OR<br>        - Total bilirubin >ULN to =1.5x ULN with ALT and AST = ULN<br><br>- Adequate renal function - creatinine <1.5 times the institutional ULN OR a glomerular filtration rate =50 mL/min. Confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN. <br><br>- Adequate coagulation parameters - INR <1.5 x ULN and activated partial thromboplastin time <1.5 x ULN unless patients are receiving therapeutic anti coagulation which affects these parameters.  <br><br>- Patients with known tumour thrombus or deep vein thrombosis are eligible if clinically stable on low molecular weight heparin for =2 weeks.<br><br>- ECOG/WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.<br><br>- Females of childbearing potential must be using highly effective contraceptive measures and have a negative pregnancy test.<br><br>- Males with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 6 months following discontinuation of study drug.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 113<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 84<br>","Exclusion criteria: <br>- Unresolved toxicities from any prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy.<br><br>- As judged by the investigator, active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhoea Grade =2, malabsorption syndrome or previous significant bowel resection).<br><br>- Any of the following cardiac diseases currently or within the last 6 months:<br>Unstable angina pectoris<br>Congestive heart failure (New York Heart Association [NYHA] =Grade 2) <br>Acute myocardial infarction<br>Stroke or transient ischemic attack <br>        Uncontrolled hypertension (BP =150/95 mmHg despite medical therapy).<br>        Mean resting correct QT interval (QTcF) >470 msec for women and >450 msec for men at <br><br>Screening, obtained from 3 ECGs using the screening clinic ECG machine derived QTcF value.<br>Any factors that may increase the risk of QTcF prolongation or risk of arrhythmic events such as heart failure, chronic hypokalaemia not correctable with supplements, congenital or familial long QT syndrome, family history of unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes.<br>Any clinically important abnormalities in rhythm, conduction or morphology of resting ECGs, eg, complete left bundle branch block, third degree heart block, second degree heart block, P-R interval >250 msec.<br>Acute coronary syndrome<br><br>- Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered =28 days or limited field radiation for palliation =7 days prior to starting study drug or has not recovered from side effects of such therapy. <br><br>- Major surgical procedures =28 days of beginning study drug or minor surgical procedures =7 days<br><br>- Evidence of severe or uncontrolled systemic diseases, including renal transplant, active bleeding diatheses or uncontrolled hypertension, which in the investigator’s opinion makes it undesirable for the patient to participate <br><br>- Active hepatitis B or C  or known serious active infection e.g. tuberculosis or human immunodeficiency virus. Viral testing is not required for assessment of eligibility for the study. <br><br>- Presence of other active cancers, or history of treatment for invasive cancer, within the last 5 years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.<br><br>- Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment.<br><br>- Past medical history of interstitial lung disease(ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.<br><br>-Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values<br>Absolute neutrophil count <1.5 x 109/L<br>Platelet count <100 x 109/L<br>Haemoglobin <90 g/L<br><br>- Prior or current treatment with a 3rd g","Main Objective: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+, locally advanced or metastatic NSCLC who have progressed on osimertinib.;Secondary Objective: - To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+ (determined centrally by FISH and centrally confirmed by IHC) locally advanced or metastatic NSCLC who have progressed on osimertinib.<br><br>- To assess the impact of savolitinib and osimertinib on disease related symptoms and HRQoL in this patient population (in patients MET+ by FISH, MET+ by IHC and in all patients).<br><br>- To evaluate the pharmacokinetics of osimertinib and savolitinib in this patient population (all patients).<br><br>- To determine the prevalence of ctDNA clearance after osimertinib and savolitinib treatment in this patient population (in patients MET+ by FISH, MET+ by IHC and in all patients).<br><br>- To evaluate the safety and tolerability of savolitinib in combination with osimertinib.;Primary end point(s): Overall Response Rate (ORR) by investigator assessment in accordance with RECIST 1.1;Timepoint(s) of evaluation of this end point: The primary analysis of ORR will occur when all patients have had the opportunity to be treated for 6 months. The final analysis of ORR will occur when 70% of patients have progressive disease or have died or 18 months after the last patient in (which ever occurs first).","Secondary end point(s): - ORR by investigator assessment in accordance with RECIST 1.1.<br><br>- PFS by investigator assessment in accordance with RECIST 1.1.<br>  OS<br>  DoR<br>  Percentage change in tumour size by investigator assessment in accordance with RECIST 1.1.<br><br>- Mean change from baseline in EORTC QLQ-C30 and QLQ-LC13.  <br><br>- Plasma concentrations of osimertinib, savolitinib and their metabolites.<br><br>- Total clearance in EGFR mutations at 6-weeks after therapy initiation (percentage and absolute change from baseline in EGFR mutation allele frequencies).<br><br>- AEs, SAEs and discontinuation rate due to AEs.<br>Clinical chemistry/haematology including LFTs.<br>ECHOs, ECGs and vital signs including blood pressure and heart rate.;Timepoint(s) of evaluation of this end point: ORR & PFS: baseline; every 6 weeks after treatment start until Cycle 7 (C7), then every 8 weeks until disease progression. Survival follow-up every 12 weeks.<br><br>EORTC QLQ-C30 and QLQ-LC13: baseline; QLQ-C30 every 4 weeks after treatment start, QLQ-LC13 weekly after treatment start in C1 and C2, then every 4 weeks from C3 onwards; 7 days after treatment discontinuation.<br><br>Plasma concentrations: C1 and C2 on Day 1 pre-dose, 1 hour and 3 hours post-dose; Day 1 of C3, 6, and 11; discontinuation visit.<br><br>EGFR: Pre-dose on C1 Day 1; C1 Days 8, 15, 22; C2 Day 1; then at the time of every RECIST 1.1 scan <br><br>AEs, vital signs, ECGs, safety labs at every clinic visit (every 7 during C1, every 28 during treatment (MUGA/ECHO every 12 weeks), 7 days after final dose, 28 day follow-up).",child,NULL,Date trial authorised,NA,NA,"A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,May 15 2019 12:00AM,NA,NA,NA,NA
EUCTR2019-001100-38-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001100-38,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study)",Multiple System Atrophy <br>MedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],<br>Product Name: BHV-3241<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Verdiperstat<br>Current Sponsor code: BHV-3241<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study),EUCTR,2019-10-03,2019-12-13,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,252,"Biohaven Pharmaceuticals, Inc",United States;France;Austria;Germany;Italy;United Kingdom,NCT03952806,NULL,03/10/2019,13/12/2019,EUCTR2,11 March 2020,BHV3241-301;NCT03952806,Medical Information,NA,215 Church Street,medinfo@biohavenpharma.com,+12012444239,Biohaven Pharmaceuticals Inc,Medical Information,NA,215 Church Street,medinfo@biohavenpharma.com,+12012444239,Biohaven Pharmaceuticals Inc,Authorised-recruitment may be ongoing or finished,NULL,"Biohaven Pharmaceuticals, Inc",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>Informed Consent<br>a. Subjects must provide a written signed and dated informed consent form/forms prior to the initiation of any protocol required procedures.<br>b. Caregivers must be willing to sign and date an IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines.<br><br>Age and Sex<br>a. Male and female subjects between the ages of >40 to <75 years at time of Screening.<br><br>Target Population<br>a. Diagnosis of probable or possible MSA according to consensus clinical criteria  including subjects with MSA of either subtype (MSA-P or MSA-C). <br>b. Able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps. Use of assistive devices is allowed. <br>c. Anticipated survival of at least 3 years at the time of Screening, as judged by the Investigator. <br>d. A brain MRI scan (conducted within 14 days of Baseline/Day 1) that does not rule out a diagnosis of MSA. <br>e. Able to tolerate MRI.<br>f. Body mass index (BMI) < 35 kg/m2 at Screening. <br>g. Able to swallow tablets whole and anticipated to be able to do so throughout the duration of the study.<br>h. Willing and able to adhere to the study drug regimen.<br>i. Willing and able to perform all protocol-specified assessments and comply with the study visit schedule. <br>j. Able to read, understand, and speak local language fluently to ensure comprehension of informed consent and protocol-specified assessments.<br>k. Must have reliable caregiver to accompany subject to all study visits. Caregiver must be able to read, understand, and speak local language fluently to ensure comprehension of informed consent and protocol-specified assessments. Caregiver must also have frequent contact with subject (at least 3 hours per week at one time or different times) and be willing to monitor the subject's health and concomitant medications throughout the study. <br>l. If subject is receiving treatment for MSA, the doses must have been stable for at least 60 days prior to Screening and expected to remain relatively stable during the study period. This may include medications commonly used for Parkinson's disease or those for autonomic dysfunction.<br>m. Stable on other chronic medications and supplements for at least 30 days prior to Screening.<br>n. Women of child bearing potential (WOCBP) and fertile men (including those vasectomized for less than 6 months) with female partners who are WOCBP (not surgically sterile and not post-menopausal) must agree to use highly effective birth control, including two methods of contraception, for the duration of the study (beginning 30 days prior to Baseline and extending to 30 days for women and 90 days for men after the last dose of study drug). The two methods of contraception should include:<br> - one barrier method (e.g. diaphragm with spermicide, condom with spermicidal gel, intrauterine contraceptive devices [placed at least 4 weeks prior to sexual intercourse], cervical cap); <br> - and one other method that could include hormonal contraceptives (e.g. oral  contraceptives, injectable contraceptives, contraceptive implant, patch) used for at least 4 weeks prior to sexual intercourse or another barrier method.<br>o. WOCBP must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within approximately 24 hours prior to dosing at Baseline. <br><br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subject","Exclusion criteria: <br>Target Disease Exceptions <br>a. Subjects having advanced disease as defined in the protocol. <br>b. Subjects having significant cognitive impairment, defined by a score of less than or equal to 23 on the MoCA <br><br>Medical History Exclusions<br>a. Any condition that would interfere with the subject’s ability to comply with<br>study instructions, place the subject at unacceptable risk, and/or confound the<br>interpretation of safety or efficacy data from the study, as judged by the<br>Investigator.<br>b. Diagnosis of neurological disorders, other than MSA as defined in the protocol<br>c. History of or Screening brain MRI scan indicative of significant abnormality.<br>d. Contraindication to MRI examination for any reason.<br>e. For optional CSF sub-study: contraindication to undergoing an LP.<br>f. History or presence of clinically significant thyroid disease<br>g. Within 1 year prior to screen or between screen and Baseline (Day -1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope not related to MSA.<br>h. Diagnosis of clinically significant psychiatric disorder as defined in the protocol.<br>i. History of substance use disorder (drug or alcohol) in the last 12 months, with <br>the exception of nicotine, as defined by DSM-V criteria. <br>j. History or presence of gastrointestinal or other disease known to interfere with absorption, distribution, metabolism, or excretion of drugs, or a history of surgery known to interfere with absorption or excretion of drugs.<br>k. History of any other clinically significant disease that, based on the judgment of the Investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject’s ability to complete the study, or could influence the study results.<br>l. History of human immunodeficiency virus infection.<br>m. Hematologic or solid malignancy diagnosis within 5 years prior to Screening.<br>n. Any major surgery within 4 weeks of Screening.<br>o. Blood transfusion within 4 weeks of Screening.<br>p. History of brain surgery for Parkinsonism.<br>q. History of stem-cell treatment.<br>r. Women who are pregnant or breastfeeding.<br>s. Subjects or prisoners who are involuntarily detained or incarcerated for treatment of either a psychiatric or physical illness must not be enrolled into the study.<br>t. Any medical condition, based on the judgement of the Investigator, that  would confound the ability to adequately assess safety and efficacy outcome measures<br><br>Physical and Laboratory Test Findings<br>a. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG,  or clinical laboratory determinations beyond what is consistent with the target population. <br>b. Clinically significant abnormality on 12-lead ECG prior to study drug administration beyond what is consistent with the target population, confirmed by repeat.<br>c. QTcF (Fridericia) interval = 470 msec during the Screening/Baseline period or uncontrolled arrhythmia or frequent premature ventricular contraction (PVCs) (> 5/minute) or Mobitz Type II second or third degree atrioventricular (AV) block or left bundle branch block, or right bundle branch block with a QRS<br>duration = 150 msec or intraventricular conduction defect with a QRS duration = 150 msec or evidence of acute or sub-acute myocardial infarction or ischem","Main Objective: • To evaluate the efficacy of BHV-3241, compared to placebo, as measured by a change from baseline in a modified Unified MSA Rating Scale (UMSARS), consisting of a subset of items from Part I and Part II, at Week 48. <br>• To assess the safety and tolerability of BHV-3241, relative to placebo, in subjects with MSA.  ;Secondary Objective: Key Secondary<br>• To evaluate the efficacy of BHV-3241, compared to placebo, as measured by the Clinical Global Impression of Improvement (CGI-I) score at Week 48.<br>•To assess the impact of BHV-3241 on quality of life, relative to placebo, as  measured by a change from baseline in the motor subscale of the MSA-Quality of Life (MSA-QoL) scale at Week 48.<br>• To assess the impact of BHV-3241 on quality of life, relative to placebo, as measured by a change from baseline in the non-motor subscale of the MSA- QoL scale at Week 48.<br>•To evaluate the efficacy of BHV-3241, compared to placebo, as measured by a change from baseline in the UMSARS Part I and Part II total score at Week 48.<br><br>Other Secondary<br>• To evaluate the efficacy of BHV-3241, compared to placebo, as measured by a change from baseline at Week 48 in the following instruments:<br> - Patient Global Impression of Severity (PGI-S),<br> - Clinical Global Impression of Severity (CGI-S),<br> - UMSARS Part III,<br> - UMSARS Part IV.<br>;Primary end point(s): • The primary efficacy endpoint will be evaluated by comparing the change from baseline in a modified UMSARS score, based on a subset of items from Part I  and II,  at Week 48 in subjects treated with BHV-3241 relative to the change in the modified UMSARS score in subjects treated with placebo.<br>• The primary safety endpoint will be assessed using the frequency of unique  subjects with: serious adverse events; adverse events leading to discontinuation; adverse events judged to be related to study medication; clinically significant ECG abnormalities and clinically significant laboratory abnormalities. ;Timepoint(s) of evaluation of this end point: Efficacy:<br>Unified MSA Rating Scale (UMSARS) Parts I-II -  Screening, Baseline, Wks 4, 12, 24, 36, 48 or early disontinuation<br><br><br>Safety:<br>Physical Examination; Vital Signs; Sheehan Suicidality Tracking Scale -<br>Screening, Baseline, Wks 2, 4, 12, 24, 36, 48 or Early Discontinuation. <br>Physical Measurements - Screening, Baseline, Wk48 or Early Discontinuation. <br>ECG (12-lead); Laboratory Tests; Pregnancy Test - Screening, Baseline,<br>Wk 4, 12, 24, 36, 48 or Early Discontinuation. <br>SAE/AEs - throughout the study<br>","Secondary end point(s): Key Secondary<br>• The impact of BHV-3241 on the CGI-I score will be evaluated at Week 48 by comparing the CGI-I scores BHV-3241-treated subjects relative to that of  placebo-treated subjects.<br>• The impact of BHV-3241 on the MSA-QoL motor subscale will be evaluated by comparing the change from baseline at Week 48 in the BHV-3241-treated subjects relative to that of the placebo treated subjects.<br>• The impact of BHV-3241 on the MSA-QoL non-motor subscale will be evaluated by comparing the change from baseline at Week 48 in the BHV-3241-treated subjects relative to that of the placebo-treated subjects. <br>• The impact of BHV-3241 on the UMSARS Part I and II total score will be evaluated by comparing the change from baseline at Week 48 in subjects treated with BHV-3241 relative to that of the placebo-treated subjects.<br><br>Other Secondary<br>• The impact of BHV-3241 will be evaluated by assessing the change from baseline at Week 48 in the BHV-3241-treated subjects relative to that of the placebo treated subjects on the following instruments:<br> - PGI-S,<br> - CGI-S,<br> - UMSARS Part III,<br> - UMSARS Part IV.<br>;Timepoint(s) of evaluation of this end point: • Clinical Global Impression of Improvement (CGI-I)- Wks 4, 12,  24, 36, 48 or Early Discontinuation.  <br>• MSA QoL at Baseline and Weeks 24 and 48 or Early Discontinuation<br>• UMSARS (Part I - IV) - Screening, Baseline, Wks 4, 12, 24, 36, 48 or Early Discontinuation<br>• Patient Global Impression of Severity (PGI-S) - Baseline, Wks 4, 12, 24, 36, 48 or Early Discontinuation<br>• Clinical Global Impression of Severity (CGI-S) - Baseline, Wks 4, 12, 24, 36, 48 or Early Discontinuation<br><br>",child,NULL,Date trial authorised,NA,NA,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study)",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Oct 22 2019 12:00AM,NA,NA,NA,NA
EUCTR2019-001155-39-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001155-39,"A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY TREATMENT OPTIONS",Solid tumors and primary central nervous system (CNS) tumors <br>MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864 <br>MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04],"<br>Product Name: Entrectinib<br>Product Code: RO7102122/F03<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F01<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F08<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F09<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F11<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F04<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F06<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concen",A Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who Have No Satisfactory Treatment Options,EUCTR,2019-07-16,2019-11-22,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,68,F. Hoffmann-La Roche Ltd,United States;France;Spain;Germany;Italy;United Kingdom,EUCTR2019-001155-39-FR,NULL,16/07/2019,22/11/2019,EUCTR2,2 June 2020,CO40778,Trial Information Support Line-TISL,NA,Grenzacherstrasse 124,global.rochegenentechtrials@roche.com,NA,F. Hoffmann-La Roche Ltd,Trial Information Support Line-TISL,NA,Grenzacherstrasse 124,global.rochegenentechtrials@roche.com,NA,F. Hoffmann-La Roche Ltd,Authorised-recruitment may be ongoing or finished,NULL,F. Hoffman-La Roche Ltd.,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>   -  Age: Male or female from birth to age > 18 years.<br>  <br>Disease status:<br>  -  Phase 1 portion (closed): Patients must have measurable or evaluable disease<br>  -  Phase 2 portion: <br>– Parts B and D:Patients must have measurable or evaluable disease<br>- Part C (closed): Patients must have measurable or evaluable disease<br>– Part E (closed): Patients must have measurable or evaluable disease and will be assessed according to tumor type<br>  -  Tumor types included below harboring NTRK1/2/3 or ROS1 gene fusions as determined locally by an appropriately validated assay performed in a Clinical Laboratory Improvement Amendments-certified or equivalently-accredited diagnostic laboratory, or centrally by a Foundation Medicine Clinical Trial Assay or the alternative, approved central laboratory for that region::<br>o Phase 1 portion:<br>– Part A: Relapsed or refractory extracranial solid tumors<br>o Phase 2 portion:<br>– Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions <br>– Part D: Extracranial solid tumors with NTRK1/2/3 or ROS1 gene fusions<br>  -  Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse<br>  -  For patients enrolled via local molecular testing, an archival tumor tissue from diagnosis or, preferably, from relapsed disease is required to be submitted for independent central testing at Foundation Medicine, Inc. laboratory or the alternative, approved central assay laboratory for that region<br>  -  Performance status: Lansky or Karnofsky score >= 60% and minimum life expectancy of at least 4 weeks<br>  -  Prior therapy: Patient’s must have a a disease that is locally advanced, metastatic, or where<br>surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive.Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment<br>  -  Adequate bone marrow, liver, renal, cardiac and neurologic function<br>  -  Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation and in the following 90 days after discontinuation of study treatment<br>  -  For male patients with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug<br>  -  Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures <br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 50<br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 18<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>  -  Current participation in another therapeutic clinical trial<br>  -  Known congenital long QT syndrome<br>  -  History of recent (3 months) symptomatic congestive heart failure or ejection fraction =50% at screening<br>  -  Known active infections (bacterial, fungal, or viral)  -  Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia<br>  -  Receiving Enzyme Inducing Antiepileptic Drugs<br>  -  All Phase 2 patients: Prior treatment with approved or investigational tyrosine receptor kinase inhibitor (TRK) or ROS1 inhibitors<br>  -  Patients with known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product<br>  -  Patients with NB with bone marrow space-only disease<br>  -  Incomplete recovery from acute effects of any surgery prior to treatment<br>  -  Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption<br>  -  Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or entrectinib administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry in to this study or could compromise protocol objectives in the opinion of the Investigator and/or Sponsor<br>","Main Objective: • To determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D), of F1 entrectinib formulation in pediatric patients (pediatrics and young adults) with relapsed or refractory solid tumors (Part A) <br>• To confirm RP2D of F06 entrectinib formulation in pediatric patients able to swallow intact capsules and in patients dosed via feeding tube (nasogastric tube or gastric tube)<br>• To confirm RP2D of minitablets/F15 formulation in pediatric patients unable to swallow intact capsules<br>• To evaluate efficacy of entrectinib as assessed by objective response rate (ORR) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions (Part B) using Response Assessment in Neuro-Oncology Criteria (RANO) and in patients with extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions (Part D) using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), as assessed by blinded independent central review (BICR);Secondary Objective: •To describe the safety profile of entrectinib<br>•To characterize the PK of entrectinib<br>•To determine the duration of response (DOR), time to response (TTR), clinical benefit rate (CBR), progression-free survival (PFS) and overall survival (OS) in all enrolled patients receiving entrectinib at the RP2D<br>•To determine the intracranial tumor response, DOR, TTR, and CNS-PFS in Parts B and D patients receiving entrectinib at the RP2D and presenting with measurable primary or secondary CNS disease at baseline, using RANO or RANO-BM, as applicable<br>•To describe growth, puberty, neurological and neurocognitive function of patients on treatment<br>•To evaluate the efficacy of entrectinib as assessed by ORR in all patients with NTRK1/2/3 gene fusions, regardless of study phase or cohorts using RANO for CNS tumors or RECIST v1.1 for extra-cranial tumors, as assessed by BICR and by investigators<br>•To characterize palatability and tolerability of the different formulations used in the clinical trial;Primary end point(s): 1. Dose limiting toxicity of entrectinib (Part A)<br>2. Objective response rate (Parts B and D)<br>;Timepoint(s) of evaluation of this end point: 1. Day 1-28 of Cycle 1<br>2. Up to 30 days after last dose of study drug<br>","Secondary end point(s): 1. Incidence and severity of adverse events, laboratory and electrocardiogram (ECG) abnormalities<br>2. Maximal plasma concentration (Cmax) of entrectinib<br>3. Time of maximal plasma concentration (Tmax) of entrectinib<br>4. Area under the plasma concentration vs. time curve (AUC) of entrectinib<br>5. Duration of response in patients with relapsed or refractory extracranial solid tumors<br>6. Time to response in patients with relapsed or refractory extracranial solid tumors<br>7. Clinical benefit rate in patients with relapsed or refractory extracranial solid tumors<br>8. Progression-free survival in patients with relapsed or refractory extracranial solid tumors<br>9. Intracranial tumor response in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline<br>10. Duration of response in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline<br>11. Time to response in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline<br>12. CNS- Progression-free survival in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline<br>13. Overall survival for all patients<br>14. Objective response rate in all patients<br>15. Analysis of markers of bone formation and resorption and markers of calcium metabolism including P1NP, osteocalcin, BSAP, CTX-1, Vitamin D, parathyroid hormone) plus tartrate resistant acid phosphatase 5b (TRAP5b), sclerostin and Myostatin (GDF8<br>16. Assessment of bone growth (serial hand/wrist and knee X-rays) and bone mineral density (BMD) via dual x-ray absorptiometry (DXA) scans in patients<br>17. Acceptability and palatability assessment for capsules and age-appropriate dosage form;Timepoint(s) of evaluation of this end point: 1. Up to 30 days after last dose and every 3 months until death<br>2-4. Cycle 1 Day 1 pre-dose and at 1, 2, 4, 6, and 24 hours post-dose; Cycle 1 Days 8, 15 and 22 pre-dose; on Cycle 2 Day 1 pre-dose and at 1, 2, 4, 6, and 24 hours post-dose; and on Day 1 of every cycle thereafter pre-dose<br>5-14. Up to 30 days after last dose of the study drug and every 3 months until death<br>15-16. Up to 30 days after last dose of the study drug<br>17. Day 1 of Cycle 1<br><br>",parent,NULL,Date trial authorised,NA,NA,"A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY TREATMENT OPTIONS",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Nov 22 2019 12:00AM,NA,NA,NA,NA
EUCTR2017-002491-10-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002491-10,Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula,Perianal fistulising Crohn´s disease <br>MedDRA version: 20.0Level: PTClassification code 10002156Term: Anal fistulaSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06],<br>Trade Name: Alofisel<br>Product Name: Cx601<br>Product Code: Cx601<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Darvadstrocel<br>Current Sponsor code: Allogenic eASCs<br>Other descriptive name: Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs<br>Concentration unit: Other<br>Concentration type: equal<br>Concentration number: 5000000-<br><br>,Postauthorization Safety Study of Darvadstrocel Repeat Administration,EUCTR,2019-11-27,2020-03-10,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 1<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,50,"Millennium Pharmaceuticals, Inc (MPI)",France;Czech Republic;Spain;Austria;Germany;United Kingdom,NCT04118088,NULL,27/11/2019,10/03/2020,EUCTR2,13 October 2020,Alofisel-4001;not appliable,Clinical Science,NA,40 Landsdowne Street,Starr.chen@takeda.com,0018576004183,"Millennium Pharmaceuticals, Inc (MPI)",Clinical Science,NA,40 Landsdowne Street,Starr.chen@takeda.com,0018576004183,"Millennium Pharmaceuticals, Inc (MPI)",Authorised-recruitment may be ongoing or finished,NULL,"Millennium Pharmaceuticals, Inc (MPI)",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.<br>2. The subject signs and dates a written, informed consent form (ICF) and any required privacy authorization before the initiation of any study procedures.<br>3. The subject is male or female and aged 18 years or older.<br>4. The subject has complex perianal fistula(s) with a maximum of 2 internal openings and a maximum of 3 external openings based on clinical assessment; the fistula must be actively draining.<br>5. The subject has already received treatment with darvadstrocel for a complex perianal fistula, and their physician has planned a repeat treatment administration for the original tract (full remission not obtained or relapse of fistula draining) or for a new fistula tract.<br>6. The subject has controlled or mildly active CD (defined as patient reported outcomes measure derived from Crohn’s Disease Activity Index [CDAI] patient reported outcome score-2<br>[PRO-2] score <14).<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 42<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 8<br>","Exclusion criteria: <br>1. The subject has lack of clinical response to prior treatment with darvadstrocel, where clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression or in the case of a unique fistula, a partial closure of the fistula.<br>2. The subject has a history of hypersensitivity or allergies to darvadstrocel or related compounds.<br>3. The subject has a history of hypersensitivity or allergies to penicillin or aminoglycosides; Dulbecco modified eagle medium; bovine serum; local anesthetics or gadolinium.<br>4. The subject is currently participating in a double-blind clinical study with darvadstrocel. Subjects participating in the ongoing INSPIRE1 registry study may withdraw from that study to enroll in this PASS.<br>5. The subject is currently receiving or has received any other IMP within the last 3 months or at least 5 times the respective elimination half-life time, whichever is longer, before signing the ICF.<br>6. The subject has known or suspected COVID-19 by the investigator within the past 2 months (additional testing may be performed at the discretion of the investigator). Positive antibody<br>testing for COVID without other evidence of current or recent active infection does not exclude participation.<br>a) Subjects who were in screening at the time that COVID-19–related factors resulted in discontinuation may also be  rescreened with approval of the sponsor or designee.<br>7. The subject has major alterations in any of the following laboratory tests:<br>a) Serum creatinine levels >1.5 times the upper limit of normal(ULN).<br>b) Total bilirubin >1.5 × ULN.<br>c) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3.0 × ULN.<br>d) Hemoglobin <10.0 g/dL.<br>e) Platelets <75.0 × 109/L.<br>f) Albumin <3.0 g/dL.<br>8. The subject has an increased risk for surgical procedure.<br>9. The subjects has a known chronically active hepatopathy of any origin, including cirrhosis and subjects with persistent  positive hepatitis B surface antigen and quantitative hepatitis B virus polymerase chain reaction (PCR) or positive serology for hepatitis C virus (HCV) and quantitative HCV PCR within 6 months before the baseline visit.<br>10. If female, the subject is pregnant or breastfeeding, or intending to become pregnant before participating in this study, during the study, or intending to donate ova during such time period.<br>11. If male, the subject intends to donate sperm during this study.<br>12. The subject has a contraindication to MRI scan (eg, due to the presence of pacemaker, hip replacement, severe claustrophobia, or renal insufficiency as defined by local clinical guidelines).<br>13. The subject has a contraindication to the anesthetic procedure.<br>14. The subject has severe rectal and/or anal stenosis that would make it impossible to follow the surgery procedure.<br>15. The subject has severe proctitis (rectal ulcers >0.5 cm) that would make it impossible to follow the surgery procedure.<br>16. The subject has any prior invasive malignancy diagnosed within the last 3 years before baseline visit. Subjects with basal cell carcinoma of the skin completely resected outside the perineal region can be included.<br>17. The subject has a current or recent (within 6 months before the baseline visit) history of severe, progressive, and/or uncontrolled hepatic, hematologic, gastrointestinal (other than CD), renal, endocrine, pulmonary, cardiac, neurologic, or psychiatric disease that may result in subject","Main Objective: To assess the long-term safety of repeat administration of darvadstrocel in subjects with CD and complex perianal fistula by evaluation of AEs, serious adverse events (SAEs), adverse events of special interest (AESIs), and special situation reports (SSRs).<br>;Secondary Objective: To evaluate the long-term efficacy of repeat administration of darvadstrocel in subjects with CD and complex perianal fistula.<br>;Primary end point(s): The primary endpoint of the study will include assessment of the following safety parameters:<br>- Incidence of treatment-emergent adverse events<br>- Incidence of treatment-emergent SAEs<br>- SSRs (pregnancy)<br>- Specific AESIs, including:<br>– Immunogenicity/alloimmune reactions<br>– Hypersensitivity<br>– Transmission of infectious agents<br>– Tumorgenicity<br>– Ectopic tissue formation<br>– Medication errors<br>;Timepoint(s) of evaluation of this end point: Subjects will be assessed before repeat administration at the baseline and preparatory visit, and at Weeks 6 (±8 days), 24 (±15 days), 52 (±15 days), 104 (±30 days), and 156 (±30 days) following repeat administration. The Week 6 assessment will be primarily to capture immunogenicity/donor-specific antibody (DSA)/soluble factors.<br>Blood samples for central laboratory tests will be collected at baseline, Weeks 24 (±15 days), 156 (±30 days), and the<br>early termination visit. Blood samples for DSA levels and exploratory immunogenicity testing will be collected at the<br>baseline visit and at Weeks 6 (±8 days), 24 (±15 days), and 156 (±30 days). Blood samples for these tests will be<br>analyzed in batches as the study progresses, and available results will be provided with the interim reports.<br>","Timepoint(s) of evaluation of this end point: Subjects will be assessed before repeat administration at the baseline and preparatory visit, and at Weeks 6 (±8 days),<br>24 (±15 days), 52 (±15 days), 104 (±30 days), and 156 (±30 days) following repeat administration. ;Secondary end point(s): Efficacy will be assessed by evaluating the following endpoints:<br>- Proportion of subjects who achieve combined remission of perianal fistula(s) at Weeks 24 and 156 after investigational medicinal product (IMP) administration, where combined remission is defined as:<br>- The closure of all treated external openings that were draining at baseline (ie, baseline visit), despite gentle finger compression,<br>AND<br> > Absence of collection(s) >2 cm (in at least 2 dimensions) of the treated perianal fistula(s) confirmed by central MRI assessment.<br><br>- Proportion of subjects who achieve clinical remission at Weeks 6, 24, 52, 104, and 156 after IMP administration.<br> > Clinical remission is defined as closure of all treated external fistula openings that were draining at baseline despite gentle finger compression.<br><br>- Proportion of subjects who achieve clinical response at Weeks 6, 24, 52, 104, and 156 after IMP administration.<br> > Clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression.<br><br>- Proportion of subjects with relapse from Week 24 combined remission, where relapse is defined as:<br>- Reopening of any of the treated fistula(s) external openings with active drainage as clinically assessed that were in combined remission at Week 24,<br>OR<br>- The development of a collection >2 cm (in at least 2 dimensions) confirmed by centrally read MRI assessment.<br>- Time to reopening of any of the treated external openings with active drainage as clinically assessed, measured in days relative to Week 24.<br>- Proportion of subjects with new perianal abscess in treated fistula.<br>- Change from baseline to Weeks 6, 24, 52, 104, and 156 after IMP administration in scores of discharge and pain items of Perianal Disease Activity Index (PDAI) score.<br>",child,NULL,Date trial authorised,NA,NA,Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula,NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Dec  4 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-003739-32-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003739-32,"Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors. - Actuate 1801: Phase 1/2 of 9-ING-41 in Refractory Malignancies","Refractory Hematologic Malignancies or Solid Tumors <br>MedDRA version: 21.1Level: PTClassification code 10066476Term: Haematological malignancySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) <br>MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]","<br>Product Name: 9-ING-41<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: 9-ING-41<br>CAS Number: 1034895-42-5<br>Other descriptive name: 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-1H-pyrrole-2,5-dione<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>","A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs",EUCTR,2019-10-30,2020-02-28,FALSE,Interventional clinical trial of medicinal product,"Controlled: noRandomised: noOpen: yesSingle blind: noDouble blind: noParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: no",Human pharmacology (Phase I): yesTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,350,Actuate Therapeutics Inc,France;United States;Spain;Denmark;Germany;Netherlands;United Kingdom,NA,NULL,30/10/2019,28/02/2020,EUCTR2,18 March 2020,1801;NCT03678883,Clinical Operations,NA,"1751 River Run, Suite 400",clinops@actuatetherapeutics.com,NA,Actuate Therapeutics Inc,Clinical Operations,NA,"1751 River Run, Suite 400",clinops@actuatetherapeutics.com,NA,Actuate Therapeutics Inc,Authorised-recruitment may be ongoing or finished,NULL,Actuate Therapeutics Inc,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures.<br>2. Is aged = 18 years<br>3. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:<br>a. Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition<br>b. Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit<br>c. Malignancy has relapsed after standard therapy<br>d. Malignancy for which there is no standard therapy that improves survival by at least 3 months<br>4. Has evaluable tumor(s) by standard radiological and/or laboratory assessments as applicable to their malignancy – in Part 3, patients with solid tumors must have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria, measured preferably by computed tomography (CT) scan or magnetic resonance<br>image (MRI). In Part 3, patients with glioblastoma multiforme (GBM) or other central nervous system (CNS) tumors, the tumor must be measurable, defined as a clearly enhancing tumor with at least two perpendicular diameters at entry equal or superior to 1cm. Patients with GBM will have progression after chemoradiotherapy with or without antiangiogenic treatment at least 3 months after the end of radiotherapy. Radiotherapy at a dose of no more than 65 Gy with stereotactic radiosurgery or brachytherapy is allowable if recurrence was histologically proven.<br>5. Has laboratory function within specified parameters (may be<br>repeated):<br>a. Adequate bone marrow function: absolute neutrophil count (ANC) = 500/mL; hemoglobin = 8.5 g/dL, platelets = 50,000/mL<br>b. Adequate liver function: transaminases (aspartate <br>aminotransferase/alanine aminotransferase, AST/ALT) and alkaline phosphatase = 3 (= 10X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with malignant cells) x ULN; bilirubin = 1.5 x ULN<br>c. Adequate renal function: creatinine clearance = 60 mL/min (Cockcroft and Gault)<br>d. Adequate blood coagulation: international normalized ratio (INR) =2.3<br>e. Serum amylase and lipase = 1.5 x ULN<br>6. Has adequate performance status (PS): Eastern Co-operative<br>Oncology Group (ECOG) PS 0-2<br>7. Has received the final dose of any of the following treatments/procedures with the specified minimum intervals before first dose of study drug (unless in the opinion of the investigator and the study medical coordinator the treatments/ procedures will not compromise patient safety or interfere with study conduct:<br>• Chemotherapy, immunotherapy, or systemic radiation therapy - 14 days or = 5 half-lives (whichever is shorter)<br>• Focal radiation therapy – 7 days<br>• Systemic and topical corticosteroids – 7 days<br>• Surgery with general anesthesia – 7 days<br>• Surgery with local anesthesia – 3 days<br>8. May continue endocrine therapies (e.g. for breast or prostate cancer) and/or anti-human epidermal growth factor (Her2) therapies while on this study <br>9.Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for","Exclusion criteria: <br>1. Is pregnant or lactating <br>2. Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation<br>3. Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as <br>= Grade 1 severity per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (v 4.03)<br>4. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening<br>5. Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41 or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator or study medical coordinator <br>6. Has symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug<br>7. Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major)<br>8. Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation<br>9. Has received an investigational anti-cancer drug in the 14-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial<br>10. Has a current malignancy other than the target cancer <br>11. Is considered to be a member of a vulnerable population (for example, prisoners)<br><br>","Main Objective: Parts 1 and 2: To evaluate the safety and tolerability, describe any dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) or highest protocol-defined doses (in the absence of exceeding the MTD) and the recommended Phase 2 study dose (RP2D) for 9-ING-41 as monotherapy (Study Part 1) and in combination with chemotherapies (Study Part 2) in patients with relapsed or refractory malignancies. <br>Part 3: To assess clinical benefit in patients with relapsed or refractory malignancies treated with 9-ING-41-based combinations at the RP2D established in Part 2.<br>To assess clinical benefit in patients with relapsed or refractory<br>malignancies treated with 9-ING-41-based combinations at the RP2D established in Part 2.;Secondary Objective: 1. To assess pharmacokinetics and pharmacodynamics of 9-ING-41<br>2. To correlate response rates with specific molecular tumor profile(s) in a descriptive fashion<br>;Primary end point(s): The efficacy endpoints are the following:<br>• Objective response rate (ORR), defined as the percent of patients with Complete Response (CR) or Partial Response (PR) according to RECIST 1.1 criteria or other standard malignancy-specific response criteria, relative to the efficacy population.  <br>• Duration of Response (DoR), defined as the time from documentation of tumor response to disease progression<br>• Progression-Free Survival (PFS), defined as the time from study enrolment until objective tumor progression or death<br>• Overall survival (OS), defined as the time from study entry to death from any cause  <br><br>Adverse events will be monitored during the period starting on the date of receipt of first administration of 9-ING-41  and ending 30 days after the final administration of 9 ING-41. All patients who receive any dose (any amount) of 9-ING-41 or combination regimen will be included in the summaries and listings of safety data. Overall safety profile and tolerability will be characterized by type, frequency, severity, timing, duration and relationship of study drug to adverse events and laboratory abnormalities. <br>;Timepoint(s) of evaluation of this end point: Efficacy/response endpoints will be evaluated as per study assessment defined in the protocol (Section 3.5 Assessments During Study)<br><br>Safety will be monitored during the period starting on the date of first dose of investigational product and ending 30 days +/- 5 days after the final administration of 9 ING-41.","Secondary end point(s): Specific secondary end points for patients with GBM or other CNS malignancies will include progression free survival, land­mark analyses for progression free and overall survival, response rates according to the Response Assessment in Neuro­Oncology (RANO) criteria, neurologic deterioration–free survival (defined as the time from study entry to documentation of neurologic deterioration or death), clinical or neurologic deterioration–free survival, glucocorticoid use, the development of symptoms of neurocognitive deterioration, and assessments of predictive factors. ;Timepoint(s) of evaluation of this end point: Defined as the time from study entry to documentation of neurologic deterioration or death",NA,NULL,Date trial authorised,NA,NA,"Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors.",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Feb 28 2020 12:00AM,NA,NA,NA,NA
EUCTR2016-005141-23-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-005141-23,"A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)",Focal segmental glomerulosclerosis (FSGS) <br>MedDRA version: 21.1Level: PTClassification code 10067757Term: Focal segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23],"<br>Product Name: Sparsentan<br>Product Code: RE-021<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Sparsentan<br>CAS Number: 254740-64-2<br>Current Sponsor code: RE-021<br>Other descriptive name: SPARSENTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Irbesartan tablets<br>Product Name: over-encapsulated Irbesartan Tablets<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Irbesartan<br>CAS Number: 138402-11-6<br>Other descriptive name: IRBESARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>Trade Name: Irbesartan tablets<br>Product Name: over-encapsulated Irbesartan Tablets<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Irbesartan<br>CAS Number: 138402-11-6<br>Other descriptive name: IRBESARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>",Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS),EUCTR,2019-04-12,2019-09-23,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,300,"Retrophin, Inc.","United States;Portugal;Taiwan;Estonia;Hong Kong;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Sweden;Korea, Republic of",EUCTR2016-005141-23-ES,NULL,12/04/2019,23/09/2019,EUCTR2,29 June 2020,021FSGS16010;2016-005141-23-GB,Retrophin Call Center,NA,"3721 Valley Centre Drive, Suite 200",callcenter@retrophin.com,+18776595518,"Retrophin, Inc.",Retrophin Call Center,NA,"3721 Valley Centre Drive, Suite 200",callcenter@retrophin.com,+18776595518,"Retrophin, Inc.",Authorised-recruitment may be ongoing or finished,NULL,"Retrophin, Inc.",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. Biopsy-proven FSGS or documentation of a genetic mutation in a<br>podocyte protein associated with FSGS.<br>2. Male or female aged 18 to 75 years, inclusive weighing at least 20 kg<br>at screening (Note: patients under 18 may be recruited only in the<br>United States).<br>3. UP/C =1.5 g/g at screening.<br>4. eGFR =30 mL/min/1.73 m2 at screening.<br>5. Mean seated blood pressure =100/60 mmHg and =160/100 mmHg.<br>6. WOCBP agree to the use of contraception and pregnancy testing as<br>described in the protocol.<br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 60<br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 180<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 60<br>","Exclusion criteria: <br>1. FSGS secondary to another condition.<br>2. Positive findings on serological tests of another primary or secondary<br>glomerular disease.<br>3. History of type 1 diabetes mellitus, uncontrolled type 2 diabetes<br>mellitus (hemoglobin A1c [HbA1c] >8%), or nonfasting blood glucose >180 mg/dL at screening.<br>4. Any organ transplantation, with the exception of corneal transplants.<br>5. Treatment with any of the prohibited concomitant medications.<br>6. Treatment with rituximab, cyclophosphamide, or abatacept within =3<br>months prior to screening. If a patient is taking other chronic<br>immunosuppressive medications, the dosage must be stable for =1<br>month prior to screening.<br>7. Documented history of heart failure and/or previous hospitalization<br>for heart failure or unexplained dyspnea, orthopnea, paroxysmal<br>nocturnal dyspnea, ascites, and/or peripheral edema.<br>8. Clinically significant cerebrovascular disease and/or coronary artery<br>disease.<br>9. Hemodynamically significant valvular disease.<br>10. Jaundice, hepatitis, or known hepatobiliary disease (excluding<br>asymptomatic cholelithiasis), or transaminase levels >2 times the upper<br>limit of the normal range at screening.<br>11. Positive at screening for the human immunodeficiency virus (HIV) or<br>markers indicating acute or chronic hepatitis B (HBV) infection or<br>hepatitis C virus (HCV) infection.<br>12. History of malignancy other than adequately treated basal cell or<br>squamous cell skin cancer or cervical carcinoma within the past 2 years.<br>13. A screening hematocrit value <27% or hemoglobin value <9 g/dL.<br>14. A screening potassium value of >5.5 mEq/L.<br>15. Body mass index (BMI) >40 and there is a causal relationship to the<br>FSGS lesion.<br>16. History of alcohol or illicit drug use, or excessive alcohol intake (>21<br>units per week within 2 years of screening)<br>17. History of serious side effect or allergic response to any angiotensin<br>II antagonist or endothelin receptor antagonist or hypersensitivity to<br>any of the excipients<br>18. Female patient is pregnant, breastfeeding, or planning to conceive<br>during the study.<br>19. Participation in a study of another investigational product within 28<br>days prior to screening.<br>20. Prior exposure to sparsentan.<br>21. Unable to adhere to the requirements of the study, including<br>swallowing the study medication capsules whole.<br>",Main Objective: The efficacy objective of the study is to determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic FSGS.<br><br>The safety objective of the study is to assess the safety and tolerability of sparsentan by double-blind monitoring of safety endpoints.;Secondary Objective: Not applicable;Primary end point(s): Efficacy End points:<br>The primary efficacy endpoint is the slope of eGFR.<br><br>The surrogate efficacy endpoint is the proportion of patients achieving a target reduction in proteinuria<br><br>Safety End points:<br>• Descriptive statistics will be used to summarize the safety data.;Timepoint(s) of evaluation of this end point: Week 36 and Week 108<br>,Secondary end point(s): Secondary efficacy endpoints include:<br>-The percent change in eGFR.<br>-The percent change in eGFR from baseline to 4 weeks post-treatment.<br><br>;Timepoint(s) of evaluation of this end point: Weeks 108 and 112,child,NULL,Date trial authorised,NA,NA,"A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Sep 23 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-002303-33-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002303-33,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy",Focal-Onset Seizures <br>MedDRA version: 20.0Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],<br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy,EUCTR,2019-05-21,2019-04-24,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 4",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,555,UCB Biopharma SPRL,Serbia;United States;Portugal;Estonia;Slovakia;Greece;Spain;Italy;Switzerland;France;Denmark;Netherlands;Bosnia and Herzegovina;Finland;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Belgium;Poland;Croatia;Bulgaria;Germany;Sweden,NCT03739840,1,21/05/2019,24/04/2019,EUCTR2,15 June 2020,EP0092;2018-002303-33-EE,Clin Trial Reg & Results Disclosure,NA,Alfred-Nobel-Strasse 10,clinicaltrials@ucb.com,NA,UCB BIOSCIENCES GmbH,Clin Trial Reg & Results Disclosure,NA,Alfred-Nobel-Strasse 10,clinicaltrials@ucb.com,NA,UCB BIOSCIENCES GmbH,Not Recruiting,NULL,UCB Biopharma SPRL,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>- Diagnosis of focal epilepsy per 1989 International League Against Epilepsy (ILAE) criteria at least 3 years before study entry<br>- Subject has failed to achieve seizure control with >=4 tolerated and appropriately chosen prior antiepileptic drugs (AED), including past and ongoing treatment, that were individually optimized for adequate dose and duration. Prior discontinued AED treatment would need to be assessed by the Investigator considering the patient medical records and patient and/or caregiver interview. 'Prior AED' is defined as all past and ongoing AED treatments with a start date before the Screening Visit (Visit 1)<br>- Average of >= 4 spontaneous and observable focal seizures (type IA1 (i.e. focal aware), IB (i.e. focal impaired awareness), IC (i.e. focal to bilateral tonic-clonic)) per month<br>- Current treatment with an individually optimized and stable dose of at least 1 and up to 3 AEDs for the 8 weeks prior to the Screening Visit with or without additional Vagus Nerve Stimulation (VNS) or other neurostimulation treatments<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 550<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 5<br>","Exclusion criteria: <br>- Subject has a history of or signs of generalized or combined generalized and focal epilepsy<br>- Cluster seizures which are uncountable in the previous 8 weeks before study entry and during 4 weeks prospective baseline<br>- Current treatment with carbamazepine, phenytoin, primidone, phenobarbital<br>- Current treatment/ use of (non-AED) prescription, nonprescription, dietary (eg, grapefruit or passion fruit), or herbal products that are potent inducers or inhibitors of the CYP3A4 or 2C19 pathway for 2 weeks (or 5 half-lives, whichever is longer) prior to the Baseline Visit<br>- Subjects taking sensitive substrates of CYP2C19 for 2 weeks (or 5 half-lives, whichever is longer) prior to the Baseline Visit<br>- Subject has been taking vigabatrin less than 2 years at study entry<br>- Subject has been taking felbamate for less than 12 months<br>- Subject taking retigabine for less than 4 years<br>- Current treatment with benzodiazepines (i.e. GABA-A-ergic drugs like zolpidem, zaleplon, or zopiclone, excluding GABA-A-ergic AEDs) <3 times per week for emergencies<br>- Subject has a current medical condition that occurred within the last 12 months which, in the opinion of the investigator, could compromise his/her safety or ability to participate in this study<br>",Main Objective: The primary objective is to evaluate the efficacy of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.;Secondary Objective: The secondary objective is to assess the safety and tolerability of padsevonil (PSL) in relation to placebo.;Primary end point(s): 1. 75% responder rate from Baseline over the 12-week Maintenance Period<br>2. Incidence of Treatment-Emergent Adverse Events (TEAEs)<br>3. Incidence of Treatment-Emergent Adverse Events (TEAEs) leading to study withdrawal<br>4. Incidence of treatment-emergent serious adverse events (SAEs);Timepoint(s) of evaluation of this end point: 1: From Baseline over the 12 Week Maintenance Period (up to Week 16)<br>2-4: From Baseline until Safety Follow-Up (up to Week 23),"Secondary end point(s): 1. Change in log-transformed observable focal-onset seizure frequency from Baseline over the 12-week Maintenance Period<br>2. 50% responder rate status, from Baseline, over the 12-week Maintenance Period<br>3. Percent reduction in observable focal-onset seizure frequency from Baseline over the 12-week Maintenance Period;Timepoint(s) of evaluation of this end point: 1 - 3: From Baseline until Safety Follow-Up (up to Week 23)",child,NULL,Date trial authorised,NA,NA,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Apr 11 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-002152-32-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002152-32,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA) - TENAYA",Neovascular age-related macular degeneration <br>                MedDRA version: 20.0                Level: PT                Classification code 10071129                Term: Neovascular age-related macular degeneration                System Organ Class: 10015919 - Eye disorders            ;Therapeutic area: Diseases [C] - Eye Diseases [C11],"<br>                Product Name: Faricimab<br>                Product Code: RO6867461/F06<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: not available<br>                CAS Number: 1607793-29-2<br>                Current Sponsor code: RO6867461<br>                Other descriptive name: VA2, VEGF-Ang2 ophtha Humanized anti-VEGF-A  anti-Ang-2 bispecific Antibody<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 120-<br><br>                Trade Name: Eylea<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: Aflibercept<br>                CAS Number: 862111-32-8<br>                Current Sponsor code: Ro 717-1571<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 40-<br><br>",A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Tenaya),EUCTR,2019-03-25,2019-04-04,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,640,F.Hoffmann La-Roche Ltd,United States;Spain;Turkey;Russian Federation;Israel;Switzerland;United Kingdom;Italy;Hungary;Mexico;Canada;Poland;Brazil;Netherlands;Germany;Japan,NCT03823287,NULL,25/03/2019,04/04/2019,EUCTR2,30 April 2019,GR40306;2018-002152-32-DE,Trial Information Support Line-TISL,NA,Grenzacherstrasse 124,global.rochegenentechtrials@roche.com,NA,F. Hoffmann-La Roche LTD,Trial Information Support Line-TISL,NA,Grenzacherstrasse 124,global.rochegenentechtrials@roche.com,NA,F. Hoffmann-La Roche LTD,Authorised-recruitment may be ongoing or finished,NULL,F.Hoffmann La-Roche Ltd - Basel,NA,NA,<br> Female: yes<br> Male: yes<br>,Inclusion criteria: <br>                -  Age >= 50 years <br>                -  Ability to comply with the study protocol<br>                -  For women of childbearing potential:  agreement to remain abstinent or use acceptable contraceptive methods during the treatment period and for at least 3 months after the final dose of study treatment<br>                -  Treatment-naïve choroidal neovascularization (CNV) secondary to AMD (nAMD) in the study eye<br>                -  BCVA of 20/32 to 20/320 (letter score of 78 to 24) in the study eye at the initiation of treatment<br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 165<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 475<br>,"Exclusion criteria: <br>                -  Uncontrolled blood pressure<br>                -  Pregnancy or breastfeeding, or intention to become pregnant during the study<br>                -  CNV due to causes other than AMD in the study eye<br>                -  Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye<br>                -  Presence at screening of central serous chorioretinopathy in the study eye<br>                -  Retinal pigment epithelial tear involving the macula on Day 1 in the study eye<br>                -  On FFA/ Color fundus photograph: <br>                o Subretinal hemorrhage of > 50% of the total lesion area and/or that involves the fovea<br>                o Fibrosis or atrophy of > 50% of the total lesion area and/or that involves the fovea<br>                -  Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study <br>                -  Current vitreous hemorrhage on Day 1 in the study eye<br>                -  Uncontrolled glaucoma in the study eye<br>                -  Spherical equivalent of refractive error demonstrating more than 8 diopters of myopia in the study eye<br>                -  Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye<br>                -  Any cataract surgery or treatment for complications of cataract surgery with steroids or YAG laser capsulotomy in the study eye within 3 months prior to Day 1<br>                -  Any other intraocular surgery in the study eye<br>                -  Prior periocular pharmacological or IVT treatment for other retinal diseases in the study eye<br>                -  Prior IVT administration of faricimab in either eye<br>                -  Active ocular inflammation or suspected or active ocular or periocular infection in either eye<br>","Timepoint(s) of evaluation of this end point: 1. Baseline (Day 1), Weeks 40, 44, and 48;<br>                Primary end point(s): 1. Change in BCVA from baseline to average at Weeks 40, 44 and 48<br>                <br>                <br>            ;<br>                Secondary Objective: • To evaluate the efficacy of faricimab on additional BCVA outcomes<br>                • To evaluate the frequency of study drug administration<br>                • To evaluate the efficacy of faricimab on anatomical outcome measures using optical coherence tomography (OCT) and fundus fluorescein angiography (FFA)<br>                • To evaluate the ocular and non-ocular safety and tolerability of faricimab<br>                • To characterize the systemic pharmacokinetics of faricimab<br>                • To evaluate the immune response to faricimab<br>                • To evaluate potential effects of anti-drug antibody (ADA)s<br>            ;Main Objective: • To evaluate the efficacy of IVT (intravitreal) injections of faricimab on change in best-corrected visual acuity (BCVA)","<br>                Timepoint(s) of evaluation of this end point: 1-6. Baseline to Week 112<br>                7-8. Week 48, 60, and 112<br>                9-15. Baseline to Week 112<br>                16-17. Baseline, Week 48 and 112<br>                18-19. Up to Week 112<br>                20. Week 1, 4, 16, 20, 48, 76, 112<br>                21-22. Week 1, 4, 20, 48, 76, 112<br>                <br>            ;<br>                Secondary end point(s): 1. Change from baseline in BCVA over time <br>                2. Proportion of patients gaining >= 15, >= 10, >= 5, or >= 0 letters in BCVA from baseline over time<br>                3. Proportion of patients avoiding loss of >= 15, >= 10, >=5, or >= 0 letters in BCVA from baseline over time<br>                4. Proportion of patients with BCVA Snellen equivalent of 20/40 or better over time<br>                5. Proportion of patients gaining >= 15 letters or achieving BCVA of >= 84 letters over time<br>                6. Proportion of patients with BCVA Snellen equivalent of 20/200 or worse over time<br>                7. Proportion of patients on different treatment intervals at Weeks 48, 60, and 112 <br>                8. Number of study drug injections received through Weeks 48, 60, and 112 <br>                9. Change from baseline in CST based on an average at Weeks 40, 44, and 48<br>                10. Change from baseline in CST over time <br>                11. Proportion of patients with absence of intraretinal fluid over time<br>                12. Proportion of patients with absence of subretinal fluid over time<br>                13. Proportion of patients with absence of intraretinal and subretinal fluid over time<br>                14. Proportion of patients with absence of intraretinal cysts over time<br>                15. Proportion of patients with absence of pigment epithelium detachment over time<br>                16. Change from baseline in total area of CNV lesion at Week 48 and Week 112<br>                17. Change from baseline in total area of leakage at Week 48 and Week 112<br>                18. Incidence and severity of ocular adverse events<br>                19. Incidence and severity of non-ocular adverse events<br>                20. Plasma concentration of faricimab over time<br>                21. Presence of ADAs during the study relative to the presence of ADAs at baseline<br>                22. Relationship between ADA status and efficacy, safety, or pharmacokinetic endpoints<br>",child,NULL,Date trial authorised,NA,NA,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2019-001458-24-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001458-24,"APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) - A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy",Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) <br>MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],<br>Trade Name: Onpattro<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PATISIRAN<br>CAS Number: 1386913-72-9<br>Current Sponsor code: ALN-TTR02<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2.0-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy,EUCTR,2019-08-30,2019-11-12,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 1",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,300,"Alnylam Pharmaceuticals, Inc.","United States;Portugal;Hong Kong;Taiwan;Colombia;United Kingdom;Mexico;Argentina;Brazil;Australia;Denmark;Bulgaria;Japan;Korea, Republic of",NCT03997383,NULL,30/08/2019,12/11/2019,EUCTR2,6 October 2020,ALN-TTR02-011;2019-001458-24-DK,Clinical Trials Information Line,NA,300 Third Street,clinicaltrials@alnylam.com,+ 001877 256 9526,"Alnylam Pharmaceuticals, Inc",Clinical Trials Information Line,NA,300 Third Street,clinicaltrials@alnylam.com,+ 001877 256 9526,"Alnylam Pharmaceuticals, Inc",Authorised-recruitment may be ongoing or finished,NULL,"Alnylam Pharmaceuticals, Inc",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. Age 18 (or age of legal consent, whichever is older) to 85 years, inclusive.<br>2. Documented diagnosis of ATTR amyloidosis with cardiomyopathy, classified as either hATTR amyloidosis with cardiomyopathy or wtATTR  amyloidosis with cardiomyopathy:<br><br>Hereditary ATTR amyloidosis with cardiomyopathy diagnosed based on meeting all of the following criteria:<br>     a. TTR pathogenic mutation consistent with hATTR.<br>     b. Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness >12 mm (based on central echocardiogram reading at screening).<br>     c. Amyloid deposits in cardiac or noncardiac tissue (eg, fat pad aspirate, salivary gland, median nerve connective sheath) confirmed by Congo Red (or equivalent) staining OR technetium (99mTc) scintigraphy (99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid [DPD-Tc], 99mTc-pyrophosphate [PYP-Tc], or 99mTc-hydroxymethylene diphosphonate (HMDP] with Grade 2 or 3 cardiac uptake, if monoclonal gammopathy of undetermined significance<br>(MGUS) has been excluded.<br>     d. If MGUS, confirm TTR protein in tissue with immunohistochemistry (IHC) or mass spectrometry.<br><br>Wild-type ATTR amyloidosis with cardiomyopathy diagnosed based on meeting all of the following criteria:<br>     a. Absence of pathogenic TTR mutation.<br>     b. Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness >12mm (based on central echocardiogram reading at screening).<br>     c. Amyloid deposits in cardiac tissue with TTR precursor identification by IHC, mass spectrometry, OR technetium (99mTc) scintigraphy (99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid [DPD-Tc], 99mTc-pyrophosphate [PYP-Tc] or 99mTc-hydroxymethylene diphosphonate [HMDP] with Grade 2 or 3 cardiac uptake, if MGUS has been excluded.<br>     d. If MGUS, confirm TTR protein in cardiac tissue with IHC or mass spectrometry<br><br>3. Medical history of HF with at least 1 prior hospitalization for HF (not due to arrhythmia or a conduction system disturbance treated with a permanent pacemaker) OR clinical evidence of HF (with or without hospitalization) manifested by signs and symptoms of volume overload or elevated intracardiac pressures (eg, elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on x-ray or auscultation, peripheral<br>edema) that currently requires treatment with a diuretic.<br><br>4. Patient meets one of the following criteria:<br>     a. Tafamidis naïve; in addition to patients who have never taken tafamidis, those who have been on tafamidis for =30 days total and have not received any tafamidis in the 6 months prior to baseline will be considered tafamidis naïve and may qualify for the study.<br>     b. Currently on tafamidis (for =6 months) and has demonstrated disease progression, as determined by the Investigator. (At the time of study entry, tafamidis treatment must be on-label use of commercial tafamidis for the treatment of ATTR amyloidosis with cardiomyopathy at<br>the approved dose in the country of use.)<br><br>5. Patient is clinically stable, with no CV-related hospitalizations within 6 weeks prior to randomization, as assessed by the Investigator.<br>6. Able to complete =150 m on the 6-MWT at screening.<br>7. Screening NT-proBNP >300 ng/L and <8500 ng/L; in patients with<br>permanent or persistent atrial fibrillation, screening NT-proBNP >600 ng/L and <8500 ng/L.<br>8. Patient is able to understand and is willing and able to comply with the study requiremen","Exclusion criteria: <br>1. Has known primary amyloidosis (AL) or leptomeningeal amyloidosis.<br>2. NYHA Class III AND ATTR amyloidosis disease Stage 3 (defined as both NT-proBNP >3000 ng/L and estimated glomerular filtration rate [eGFR] <45 ml/min/1.73 m2).[Gillmore 2018]<br>3. NYHA Class IV at the Screening visit.<br>4. Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV (requires cane or stick to walk, or is wheelchair bound) at the Screening visit.<br>5. Has any of the following laboratory parameter assessments at screening:<br>     a. Aspartate transaminase (AST) or alanine transaminase (ALT) levels >2.0 × the upper limit of normal (ULN).<br>     b. Total bilirubin >2 x ULN. <br>     c. International normalized ratio (INR) >1.5 (unless patient is on anticoagulant therapy, in which case excluded if INR >3.5).<br>6. Has eGFR <30 mL/min/1.73 m2 (using the modification of diet in renal disease [MDRD] formula).<br>7. Has known human immunodeficiency virus infection; or evidence of current or chronic hepatitis C virus or hepatitis B virus infection.<br>8. Tafamidis naïve patients (at baseline) for whom the Investigator actively plans or anticipates commencing treatment with tafamidis during the 12-month double-blind period, taking into consideration clinical status, patient preference and/or commercial availability of tafamidis.<br>9. Is currently taking diflunisal; if previously on this agent, must have at least a 30-day wash-out prior to dosing (Day 1).<br>10. Is currently taking doxycycline, ursodeoxycholic acid or tauroursodeoxycholic acid; if previously on any of these agents, must have completed a 30-day wash-out prior to dosing (Day 1).<br>11. Received prior TTR-lowering treatment (including patisiran) or participated in a gene therapy trial for hATTR amyloidosis.<br>12. Current or future participation in another investigational device or drug study, scheduled to occur during this study, or has received an investigational agent or device within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to dosing (Day 1). In the case of investigational TTR stabilizer drugs, washout for 6 months prior to dosing (Day 1) is required; this does not apply to patients who are on tafamidis at baseline (per inclusion Criterion 4).<br>13. Requires chronic treatment with non-dihydropyridine calcium channel blockers (eg, verapamil, diltiazem) .<br>14. Other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due to valvular heart disease, or cardiomyopathy due to ischemic heart disease (eg, prior myocardial infarction with documented history of cardiac enzymes and electrocardiogram [ECG] changes).<br>15. Has non-amyloid disease affecting exercise testing (eg, severe chronic obstructive pulmonary disease, severe arthritis, or peripheral vascular disease affecting ambulation).<br>16. Recent or planned orthopedic procedure during the double-blind period (eg, lower extremity or back surgery) that could impact 6-MWT.<br>17. Unstable congestive heart failure (CHF) (eg, no adjustment of diuretics at time of screening required to achieve optimal treatment of CHF).<br>18. Had acute coronary syndrome or unstable angina within the past 3 months.<br>19. Has history of sustained ventricular tachycardia or aborted ventricular fibrillation.<br>20. Has history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker is indicated but will not be placed.<br>21. Has persistent elevation of systolic (?180 mmHg) and diastolic (?100 mmHg) blood pressure that is considered uncontrolled","Timepoint(s) of evaluation of this end point: month 12;Primary end point(s): Change from baseline at Month 12 in 6-MWT;Secondary Objective: To evaluate the efficacy of patisiran compared<br>with placebo treatment on:<br>- Health status and health-related quality of life<br>- Patient mortality and hospitalizations, and urgent heart failure (HF) visits;Main Objective: To evaluate the efficacy of patisiran compared with placebo treatment on functional capacity (6-minute walk test [6-MWT]) in patients with ATTR amyloidosis with cardiomyopathy","Timepoint(s) of evaluation of this end point: month 12 (Weeks 52-53); this assessment will also be performed at Month 6 (Weeks 25-26) and Month 9 (Weeks 37-38);Secondary end point(s): -Change from baseline at Month 12 in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score<br><br>-Composite endpoint of all-cause mortality, frequency of cardiovascular (CV) events (CV hospitalizations and urgent HF visits) and change from baseline in 6-MWT over the 12-month double-blind period<br><br>-Composite endpoint of all-cause mortality and frequency of all-cause hospitalizations and urgent HF visits over the 12-month double-blind period",child,NULL,Date trial authorised,NA,NA,"APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Oct  2 2019 12:00AM,NA,NA,NA,NA
EUCTR2019-001560-30-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001560-30,"Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions referred for contrast-enhanced MRI of the CNS","Central nervous system (CNS) pathology <br>MedDRA version: 22.1Level: LLTClassification code 10029820Term: Nuclear magnetic resonance imaging gadolinium-enhancedSystem Organ Class: 100000004848 <br>MedDRA version: 20.0Level: PTClassification code 10051290Term: Central nervous system lesionSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]",<br>Product Name: BAY 1747846<br>Product Code: BAY 1747846<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: BAY 1747846<br>Other descriptive name: BAY 1747846<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 193.43-<br><br>Trade Name: Gadovist<br>Product Name: Gadovist<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: gadobutrol<br>CAS Number: 138071-82-6<br>Other descriptive name: GADOBUTROL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 604.72-<br><br>,Study to find the appropriate dose of a new gadolinium-based contrast agent (GBCA) for adults undergoing magnetic resonance imaging (MRI) for known or highly suspected brain and/or spinal cord conditions,EUCTR,2019-11-27,2020-05-04,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: no<br>Open: no<br>Single blind: yes<br>Double blind: no<br>Parallel group: no<br>Cross over: yes<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 1<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,180,Bayer AG,United States;Germany;Japan,NCT04307186,NULL,27/11/2019,04/05/2020,EUCTR2,3 November 2020,20241,Bayer Clinical Trials Contact,NA,N/A,clinical-trials-contact@bayer.com,004930300139003,Bayer AG,Bayer Clinical Trials Contact,NA,N/A,clinical-trials-contact@bayer.com,004930300139003,Bayer AG,Authorised-recruitment may be ongoing or finished,NULL,Bayer AG,NA,NA,<br>Female: yes<br>Male: yes<br>,Inclusion criteria: <br>1. Participant must be at least 18 years of age at the time of signing the informed consent. 2. Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of the CNS. 3. Male and female. 4. Estimated glomerular filtration rate (eGFR) value =60 mL/min/1.73m^2.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 150<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 30<br>,"Exclusion criteria: <br>1. Considered clinically unstable or has a concomitant/intercurrent condition (e.g. COVID-19 infection) that would not allow participation for the full planned study period in the judgement of the investigator. 2. Severe cardiovascular disease. 3. Patients undergoing liver transplantation. 4. Any contraindication to MRI examinations. 5. History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents, foods, chemicals or other substances. 6. History of allergic asthma and/ or atopic dermatitis. 7. Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI: • Lepto-meningeal disease (e.g. leptomeningeal carcinomatosis). Dural lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded • Pituitary adenomas (macro and micro) • Tumors of the choroid plexus • Tumors of the pineal gland • Dermoid/epidermoid tumors • Infectious disease (e.g. brain abscess, cisticercosis, etc.) • Venous angiomas • Subacute/chronic ischemia • Encephalitis • Multiple sclerosis (acute and chronic) • Optic neuritis • Chordomas • Von Hippel Lindau syndrome • Hypertensive leukoencephalopathy. 8. Receipt of any contrast agent <72 h prior to the study MRIs, or planned receipt of any contrast agent within 72 h after the second study MRI. 9. Planned or expected biopsy in the region of interest or any interventional therapeutic procedure from the first study MRI up to 24 h after the second study MRI. 10. Planned or expected change in any treatment or procedure between the two study MRIs that may alter image comparability and /or chemotherapy which is changed between the two MRI procedures. 11. Contraindications to the administration of gadobutrol, i.e. history of severe hypersensitivity reaction to gadobutrol (depending on local product label).<br>",Main Objective: To identify a dose for further development that has an overall diagnostic preference rate similar to that of the comparator gadobutrol at 5 min post injection;Secondary Objective: To show non-inferiority of BAY1747846 compared to gadobutrol at 5 min post injection with respect to sum of lesion visualization parameters;Primary end point(s): Overall diagnostic preference;Timepoint(s) of evaluation of this end point: At 5 minute post injection,Secondary end point(s): Sum of lesion visualization parameters;Timepoint(s) of evaluation of this end point: At 5 minute post injection,parent,NULL,Date trial authorised,NA,NA,"Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions referred for contrast-enhanced MRI of the CNS",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,May  4 2020 12:00AM,NA,NA,NA,NA
EUCTR2018-004567-31-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004567-31,"A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk",Metastatic Renal Cell Carcinoma <br>MedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04],<br>Trade Name: CABOMETYX®<br>Product Name: Cabozantinib <br>Product Code: XL184<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: CABOZANTINIB<br>CAS Number: 1140909-48-3<br>Current Sponsor code: XL184<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: YERVOY®<br>Product Name: Ipilimumab<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IPILIMUMAB<br>Current Sponsor code: BMS-734016 MDX-010<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: OPDIVO®<br>Product Name: Nivolumab<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>Current Sponsor code: BMS-936558  MDX1106  ONO-4538<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>,"This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated subjects with intermediate- and poor-risk advanced or metastatic RCC",EUCTR,2019-05-20,2019-12-11,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,676,"Exelixis, Inc.",United States;Hong Kong;Finland;Spain;Austria;Israel;Chile;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;New Zealand,EUCTR2018-004567-31-ES,NULL,20/05/2019,11/12/2019,EUCTR2,6 July 2020,XL184–313;2018-004567-31-GB,Exelixis Medical Affairs,NA,1851 Harbor Bay Parkway,druginfo@exelixis.com,1888393 5494,"Exelixis, Inc.",Exelixis Medical Affairs,NA,1851 Harbor Bay Parkway,druginfo@exelixis.com,1888393 5494,"Exelixis, Inc.",Authorised-recruitment may be ongoing or finished,NULL,"Exelixis, Inc.",NA,NA,<br>Female: yes<br>Male: yes<br>,Inclusion criteria: <br>- Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.<br>- Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.<br>- Measurable disease per RECIST 1.1 as determined by the Investigator. <br>- Karnofsky Performance Status (KPS) = 70%.<br>- Adequate organ and marrow function.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 418<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 258<br>,"Exclusion criteria: <br>- Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC including investigational agents.<br>- Uncontrolled, significant intercurrent or recent illness including, but not limited to serious cardiovascular disorders (including uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment), GI disorders associated with high risk for perforation or fistula formation, tumors invading GI tract, bowel obstruction, intra-abdominal abscess, clinically significant bleeding events, cavitating pulmonary lesions, or lesion invading major pulmonary blood vessels.<br><br>-Other clinically significant disorders such as:<br>  i. Autoimmune disease that has been symptomatic or required<br>treatment within the past two years from the date of randomization<br>  ii. Any condition requiring systemic treatment with either<br>corticosteroids (> 10 mg daily prednisone equivalent) or other<br>immunosuppressive medications within 14 days of randomization.<br>  iii. Active infection requiring systemic treatment. Acute or chronic<br>hepatitis B or C infection, known human immunodeficiency virus (HIV)<br>or acquired<br>immunodeficiency syndrome (AIDS)-related illness, or known positive<br>test for tuberculosis infection where there is clinical or radiographic<br>evidence of active mycobacterial infection.<br>-Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain<br>metastasis) within 4 weeks prior to randomization. Minor surgeries<br>within 10 days prior to randomization. Subjects must have complete<br>wound healing from majo or minor surgery before randomization.<br>- Any other active malignancy at time of randomization or diagnosis of<br>another malignancy within 3 years prior to randomization that requires<br>active treatment, except for locally curable cancers that have been<br>apparently cured, such as basal or squamous cell skin cancer, superficial<br>bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.   <br>","Main Objective: The objective of this study is to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated subjects with intermediate- and poor-risk advanced or metastatic RCC. ;Secondary Objective: Not applicable;Primary end point(s): Duration of PFS (Progression-Free Survival), per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)<br>;Timepoint(s) of evaluation of this end point:  The first tumor assessment after randomization should be performed at W10D1 (± 7 days). Subsequent tumor assessments should be performed every 8 weeks (± 7 days) from randomization through Week 50. Upon completion of 50 weeks on study, these assessments will be performed every 12 weeks (± 7 days). Additional imaging of potential disease sites should be performed whenever radiographic PD is suspected.","Secondary end point(s): Duration of OS (overall survival);Timepoint(s) of evaluation of this end point: Overall survival (OS) will continue to be assessed every 12 weeks (± 14 days) after the second post-treatment follow-up visit (FU-2), which occurs 100 (±14) days after discontinuation of study treatment. Subjects will be followed until death or Sponsor decision to no longer collect these data",parent,NULL,Date trial authorised,NA,NA,"A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Oct 11 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-001271-20-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001271-20,"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO",Vitiligo <br>                MedDRA version: 20.0                Level: PT                Classification code 10047642                Term: Vitiligo                System Organ Class: 10040785 - Skin and subcutaneous tissue disorders            ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17],<br>                Product Code: PF-06651600<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06651600<br>                Current Sponsor code: PF-06651600<br>                Other descriptive name: PF-06651600-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Product Code: PF-06651600<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06651600<br>                Current Sponsor code: PF-06651600<br>                Other descriptive name: PF-06651600-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Product Code: PF-06700841<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06700841<br>                Current Sponsor code: PF-06700841<br>                Other descriptive name: PF-06700841-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Product Code: PF-06700841<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06700841<br>                Current Sponsor code: PF-06700841<br>                Other descriptive name: PF-06700841-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 25-<br><br>,A medical research study to evaluate the safety and effectiveness of two investigational medications for vitiligo,EUCTR,2019-04-30,2019-06-13,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: yes<br>                Other trial design description: partially blinded extension period<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 12<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,660,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","United States;Taiwan;Canada;Belgium;Spain;Australia;Germany;Japan;Italy;Korea, Republic of",NCT03715829,NULL,30/04/2019,13/06/2019,EUCTR2,30 June 2019,B7981019;NCT03715829,Clinical Trials.gov Call Center,NA,235 E 42nd Street,ClinicalTrials.gov_Inquiries@pfizer.com,+18007181021,Pfizer Inc,Clinical Trials.gov Call Center,NA,235 E 42nd Street,ClinicalTrials.gov_Inquiries@pfizer.com,+18007181021,Pfizer Inc,Authorised-recruitment may be ongoing or finished,NULL,Pfizer Inc.,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                - Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.<br>                - Must have moderate to severe active non-segmental vitiligo.<br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 660<br>                F.1.3 Elderly (>=65 years) no<br>                F.1.3.1 Number of subjects for this age range 0<br>",Exclusion criteria: <br>                - History of human immunodeficiency virus (HIV) or positive HIV serology at screening.<br>                - Infected with hepatitis B or hepatitis C viruses.<br>                - Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).<br>,"Timepoint(s) of evaluation of this end point: baseline, 24 weeks;  baseline up to end of study (56 weeks);<br>                Primary end point(s): - Percent change from baseline of vitiligo area scoring index (VASI) at Week 24<br>                - Number of treatment emergent adverse events(TEAEs)<br>                - Number of subjects with change from baseline in laboratory tests results<br>                - Number of subjects reporting TEAEs<br>                - Number of specific clinical laboratory abnormalities<br>                - Number of treatment emergent serious adverse events (TESAEs)<br>                - Number of subjects who experienced TESAEs<br>            ;<br>                Secondary Objective: Dose Ranging Period:<br>                - To evaluate the efficacy of PF-06651600 compared to placebo as measured by other clinical assessments over time in adult subjects with active non segmental vitiligo<br>            ;<br>                Main Objective: Dose Ranging Period:<br>                - To evaluate the efficacy of PF-06651600 dose/dosing regimens at Week 24 in adult subjects with active non segmental vitiligo<br>                - To evaluate the safety and tolerability of PF-06651600 over time in adult subjects with active non segmental vitiligo<br>                Extension Period:<br>                - To evaluate the safety and tolerability of PF-06651600 and PF-06700841 in adult subjects with active non segmental vitiligo<br>","Timepoint(s) of evaluation of this end point: at week 24; baseline to week 20; baseline to week 24;<br>                Secondary end point(s): - Percentage of subjects achieving at least 50% improvement in VASI from baseline (VASI50) (at Week 24)<br>                - Percent change from baseline in VASI (baseline to week 20)<br>                - Percent change from baseline in facial VASI (baseline to week 24)<br>                - Percent change from baseline in vitiligo extent score (VES) (baseline to week 24)<br>                - Percent change from baseline in self- assessment vitiligo extent score (SA-VES) (baseline to week 24)<br>                - Absolute change from baseline in VASI (baseline to week 24)<br>                - Percentage of subjects achieving VASI50 (baseline to week 20)<br>                - Percentage of subjects achieving at least 75% improvement in VASI from baseline (VASI75) (baseline to week 24)<br>                - Percentage of subjects achieving at least 90% improvement in VASI from baseline (VASI90) (baseline to week 24)<br>                - Percentage of subjects achieving at least 100% improvement in VASI from baseline (VASI100) (baseline to week 24)<br>                - Percentage of subjects achieving facial VASI50 (baseline to week 24)<br>                - Percentage of subjects achieving facial VASI75 (baseline to week 24)<br>                - Percentage of subjects achieving facial VASI90 (baseline to week 24)<br>                - Percentage of subjects achieving facial VASI100 (baseline to week 24)<br>                - Percentage of subjects achieving at least 50% improvement in VES (VES50) (baseline to week 24)<br>                - Percentage of subjects achieving at least 75% improvement in VES (VES75) (baseline to week 24)<br>                - Percentage of subjects achieving at least 90% improvement in VES (VES90) (baseline to week 24)<br>                - Percentage of subjects achieving at least 100% improvement in VES (VES100) (baseline to week 24)<br>                - Change from baseline in vitiligo specific quality of life (VitiQoL) (baseline to week 24)<br>                - Percentage of subjects achieving a static investigator global assessment (sIGA) 0 or 1, and at least 2-point improvement (week 24)<br>",child,NULL,Date trial authorised,NA,NA,"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2019-000069-19-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000069-19,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials - CLASSIC-MS,Multiple Sclerosis <br>MedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disorders <br>MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],<br>Trade Name: MAVENCLAD<br>Product Name: Cladribine tablets<br>Product Code: Not applicable<br>Pharmaceutical Form: Tablet<br><br>,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials,EUCTR,2019-05-13,2019-10-14,FALSE,Interventional clinical trial of medicinal product,"Controlled: noRandomised: noOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: yesOther trial design description: Ambispective; data from patients participating to past trials. No IMP treatment during this studyIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: no",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,1000,Merck KGaA,"Romania;Serbia;United States;Portugal;Estonia;Morocco;Greece;Spain;Ukraine;Lebanon;Russian Federation;Switzerland;Italy;France;Australia;Tunisia;Latvia;Korea, Republic of;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Canada;Poland;Belgium;Croatia;Bulgaria;Georgia;Norway;Germany;Sweden",EUCTR2019-000069-19-CZ,NULL,13/05/2019,14/10/2019,EUCTR2,16 December 2019,MS700568_0026;2019-000069-19-CZ,Communication Center Merck KGaA,NA,Frankfurter Str. 250,service@merckgroup.com,+496151 725200,Merck KGaA,Communication Center Merck KGaA,NA,Frankfurter Str. 250,service@merckgroup.com,+496151 725200,Merck KGaA,Authorised-recruitment may be ongoing or finished,NULL,Merck KGaA,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>For Main Study and MRI Sub-Study:<br>1. Patients with MS randomised in CLARITY/CLARITY-EXT clinical trial(s) who have received = 1 course of IMP (Cladribine Tablets or placebo).<br>or<br>Patients with their FCDE randomised in ORACLE MS clinical trial who have received<br>= 1 course of IMP (Cladribine Tablets or placebo).<br>2. Patients can give signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and this protocol. <br><br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 920<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 80<br>","Exclusion criteria: <br>Main study:<br>   Any condition, including any uncontrolled disease state other than MS, that in the Investigator’s <br>   opinion, constitutes an inappropriate risk or a contraindication for participation in the study or that <br>   could interfere with the study objectives, conduct, or evaluation.<br>MRI-Substudy:<br>a. Female study participants who are pregnant<br>b. Patient is taking Cladribine Tablets as part of another study at the time of the start of<br>this study (i.e. patients participating in a clinical trial or observational study but do not<br>receive Cladribine Tablets as part of these studies are allowed to participate in the substudy).<br><br><br>","Main Objective: To evaluate long-term mobility after treatment with an investigational medicinal product (IMP; Cladribine<br>Tablets or placebo) as part of the Phase III ORACLE MS and CLARITY/CLARITY-EXT clinical trials.;Secondary Objective: 1. To assess the long-term disability status after treatment with IMP as part of the Phase III ORACLE MS and CLARITY/CLARITY-EXT clinical trials for the CLARITY/CLARITY-EXT and ORACLE MS populations.<br>2. To evaluate differences in clinical characteristics between long-term responders and study participants<br>requiring alternate therapies following treatment with IMP for the CLARITY/CLARITY-EXT and ORACLE<br>MS populations.<br>MRI Sub-Study:<br>3. To evaluate differences in magnetic resonance imaging (MRI) characteristics between long-term responders and study participants requiring alternate therapies following treatment with IMP for the<br>CLARITY/CLARITY-EXT and ORACLE MS populations.;Primary end point(s): Proportion of study participants using a wheelchair (defined as unable to walk beyond approximately 5 meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and<br>transfers alone; up and about in wheelchair some 12 hours a day) the majority of the time in the 3 month prior to Study Visit 1 for the CLARITY/CLARITY-EXT and ORACLE MS populations, determined via:<br>• Expanded Disability Status Scale (EDSS)<br>score of 7.0 or higher (if available), or<br>• Alternative clinical description data in medical records.;Timepoint(s) of evaluation of this end point: Study visit 1",Secondary end point(s): 1. Proportion of study participants with 3-month sustained EDSS of 6.0 or higher in the last year prior to enrolment (i.e.ambulatory disability consistent with EDSS on at least 2 clinic visits no less than 3 months apart) as determined by EDSS documentation or corresponding clinical description in medical records for the CLARITY/CLARITY-EXT and ORACLE MS populations<br>2. Clinical characteristics of long-term responders (defined as study participants who did not demonstrate any evidence of disease reactivation based on Investigator assessment of clinical and imaging outcomes until Year 4 or later following their last dose of IMP and who did not receive disease modifying treatment until Year 4 or later following their last dose of IMP) compared to those of other study participants who started on alternate therapy less than 4 years following their last dose of IMP for the CLARITY/CLARITY-EXT and ORACLE MS populations.<br>MRI Sub-Study:<br>3. MRI characteristicsc at Study Visit 2 of longterm responders (defined as study participants who did not demonstrate any evidence of disease reactivation based on Investigator assessment of clinical and<br>imaging outcomes until Year 4 or later following their last dose of IMP and who did not receive disease modifying treatment until Year 4 or later following their last dose of IMP) compared to those of other study participants who started on alternate therapy less than 4 years following their last dose of IMP for the CLARITY/CLARITY-EXT and ORACLE MS populations.;Timepoint(s) of evaluation of this end point: ad 1. Study Visit 1<br>ad 2. Study Visit 1<br>ad 3.  Study visit 2,child,NULL,Date trial authorised,NA,NA,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials,NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2017-004026-15-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004026-15,"A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease",Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD) <br>MedDRA version: 20.0Level: LLTClassification code 10022974Term: Iron deficiency anemiaSystem Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18],<br>Trade Name: Feraheme®<br>Product Name: Ferumoxytol<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Ferumoxytol<br>CAS Number: 722492-56-0<br>Other descriptive name: FERUMOXYTOL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Venofer®<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: iron sucrose<br>CAS Number: 8047-67-4<br>Other descriptive name: IRON SUCROSE<br>Concentration unit: mg/l milligram(s)/litre<br>Concentration type: equal<br>Concentration number: 20-<br><br>,"Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with chronic kidney disease (CKD) and iron deficiency anemia (IDA) or who are at risk of developing IDA, and to see how safe it is compared to another marketed iron product – iron sucrose.",EUCTR,2019-03-20,2019-07-11,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: yesSingle blind: noDouble blind: noParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,129,"AMAG Pharmaceuticals, Inc.",United States;Hungary;Mexico;Poland;Lithuania,EUCTR2017-004026-15-LT,NULL,20/03/2019,11/07/2019,EUCTR2,6 October 2020,AMAG-FER-CKD-354;2017-004026-15-HU,Medical Information,NA,1100 Winter Street,amag@druginfo.com,+1877-411-2510,"AMAG Pharmaceuticals, Inc.",Medical Information,NA,1100 Winter Street,amag@druginfo.com,+1877-411-2510,"AMAG Pharmaceuticals, Inc.",Authorised-recruitment may be ongoing or finished,NULL,"AMAG Pharmaceuticals, Inc.",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. Male or female 2 years to <18 years of age at time of consent <br>2. Has IDA defined as: a) hemoglobin <12.0 g/dL and b) with either TSAT <40% or ferritin <100 ng/mL; or considered to be at risk of development of IDA, i.e., TSAT<20% with falling hemoglobin during the preceding 2 months and a history of hemoglobin <12 g/dL<br>3. Has Chronic Kidney Disease defined as one of the following:<br>a. on chronic hemodialysis;<br>b. receiving chronic peritoneal dialysis;<br>c. eGFR of <60 mL/min/1.73 m2;<br>d. has evidence of structural and/or functional abnormalities e.g., persistent albuminuria, abnormal urine sediment, electrolyte and other abnormalities due to tubular disorders for > 3 months<br>4. For patients other than hemodialysis dependent CKD patients, documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate <br>5. All subjects (female and male) of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to Day 1 Dosing and agree to remain on birth control until completion of the study<br>6. Subject and/or legal guardian is capable of understanding and complying with the protocol requirements and is available for the duration of the study<br>7. Subject and/or legal guardian has been informed of the investigational nature of this study and has given voluntary written informed consent and, if appropriate, the child/adolescent has provided ‘assent’ and Health Insurance Portability and Accountability Act (HIPAA) or patient protection authorization had been adhered to in accordance with institutional, local, and national personal health data protection guidelines<br><br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 129<br>F.1.2 Adults (18-64 years) no<br>F.1.2.1 Number of subjects for this age range <br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>1. Known hypersensitivity reaction to any component of ferumoxytol and iron sucrose<br>2. History of allergy to intravenous (IV) iron<br>3. History of multiple drug allergies (>2)<br>4. Low systolic blood pressure (Age 1-9 years <70 + [age in years x 2] mmHg, Age 10-17 years <90 mmHg)  <br>5. Hemoglobin =7.0 g/dL<br>6. Serum ferritin level >600 ng/mL<br>7. Parenteral iron therapy within 4 weeks prior to Day 1 Dosing; or blood transfusion within 4 weeks prior to Day 1 Dosing or planned at the time of Screening<br>8. Erythropoiesis-stimulating agent (ESA) therapy initiated, stopped or dose changed by >25% within 4 weeks prior to Screening, or anticipated ESA dose change of >20% during the study<br>9. Known causes of anemia other than iron deficiency (eg, vitamin B12 or folate deficiency, hemolytic anemia, etc)<br>10. Major surgery or invasive intervention within 4 weeks prior to Screening, or any planned major surgery or intervention during the course of the study<br>11. Active malignancy within 2 years prior to Screening (except non-melanoma skin cancer or carcinoma in situ that has been excised)<br>12. Active clinically significant infection (eg, systemic bacterial infection) or acute serious medical illness requiring treatment or intervention within 2 weeks prior to Screening<br>13. Received another investigational agent within 4 weeks prior to Screening, or planned receipt of an investigational agent not specified by this protocol during the study period<br>14. Female subjects who are pregnant or intend to become pregnant, or are breastfeeding, are within 3 months postpartum, or have a positive pregnancy test<br>15. Any other clinically significant medical or psychiatric disease or condition or subject responsibility that, in the Investigator’s opinion, may interfere with a subject’s (and/or legal guardian’s) ability to adhere to the protocol, interfere with assessment of the investigational product, or serve as a contraindication to the subject’s participation in the study<br><br>","Main Objective: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol (7.0 mg Fe/kg x 2 [max 510 mg/dose]) in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA.;Secondary Objective: To determine the single-dose PK and PD profile of ferumoxytol (7.0 mg Fe/kg, max 510 mg/dose) in pediatric subjects.;Primary end point(s): Efficacy Endpoints:<br>? Primary endpoint: Proportion of patients achieving a hemoglobin increase of at least 0.5 g/dL during the period from Baseline to Week 5<br>? Proportion of patients achieving a hemoglobin increase of at least 0.5 g/dL or TSAT increase of at least 10% during the period from Baseline to Week 5 <br>? Proportion of patients achieving a TSAT increase of at least 10% during the period from Baseline to Week 5<br>? Change in hemoglobin from Baseline to Week 5<br>?Whether or not the subject had an increase in hemoglobin =1.0 g/dL during the period from Baseline to Week 5<br>? Change in TSAT from Baseline to Week 5<br>? Whether or not the subject required initiation of ESA or a >20% increase in dose during the study<br>? Whether or not the subject received blood transfusions during the study<br>? Change in other markers of iron stores (e.g., serum ferritin and serum iron) from Baseline to Week 5<br><br>Safety Endpoints:<br>? Incidence of adverse events of special interest (AESI) (hypotension and hypersensitivity) <br>? Incidence of SAEs<br>? Incidence of Severe AEs<br>? Incidence of Cardiovascular AEs (myocardial infarction, heart failure, moderate to severe hypertension, and hospitalization due to any cardiovascular cause)<br>? Incidence of AEs leading to study drug discontinuation<br>? Incidence of treatment emergent AEs<br>? Change in vital signs (blood pressure, heart rate, respiration rate) and body temperature, and routine laboratory parameters (hematology, chemistry, and iron panel);Timepoint(s) of evaluation of this end point: Efficacy endpoints: Week 5<br>Safety endpoints: ongoing during the study duration","Secondary end point(s): Pharmacokinetic Endpoints:<br>• Area Under the Curve (AUC)<br>• Clearance<br>• Distribution and elimination half-lives<br>;Timepoint(s) of evaluation of this end point: Blood samples for PK will be collected 10 minutes prior to administering the first dose; at 18 minutes (not before infusion ends and no later than 10 minutes after infusion ends), 1 hour (±15 minutes), 3 hours (±30 minutes), 5 hours (±30 minutes), 24 hours (±2 hours) and 48 hours (±4 hours) post the start of the infusion",child,NULL,Date trial authorised,NA,NA,"A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Feb 28 2019 12:00AM,NA,NA,NA,NA
EUCTR2019-000119-10-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000119-10,"An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis - JUVE-BRIGHT",Juvenile Idiopathic Arthritis Associated Uveitis or Anterior Antinuclear Antibody-Positive Uveitis <br>MedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11],<br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4-<br><br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: LY3009104<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Suspension for oral suspension<br>INN or Proposed INN: BARICITINIB<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Humira<br>Product Name: Humira<br>Product Code: L04AB04<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ADALIMUMAB<br>CAS Number: 331731-18-1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>Trade Name: Humira<br>Product Name: Humira<br>Product Code: L04AB04<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ADALIMUMAB<br>CAS Number: 331731-18-1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br><br>,A study of Baricitinib in children and young adults with JIA associated eye inflammation,EUCTR,2019-04-17,2019-08-06,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,42,Eli Lilly and Company,France;Germany;United Kingdom,EUCTR2019-000119-10-FR,NULL,17/04/2019,06/08/2019,EUCTR2,15 September 2020,I4V-MC-JAHW,Clinical Trial Registry Office,NA,"Lilly Corporate Center, DC 1526",EU_Lilly_Clinical_Trials@lilly.com,NA,Eli Lilly,Clinical Trial Registry Office,NA,"Lilly Corporate Center, DC 1526",EU_Lilly_Clinical_Trials@lilly.com,NA,Eli Lilly,Authorised-recruitment may be ongoing or finished,NULL,Eli Lilly and Company,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>[1]Are at least 2 years and less than 18 years of age; full date of birth will be collected except in countries in which it is not allowed.<br>[2]Have a diagnosis of JIA U or chronic ANA positive uveitis without systemic features.<br>[3]Have active anterior uveitis, defined as cellular infiltrate in the anterior chamber of SUN criteria grade =1+ at Visit 1 (screening) and Visit 2 (potential randomization), despite prior treatment with adequate doses of topical steroid therapy and MTX.<br>[4]Have an inadequate response or intolerance to MTX (minimum dose of 10 mg/m2/week, with a maximum dose of 25 mg/m2/week).  Patients considered to have inadequate response must have received MTX for at least 12 weeks before an inadequate response may be determined, and must have been on a stable dose for at least 4 weeks prior to screening if continuing MTX therapy during the study.<br>[5]Are receiving topical corticosteroid eye drops at a stable dose for at least 2 weeks prior to screening (maximum of 4 drops/day per eye at screening).<br>[6]Both a parent or legal guardian and the patient (as appropriate) are able to understand and fully participate in the activities of the study and sign their consent and assent, respectively, in accordance to local guidelines.<br>[7]Male or nonpregnant, nonbreastfeeding female patients<br>Patients of child-bearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) must agree to remain abstinent.<br>Total abstinence is defined as refraining from intercourse during the entirety of the study and for at least 1 week following the last dose of investigational product.  Periodic abstinence such as calendar, ovulation, symptothermal, postovulation methods and withdrawal are not acceptable methods of contraception.<br>Otherwise, patients and their partners of child bearing potential must agree to use 2 effective methods of contraception, where at least 1 form is highly effective for the entirety of the study and for at least 1 week following the last dose of investigational product.<br>The following contraception methods are considered acceptable (the patient, and their partner, should choose 2, and 1 must be highly effective [defined as less than 1% failure rate per year when used consistently and correctly]):<br>•Highly effective birth control methods:<br>oCombined (estrogen- and progestogen containing) hormonal contraception associated with inhibition of ovulation:  oral, intravaginal, or transdermal<br>oProgestogen-only hormonal contraception associated with inhibition of ovulation:  oral, intravaginal, or implantable<br>oIntrauterine device/intrauterine hormone releasing system<br>oVasectomized partner (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate).<br>•Effective birth control methods:<br>oMale or female condom with spermicide.  It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.<br>oDiaphragm with spermicide<br>oCervical sponge<br>oCervical cap with spermicide<br>Note:  When local guidelines concerning highly effective or effective methods of birth control differ from the above, the local guidelines must be followed.<br>Adolescent females who have started menses (even 1 cycle and any amount of spotting) are considered to be of child-bearing potential.<br>Women of nonchild-bearing potential are not required to use birth control and they are defined as:<br>•W","Exclusion criteria: <br>[8]Have uveitis without a diagnosis of JIA or chronic anterior uveitis without positive ANA.<br>[9]Have a history or presence of any autoimmune inflammatory condition other than JIA, such as Crohn’s disease or ulcerative colitis.<br>[10]Have any contraindications to adalimumab as addressed in local product labeling or local clinical practice that would preclude the patient from participating in this study.<br>Exception:  Patients who are bDMARD IR with a contraindication to adalimumab may be enrolled, as they will be assigned to baricitinib.<br>[11]Have increased intraocular pressure =25 mm Hg or that required treatment, including increases in medications, surgery, or hospitalization, within 4 weeks prior to baseline that, in the opinion of the investigator, would pose an unacceptable risk to the patient if participating in the study.<br>[12]Have had intraocular surgery within the 3 months prior to screening (such as for cataract(s), glaucoma or vitrectomy).<br>[13]Are pregnant or breastfeeding.  Prior to initiation of treatment, female patients of child-bearing potential must have a negative serum pregnancy test at the central laboratory during screening and a negative urine pregnancy test at Visit 2.<br>[14]Have a current or recent (<4 weeks prior to baseline) clinically serious viral, bacterial, fungal, or parasitic infection or any other active or recent infection that, in the opinion of the investigator, would pose an unacceptable risk to the patient if participating in the study.<br>[15]Have had an infection of bone or joint within 6 months prior to screening.<br>[16]Have symptomatic herpes simplex at baseline.<br>[17]Have had symptomatic herpes zoster infection within 12 weeks prior to baseline.<br>[18]Have a history of multidermatomal herpes zoster, or complicated herpes zoster (e.g., ocular or motor nerve involvement or disseminated herpes zoster such as systemic infection).<br>[19]Have a positive test for hepatitis B virus (HBV) at screening defined as:<br>a.positive for hepatitis B surface antigen (HBsAg), or<br>b.positive for hepatitis B core antibody (HBcAb) and positive for HBV deoxyribonucleic acid (DNA)<br>[20]Have hepatitis C virus (HCV) infection (hepatitis C antibody positive and confirmed presence of HCV ribonucleic acid [RNA]).<br>[21]Have evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.<br>[22]Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.<br>[23]Have evidence of active TB or untreated/inadequately/inappropriately treated latent TB<br>a.Have evidence of active TB, defined in this study as the following:<br>•Positive PPD test (=5 mm induration between approximately 48 and 72 hours after application, regardless of vaccination history), medical history, and clinical features.<br>•QuantiFERON® TB Gold test or T SPOT®.TB test (as available and if compliant with local TB guidelines) may be used instead of the PPD test.  Patients are excluded from the study if the test is not negative and there is clinical evidence of active TB.<br>b.Have evidence of untreated/inadequately or inappropriately treated latent TB, defined in this study as the following:<br>•Positive PPD test, no clinical features consistent with active TB, and a chest x ray with no evidence of active TB at screening; or <br>•If the PPD test is positive and the patient has no medical history or chest x ray findings consistent with active TB, the patient may have a QuantiFERON®","Main Objective: The primary objective of this protocol is to evaluate the efficacy of baricitinib in children with JIA-U or ANA-positive uveitis;Secondary Objective: The secondary objectives of this trial are to:<br>-To evaluate the efficacy of baricitinib in children with JIA-U or ANA-positive uveitis in the most severely affected eye and less affected eye.<br>-To evaluate the efficacy of adalimumab in children with JIA-U or ANA-positive uveitis in the most severely affected eye and less affected eye.<br>-To evaluate the safety of baricitinib in children with JIA-U or ANA-positive children with JIA-U or ANA-positive uveitis<br>;Primary end point(s): The primary endpoint is the percentage of responders at Week 24. Response is defined according to the Standardization of Uveitis Nomenclature (SUN) criteria as a 2-step decrease in the level of inflammation (anterior chamber cells) or decrease to zero through week 24, in the eye most severely affected at baseline.;Timepoint(s) of evaluation of this end point: At Week 24",Secondary end point(s): -Change in SUN grade of cells in the anterior chamber through Week 24 in the most severely affected eye.<br>- Change in SUN grade of cells in the anterior chamber through week 24 in the less severely affected eye.<br>-Change in visual acuity by age-appropriate assessments through week 24.<br>-Change in vitreous haze through week 24.<br>-Change in grade of flare in the anterior chamber through week 24.<br>-Change in overall uveitis-related disability (assessment by parent and child VAS) through week 24.<br>-Proportion of patients with inactive anterior uveitis disease (using SUN definition) through Week 24.<br>-Time to inactive anterior disease (using SUN definition).<br>-Adverse events including serious adverse events.<br>-Change in SUN grade of cells in the anterior chamber through week 284 in the most severely affected eye.<br>-Change in SUN grade of cells in the anterior chamber through week 284 in the less severely affected eye.<br>-Change in visual acuity by age-appropriate assessments through week 284.<br>-Change in vitreous haze through Week 284.<br>-Change in grade of flare in the anterior chamber through week 284.<br>-Change in overall uveitis-related disability through week 284.;Timepoint(s) of evaluation of this end point: Week 24 and Week 284,child,NULL,Date trial authorised,NA,NA,"An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Aug  6 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-004451-20-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004451-20,"A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",Adult men and women with palmoplantar pustulosis <br>                MedDRA version: 21.1                Level: PT                Classification code 10050185                Term: Palmoplantar pustulosis                System Organ Class: 10040785 - Skin and subcutaneous tissue disorders            ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17],<br>                Product Name: Guselkumab<br>                Product Code: CNTO 1959<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: Guselkumab<br>                CAS Number: 1350289-85-8<br>                Current Sponsor code: CNTO 1959<br>                Other descriptive name: GUSELKUMAB<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>,"A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",EUCTR,2019-04-09,2019-07-17,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: no<br>                Randomised: no<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 1<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,50,Rheinische Friedrich-Wilhelms-Universität Bonn,Germany,NA,NULL,09/04/2019,17/07/2019,EUCTR2,10 December 2019,DER201702,Dr. Christina Panknin,NA,Venusberg-Campus 1,christina.panknin@ukbonn.de,004922828714035,Studienzentrale Studienzentrum Bonn (SZB),Dr. Christina Panknin,NA,Venusberg-Campus 1,christina.panknin@ukbonn.de,004922828714035,Studienzentrale Studienzentrum Bonn (SZB),Authorised-recruitment may be ongoing or finished,NULL,Janssen-Cilag GmbH,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                Each potential subject must satisfy all of the following criteria to be enrolled in the study:<br><br>                1.Male or female, aged 18 years or more at screening visit<br>                2.given written consent to participate in the study<br>                3.has moderate to severe PPP defined as a ppPPPASI = 12 at baseline (week 0) with or without concomitant plaque-type psoriasis<br>                4.a candidate for systemic treatment defined as having PPP inadequately controlled by topical treatment and/or phototherapy and/or previous sys-temic therapy<br>                5.has chronic disease of PPP of 6 months calculated from date at which first symptoms were reported by subject to date of screening visit<br>                6.Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug<br>                7.Agree not to receive a BCG vaccination during the study, or within 12 months after the last administration of study drug<br>                8.Subjects with the ability to follow study instructions and likely to attend and complete all required visits<br>                Reproduction-related inclusion criteria<br>                Contraceptive (birth control) use by men or women should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.<br>                Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for subjects in clinical studies.<br>                9.Before first administration of study drug, a woman must be<br>                a. Not of childbearing potential<br>                b. Of childbearing potential and practicing a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly) and agrees to remain on a highly effective method method while receiving study treatment and until 12 weeks after last dose - the end of relevant systemic exposure. Examples of highly effective methods of contraception are located in section 9.4.<br>                10.A woman of childbearing potential must have a negative urine preg-nancy test at screening and agree to urine pregnancy testing before re-ceiving injections and at safety follow-up.<br>                11.A woman must agree not to donate eggs (ova, oocytes) for the pur-poses of assisted reproduction during the study and for a period of 12 weeks after receiving the last administration of guselkumab.<br>                12.A male subject must wear a condom when engaging in any activity that allows for passage of ejaculate to another person.<br>                13.A male subject must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 12 weeks after receiving the last dose of study treatment.<br><br>                TB-related inclusion criteria:<br>                14. It is the responsibility of the investigator to verify the adequacy of previous anti-TB treatment and provide appropriate documentation.<br>                a.Have no history of latent or active TB before screening<br>                b.Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.<br>                c.Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician speci","Exclusion criteria: <br>                General Exclusion Criteria:<br>                1.Subject without legal capacity or is unable to understand the nature, scope, significance and consequences of this clinical trial<br>                2.Simultaneously participation in another clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 4 weeks or 5 pharmacokinetic/pharmacodynamics half-lives (which-ever is longer)prior to participation in present clinical trial<br>                3.Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial<br>                4.Known or persistent abuse of medication, drugs or alcohol<br>                Indication specific exclusion criteria:<br>                5. Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure or to any components of guselkumab<br>                6.Evidence of skin conditions (eg eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.<br>                7.Ultraviolet B (UVB) therapy, topical steroids, topical calcineurin inhibitors, topical Vitamin A or D analog preparations, or anthralin within 14 days of baseline.<br>                Exceptions: low potency corticosteroids will be allowed as   therapy for the face, groin, axillae in accordance with the manufacturers suggested usage dose.<br>                8.Psoralen plus ultraviolet A radiation (PUVA), ciclosporin, acitretin, ale-facept (AmeviveTM), anakinra (KineretTM), systemic corticosteroids, methotrexate, fumaric acids, apremilast or any other systemic anti-psoriasis therapy within 28 days of baseline<br>                9.antipsoriatic biologic therapy with TNF-a blockers or IL-17 blockers within 3 months and/or ustekinumab within 4 months<br>                10.Prior treatment with guselkumab or other IL23-blockers<br>                11.Receipt of ANY live (attenuated) vaccine within 3 months prior to baseline (week 0), and BCG vaccination within 12 months of screening.<br><br>                12.Significant concurrent medical conditions at the time of screening, includ-ing:<br>                a. Risk factors for renal toxicity (renal inflammation)<br>                b. Severe hepatic dysfunction<br>                c. Unstable angina pectoris<br>                d. Uncompensated congestive heart failure<br>                e. Severe pulmonary disease requiring hospitalization or supple-mental oxygen therapy<br>                f. Immunodeficiency disorders: primary or secondary<br>                g.Previous test positive for Human immunodeficiency virus (HIV, test result may not be older than 8 weeks at screening date)<br>                h. Previous tests positive for hepatitis B virus (HBV) infection or tests seropositive for antibodies to hepatitis C virus (HCV), unless the patient has 2 negative  HCV RNA test results 6 months apart after completing antiviral treatment and prior to baseline and has a third negative HCV RNA test result at baseline (test results may not be older than 8 weeks at screening date).<br>                i. history of active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening. Refer to inclusion criterion 15 and 16 for information regarding eligibility with a history of latent TB<br>                j. Uncontrol","<br>                Timepoint(s) of evaluation of this end point: week 24 compared to baseline (week 0)<br><br>            ;Primary end point(s): Analysis of skin lesions at week 24 compared to baseline in moderate to severe chronic PPP under guselkumab therapy, as assessed by palmoplantar Pustulosis Psoriasis Severity Index (ppPASI) score;Main Objective: Demonstration of improvement in moderate to se-vere chronic PPP after guselkumab administration ;<br>                Secondary Objective: 1.Evaluation of efficacy and safety of guselkumab application in patients with moderate to severe PPP<br>                2.Determination of improvement of quality of life due to guselkumab administration in patients with moderate to severe PPP<br>                3.Demonstration of improvement in moderate to severe chronic PPP after guselkumab administration<br>","<br>                Timepoint(s) of evaluation of this end point: all assessment timepoints (week 4, 12 , 24 and 32 depending on the endpoint) compared to week 0 (baseline)<br>                For AEs and SAEs assessment aditionally on week 20 (no comparison to week 0)<br>            ;<br>                Secondary end point(s): 1 a) Analysis of skin lesions at all assessment times compared to baseline in moderate to severe chronic PPP under guselkumab therapy, as assessed by ppPASI score<br>                1 b) Evaluation of safety of guselkumab in patients with moderate to severe PPP, as assessed by AEs<br>                2 a) Evaluation of possible alterations in quality of life assessement measures during guselkumab-treatment:  Dermatology  Life  Quality Index (DLQI) palmoplantar Quality of Life (ppQoL) and work productivity and activity impairment questionnaire-psoriasis (WPAI-Pso) at all assessment times com-pared to baseline<br>                3 a) Evaluation of time course of Hand and Feet   Physician Global Assessment (H&F PGA) at all assessment times.<br>                3 b) Absolute and percent change in PPSI score as compared to baseline during the 24 weeks treat-ment period.<br>                3 c) Pustules count 50 response or Pustules count 75 response defined as a minimum of 50% or a minimum of 75% decrease in Pustules count re-spectively as compared to baseline, during the 24 weeks treatment period<br>                3 d) Evaluation of differences in the mean change of Numereous Analogue Scale (NRS) discomfort / pain, NRS pruritus / itch at all assessment times as compared to day 0 (baseline)<br>                3 e) Evaluation of changes in Psoriasis Area Severi-ty Index (PASI) and Physician  Global Assessment (PGA) if plaque psoriasis is present comparing baseline  to all assessment times<br>",NA,NULL,Date trial authorised,NA,NA,"A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2017-003342-25-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003342-25,Long-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis - API-CAT,"Any cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intra-cerebral metastasis) with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after at least 6 months of anticoagulant therapy for the treatment of the index event, with no objectively documented symptomatic recurrence of VTE between the index event and  randomization. <br>                MedDRA version: 21.1                Level: LLT                Classification code 10076654                Term: Cancer-associated thrombosis                System Organ Class: 100000004864            ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]","<br>                Trade Name: ELIQUIS 5mg<br>                Product Name: ELIQUIS 5mg<br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: APIXABAN<br>                CAS Number: 503612-47-3<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br>                Pharmaceutical form of the placebo: Coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: ELIQUIS 2,5mg<br>                Product Name: ELIQUIS 2,5mg<br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: APIXABAN<br>                CAS Number: 503612-47-3<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2.5-<br>                Pharmaceutical form of the placebo: Coated tablet<br>                Route of administration of the placebo: Oral use<br><br>",Long-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis,EUCTR,2019-04-10,2019-12-20,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,1722,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),France;Greece;Belgium;Spain;Poland;Netherlands;Italy;United Kingdom;Switzerland,EUCTR2017-003342-25-ES,NULL,10/04/2019,20/12/2019,EUCTR2,1 February 2020,P170604J,DRCI Hôpital St Louis,NA,1 av. Claude Vellefaux,aurelie.zindjirdjian@aphp.fr,NA,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),DRCI Hôpital St Louis,NA,1 av. Claude Vellefaux,aurelie.zindjirdjian@aphp.fr,NA,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Authorised-recruitment may be ongoing or finished,NULL,Bristol Myers Squibb SARL,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                - Signed Written Informed Consent<br><br>                - Any cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intra-cerebral metastasis<br><br>                - Active cancer defined as the presence of measurable disease or ongoing (or planned) chemotherapy, radiotherapy, hormonotherapy, targeted therapy, immunotherapy at inclusion.<br><br>                - Objectively documented index event of :<br>                symptomatic or incidental proximal lower-limb, iliac, inferior cava vena DVT or symptomatic or incidental PE in a segmental or larger pulmonary artery<br>                (1) Proximal DVT is defined as DVT that involves at least the popliteal vein or a more proximal vein, demonstrated by imaging with compression ultrasound (CUS), including grey-scale or color-coded Doppler, or ascending contrast venography or contrast enhanced computed tomography or magnetic resonance imaging.<br>                (2) PE has to be demonstrated by imaging as follows:<br>                an intraluminal filling defect in segmental or more proximal branches on contrast enhanced chest computed tomography or on computed tomography pulmonary angiography ; or<br>                an intraluminal filling defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram; or<br>                a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)<br>                (3) Incidental VTE is defined as proximal DVT or PE detected by imaging incidentally when a patient undergoes imaging studies as standard of care for the management of his or her malignancy or other reasons but not for a VTE suspicion(e.g. cancer diagnosis or staging).<br><br>                - At least 6 months of anticoagulant therapy at therapeutic dosage (whatever the drug and the dosing), or completed assigned a clinical trial study treatment, for the treatment of the index event; and patient still receiving anticoagulant treatment after occurrence or the VTE index event.<br><br>                - No objectively documented symptomatic recurrence of VTE between the index event and randomization.<br><br>                - Anticipated duration of anticoagulant treatment of at least 12 months at the time of randomization.<br><br>                - Patient affiliated to social security for French centers.<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 1722<br>                F.1.3 Elderly (>=65 years) no<br>                F.1.3.1 Number of subjects for this age range<br>","Exclusion criteria: <br>                - WOCBP who are unwilling or unable to use an acceptable method of birth control [such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (condoms)] to avoid pregnancy for the entire study<br><br>                - Women who are pregnant or breastfeeding<br><br>                - Women with a positive pregnancy test on enrollment or prior to investigational product administration<br><br>                - Isolated sub-segmental incidental or symptomatic PE without associated DVT<br><br>                - Isolated distal DVT of the legs<br><br>                - Isolated upper-extremity DVT or superior vena cava thrombosis<br><br>                - Isolated visceral thrombosis<br><br>                - Isolated catheter thrombosis<br><br>                - Objectively documented symptomatic recurrence of VTE after the index event under anticoagulant treatment<br><br>                - VTE during anticoagulant treatment given at therapeutic dosage<br><br>                - Subjects with indications for long-term treatment with a VKA, such as:<br>                - Mechanical heart valve<br>                - Antiphospholipid syndrome<br><br>                - Subjects with indication for long-term anticoagulation with a VKA or a DOAC at therapeutic dosage<br><br>                - Conditions increasing the risk of serious bleeding<br>                - intracranial or intraocular bleeding within the 6 months ;<br>                - major surgery within 2 weeks prior to randomization;<br>                - overt major bleeding at time of randomization.<br><br>                - Life expectancy < 12 months<br><br>                - Eastern Cooperative Oncology Group (ECOG) level 3 or 4<br><br>                - Bacterial endocarditis<br><br>                - Uncontrolled hypertension: systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg<br><br>                - Platelet count <75,000/mm3;<br><br>                - Hemoglobin < 8g /dl<br><br>                - Creatinine clearance < 30 ml /min based on the Cockcroft Gault equation; (see Section 5.9.2);<br><br>                - Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range<br><br>                - Subjects requiring ASA >165 mg/day at randomization or thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor).<br><br>                - Subjects requiring dual anti-platelet therapy (such as ASA plus clopidogrel or ASA plus ticlopidine) at randomization. Subjects who transition from dual antiplatelet therapy to monotherapy prior to randomization will be eligible for the trial.<br><br>                - Concomitant use of strong inhibitors of both cytochrome P-450 3A4 and P Glycoprotein (e.g., human immunodeficiency virus protease inhibitors or systemic ketoconazole) or strong inducers of both cytochrome P-450 3A4 and P Glycoprotein (e.g., rifampicin, carbamazepine, or phenytoin).<br><br>                - Prisoners or subjects who are involuntarily incarcerated<br><br>                - Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness<br><br>                - Hypersensitivity to apixaban<br><br>                - Subjects participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the coagulation system<br><br>                - Under 18 years old ;<br><br>","Main Objective: To determine whether a low-dose regimen of apixaban (2.5 mg bid) is non-inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent VTE in patients with cancer who have completed at least 6 months of anticoagulant therapy for treating a documented index event of proximal deep venous thrombosis (DVT) (symptomatic or incidental) or pulmonary embolism (PE) (symptomatic or incidental).;<br>                Secondary Objective: The key secondary objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is safer than a full dose regimen of apixaban (5 mg bid) in patients with active cancer who have completed at least 6 months of anticoagulant therapy for treating a documented index event of proximal DVT (symptomatic or incidental) or PE (symptomatic or incidental).<br><br>                Other secondary objectives<br>                To compare treatment effects of the reduced apixaban doses relative to full dose for the following:<br>                - recurrent symptomatic VTE ;<br>                - VTE-related death ;<br>                - all-cause death ;<br>                - major bleeding.<br>            ;Primary end point(s): The primary efficacy endpoint is the incidence of an adjudicated composite of recurrent symptomatic VTE (proximal and/or distal DVT and/or symptomatic PE and/or upper limb or CVC thrombosis) or incidental VTE (proximal DVT or PE), or death due to PE during the treatment period.;Timepoint(s) of evaluation of this end point: 12 months","<br>                Secondary end point(s): The key secondary outcome is the incidence of adjudicated major and clinically relevant non-major bleeding during the treatment period.<br><br>                Other secondary endpoints:<br>                Adjudicated composite of :<br>                - Recurrent symptomatic VTE ;<br>                - VTE related-death ;<br>                - All-cause death: all deaths will be adjudicated by the ICAC and classified as either VTE-related, cancer death (including all deaths due to the underlying cancer), bleeding-related or others, including all deaths due to a clearly documented other cause, such as for example respiratory failure (e.g., terminal emphysema), infections/sepsis, etc. ;<br>                - Adjudicated major bleeding.<br>            ;Timepoint(s) of evaluation of this end point: 13 months",child,EUCTR2017-003342-25-ES;EUCTR2017-003342-25-FR,Date trial authorised,NA,NA,Long-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis,NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Apr 10 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-001044-54-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001044-54,A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS:                 A RANDOMIZED PROSPECTIVE TRIAL - BosuPeg,Chronic myeloid leukemia at diagnosis-chronich phase;Therapeutic area: Diseases [C] - Cancer [C04],<br>                Trade Name: Bosulif<br>                Pharmaceutical Form: Tablet<br><br>                Product Name: Pegylated proline-interferon alpha 2b<br>                Product Code: AOP2014<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br><br>,A study of effect and safety of a new combination of drugs for chronic myeloid leukemia in chronic phase. Bosutinib is the basis treatment  and patients will be randomized to receive or not to receive a long-acting low dose of Ropeginterferon.,EUCTR,2019-03-15,2019-06-12,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: no<br>                Other: yes<br>                Other specify the comparator: Bosutinib alone<br>                Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,212,St Olavs Hospital -Trondheim University Hospital,France;Finland;Denmark;Norway;Sweden,NCT03831776,NULL,15/03/2019,12/06/2019,EUCTR2,30 June 2019,Bosupeg,Henrik Hjorth-Hansen,NA,PB 3250 Sluppen,henrik.hjorth-hansen@ntnu.no,4772825176,St Olavs Hospital,Henrik Hjorth-Hansen,NA,PB 3250 Sluppen,henrik.hjorth-hansen@ntnu.no,4772825176,St Olavs Hospital,Authorised-recruitment may be ongoing or finished,NULL,Pfizer Norge AS;AOP Orphan Pharmaceuticals AG,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                1)Signed written informed consent form (ICF) before any procedure related to the study <br>                2)Target Population<br>                a)Men and women, ages 18 to 75 years <br>                b)Newly diagnosed (= 3 months) BCR-ABL positive chronic myeloid leukemia in chronic phase <br>                c)Major BCR-ABL transcripts (p210 b2a2(e13a2) and/or b3a2(e14a2))<br>                d)Not previously treated for CML except with hydroxyurea or anagrelide  <br>                e)ECOG Performance Status (ECOG PS) = 2<br>                f)Adequate organ function.<br>                i.Total bilirubin < 1,5 times the institutional Upper Limit of Normal (ULN)<br>                ii.Hepatic enzymes ASAT and ALAT < 2 times the institutional ULN <br>                iii.Serum Creatinine < 1.5 time the institutional ULN<br>                iv.Lipase < 1.5 time the institutional ULN<br>                3)Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study. <br>                4)WOCBP must have a negative serum or urine pregnancy test at screening.<br>                5)A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study to minimize the risk of pregnancy.<br>                6)Free subject, without guardianship nor subordination<br>                7)Health insurance coverage.<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 145<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 67<br>","Exclusion criteria: <br>                1)Patients with BCR-ABL transcript other than M-BCR-ABL<br>                2)Patients previously treated with tyrosine kinase inhibitors (TKIs). <br>                3)Medical history and concurrent diseases:<br>                a)Hypersensitivity to any of the excipients of BOS or RoPegIFN<br>                b)Prior treatment with Interferon-a, contraindication to interferon-a, <br>                c)Autoimmune disorder, concomitant immunosuppressive treatment or corticosteroids, <br>                d)Pre-existing thyroid disease unless controlled with conventional treatment, auto-immune thyroiditis <br>                e)Chronic liver disease,<br>                f)Prior or ongoing severe psychiatric disease<br>                g)HIV positivity, chronic hepatitis B or C<br>                h)Uncontrolled or severe cardiac (NYHA Class III or IV) or pulmonary disease, <br>                Echocardiography with LVF < 45% or LLN, peak velocity of tricuspid regurgitant flow > 2,8 m/s<br>                Pulmonary arterial hypertension (PAH),<br>                QTc>450 ms (by Barrets correction)<br>                i)Other malignant disease during the last 5 years prior to the inclusion except non-melanoma skin carcinoma or carcinoma in situ of the cervix, <br>                j)History of significant bleeding disorder unrelated to CML or diagnosed congenital bleeding disorder, <br>                k)Subjects with an uncontrolled undercurrent illness or any concurrent condition that, in the investigator’s opinion, would jeopardize the safety of the subject or compliance with the protocol. <br>                4)Prohibited treatments and/or therapies: strong inhibitors/inducers of the CYP 3A4, <br>                5)History / any condition for poor compliance to medical treatment. <br>                6)Women who are pregnant or breastfeeding are not eligible for this study<br>                7)Inability to freely provide consent through judiciary or administrative condition.<br>                8)Ongoing participation to another clinical investigational study.<br><br>","Main Objective: To estimate efficacy of the addition of RoPegIFN to BOS in terms of deep molecular response with the aim of increasing the proportion of patients who may achieve treatment free remission.   ;Primary end point(s): To compare the rate of molecular response 4 (MR4) at 12 months in each treatment arm.;Timepoint(s) of evaluation of this end point: 12 months of treatment;<br>                Secondary Objective: •To compare cytogenetic and molecular response including kinetics through the treatment course. <br>                •To assess the proportion of patients eligible for randomization after the initial 3 months of BOS.<br>                •To determine and to compare safety and tolerability of the treatment in each arm.<br>                •To estimate reasons and cumulative rates of RoPegIFN and BOS discontinuation and the median dose of each drug by study arm. <br>                •To evaluate the tolerability, of a step-by-step dose schedule for BOS initiation (BOSUSTEP substudy)<br>                •To estimate the progression free, event-free and overall survival in each arm. <br>                •To estimate the proportion of patients achieving a durable deep molecular response and secondary eligibility for treatment discontinuation. <br>                •To compare the measurement of deep molecular response (by standard RTQPCR and digital droplet PCR (ddPCR), <br>                •To estimate and compare the rate of successful treatment discontinuation after M48 in each arm<br>                <br>","<br>                Secondary end point(s): •The rates of molecular responses MR2, MR3, MR4, MR4.5, at 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 months and every 6 months thereafter in each arm. <br>                •The cumulative incidence of MR3, MR4, MR4.5 within the same periods in each arm.<br>                •The rates of complete cytogenetic response (CCyR) at 3, 6, 12 months.<br>                •The rates of undetectable molecular responses for the patients who achieved an MR4 and an MR4.5 in each arm. <br>                •The rates of MR4 and MR4.5 by standard RTQPCR IS and digital droplet PCR (ddPCR) on the centralized molecular samples, for the patients who achieve an MR4 or better: comparison for sensitivity and accuracy of the 2 methods at key time points to be decided (ie Month 12 and Month 48)<br>                • Time to and duration of CCyR, MR3, MR4, MR4.5.<br>                •The proportion of patients eligible for randomization after 3 months of BOS<br>                •The rates and characteristics of severe adverse events (SAE) and adverse events (AE) related to BOS and RoPegIFN, from clinical and biological assessments: type and grade according to the NCI CTCAE v4.03.<br>                •The dose intensity of RoPegIFN and BOS administered during the first two years of study treatment. The cumulative incidence of discontinuation of the therapies. Reasons of discontinuation.<br>                •Other endpoints for the BOSUSTEP substudy within the first three months of BOS: <br>                -Any grade of diarrhea and GI toxicity <br>                -Other AE > grade 1 related to BOS<br>                -The final dose level of BOS by 3 months <br>                -The proportion of patients with transient treatment discontinuation<br>                -The proportion of patients with permanent treatment discontinuation<br>                -Cytogenetic and Molecular responses assessed by BCR-ABL IS at M3 and M6<br>                -The relationship between plasma residual concentration (Cmin) after dose escalation steps and tolerance / efficacy of BOS in a subset of patients (French cohort), and at M3 for Nordic patients who take part in ancillary projects.<br>                •The progression free survival, the event-free survival and the overall survival. Occurrence and type of BCR-ABL TK mutation<br>                •Quality of life assessment by QLQC30 and CML24 questionnaires at key time point (Day 1, M3, M6, M12, M24, M48, M54, M72)<br>                •The proportion of patients achieving a durable deep molecular response and being eligible for treatment discontinuation at month 48. Sustained deep molecular response criteria will be defined according updated data and ELN guidelines before the first patient will achieve Month 48 (at least a MR4 over a 12 months period and confirmed on the last centralized measurement at M48)<br>                •The proportion of patients in treatment free remission after 6, 12, 24 and 36 months of BOS discontinuation, from M48. <br>            ;Timepoint(s) of evaluation of this end point: See text above in E5.2.Many time points",child,NULL,Date trial authorised,NA,NA,A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS:                  A RANDOMIZED PROSPECTIVE TRIAL,NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2018-001771-21-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001771-21,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of                Cabozantinib (XL184) in Subjects with Radioiodine-Refractory                Differentiated Thyroid Cancer Who Have Progressed after Prior                VEGFR-Targeted Therapy","Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior                VEGFR-targeted therapy <br>                MedDRA version: 20.0                Level: PT                Classification code 10066474                Term: Thyroid cancer                System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)            ;Therapeutic area: Diseases [C] - Cancer [C04]",<br>                Trade Name: Cabometyx™<br>                Product Name: Cabozantinib<br>                Product Code: XL184<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: CABOZANTINIB<br>                CAS Number: 1140909-48-3<br>                Current Sponsor code: XL184<br>                Other descriptive name: Cabozantinib<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Cabometyx™<br>                Product Name: Carbozantinib<br>                Product Code: XL184<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: CABOZANTINIB<br>                CAS Number: 1140909-48-3<br>                Current Sponsor code: XL184<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 60-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>,Efficacy and safety of Cabozantinib (XL184) in subjects who have progressed after VEGFR-targeted treatment,EUCTR,2019-04-11,2019-05-14,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: no<br>                Cross over: yes<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,300,"Exelixis, Inc.","Portugal;United States;Taiwan;Hong Kong;Thailand;Spain;Ukraine;Russian Federation;Chile;Israel;Italy;France;Australia;Netherlands;Korea, Republic of;Austria;United Kingdom;Czech Republic;Hungary;Canada;Argentina;Poland;Brazil;Belgium;Singapore;Romania;Croatia;Georgia;Germany;New Zealand",NCT03690388,NULL,11/04/2019,14/05/2019,EUCTR2,30 June 2019,"XL184–311;NCT03690388;113,446;2018-001771-21-DE",Exelixis Medical Affairs,NA,1851 Harbor Bay Pkwy.,druginfo@exelixis.com,NA,"Exelixis, Inc.",Exelixis Medical Affairs,NA,1851 Harbor Bay Pkwy.,druginfo@exelixis.com,NA,"Exelixis, Inc.",Authorised-recruitment may be ongoing or finished,NULL,"Exelixis, Inc.",NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                1. Histologically or cytologically confirmed diagnosis of DTC, including the following subtypes (Note: results of a previous biopsy will be accepted):<br>                a. PTC including histological variants of PTC such as follicular variant, tall cell, columnar cell, cribriform-morular, solid, oxyphil, arthin-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated<br>                b. FTC including histological variants of FTC such as Hürthle cell, clear cell, insular, and poorly differentiated<br>                2. Measurable disease according to RECIST 1.1 on CT/MRI performed within 28 days prior to randomization<br>                3. Must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC<br>                4. Must have been previously treated with at least one of the following VEGFR-targeting TKI agents for DTC: lenvatinib or sorafenib.<br>                (Note: Up to two prior VEGFR-targeting TKI agents are allowed including (but not limited to) lenvatinib and sorafenib.)<br>                5. Must have experienced documented radiographic progression per RECIST 1.1 per Investigator during or following treatment with a VEGFR-targeting TKI prior to starting the next anticancer therapy (which may be treatment in this study)<br>                6. Recovery to baseline or = Grade 1 (Common Terminology Criteria for Adverse Events Version 5 [CTCAE v5]) from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy<br>                7. Age = 16 years old on the day of consent<br>                8. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1<br>                9. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 10 days before randomization:<br>                a. Absolute neutrophil count = 1500/mm3 (= 1.5 GI/L) without receipt of granulocyte colony-stimulating factor support within 2 weeks before screening laboratory sample collection<br>                b. Platelets = 100,000/mm3 (= 100 GI/L) without receipt of transfusion within 2 weeks before screening laboratory sample collection<br>                c. Hemoglobin = 9 g/dL (= 90 g/L) without receipt of transfusion within 2 weeks before screening laboratory sample collection<br>                d. Alanine aminotransferase (ALT), AST, and alkaline phosphatase (ALP) = 3 × upper limit of normal (ULN). ALP = 5 × ULN if the subject has documented bone metastases<br>                e. Bilirubin = 1.5 × the ULN. For subjects with known Gilbert’s disease = 3 × ULN<br>                f. Serum creatinine = 2.0 × ULN or calculated creatinine clearance = 30 mL/min (= 0.5 mL/sec) using the Cockcroft-Gault (see Table 5-2 for Cockcroft-Gault formula).<br>                g. Urine protein/creatinine ratio (UPCR) = 1 mg/mg (= 113.2 mg/mmol)<br>                10. Must be receiving thyroxine suppression therapy, and TSH must be below the lower cutoff of the reference range or less than 0.50 mIU/L (< 0.50 µIU/mL), whichever is lower,  within 28 days before randomization.<br>                (Note: If hormone replacement therapy is tolerated a TSH level of = 0.1 mIU/L should be targeted.)<br>                11. Capable of understanding and complying with the protocol requirements and signed informed consent (or informed assent and parental/guardian consent for subjects < 18 years of age)<br>                12. Sexually","Exclusion criteria: <br>                1. Prior treatment with any of the following:<br>                a. Cabozantinib<br>                b. Selective small-molecule BRAF kinase inhibitor (eg, vemurafenib, dabrafenib)<br>                c. More than 2 VEGFR-targeting TKI agents (eg, lenvatinib, sorafenib, sunitinib, pazopanib, axitinib, vandetanib)<br>                d. More than 1 immune checkpoint inhibitor therapy (eg, PD-1 or PD-L1 targeting agent)<br>                e. More than 1 systemic chemotherapy regimen (given as single agent or in combination with another chemotherapy agent)<br>                2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before randomization<br>                3. Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization<br>                4. Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy that have not completely resolved are not eligible (eg, radiation esophagitis or other inflammation of the viscera).<br>                5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of randomization.<br>                6. Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel), except for the following allowed anticoagulants:<br>                • Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH)<br>                • Anticoagulation with therapeutic doses of LMWH in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before randomization and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor<br>                7. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:<br>                a. Cardiovascular disorders:<br>                i. Congestive heart failure class 3 or 4 as defined by the New York Heart Association, unstable angina pectoris, serious cardiac arrhythmias<br>                ii. Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment<br>                iii. Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis [DVT], pulmonary embolism) within 6 months before randomization. Subjects with a more recent diagnosis of DVT are allowed if stable, asymptomatic, and treated with LMWH for at least 6 weeks before randomization.<br>                b. Gastrointestinal disorders (GI; eg, malabsorption syndrome or gastric outlet obstruction) including those associated with a high risk of perforation or fistula formulation:<br>                i. Tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis,",Main Objective: The objective of this study is to evaluate the effect of cabozantinib compared with placebo on Progression Free Survival (PFS) and Objective Response Rate (ORR) in subjects with Radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.;Secondary Objective: Not applicable;<br>                Primary end point(s): • Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent radiology committee (BIRC)<br>                • Objective response rate (ORR) per RECIST 1.1 by BIRC<br>            ;Timepoint(s) of evaluation of this end point: Throughout the study and based on study assessments and procedures as stated in the protocol section 5,"Timepoint(s) of evaluation of this end point: Throughout the study and based on study assessments and procedures as stated in the protocol section 5;<br>                Secondary end point(s): • Overall survival (OS)<br>                • Duration of objective tumor response<br>                • Safety and tolerability<br>                • Pharmacokinetics (PK) of cabozantinib<br>                • Relationship of baseline and postbaseline changes in biomarkers, serum thyroglobulin (Tg), and circulating tumor cells (CTCs) and/or circulating DNA (ctDNA) with treatment and/or clinical outcome assessments may be performed<br>                • Change in mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and global health as assessed by the EuroQol Health questionnaire instrument (EQ-5D-5L)<br>                • Health care resource utilization<br>",child,NULL,Date trial authorised,NA,NA,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of                 Cabozantinib (XL184) in Subjects with Radioiodine-Refractory                 Differentiated Thyroid Cancer Who Have Progressed after Prior                 VEGFR-Targeted Therapy",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2019-001565-33-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001565-33,"A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT",Generalized Myasthenia Gravis <br>MedDRA version: 20.0Level: LLTClassification code 10028415Term: MyastheniaSystem Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],<br>Product Name: Zilucoplan<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: Zilucoplan<br>CAS Number: 1841136-73-9<br>Current Sponsor code: RA101495<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>,Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis,EUCTR,2019-11-01,2019-10-30,FALSE,Interventional clinical trial of medicinal product,"Controlled: noRandomised: noOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: noNumber of treatment arms in the trial: 1",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,200,"Ra Pharmaceuticals, Inc.",France;United States;Canada;Spain;Norway;Germany;Japan;Italy;United Kingdom,NA,1,01/11/2019,30/10/2019,EUCTR2,16 December 2019,RA101495-02.302,Clinical Trial Information,NA,87 Cambridge Park Drive,trials@rapharma.com,+1 617 4014060,"Ra Pharmaceuticals, Inc",Clinical Trial Information,NA,87 Cambridge Park Drive,trials@rapharma.com,+1 617 4014060,"Ra Pharmaceuticals, Inc",Authorised-recruitment may be ongoing or finished,NULL,"Ra Pharmaceuticals, Inc.",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>To be eligible for this study, subjects must meet ALL of the following inclusion criteria:<br>1.Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study <br>2.Able to provide informed consent, including signing and dating the informed consent form (ICF)<br>3.Vaccination with a quadrivalent meningococcal vaccine and, where available, meningococcal serotype B vaccine. A booster vaccination should also be administered as clinically indicated, according to the local SOC, for subjects who have been previously vaccinated against Neisseria meningitidis<br>4.Female subjects of childbearing potential must have a negative urine pregnancy test within 24 hours prior to the first dose of study drug<br>5.Sexually active female subjects of childbearing potential (i.e., women who are not postmenopausal or who have not had a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) and all male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study. Postmenopausal women are, for the purposes of this protocol, defined as women who have gone 12 consecutive months without menstruation<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: 0<br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 150<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 50<br>","Exclusion criteria: <br>Subjects who meet ANY of the following exclusion criteria must be excluded from the study:<br>1.Pregnant, planning to become pregnant, or nursing female subjects<br>2.With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted) <br>3.Unable or unwilling to comply with the requirements of the study<br>4.Did not start any disallowed medication per the exclusion criteria from the qualifying zilucoplan study or alter the dose of any other concomitant medication, unless medically indicated<br>5.Any new or worsening medical condition (since entry into the qualifying zilucoplan study) or any other reason that, in the opinion of the investigator or Sponsor, would disqualify the subject from participation in this study <br><br>",Main Objective: •To provide access to zilucoplan for subjects with gMG who have completed a qualifying Ra Pharmaceuticals sponsored zilucoplan study and who wish to continue receiving zilucoplan<br>•To evaluate the long-term efficacy of zilucoplan in subjects with gMG who have completed a qualifying Ra Pharmaceuticals sponsored zilucoplan clinical study<br>•To evaluate the long-term safety and tolerability of zilucoplan in subjects with gMG who have completed a qualifying Ra Pharmaceuticals sponsored zilucoplan clinical study<br>;Secondary Objective: Not applicable;Primary end point(s): Efficacy endpoints: <br>•MG-ADL Score<br>•QMG Score<br>•MG-QOL15r<br>•MGC Score<br>Safety endpoints<br>;Timepoint(s) of evaluation of this end point: during each visit,Secondary end point(s): Not applicable ;Timepoint(s) of evaluation of this end point: Not applicable,NA,NULL,Date trial authorised,NA,NA,"A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2018-001671-21-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001671-21,"An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor","Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF) <br>                MedDRA version: 20.0                Level: PT                Classification code 10077161                Term: Primary myelofibrosis                System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)             <br>                MedDRA version: 21.0                Level: LLT                Classification code 10074689                Term: Post polycythemia vera myelofibrosis                System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)             <br>                MedDRA version: 21.0                Level: LLT                Classification code 10074690                Term: Post essential thrombocythemia myelofibrosis                System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)            ;Therapeutic area: Diseases [C] - Cancer [C04]",<br>                Product Name: KRT-232<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: -<br>                Current Sponsor code: KRT-232<br>                Other descriptive name: AMG-232<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br><br>                Product Name: KRT-232<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: -<br>                Current Sponsor code: KRT-232<br>                Other descriptive name: AMG-232<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 60-<br><br>,"Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor",EUCTR,2019-08-12,2019-10-09,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: no<br>                Randomised: yes<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 7<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,247,"Kartos Therapeutics, Inc.",France;United States;Hungary;Czech Republic;Canada;Poland;Spain;Australia;Israel;Bulgaria;Germany;United Kingdom,EUCTR2018-001671-21-ES,NULL,12/08/2019,09/10/2019,EUCTR2,10 December 2019,KRT-232-101;2018-001671-21-GB,Clinical Operations,NA,275 Shoreline Drive,jmei@kartosthera.com,NA,"Kartos Therapeutics, Inc.",Clinical Operations,NA,275 Shoreline Drive,jmei@kartosthera.com,NA,"Kartos Therapeutics, Inc.",Authorised-recruitment may be ongoing or finished,NULL,"Kartos Therapeutics, Inc.",NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                1. Adults >18 years of age<br>                2. Palpable spleen measuring = 5 cm below the left lower costal margin or spleen volume of = 450 cm3 by MRI or CT scan assessment<br>                3. Confirmed diagnosis of PMF, post–PV-MF, or post–ET-MF according to the World Health Organization (WHO) criteria<br>                4. High-risk, intermediate-2 risk, or intermediate-1 risk, defined by Dynamic International Prognostic System (DIPSS)<br>                5. ECOG performance status of 0 to 2<br>                6. Adequate hematological, hepatic, and renal organ function (as per protocol definition and within 28 days prior to the first dose of KRT-232)<br>                7.Female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential must both use an effective contraception method during the study. In addition, male subjects must continue to use contraception for 3 months and 1 week after the last dose of study drug and female subjects must continue to use contraception for 1 month and 1 week after the last dose of study drug. Effective birth control for males includes either vasectomy or use of condoms. Effective birth control for females includes (a) combined, estrogen and progestogen containing, hormonal contraception (oral, intravaginal, transdermal); (b) progestogen-only hormonal contraception (oral, injectable, implantable); (c) intrauterine device; (d) intrauterine hormone-releasing system; (e) bilateral tubal occlusion; and (f) sexual abstinence, when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.<br>                Subjects in Part A must meet the following JAK inhibitor treatment failure criteria in order to be eligible for the study:<br>                JAK Inhibitor treatment failure in Part A must meet either criterion (a) or (b) below:<br>                a) Either a lack of spleen response defined as receiving at least 12 weeks of JAK inhibitor treatment and having both of the following:<br>                • Persistent splenomegaly, by physical exam, that is palpable = 5 cm below the lower costal margin (LCM)<br>                • and TSS of >10 on the MPN-SAF TSS v2.0 or patients with a single symptom score of >5 or two symptoms of >3, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats<br>                b) Or progressive disease any time while on JAK inhibitor treatment as defined by any one of<br>                the following:<br>                • Spleen volume increase by = 25% from the nadir as assessed by MRI or CT<br>                • Appearance of new splenomegaly that is palpable at least 5 cm below the LCM<br>                • A = 100% increase in palpable distance, below the LCM, for baseline splenomegaly of 5 to 10 cm<br>                • A = 50% increase in palpable distance, below the LCM, for baseline splenomegaly of > 10 cm<br>                Subjects in Part B must meet the following ruxolitinib treatment failure criteria in order to<br>                be eligible for the study.<br>                Ruxolitinib treatment failure in Part B must meet either criterion (a) or (b) below:<br>                a) Either a lack of spleen response defined as receiving at least 12 weeks of ruxolitinib treatment and having at least one of the following:<br>                • For subject","Exclusion criteria: <br>                1. Patients who are positive for p53 mutations<br>                2. Participation in another interventional clinical trial within the past 4 weeks of the first dose of KRT-232 (participation in observational studies is permitted)<br>                3. Major surgery within the first 28 days of KRT-232<br>                4. Chemotherapy, immunomodulatory drug therapy within 14 days prior to first dose of KRT-232<br>                5. Prior splenectomy<br>                6. Splenic irradiation within 3 months prior to the first dose of KRT-232<br>                7. Prior allogeneic stem-cell transplantation or eligible for allogeneic stem cell transplantation<br>                8. Previous treatment with histone deacetylase (HDAC) inhibitors or BCL-2 inhibitors<br>                9. Prior MDM2 inhibitor therapy or p53-directed therapy<br>                10. Women who are pregnant or breastfeeding<br>                11. History of major organ transplant<br>                12. Uncontrolled intercurrent illness including, but not limited to, acute hepatitis A; known history of human immunodeficiency virus (HIV)-positive; clinically significant cardiac disease (New York Heart Association Class III or IV); symptomatic congestive heart failure; unstable angina pectoris; ventricular<br>                arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements<br>                13. Subjects with clinically significant bacterial, fungal, parasitic, or viral infection that requires therapy. Subjects with acute bacterial infections requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.<br>                14. Other malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated nonmetastatic prostate cancer with normal prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma<br>                15. Grade 2 or higher QTc prolongation (>480 milliseconds per NCI-CTCAE criteria, version 5.0)<br>                16. Growth factor treatment (e.g., erythropoeitin) within 14 days prior to first dose of KRT-232; no darbepoetin within 28 days prior to first dose of KRT-232<br>                17. Active or chronic bleeding within 4 weeks prior to the first dose of KRT-232<br>","Main Objective: To determine spleen response;Primary end point(s): The proportion of subjects achieving a =35% spleen volume reduction from Baseline to Week 24, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scan;Timepoint(s) of evaluation of this end point: The Primary Endpoint will be assessed 24 weeks after each subject is enrolled.;<br>                Secondary Objective: To determine the change in modified MPN-SAF Total Symptom Score (TSS) at Week 24 and Week 48;<br>                To determine the duration of spleen response (DoR-spleen);<br>                To determine spleen size reduction as measured by palpation;<br>                To determine red blood cell (RBC) transfusion usage;<br>                To determine the clinical response rate at Week 24;<br>                To determine the overall survival (OS) rate;<br>                To determine the leukemia free survival rate;<br>                To determine the safety and tolerability of KRT-232;<br>                To determine the pharmacokinetic/ pharmacodynamic (PK/PD) profile of KRT-232;<br>","Timepoint(s) of evaluation of this end point: Week 24, Week 48 and duration of study. Please refer to protocol for full details.;<br>                Secondary end point(s): Proportion of subjects who have at least 50% reduction from baseline to Week 24 and Week 48 in the total symptom score as measured by the modified MPN-SAF v2.0.<br>                Duration of a =35% or more reduction from Baseline in spleen volume as measured by MRI (or by CT for applicable subjects)<br>                Reduction in spleen size from Baseline to each visit at which spleen is palpated, including the proportion of subjects who have a =50% decrease<br>                • RBC transfusions (average number of RBC units per patient-month)<br>                • RBC transfusion independence at Week 24 (proportion of patients who were transfusion-independent at Week 24, defined as absence of RBC transfusions and no hemoglobin <8 g/dL in the previous 12 weeks)<br>                Complete remission (CR) and partial remission (PR) defined according to International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and modified European LeukemiaNet (ELN) criteria<br>                Overall survival is defined as the interval from randomization to death from any cause<br>                Leukemia-free survival is defined as the interval from randomization to the date of first documented leukemia transformation or death from any cause<br>                Analyses of the safety endpoints will include the following measurements or assessments: physical<br>                examinations, laboratory tests, adverse events (AEs), serious AEs (SAEs), ECGs, vital signs<br>                KRT-232 and acyl glucuronide metabolite (M1) PK parameters, including but not limited to, maximum observed concentration (Cmax), minimum observed concentration (Cmin), area under the plasma concentration-time curve (AUC), and terminal elimination half-life (t1/2z)<br>",child,NULL,Date trial authorised,NA,NA,"An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2019-001222-98-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001222-98,"A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) - CheckMate73L","Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) <br>MedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]","<br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10ml vial-COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Yervoy<br>Product Name: Ipilimumab (40ml Vial)<br>Product Code: BMS-734016<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IPILIMUMAB<br>CAS Number: 477202-00-9<br>Current Sponsor code: BMS-734016<br>Other descriptive name: BMS734016<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Cisplatin NeoCorp 1 mg/ml - Concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: CISPLATIN<br>CAS Number: 15663-27-1<br>Other descriptive name: Cisplatin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Cisplatin-Ebewe, 1 mg/ml concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: CISPLATIN<br>CAS Number: 15663-27-1<br>Other descriptive name: Cisplatin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Cisplatin Teva® 1 mg/ml concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: CISPLATIN<br>CAS Number: 15663-27-1<br>Other descriptive name: Cisplatin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: ETO-Cell<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ETOPOSIDE<br>CAS Number: 33419-42-0<br>Other descriptive name: ETOPOSIDE<br>Concentration unit: mg/ml mill",A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery,EUCTR,2019-07-22,2019-08-28,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 3<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,1400,Bristol-Myers Squibb International Corporation,"United States;Taiwan;Spain;Ireland;Russian Federation;Chile;Italy;Switzerland;United Kingdom;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Australia;Netherlands;Germany;Japan;China;Korea, Republic of;Sweden",EUCTR2019-001222-98-SE,NULL,22/07/2019,28/08/2019,EUCTR2,10 December 2019,CA209-73L;2019-001222-98-SE,GCT-SU,NA,"Parc de l'Alliance - Avenue de Finlande, 4",clinical.trials@bms.com,NA,Bristol-Myers Squibb International Corporation,GCT-SU,NA,"Parc de l'Alliance - Avenue de Finlande, 4",clinical.trials@bms.com,NA,Bristol-Myers Squibb International Corporation,Authorised-recruitment may be ongoing or finished,NULL,Bristol-Myers Squibb International Corporation,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>- Eastern Cooperative Oncology Group (ECOG) performance status =1<br>- Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) histologically-confirmed NSCLC, according to 8th TNM classification<br>- Newly diagnosed and treatment-naïve, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease<br><br>Other protocol defined inclusion criteria could apply<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 770<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 630<br>","Exclusion criteria: <br>- Any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the Investigator would preclude the patient from adhering to the protocol or would increase the risk associated with study participation<br>- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti- CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways<br>- Active infection requiring systemic therapy within 14 days prior to randomization<br>- Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured<br>- Participants with an active, known or suspected autoimmune disease or a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of randomization.<br>- History of organ or tissue transplant that requires systemic use of immune suppressive agents.<br>- Clinical evidence of hearing loss<br>- Prior thoracic radiotherapy<br><br>Other protocol defined exclusion criteria could apply<br>",Main Objective: - To compare the efficacy of nivolumab + CCRT followed by nivolumab + ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated LA NSCLC;Secondary Objective: - To compare the efficacy of nivolumab + CCRT followed by nivolumab ipilimumab (Arm A) or nivolumab + CCRT followed by nivolumab alone (Arm B) as maintenance vs CCRT followed by durvalumab (Arm C) in participants with untreated LA NSCLC<br>- To assess safety and tolerability<br>- To compare the efficacy of nivolumab + CCRT followed by nivolumab + ipilimumab (Arm A) or nivolumab + CCRT followed by nivolumab alone (Arm B) as maintenance vs CCRT followed by durvalumab (Arm C) in participants with untreated LA NSCLC;Primary end point(s): 1. Progression Free Survival (PFS) Assessed by RECIST 1.1 per Blinded Independent Central Review (BICR) for Arm A and Arm C<br>2. Overall Survival (OS) for Arm A and Arm C;Timepoint(s) of evaluation of this end point: 1. Up to 5 Years<br>2. Up to 5 Years<br>,"Secondary end point(s): 3. Overall Survival (OS) for Arm B and Arm C<br>4. Progression Free Survival (PFS) Assessed as per BICR for Arm B and Arm C<br>5. Objective Response Rate (ORR) and Complete Response Rate Assessed as per BICR<br>6. Duration of Response (DOR) Assessed as per BICR<br>7. Time to Response (TTR) Assessed as per BICR<br>8. Time to Death or Distant Metastases (TTDM) Assessed as per BICR<br>9. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and selected AEs<br>10. Percentage of Participants Without Meaningful Symptom Deterioration Following 48 Weeks of Maintenance Therapy Based on Lung Cancer Subscale (LCS) of FACT-L and NSCLC-SAQ;Timepoint(s) of evaluation of this end point: 3. Up to 5 Years<br>4. Up to 5 Years<br>5. Up to 5 Years<br>6. Up to 5 Years<br>7. Up to 5 Years<br>8. Up to 5 Years<br>9. Up to 5 Years<br>10. 48 weeks",child,NULL,Date trial authorised,NA,NA,"A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2019-000733-39-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000733-39,"A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.",Moderate to Severe Ulcerative Colitis <br>MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06],"<br>Product Code: ABX464<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ABX464<br>Current Sponsor code: ABX464<br>Other descriptive name: ABX464<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>",Open-label maintenance therapy in moderate to severe Ulcerative Colitis patients,EUCTR,2019-09-12,2019-11-09,FALSE,Interventional clinical trial of medicinal product,"Controlled: noRandomised: noOpen: yesSingle blind: noDouble blind: noParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: noOther: noNumber of treatment arms in the trial: 1",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,232,ABIVAX,Serbia;Belarus;Slovakia;Slovenia;Spain;Ukraine;Ireland;Austria;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Netherlands;Germany,EUCTR2019-000733-39-ES,NULL,12/09/2019,09/11/2019,EUCTR2,20 April 2020,ABX464-104;2019-000733-39-SK,Clinical Operations,NA,5 Rue de la Baume,Paul.Gineste@abivax.com,+33153830961,ABIVAX,Clinical Operations,NA,5 Rue de la Baume,Paul.Gineste@abivax.com,+33153830961,ABIVAX,Authorised-recruitment may be ongoing or finished,NULL,ABIVAX,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>A patient will be eligible to participate in this study if ALL the following criteria are met:<br>? Patients must have completed the 16-week induction treatment period (ABX464-103);<br>? Patients are able and willing to comply with study visits and procedures as per protocol;<br>? Patients should understand, sign and date the written voluntary informed consent form prior to any protocol-specific procedures are performed;<br>? Patients should be affiliated to a social security regimen (for French sites only);<br>? Females and males receiving the study treatment (potentially in combination with immunosuppressant)  and their partners must agree to use a highly effective contraceptive method during the study and for 6 months (180 days) after end of study or early termination. Contraception should be in place at least 2 weeks prior to screening. Women must be surgically sterile or if of childbearing potential must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, vasectomized partner. True<br>abstinence is defined when this is in line with the preferred and usual lifestyle of the patient. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle. Female and male patients must not be planning pregnancy during the trial and for 6 months post completion of their participation in the trial. In addition, male patients should use condom during the trial and for 6 months (180 days) post completion of their participation in the study. Male patients must not donate sperm as long as contraception is required.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 220<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 12<br>","Exclusion criteria: <br>Patients who meet any of the following exclusion criteria will be excluded from the study:<br>? Patients who had major protocol deviation(s) in the induction study;<br>? Patients who permanently discontinued study the treatment in induction study (ABX464-103) because of an adverse event (AE) regardless of relatedness to investigational product;<br>? Patients who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study;<br>? Patients with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for<br>entry into this study;<br>? Patients who are participating or plan to participate in other investigational studies (other than induction study) during the study.<br>","Main Objective: The primary objective of the study is to assess in all patients the long-term efficacy of ABX464 given at 50 mg QD on clinical remission at week 48 compared to the induction study baseline (ISB).;Secondary Objective: To evaluate:<br>-the clinical remission at week 48 compared to the baseline of the open label study (BOLS)<br>- the proportion of patients with glucocorticoid-free clinical remission at W48 <br>-the effect of ABX464 50 mg QD:<br>  ~on Modified Mayo Score at week 48 and on partial MMS, among patients, at every study visit compared to ISB (Induction study baseline)<br>  ~on endoscopic improvement and remission and sustained endoscopic improvement and remission, by segment at W48 compared to ISB and BOLS<br>  ~on stool and rectal bleeding frequency at every study visit compared to BOLS<br>  ~on fecal calprotectin and CRP levels at W24 and W48 visits compared to BOLS<br>  ~on clinical response at W48 compared to ISB and BOLS<br>  ~on miR-124 expression in colon tissue (RNA later) and at W48 and in total blood at W24 and W48<br>  ~on patients’ quality of life at W24 and W48 compared to BOLS<br>  ~on the rectal/sigmoidal infiltrates at W48 compared to ISB and BOLS<br>-the long-term safety profile of ABX464 50 mg QD;Primary end point(s): Proportion of patients with clinical remission at week 48 compared to induction study baseline.<br>Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0,<br>AND an endoscopy sub-score =1 (excluding friability), AND at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score =1.;Timepoint(s) of evaluation of this end point: At week 48","Timepoint(s) of evaluation of this end point: 1) MMS at week 48 and pMMS at every visit<br>2) at week 48<br>3) at week 48<br>4) at week 48<br>5) at every study visit<br>6) at week 24 and 48<br>7) at week 48<br>8) at week 24 and 48<br>9) at week 24 and 48<br>10) at week 48<br>11) through the study<br>12) through the study<br>13) through the study<br>14) through the study;Secondary end point(s): ?Reduction relative to baseline in Modified Mayo Score at week 48 and in partial Modified Mayo Score at every study visit among all patients.<br>?Proportion of patients with either endoscopic improvement or/and endoscopic remission by segment at week 48 among all patients. Endoscopic improvement is defined as a Mayo endoscopic sub score of =1 (excluding friability). Endoscopic remission is defined as a Mayo endoscopic sub score of 0.<br>?Proportion of patients with sustained endoscopic improvement at week 48. Sustained endoscopic improvement is defined as the number of patients with endoscopic improvement at week 48 among patients who had endoscopic improvement during the Induction study (at week 8 or week 16).<br>?Proportion of patients with glucocorticoid-free clinical remission at week 48. Glucocorticoid-free clinical remission is defined as clinical remission in addition to not requiring any treatment with glucocorticoids for at least 8 weeks prior to week 48.<br>?Reduction relative to baseline in stool and rectal bleeding frequency at every study visit.<br>?Reduction relative to baseline in fecal calprotectin and CRP levels at week 24 and 48.<br>?Proportion of patients with clinical response at week 48.<br>Clinical response is defined as: a reduction in Mayo Score = 3 points and = 30 % from baseline with an accompanying decrease in rectal bleeding sub-score = 1 point or absolute rectal bleeding sub-score = 1 point.<br>?Change relative to baseline in miRNA-124 expression in rectal/sigmoidal biopsies at week 48 and in total blood at week 24 and week 48.<br>?Scores and changes from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domains at week 24 and 48.<br>? Reduction relative to ISB of infiltrate/histopathology (rectal/ sigmoidal biopsies) using the Robarts Histopathology Index (RHI), the Geboes and Nancy Histology Scoring Scales at week 48.<br>?Number and rate of all adverse events, causally-related adverse events, all SAE and causallyrelated SAEs classified by severity.<br>?Incidence of treatment-emergent serious adverse event, hospitalizations, total inpatient days.<br>?Incidence of adverse events leading to investigational product discontinuation.<br>?Number of clinically significant laboratory abnormalities.",parent,EUCTR2019-000733-39-AT;EUCTR2019-000733-39-SI,Date trial authorised,NA,NA,"A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Oct  2 2019 12:00AM,NA,NA,NA,NA
EUCTR2018-004024-11-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004024-11,"An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects","Hemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affects 1 in 25,000 male births. Disease severity correlates directly with the concentration of functional FIX protein in the plasma. Severe disease is characterized as having <1% of normal plasma levels of FIX (100% = 1 IU activity/mL or approximately 5000 ng protein/mL). <br>MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]",<br>Product Name: SHP648 (TAK748)<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: not applicable <br>Current Sponsor code: SHP648<br>Other descriptive name: TAK-748<br>Concentration unit: vector genomes (vg)/mL<br>Concentration type: equal<br>Concentration number: 4.1E12-<br><br>,"A Phase 1/2 study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects",EUCTR,2019-10-08,2020-02-26,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: yes<br>Other trial design description: Dose Escalation <br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 3<br>",Human pharmacology (Phase I): yesTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,21,Baxalta Innovations GmbH,France;Hungary;Spain;Turkey;Austria;Germany;Italy,EUCTR2018-004024-11-ES,NULL,08/10/2019,26/02/2020,EUCTR2,8 June 2020,SHP648-101;2018-004024-11-HU,Judit Koranyi,NA,Industriestrasse 67,judit.koranyi@takeda.com,+431201002473301,Baxalta Innovations GmbH,Judit Koranyi,NA,Industriestrasse 67,judit.koranyi@takeda.com,+431201002473301,Baxalta Innovations GmbH,Authorised-recruitment may be ongoing or finished,NULL,Baxalta Innovations GmbH,NA,NA,<br>Female: no<br>Male: yes<br>,"Inclusion criteria: <br>The subject will not be considered eligible for the study without meeting all of the criteria below.<br>1. Male, aged 18 to 75 years at the time of screening.<br>2. Established severe or moderately severe hemophilia B (plasma FIX activity<br>= 2% measured following = 5 half-lives of most recent exposure to exogenous FIX)<br>and either = 3 hemorrhages per year requiring treatment with exogenous FIX or use<br>of prophylactic therapy.<br>3. History of > 50 exposure days to exogenously administered FIX concentrates or<br>cryoprecipitates.<br>4. Sexually active men must agree to use barrier contraception (combination of a condom and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized, or contraception-practicing partners for a minimum of 6 months after administration of SHP648, or until SHP648 genomes are no longer detected in the semen (whichever is sooner).<br>5. Signed informed consent.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 19<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 2<br>","Exclusion criteria: <br>The subject will be excluded from the study if any of the following exclusion criteria are met.<br>1. Bleeding disorder(s) other than hemophilia B.<br>2. Documented laboratory evidence of having developed inhibitors (= 0.6 BU on any single test) to FIX proteins at any time.<br>3. Documented prior allergic reaction to any FIX product.<br>4. Anti-AAV8 neutralizing antibody titer = 1:5.<br>5. Known hypersensitivity to prednisolone or prednisone, or to any of the excipients.<br>6. Having a disease in which treatment with prednisolone or prednisone is not tolerated<br>(including, but not limited to osteoporosis with vertebral fractures, severe labile<br>hypertension, and brittle diabetes).<br>7. Evidence of markers of potential underlying risk for autoimmune mediated hepatic disease:<br>a. Anti-smooth muscle antibody (ASMA) titer = 1:40. Values of 1:31 to 1:39 will be<br>flagged as possibly abnormal and the Investigator and Medical Monitor will evaluate the subject for eligibility.<br>b. Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers.<br>c. Total IgG > 1.5x ULN.<br>d. Antinuclear antibody (ANA) titer > 1:320 OR ANA titer > 1:80 if demonstrated<br>concurrently with ALT that is > ULN.<br>8. Active Hepatitis C: As indicated by detectable HCV RNA by PCR.<br>9. Hepatitis B: If surface HBV antigen is positive.<br>10. Receiving chronic systemic antiviral and/or interferon therapy within 4 weeks prior to enrollment.<br>11. Clinically significant infections (e.g., systemic fungal infections) requiring systemic treatment.<br>12. Known immune disorder (including myeloma and lymphoma).<br>13. Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or other disorders.<br>14. An absolute neutrophil count < 1000 cells/mm3.<br>15. Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the following:<br>a. Platelet count < 150,000/µL.<br>b. Albumin = 3.5 g/dL.<br>c. Total bilirubin > 1.5x ULN and direct bilirubin = 0.5 mg/dL.<br>d. ALT or AST > 1.0x ULN.<br>e. Alkaline phosphatase > 2.0x ULN.<br>f. History of liver biopsy or imaging indicating moderate or severe fibrosis<br>(Metavir staging of F2 or greater).<br>g. History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy.<br>h. FibroSURE Score = 0.4.<br>i. Prothrombin time INR = 1.4.<br>16. Serum creatinine > 1.5 mg/dL.<br>17. HIV if CD4+ cell count =200 mm3 and/or viral load >20 copies/mL.<br>18. Urine protein > 30 mg/dL.<br>19. Body mass index > 38.<br>20. Orthopedic or other major surgery planned within 6 months after enrollment.<br>21. Acute or chronic disease that, in the opinion of the Investigator, would adversely affect subject safety or compliance or interpretation of study results.<br>22. Received an AAV vector previously or any other gene transfer agent in the previous 12 months prior to Study Day 0.<br>23. Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease).<br>24. History of arterial or venous thrombosis / thromboembolism, or a known pro-thrombotic condition.<br>25. Recent history of psychiatric illness or cognitive dysfunction (including drug or alcohol abuse) that, in the opinion of the Investigator, is likely to impair subject’s ability to comply with protocol mandated procedures.<br>26. Participation in another study involved with an investigational agent.<br>27. Subject is family member or employ","Main Objective: The primary objective of the study is to assess the safety of single, escalating, IV doses of SHP648.;Secondary Objective: The secondary objectives of the study are as follows:<br>• Evaluate plasma FIX levels before and after SHP648 infusion and study the relationship<br>between change in FIX activity and SHP648 dose.<br>• Evaluate bleeding episodes post SHP648 administration.<br>• Assess humoral and cellular immune responses to FIX and the viral capsid.<br>• Determine the duration of SHP648 genomes present in bodily fluids.<br>• Compare the consumption of exogenous FIX before and after gene transfer;Primary end point(s): Incidence of AEs (serious or non-serious) related to IP<br>that include development of FIX inhibitory antibodies,<br>ECG findings, and clinically significant changes in<br>standard laboratory parameters and in vital signs;Timepoint(s) of evaluation of this end point: Subjects will be monitored for 1 year after dosing. Every effort will be made to enroll subjects to an extension study and follow them for approximately 4 additional years until a 5 year total post-gene transfer period is attained.",Secondary end point(s): •Circulating plasma FIX activity and antigen levels<br>•ABR in comparison to before gene transfer<br>•Neutralizing and Binding antibody titers to AAV8<br>• T-cell response to AAV8 and FIX transgene products<br>•Presence of SHP648 genome by type of bodily fluid<br>•Percentage of change in consumption of exogenous FIX before and after gene transfer;Timepoint(s) of evaluation of this end point: Subjects will be monitored for 1 year after dosing. Every effort will be made to enroll subjects to an extension study and follow them for approximately 4 additional years until a 5 year total post-gene transfer period is attained.,child,NULL,Date trial authorised,NA,NA,"An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  9 2020 12:00AM,NA,NA,NA,NA
EUCTR2019-001085-15-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001085-15,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections. - HEARTH-OF Study.",Patients presenting recurrent orofacial herpes infections (6 or more episodes within the 12-months’ period prior to their study entry). <br>                MedDRA version: 20.0                Level: HLT                Classification code 10019972                Term: Herpes viral infections                System Organ Class: 10021881 - Infections and infestations             <br>                MedDRA version: 20.1                Level: PT                Classification code 10067152                Term: Oral herpes                System Organ Class: 10021881 - Infections and infestations             <br>                MedDRA version: 21.1                Level: PT                Classification code 10019948                Term: Herpes simplex                System Organ Class: 10021881 - Infections and infestations            ;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>                Trade Name: 2LHERP®<br>                Product Name: 2LHERP®<br>                Pharmaceutical Form: Pillules<br>                Pharmaceutical form of the placebo: Pillules<br>                Route of administration of the placebo: Oromucosal use<br><br>,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.",EUCTR,2019-08-22,2019-11-06,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,100,LABO’LIFE Belgium sprl,Belgium,NA,NULL,22/08/2019,06/11/2019,EUCTR2,16 December 2019,LLB-2018-01,"Clin Research Coord, Astrid Garreau",NA,"1, rue François Bruneau",astrid.garreau@labolife.com,33659 11 39 29,Labo’Life France,"Clin Research Coord, Astrid Garreau",NA,"1, rue François Bruneau",astrid.garreau@labolife.com,33659 11 39 29,Labo’Life France,Authorised-recruitment may be ongoing or finished,NULL,LABO’LIFE Belgium sprl,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                - Man or woman aged 18-80 years,<br>                - Patient presenting 6 or more episodes of orofacial herpes infections during the preceding 12-months’ period (prior to the study entry),<br>                - Woman of childbearing age under effective contraception,<br>                - Patient reporting a current stable sexual relationship (steady sexual partner during study duration),<br>                - Patient having faculties to understand and respect the constraints of the study,<br>                - Signature of the Informed Consent Form.<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 90<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 10<br>","Exclusion criteria: <br>                - Pregnant or breastfeeding woman,<br>                - Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months,<br>                - Patient who has a suppressive antiviral therapy during last month,<br>                - Patient who wishes to continue his/her suppressive antiviral therapy,<br>                - Patient with known lactose intolerance,<br>                - Patient who participated in a clinical study in the previous 3-month period,<br>                - Patient who is not sufficiently motivated to engage on a follow-up period of 12 months, or likely to travel or to move before the end of the study,<br>                - Patient with severe immunodeficiency disease requiring long term treatment (*) or under chemotherapy or radiotherapy or corticoid therapy,<br>                - Patient under listed homeopathic or phytotherapy treatment,<br>                - Patient using or addicted to recreational drugs.<br><br>","Timepoint(s) of evaluation of this end point: 12 months;Primary end point(s): Reduction (yes/no) in the number of recurrences of orofacial herpes infection within the 12 months following treatment initiation. ;<br>                Secondary Objective: Secondary objectives: comparison of the efficacy of 2LHERP® vs placebo according to the following aspects:<br>                a) number of episodes at 6 months and 12 months,<br>                b) time to first episode during the treatment,<br>                c) duration of episodes,<br>                d) symptomatology during the entire relapse time,<br>                e) use of Rescue Medication (RM),<br>                f) evaluation of impact on the quality of life,<br>                g) safety issues.<br><br><br>            ;Main Objective: Evaluation of the efficacy of 2LHERP® on the reduction of the number of recurrent orofacial herpes infections at 12 months.","<br>                Secondary end point(s): a.1) Remaining herpes infection recurrence free 12 months after treatment initiation (yes/no),<br>                a.2) Remaining herpes infection recurrence free 6 months after treatment initiation (yes/no),<br>                a.3) Change from baseline within the number of episodes of herpes infections observed for 12 months, where the baseline value is the number of episodes experienced within the 12 months preceeding study enrolment,<br>                a.4) Number of episodes of herpes infection observed at 6 months and at 12 months,<br>                b) Time to first recurrence of herpes infection during the treatment,<br>                c) Mean duration of episodes, the duration for a given episode being defined as the number of days between the start of the episode and the last day before all symptoms recorded as ‘none’ for 2 consecutive days, in the patient diary,<br>                d) Level of pain recorded daily on a visual analogue scale (100mm), as well as other associated symptomatology for orofacial pain (orofacial fissures, difficulties to eat/drink, orofacial pain, fever, QoL), which will be consequently measured as area under the curve (AUC),<br>                e) Use of daily rescue medicine (RM), expressed with the cumulative number of days for the treatment period, the follow-up period and the entire study period,<br>                f) Quality of life evaluated via a 6-items questionnaire,<br>                g) Occurrence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.<br>            ;<br>                Timepoint(s) of evaluation of this end point: a.1) 12 months,<br>                a.2) 6 months ,<br>                a.3) 12 months,<br>                a.4) 6 months and 12 months,<br>                b) until 12 months,<br>                c) until 12 months,<br>                d) until 12 months,<br>                e) until 12 months,<br>                f) 6 months and 12 months,<br>                g) until 6 months.<br>",NA,NULL,Date trial authorised,NA,NA,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.",NULL,1900-01-01,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
IRCT20190122042450N3,http://en.irct.ir/trial/38419,Comparison of the effect of empagliflozin and pioglitazone and placebo on liver steatosis change in fibroscan in diabetic patients with non-alcoholic fatty liver disease,Condition 1: Nonalcoholic fatty liver disease. Condition 2: Diabetes type 2. <br>Nonalcoholic steatohepatitis [NASH] <br>Type 2 diabetes mellitus;K75.81,"Intervention 1: Intervention group: Empagliflozin 10 milligram, Dr. Abidi pharmacy over 6 months. Intervention 2: Intervention group:  Pioglitazone 15 milligram, Dr. Abidi pharmacy over 6 months. Intervention 3: Control group: placebo, Dr. Abidi pharmacy over 6 months.",The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patients,IRCT,2019-05-24,2019-05-21,FALSE,interventional,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization method, 6 blocks, Blinding description: Abidi's pharmacy place the empagliflozine and pioglitazone and placebo in unique package and label as Q, M, Z and distribute between patients by non-notofied person while patient and investigator are not informed about type of drugs. Also, health-care and staffs of labroatory and radiology and fibroscan and DEXA are not informed about type of drugs. Also, Outcome evaluator and data analyzer are not informed about type of drugs.",2-3,105,Iran University of Medical Sciences,Iran (Islamic Republic of),NA,1,2019-05-24,2019-05-21,IRCT20,26 August 2019,NULL,Haleh Chehrehgosha,NA,"Behafarin ST, Karimkhan AVE, Vali-asr Sq, Tehran, Iran",hchehrehgosha@gmail.com,+98 21 8894 5246,Iran University of Medical Sciences,Mohammad Ebrahim Khamseh,NA,"Behafarin ST, KarimkhanAVE, Vali-asr Sq, Tehran, Iran",khamseh.m@iums.ac.ir,+98 21 8894 5246,Iran University of Medical Sciences,Complete,Abidi pharmacy,Iran University of Medical Sciences;Abidi pharmacy,20 years,65 years,Both,"Inclusion criteria: Age 20-65<br>Body mass index less than 40<br>Alcohol daily consumption less than 20 g in women and less than 30 g in men, for at least 3 consecutive months over 5 years ago<br>Hemoglobin A1c 7-10 percent<br>Alanin aminotransferase more than 45 in men and more than 30 in women<br>Creatinin less than 1.5 in men and less than 1.4 in women and glomerular filtration rate more than 45<br>Controlled atenuated parameter more than 230 in fibroscan or fatty liver grade equal and more than 2 in liver sonography<br>Signature of consent form","Exclusion criteria: Pregnancy, breast feeding<br>Heart failure (class II to IV)<br>History of cardiovascular disease in 3 months ago<br>History of cancer in 2 years ago<br>History of cirrhosis Abnormal TSH (uncontrolled yper or hypothyroidism)<br>Autoimmune hepatitis (abnormal ANA and ASMA)<br>Hepatitis C (positive HCV Ab)<br>Hepatitis B (positive HBS Ag)<br>Consumption of NSAIDs, Amiodarone, Tamoxifen, Fibrate, statin, Zinc, Selenium and vitamin C or other antioxidant drugs, Empagliflozin, Metformin, Pioglitazone, Vitamin E and other fatty liver drugs.<br>Diabetes type 1 or secondary diabetes<br>Consumption of corticosteroid for 14 days over 2 months ago<br>biliary obstruction in liver and gallbladder sonography",Change of CAP (Controlled attenuation parameter). Timepoint: at start and 24 weeks. Method of measurement: with fibroscan.,Weight. Timepoint: start and 12 weeks and 24 weeks after intervention. Method of measurement: with weight scale.;Nonalcoholic fatty liver disease fibrosis score. Timepoint: start and 24 weeks after intervention. Method of measurement: with use of labroatary tests and formula of the NAFLD fibrosis score.;FIB4 index. Timepoint: start and 24 weeks after intervention. Method of measurement: with use of labroatary tests and formula of the FIB4.;A/G (Android/Gynoid). Timepoint: start and 24 weeks after intervention. Method of measurement: with Dual-energy X-ray absorptiometry (DEXA).;Liver stiffness measurement (LSM). Timepoint: start and 24 weeks after intervention. Method of measurement: Liver fibroscan.;VAT (Visceral adipose tissue). Timepoint: start and 24 weeks after intervention. Method of measurement: with Dual-energy X-ray absorptiometry (DEXA).;Body mass index. Timepoint: start and 12 weeks and 24 weeks after intervention. Method of measurement: with weight and height scale and formula.,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is There is not sufficient data.,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of Iran University of Medical Sciences,NA,NA
IRCT20171230038142N8,http://en.irct.ir/trial/38309,A Comparative Study on the Effect of Handmade Del Nido Cardioplegia Solution with Handmade St. Thomas Cardioplegia Solution in terms of Quantitative Levels of Cardiac Troponin I and Phosphocreatine kinase MB  in Ventricular Septal Defect Repair in Pediatric Cardiac Surgery.,Ventricular Septal Defect Repair. <br>Ventricular septal defect as current complication following acute myocardial infarction,"Intervention 1: Intervention group: Intervention group: 30 patients receiving St. Thomas cardiopulmonary by hand perfringens with a dose of 20 ml per kg and at a temperature of 4 degrees Celsius. This solution is surgically dispensed immediately before injection of the cardioplegia solution sterilized. Then, through a cardioplegia cannula inserted by the surgeon at the root of the aorta, it is injected through the syringe. The injection rate of the cardiopulse solution is 30 to 40 mmHg and during 2 minutes and is controlled by pressure gauge in the injection route. This solution is injected into the patient in a single dose. Intervention 2: Intervention group: Intervention group: 30 patients with cardiogenic cardiopulmonary bypass grafting by perfusion. This solution is a dose of 15 ml per kilogram and a ratio of four crystalloid units at 4 ° C and one unit of complete oxygenated blood. Both solutions are surgically dispensed sterilized immediately after injection of the cardiopulmonary solution. A cardioplegia cannula inserted by the surgeon at the root of the aorta is injected through the syringe. The injection rate of the cardiopulse solution is 30 to 40 mmHg and in the It is in 2 minutes and is controlled by pressure gauge in the injection route. This solution is injected into the patient in a single dose.",The Effect of Handmade Del Nido Cardioplegia Solution with Handmade St. Thomas Cardioplegia Solution in terms of Quantitative Levels of Cardiac Troponin I and Phosphocreatine kinase MB.,IRCT,2019-03-16,2019-01-21,FALSE,interventional,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Female or male patients undergoing surgical repair of large-inferior ventricular diarrhea were easily and conveniently distributed in Chamran Hospital in Isfahan. Then they are randomly assigned random allocation and random numbers in two groups of 30, which will be used in a group of St. Thomas's handmade solution and in another group of Del NIDO solution, Blinding description: The samples are not aware of the therapeutic type and only the presenter is aware of the categorization of patients in each treatment group. Because these two solutions are injected during surgery, so patients are unaware of their drug type.",2-3,60,Esfahan University of Medical Sciences,Iran (Islamic Republic of),NA,1,2019-03-16,2019-01-21,IRCT20,25 March 2019,NULL,Hamid Bigdelian,NA,"Isfahan University of Medical Sciences, Hezar Jarib Ave.",mortezasadeghi16@gmail.com,+98 316680048,Esfahan University of Medical Sciences,Hamid Bigdelian,NA,"Isfahan University of Medical Sciences, Hezar Jarib Ave.",mortezasadeghi16@gmail.com,+98 31 3668 0048,Esfahan University of Medical Sciences,Recruiting,NULL,Esfahan University of Medical Sciences,no limit,12 years,Both,Inclusion criteria: Having less than 12 years of age.<br>Parental satisfaction from intervention.,Exclusion criteria: Having a history of heart failure.<br>Having a history of myocardial infarction.,"Quantitative Levels of Cardiac Troponin I. Timepoint: Before surgery, six hours and 12 hours after surgery. Method of measurement: Patient blood sample test.;Quantitative Levels of Phosphocreatine kinase MB. Timepoint: Before surgery, six hours and 12 hours after surgery. Method of measurement: Patient blood sample test.",NULL,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Yes - There is a plan to make this available,What will be shared: All data is unpublished after being unidentifiable and two years after the article is published.  When: Two years after the publication and publication of the results.  To whom: Assistants and Professors of the Department of Heart Surgery and Circulation Technology.  Conditions: To compare the effects of other handmade solutions on the low levels of troponin I and phospho creatine kinase MB with the present results.  Where to obtain: Accepting permission from the research vice president of Isfahan University of Medical Sciences.  How to obtain: Accepting permission from the research vice president of Isfahan University of Medical Sciences.  Comments:,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics Committee of Isfahan University of Medical Sciences,NA,NA
IRCT20180903040941N1,http://en.irct.ir/trial/33681,"The effect of  Matricaria chamomilla L. on insulin resistance, inflammatory status and other related indices in patients with non-alcoholic fatty liver","non alcoholic fatty liver. <br>Fatty (change of) liver, not elsewhere classified;K76.0","Intervention 1: Intervention group: A capsule containing 500 mg of chamomile flower powder will be taken four times a day, two fasting morning and two nights before bedtime for three months. Intervention 2: Control group: placebo capsules containing roasted wheat flour plus 50 mg of chamomile powder will be taken four times a day, two fasting morning and two nights before bedtime for three months.",To evaluate effects of Matricaria chamomilla L. on patients with non alcoholic fatty liver disease,IRCT,2019-06-03,2019-06-05,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: Simple randomization Random unit: Individual Randomization Tool: Random Numbers, Blinding description: Participants and researchers will not be aware of the study groups. Drug capsules and placebo capsules are also similar to each other and they are only labeled A and B.",N/A,44,Fasa University of Medical Sciences,Iran (Islamic Republic of),NA,NULL,2019-06-03,2019-06-05,IRCT20,26 August 2019,NULL,Sadegh amiri,NA,"Ibn Sina Square,  Fasa University of Medical Sciences",sadeghamiri2877@yahoo.com,+98 71 5331 6300,Fasa University of Medical Sciences,Dr Mohammad hashem hashempur,NA,"Ibn Sina Square,  Fasa University of Medical Sciences",hashempur@gmail.com,+98 71 5331 6300,Fasa University of Medical Sciences,Recruiting,NULL,Fasa University of Medical Sciences,25 years,65 years,Both,"Inclusion criteria: sign the consent form<br>age between 25-65 years<br>BMI between 22-35<br>Diagnosis of fatty liver and steatohepatitis with: A- serum level of Alanine Transaminease (ALT) More than one and a half times the highest normal limit(66/5000This means that more than 45 men and women more than or equal to 29 units per liter)Also, the amount of aspartate transaminase (AST) In both sexes is greater than 30 units per liter(According to the latest definition of ALT and abnormal AST in men and women). B- Diagnosis of fatty liver (moderate to high) in liver ultrasound.<br>The patient have not to consume lipid regulating drugs for four weeks<br>The patient have not to consume some drugs like silybin, ursodeoxycholic acid, Polyene Phosphatidylcholine, vitamin E and Medicinal herbs with blood lipid regulation effect and hepatoprotective effect from four weeks bfore entering to the study.","Exclusion criteria: pregnancy and lactation<br>Liver failure (acute or chronic)<br>Liver diseases such as autoimmune hepatitis, viral hepatitis B and C (active or inactive), Wilson's disease and etc.<br>Hypo and hyperthyroidism<br>Renal failure (creatinine above 1.5 mg / dL)<br>Any malignancy (treated or not)<br>Taking warfarin<br>Addiction and alcohol consumption<br>Taking contraceptives, ouroso-doxycyclic acid, glucocorticoid, statins, probiotics, vitamin E over the past three months<br>Chamomile allergy history",Fatty liver grade. Timepoint: Initially and three months later. Method of measurement: Ultrasound.;Hepatic aminotransferases. Timepoint: Initially and six weeks later and three months later. Method of measurement: Laboratory Kit.;Fatty liver index(FLI). Timepoint: Initially and three months later. Method of measurement: Using formula: [e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745) / (1 + e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745)] × 100.;Alpha Tumor Necrosis Factor. Timepoint: Initially and three months later. Method of measurement: Laboratory Kit.;Insulin resistance index. Timepoint: Initially and three months later. Method of measurement: Calculate the HOMA-IR.;Alkaline phosphatase. Timepoint: initially and three months later. Method of measurement: Laboratory Kit.,Body mass composition. Timepoint: At the entrance and three months later. Method of measurement: Body mass composition machine.;Inflammation. Timepoint: At the entrance and three months later. Method of measurement: hs-CRP labratory kit.;Lipide profile. Timepoint: At the entrance and three months later. Method of measurement: Blood test.,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is There is no further information.,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of fasa university of medical science,NA,NA
IRCT20120215009014N308,http://en.irct.ir/trial/42604,The pregnancy success rate after frozen embryo transfer with and without intrauterine injection of HCG-activated peripheral blood mononuclear cells in infertile women: a single-blind randomized clinical trial,Female infertility. <br>Female infertility,Intervention 1: Intervention group: Transfer of frozen embryos plus an intrauterine injection of 20 ml centrifuged and activated HCG from 20 ml peripheral blood. Intervention 2: Control group: Transfer of frozen embryos alone.,The pregnancy success rate after frozen embryo transfer with and without intrauterine injection of HCG-activated peripheral blood mononuclear cells in infertile women,IRCT,2019-10-13,2019-10-23,FALSE,interventional,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached, Blinding description: The patients will be unaware of the type of intervention. Thus, the trial will be run as single-blind.",N/A,92,Hamedan University of Medical Sciences,Iran (Islamic Republic of),NA,NULL,2019-10-13,2019-10-23,IRCT20,5 November 2019,NULL,Dr. Nages Sajedi,NA,"Fatemieh Hospital, Pasdaran Ave.",fahimesalarii67@gmail.com,+98 81 3828 3939,Hamedan University of Medical Sciences,Dr. Mahnaz Yavangi,NA,"Fatemieh Hospital, Pasdaran Ave.",M_yavangui@yahoo.com,+98 81 3828 3939,Hamedan University of Medical Sciences,Recruiting,NULL,Hamedan University of Medical Sciences,18 years,35 years,Female,"Inclusion criteria: Age of 18 to 35 years,<br>Female infertility,<br>Having healthy uterine,<br>Having two high-quality fetuses for transfer,<br>History of at least three times failure of IVF-ET","Exclusion criteria: Male infertility,<br>Endocrine diseases,<br>Diabetes",Serum ßHCG level. Timepoint: 14 days after the intervention. Method of measurement: Through laboratory test.;Pregnancy sac. Timepoint: 28 days after intervention. Method of measurement: By using ultrasonography.,NULL,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is It depends on the situations and the results of the study as well as approval of the financial supporting organization.,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics Committee of Hamadan University of Medical Sciences,NA,NA
IRCT20191006044993N1,http://en.irct.ir/trial/42817,Comparison of the effect of plantago major with placebo on liver enzymes in patients with nonalcoholic fatty liver disease(NAFLD): a double-blind randomized clinical trial,Non Alcoholic Fatty Liver Disease. <br>Non Alcoholic Fatty Liver Disease;K76-0,"Intervention 1: Intervention group:In the intervention group in addition to lifestyle training and in-person follow-up once every 2 weeks, the 500 mg capsule of Plantago major seed twice per day  is given, 2 capsules each time, orally for 12 weeks.The seeds of Plantago major are planted and placed in 500 mg capsules in the laboratory of the Faculty of Traditional Medicine. Intervention 2: Control group:In the intervention group in addition to lifestyle training and in-person follow-up once every 2 weeks, the 500 mg capsule of toasted flour twice per day  is given, 2 capsules each time, orally for 12 weeks.After preparation, the bread powder was placed in 500 mg capsules in the laboratory of the Faculty of Traditional Medicine.",Effect of Plantago major on nonalcoholic fatty liver disease,IRCT,2019-11-05,2019-10-23,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method is used using 4-way blocks and a random number table.Interventions A and B define six blocks of four.Using random numbers, we select and write blocks. Each individual is then assigned to an A or B intervention.For allocation concealment, sealed envelopes are used, so that the individual number is written on the envelope and the treatment group inside the envelope, Blinding description: The drug and placebo are coded in similar capsules and in identical packages, with the same color and aroma, and the patient, clinician, and researcher are unaware of how the drug or placebo is coded.",2-3,80,Iran University of Medical Sciences,Iran (Islamic Republic of);Iran (Islamic Republic of),NA,1,2019-11-05,2019-10-23,IRCT20,17 December 2019,NULL,Seyede Ferdos Jazayeri,NA,"No. 167,Mojahedine Eslam Ave.,Behnam Towers",sf.jazayeri46@gmail.com,+98 21 7752 1303,Iran University of Medical Sciences,Seyede Ferdos Jazayeri,NA,"No. 167,Mojahedine Eslam Ave.,Behnam Towers",sf.jazayeri46@gmail.com,+98 21 7752 1303,Iran University of Medical Sciences,Recruiting,NULL,Iran University of Medical Sciences,12 years,80 years,Both,Inclusion criteria: Sono graphic report of Grade 1 and 2 fatty liver<br>Increase in ALT> 40<br>Increase in AST>38<br>Ages 12 to 80 years,"Exclusion criteria: The patient's unwillingness to participate in the scheme<br>Pregnancy & lactation<br>Anti coagulant drugs consumption<br>Thyroid diseases<br>Spleen diseases<br>Cirrhosis ,viral hepatitis and obstructive  liver disese<br>Treated dyslipidemia<br>Overt Diabetes mellitus<br>Lung diseases<br>Taking any medication that affects liver metabolism and enzymes, including oral contraceptives, corticosteroids, salazines, etc.","Comprison  of the Plantago major seed with Placebo on ALT enzyme(Alanin trasaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Onset, 6th and 12th week of study.(End of study). Method of measurement: Hitachi 912 instrument.;Comprison  of the Plantago major seed with Placebo on AST enzyme(Aspartate transaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Liver enzymes measurement at baseline, 6th and 12th weeks (end of study). Method of measurement: Hitachi 912 instrument.",NULL,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is No more information.,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of Iran University of Medical Sciences,NA,NA
IRCT20190525043702N1,http://en.irct.ir/trial/39866,Effect of antiseptic and antibiotic usage within the implant on the pro-inflammatory cytokines interleukin 1ß and interleukin 6 in gingival crevicular fluid for the contact of the implant and abutment,"Implantytis. <br>Unspecified complication of internal prosthetic device, implant and graft;T85.9",Intervention 1: First Intervention group: The study is split mouth and each patient will have chlorohexidine 2% in first implant. Intervention 2: Second Intervention group: The study is split mouth and each patient will have tetracycline 3% in second implant. Intervention 3: Third Intervention group: The study is split mouth and each patient will have Saliva in third implant. Intervention 4: Control group: The study is split mouth and each patient will have dry environments in control implant.,Effect of antiseptic and antibiotic usage within the implant in gingival crevicular fluid for the contact of the implant and abutment,IRCT,2019-06-05,2019-05-22,FALSE,interventional,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.",N/A,24,Tabriz University of Medical Sciences,Iran (Islamic Republic of),NA,1,2019-06-05,2019-05-22,IRCT20,26 August 2019,NULL,Ramin Negahdari,NA,"Tabriz Dental Faculty, Golgasht Street  Tabriz  East Azarbaijan , Islamic Republic Of Iran",ramin_n_dds@yahoo.com,+98 41 1335 5965,Tabriz University of Medical Sciences,Ramin Negahdari,NA,"Tabriz Dental Faculty, Golgasht Street  Tabriz  East Azarbaijan , Islamic Republic Of Iran",ramin_n_dds@yahoo.com,+98 41 1335 5965,Tabriz University of Medical Sciences,Complete,NULL,Tabriz University of Medical Sciences,18 years,no limit,Both,Inclusion criteria: Have at least 3 implants in one jaw<br>Having at least 18 years of age<br>The probe depth around the implant between 1-3 mm,"Exclusion criteria: People have been scaling in the last three months in the last three months<br>Pregnant and lactating women<br>Patients receiving antibiotics in the last 6 months<br>Having any systemic disease, such as diabetes, that affects oral health<br>Drug addiction, cigarette or alcohol<br>History of the use of bisphosphonates<br>History of the use of bisphosphonates",Interleukin 1ß. Timepoint: 1 month. Method of measurement: Elisa kit.;Interleukin 6. Timepoint: 1 month. Method of measurement: Elisa kit.,NULL,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Yes - There is a plan to make this available,What will be shared: All data has subscription capability  When: Start the access period 6 months after printing the results  To whom: All people  Conditions: No specific case  Where to obtain: Email Dr. Negahdari  How to obtain: No specific case  Comments:,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Tabriz University of Medical Sciences Ethics Committee,NA,NA
IRCT20190410043236N1,http://en.irct.ir/trial/38837,Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure,Condition 1: Systolic Heart failure. Condition 2: Systolic Heart failure. <br>IX Diseases of the circulatory system <br>Left ventricular failure;130-152;150.1,"Intervention 1: Intervention group: Intervention group: A 50000 unit capsule of vitamin D, manufactured by Abidi company, is given weekly and at 50,000 units for 8 weeks. It should be noted that patients will not be aware of the type of medicine. Patients are monitored for 2 months. Intervention 2: Placebo group: Appearance of 50,000 capsules of vitamin D, manufactured by Abidi company, is given weekly for 8 weeks. It should be noted that patients will not be aware of the type of medicine. Patients are monitored for 2 months.",Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure,IRCT,2019-07-08,2016-05-02,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In present study, simple randomization method was used, Blinding description: This double-blind study was carried out and the cardiologist who do echocardiography patients, as well as those taking medication or placebo, are blind.",2-3,80,Zanjan University of Medical Sciences,Iran (Islamic Republic of),NA,1,2019-07-08,2016-05-02,IRCT20,7 October 2019,NULL,Dr. Reza Hassanzadeh Makuei,NA,Ayatollah Mousavi Hospital-Gawazang Road,makuei42@yahoo.com,+98 24 3353 4019,Zanjan University of Medical Sciences,Dr. Reza Hassanzadeh Makuei,NA,Ayatollah Mousavi Hospital-Gavazang Road,makuei42@yahoo.com,+98 24 3353 4019,Zanjan University of Medical Sciences,Complete,NULL,Zanjan University of Medical Sciences,40 years,no limit,Both,"Inclusion criteria: Chronic heart failure with 20%=EF=45% (based on Framingham criteria, NYAH Class I, II, III)<br>The level of 25 (OH) Vit D is less than 30 ngr / dl<br>Age over 40 years",Exclusion criteria: Hypercalcemia<br>Osteomalacia<br>Taking corticosteroid medication,Ejection Fraction. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.;End Diastolic Volume. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.;Heart Failure Class. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.,"Vitamin D. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: High Performance Liquid Chromatography.;Albumin. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Immunoassay.;Creatinine. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Immunoassay.;Calcium. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Ion Selected (Specific) Electrode.;Phosphor. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Ion Selected (Specific) Electrode.",NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Yes - There is a plan to make this available,"What will be shared: Data files related to the use of medication and medication are also the main implications of sharing.  When: The beginning of the access period was 1 year after the publication  To whom: Data and other study documentation will be available to all individuals and academic and non-academic institutions.  Conditions: Individuals with data receiving conditions can have the data available after receiving the documented consent of Zanjan University of Medical Sciences  Where to obtain: Visit Zanjan University of Medical Sciences at your personal or e-mail address and get consent for received information.  How to obtain: Individuals or institutions, in person or by email, with his introduction and explanation of the purpose of the visit to the Zanjan University of Medical Sciences has the opportunity to have information and can have information within about 1 month.  Comments:",NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Zanjan University of Medical Sciences Ethics Committee,NA,NA
IRCT20181207041876N1,http://en.irct.ir/trial/35752,"The effect of Caraway powder consumption on glycemic indices, lipid profile and Serum levels of nesfatin-1 in overweight and obese patients with type 2 diabetes",type 2 diabetes. <br>Type 2 diabetes mellitus without complications,"Intervention 1: The intervention group consumes 2 grams of Caraway powder capsules (one gram capsule after lunch and one gram capsule after a dinner)  approved by the College of Pharmacy, Kerman University of Medical Sciences for 8 weeks. Intervention 2: The control group consumes 2 grams of starch capsules (one gram capsule after lunch and one gram capsule after a dinner)  Of Shiraz Momtaz Starch Company for 8 weeks.",Effect of Caraway Powder consumption on the Treatment of Type 2 Diabetes,IRCT,2019-01-18,2019-04-09,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization,permuted block randomization will be used with Fourth blocks. According to the 48-sampled sample size, 12 Fourth block will be produced using the online site (www.sealedenvelope.com), Blinding description: All capsules given to participants in the intervention and placebo groups are  same size and color, and all of the participants will not be informed about difference between the Caraway and  placebo capsules. This is performed by a non-researcher person such as Nurses or treatment staff and will not be informed about  difference between the Caraway and placebo capsules.",3,48,Zahedan University of Medical Sciences,Iran (Islamic Republic of),NA,NULL,2019-01-18,2019-04-09,IRCT20,29 January 2019,NULL,Saber Jafari Maskouni,NA,"Alley 7, Jamaran blvd",saberjafarimaskouni@gmail.com,+98 34 4335 0154,Zahedan University of Medical Sciences,Mansour Shahraki,NA,"Alley 7,Moalem street,Daneshgah Blvd",shahrakimansour@yahoo.com,+98 915 542 1310,Zahedan University of Medical Sciences,Pending,NULL,Zahedan University of Medical Sciences,30 years,65 years,Both,Inclusion criteria: given diabetes and having a fasting blood suger level of 126 to 250 mg / dL<br>Consumption of  oral glucose-lowering medicines<br>Age range of 30 to 65 years<br>Body mass index 25 to 40,"Exclusion criteria: given Chronic diseases (high blood pressure, heart, kidney, hypothyroidism, liver, systemic infection)<br>Pregnancy and lactation<br>Hypersensitivity to Caraway",Fasting Blood Suger. Timepoint: One day before  intervention and one day after  end of intervention. Method of measurement: Enzymatic method using kits.;Nesfatin-1. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: Enzymatic method using ELISA kit.;Triglycerides. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: Enzymatic method using kits.;Fasting Blood insulin. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: Enzymatic method using ELISA kit.;Insulin resistance. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: The product of fasting glucose concentration in fasting insulin concentration divided by constant number 22.5.;High density lipoprotein. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: Enzymatic method using kits.;Low density lipoprotein. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: Enzymatic method using kits.;Total cholesterol. Timepoint: One day before  intervention and one day after  intervention. Method of measurement: Enzymatic method using kits.,NULL,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,No - There is not a plan to make this available,Justification or reason for not sharing IPD is No more information,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics Committee of Zahedan University of Medical Sciences,NA,NA
IRCT20111107008022N5,http://en.irct.ir/trial/35126,Comparative bioequivalence study of two different Metformin 750mg formulations (Koushan pharmed & reference) in 24 Iranian volunteers,Health and normal volunteers. <br>--,Intervention 1: Intervention group: Single dose of Metformin 750 mg tablet manufactured by Koushan Pharmed Pharmaceutical company in 24 healthy volunteers. Intervention 2: Intervention group: Single dose of Glucophage 750 mg tablet manufactured by Merck Pharmaceutical company in 24 healthy volunteers.,Bioequivalency study of two different Metformin formulations,IRCT,2019-03-15,2018-12-21,FALSE,interventional,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Health service research, Randomization description: In the first period, the test and the reference drug are randomly divided into two groups of 12 (group A and B), then in the second period, in the cross over form, the groups A and B will be received reference and test drug, Blinding description: In this study, the volunteers, according to the predetermined random table that is available to the researcher, are in one of the groups receiving the test and reference drug. To blind the analyst and volunteers, the information collected from the drug concentration in the plasma of them is encoded and will be unlocked the codes after completion of the analysis.",Bioequivalence,24,Kushan Pharmed  Company,Iran (Islamic Republic of),NA,1,2019-03-15,2018-12-21,IRCT20,25 March 2019,NULL,Dr.Katayoun Derakhshandeh,NA,"Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran",k.derakhshandeh@umsha.ac.ir,+98 81 3838 1590,Hamedan University of Medical Sciences,Katayoun Derakhshandeh,NA,"Faculty of Pharmacy , Hamadan University of Medical Sciences, Shaheed Fahmideh Blvd., In front of Mardom Park, Hamadan, Iran",k.derakhshandeh@umsha.ac.ir,+98 81 3838 1590,Hamedan University of Medical Sciences,Recruiting,NULL,Kushan Pharmed  Company,20 years,45 years,Both,"Inclusion criteria: Inclusion criteria: 24 healthy male and female volunteers will participate in this study. Aged 18 to 45 years, based on laboratory safety tests, no history of diseases affecting drug pharmacokinetic processes; lack of any chronic or acute medication at least 1 week before the start of the study, adherence to the criteria on the basis of moral obligation and signed an informed consent; actual weight (TBW) in the range of 20% IBW Exclusion criteria: Age outside the range mentioned; acute or chronic smoking or alcohol, failure to obtain any of the above health tests, medication two weeks before the experiment",Exclusion criteria:,"Drug plasma concentration. Timepoint: blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h following drug administration. Method of measurement: Using HPLC instrument.",Pharmacokinetic parameters. Timepoint: 0; 0.5; 1.0; 2.0; 3.0; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 8.0; 9.0; 10.0; 12.0; 16.0; 20.0; 24.0; 30.0 and 36 hours post-dose. Method of measurement: Drug analysis in plasma using a chromatographic apparatus and calculating pharmacokinetic parameters using pharmacokinetic models.,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Yes - There is a plan to make this available,"What will be shared: The pharmacokinetic data obtained from the study are for each volunteer in both the test and reference groups.  When: 6 months after the end of the study  To whom: All researchers and clinical specialists  Conditions: There is no denial of access to data  Where to obtain: The results of the project are reported in the form of a published paper  How to obtain: If results are published in online articles, there will be no problem accessing the results  Comments:",NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committees of Hamadan University of Medical Sciences,NA,NA
ISRCTN15668391,http://isrctn.com/ISRCTN15668391,High-dose oral rifampicin to improve survival from adult tuberculous meningitis: a double-blinded randomised placebo-controlled Phase III trial,Tuberculous meningitis <br>Infections and Infestations <br>Tuberculous meningitis,<br>                Participants are allocated by chance to receive either:<br>                1. Four oral rifampicin 300-mg capsules in addition to standard fixed-dose combination TB treatment<br>                2. Standard fixed-dose combination TB treatment<br>                Participants are followed up in hospital until the time of discharge and then as an outpatient for 12 months.<br>,HARVEST trial - improving outcomes from TB meningitis with high-dose oral rifampicin,ISRCTN,2019-06-17,2020-01-01,FALSE,Interventional,Double-blinded parallel group randomised placebo-controlled Phase III trial (Treatment),Phase III,500,Makerere College of Health Sciences,Indonesia;South Africa;Uganda,NA,NULL,17/06/2019,01/01/2020,ISRCTN,2 November 2020,Nil known;Nil known;MHREC 1554,NA,NA,NA,NA,NA,NA,Fiona,Cresswell,Infectious Diseases Institute,fiona.cresswell@lshtm.ac.uk,+256 (0)793420173,NA,Ongoing,NULL,Medical Research Council,NA,NA,Both,Inclusion criteria: <br>                1. First episode TBM suspected by attending physician (>3 days of meningitis symptoms and CSF abnormalities) and anti-TB treatment planned<br>                2. Age =18 years<br>                3. Provision of written informed consent by participant or surrogate<br>,"Exclusion criteria: <br>                1. Presence of jaundice, known liver cirrhosis, or known elevated ALT >5x ULN<br>                2. More than 5 doses of any TB treatment received within the previous 7 days<br>                3. Known allergy to: isoniazid, rifampicin, ethambutol, or pyrazinamide<br>                4. Known current/previous rifampicin-resistant M.tb infection<br>                5. Additional active and confirmed CNS infection<br>                6. Corticosteroids contraindicated<br>                7. Cannot or unlikely to attend regular clinic visits<br>                8. Pregnancy or breastfeeding<br>                9. Known renal failure with eGFR <30 ml/min by Modification of Diet in Renal Disease (MDRD) Study equation<br>                10. HIV Protease Inhibitor ongoing use<br>",6-month survival,"<br>                1. 12-month survival<br>                2. Functional and neurocognitive outcomes measured using the following instruments:<br>                2.1. Normalization of mental status with Glasgow coma scale score (GCS) of 15 and maintained for >2 days (among those with GCS <15 at study entry). A substantial proportion of TBM patients (~50%) present with altered mental status and depressed consciousness. In these participants, early response to treatment is assessed by determining the days from randomization until observation of a GCS of 15 which is achieved for >2 consecutive days<br>                2.2. Functional outcomes assessed by Liverpool Outcome Score at month 6 (Appendix C)<br>                2.3. Quantitative neurocognitive performance Z-scores (QNPZ-8) at 2 and 12 months (Uganda only). QNPZ-8 is derived from a test battery, which includes:<br>                2.3.1. Grooved Pegboard test<br>                2.3.2. Colour Trails 1 and 2 tests<br>                2.3.3. WAIS-III Digit Symbol test<br>                2.3.4. Finger Tapping test<br>                2.3.5. WHO-UCLA Auditory Verbal Learning Test<br>                2.3.6. Semantic Verbal Fluency test (category fluency)<br>                3. Safety and tolerability endpoints:<br>                3.1. Clinical AEs, grade 3-5 as classified by Division of AIDS (DAIDS) Toxicity Scale<br>                3.2. Laboratory AEs, grade 3-5 as classified by DAIDS Toxicity Scale<br>                3.3. All Serious AEs (SAEs)<br>                3.4. Drug-induced liver injury (grade 3-5)<br>                § Alanine transaminase (ALT) or aspartate transaminase (AST) >5x upper limit of normal (ULN)<br>                3.5. Discontinuation of TB treatment for >5 days in the first 8 weeks for any cause<br>                4. Cumulative days of hospitalization (and re-hospitalization)<br>                5. Incidence of re-hospitalization for neurologic deterioration<br>                6. Incidence and management of drug-induced liver injury<br>",NA,NULL,Anticipated,NA,NA,2020 protocol in https://pubmed.ncbi.nlm.nih.gov/33083560/ (added 23/10/2020),NULL,1900-01-01,NA,NA,NA,NA,NA,Available on request,"The researchers plan to publish the protocol in Wellcome Open Research once they have ethical approval.        The main trial paper will be published open access within 6 months of the last participant completing follow up.        Additional sub-studies will be published open access at the appropriate intervals.        The Meningitis Research Foundation is the researchers' communications partner to maximise the impact of the results. The researchers will engage other stakeholders in trial countries.         IPD sharing statement        The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Kathy Huppler Hullsiek, Biostatistician, University of Minnesota (hulls003@umn.edu).",2023-12-31,NULL,NA,Jan  1 1900 12:00AM,NA,"Current ethics approval as of 30/07/2019:                    Approved 17/06/2019, Mulago Hospital IRB (Research Office, Kampala Women’s and Children’s Hospital, Mulago Hospital, Kampala, Uganda; Tel: +256 (0)752818584; Email: evelynnamwase@gmail.com), ref: MHREC 1554.                    Previous ethics approval:                    Approval pending, Mulago Hospital IRB (Research Office, Kampala Women’s and Children’s Hospital, Mulago Hospital, Kampala, Uganda; Tel: +256 (",NA,NA
JPRN-jRCTs051180199,https://jrct.niph.go.jp/latest-detail/jRCTs051180199,S1+ intravenous and intraperitoneal Paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis; Multicenter randomized phase III trial - S1+ intravenous and intraperitoneal Paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis; Multicenter randomized phase III trial,Invasive ductal adenocarcinoma,Anti-cancer drug administration,Establishment of standard treatment for pancreatic ductal adenocarcinoma with peritoneal metastasis,JPRN,2019-03-26,2020-02-26,FALSE,Interventional,"randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose",3,180,Satoi Sohei,Japan,NA,NULL,26/03/2019,26/02/2020,JPRN-j,11 August 2020,UMIN000027229,Tomohisa,Yamamoto,"2-5-1, Shin-machi, Hirakata, Osaka",tomot1226@yahoo.co.jp,+81-72-804-2574,Kansai Medical University,Sohei,Satoi,"2-5-1, Shin-machi, Hirakata, Osaka",satoi@hirakata.kmu.ac.jp,+81-72-804-2574,Kansai Medical University,Recruiting,NULL,NULL,>= 20age old,< 80age old,Both,Inclusion criteria: Patients with peritoneal metastasis without other organ metastases,Exclusion criteria: Cytology positive in patients with resectable/borderiline resectable pancreatic ductal adenocarcinoma,Overall Survival,"Response rate, negative rate of peritoneal lavage cytology, symptom relief effect, resectability, relative dose intensity, progression-free survival, decreasing rate of tumor marker, safety",NA,NULL,actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Sep  5 2018 12:00AM,wa-rinri@wakayama-med.ac.jp,Wakayama Medical University,+81-73-441-0896,wa-rinri@wakayama-med.ac.jp
JPRN-JapicCTI-194721,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194721,A Phase I Multiple-Dose Study of RO7021610 in Japanese Patients with Ulcerative Colitis,Ulcerative colitis,Intervention name : RO7021610<br>INN of the intervention : -<br>Dosage And administration of the intervention : RO7021610 will be administrated repeatedly by IV.<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Placebo will be administrated repeatedly by IV.,A Phase I Study of RO7021610 in Patients with Ulcerative Colitis,JPRN,2019-04-17,2019-06-01,FALSE,INTERVENTIONAL,"A randomized, double-blind, placebo-controlled, inter-individual dose-escalation study",1,24,"Chugai Pharmaceutical Co., Ltd.",Japan,NA,NULL,17/04/2019,01/6/2019,JPRN-J,16 July 2019,NULL,"Chugai Pharmaceutical Co., Ltd. Clinical trials information",NA,NA,clinical-trials@chugai-pharm.co.jp,NA,NA,"Chugai Pharmaceutical Co., Ltd. Clinical trials information",NA,NA,clinical-trials@chugai-pharm.co.jp,NA,NA,recruiting,NULL,-,18,80,BOTH,"Inclusion criteria: - Japanese patients with ulcerative colitis<br>- Diagnosis of ulcerative colitis established and confirmed at least 3 months prior to screening initiation<br>- Diagnosis of moderate-to-severe ulcerative colitis (Mayo endoscopic subscore >=2)<br>- Inadequate response, loss of response, or intolerance to prior treatment for moderate to severe ulcerative colitis",Exclusion criteria: - Confirmed or suspected diagnosis of colitis other than ulcerative colitis<br>- Diagnosis of ulcerative proctitis<br>- Prior and planned surgery for ulcerative colitis<br>- History of malignancy,"safety, pharmacokinetics<br>Safety and PK",other<br>anti-drug antibody,NA,NULL,actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).",NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Keio Univ hospital institutional review board.,NA,NA
JPRN-UMIN000037291,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042438,Exploring Mechanistic Study: Potential of Luseogliflozin on Restoration of Cardiomyocyte Energy Metabolism in Diabetic Patients with Coronary Artery Disease - EXPLORE-CAD,Type 2 Diabetes,Luseogliflozin<br>Standard Therapy without Luseogliflozin,Exploring Mechanistic Study: Potential of Luseogliflozin on Restoration of Cardiomyocyte Energy Metabolism in Diabetic Patients with Coronary Artery Disease,JPRN,2019-07-05,2019-08-01,FALSE,Interventional,Parallel Randomized,Not selected,80,Kumamoto University,Japan,NA,NULL,05/07/2019,2019/08/01,JPRN-U,22 July 2019,NULL,Yuichiro,Arima,"1-1-1 Honjo, Kumamoto City, Kumamoto, JAPAN, 860-8556",arimay@kumamoto-u.ac.jp,096-373-5175,Kumamoto University Cardiovascular Medicine,Kenichi,Tsujita,"1-1-1 Honjo, Kumamoto City, Kumamoto, JAPAN",cvmhisho@kumamoto-u.ac.jp,096-373-5175,Kumamoto University Cardiovascular Medicine,Pending,NULL,KAKENHI,20years-old,85years-old,Male and Female,Inclusion criteria:,"Exclusion criteria: 1. Type 1 diabetes<br>2. Unstable angina<br>3. 3-vessel disease<br>4. insulin usage<br>5. eGFR &lt; 45ml/min/1.73m2<br>6. Liver failure (Child-Pugh: Type C)<br>7. Severe Heart failure (NYHA Stage4)<br>8. BMI &lt;18.5kg/m2<br>9. Allergic reaction to drugs<br>10. Pregnant, breastfeeding patients or suspected patients<br>11. Patients with malignant diseases",Changes of blood metabolic profiles,Change of diastolic dysfunction,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,2020-03-31,NULL,YES,Jan  1 1990 12:00AM,ski-shien@jimu.kumamoto-u.ac.jp,"Ethical Commity, Kumamoto University",096-373-5657,ski-shien@jimu.kumamoto-u.ac.jp
JPRN-UMIN000035965,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040963,NA,Glossodynia,Goreisan,The effects of Goreisan on pain perception in Glossodynia associate with dry mouth,JPRN,2019-02-21,2019-02-20,FALSE,Interventional,Single arm Non-randomized,Not selected,15,Nagasaki University,Japan,NA,1,21/02/2019,2019/02/20,JPRN-U,2 April 2019,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Pending,NULL,Nagasaki University,20years-old,Not applicable,Male and Female,Inclusion criteria: Patients with diagnosis of Glossodynia with dry mouth<br>over 20 years old<br>both gender <br>outpatients<br>patients with IC,Exclusion criteria: patients medicated with other Kampo drug<br>patients with hypertension over diastolic pressure over 120mmHg<br>severe liver and /or renal disease<br>allergy for drug<br>pregnant women<br>patients attending other clinical study within 4 months<br>patients should avoided based on researcher&#39;s evaluation,pain evaluated by VAS,NULL,NA,NULL,NA,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,NA,Jan  1 1990 12:00AM,NA,NA,NA,NA
JPRN-jRCT2063190013,https://jrct.niph.go.jp/latest-detail/jRCT2063190013,A phase I/IIa study of Ad-SGE-REIC-NS in patient with recurrent malignant glioma,reccurent malignant glioma,Ad-SGE-REIC-NS will be injected twice intra-tumorally at intervals of 14 days to  patients with recurrent malignant glioma. <br>The contrast-enhanced MRI-guided injection of Ad-SGE-REIC-NS will be done to patients undergoing burr hole surgery under local or general anesthesia by the assistance of stereotactic surgical equipment or navigation system<br>Dose will be escalated as follows:<br>   Level  1     3.0X10^10vp <br>   Level  2     1.0X10^11vp <br>   Level  3     3.0X10^11vp,A phase I/IIa study of Ad-SGE-REIC-NS in patient with recurrent malignant glioma,JPRN,2019-08-05,2019-08-05,FALSE,Interventional,"single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose",1-2,18,Date Isao,Japan,NA,NULL,05/08/2019,05/08/2019,JPRN-j,25 February 2020,Nil known,Kazuhiko,Kurozumi,"2-5-1, Shikata-cho, Kita-ku, Okayama city, Okayama prefecture",0107reic@okayama-u.ac.jp,+81-86-235-7336,Okayama University Hospital,Isao,Date,"2-5-1, Shikata-cho, Kita-ku, Okayama city, Okayama prefecture",0107reic@okayama-u.ac.jp,+81-86-235-7336,Okayama University Hospital,Recruiting,NULL,Momotaro-Gene Inc.,>= 18age old,< 80age old,Both,"Inclusion criteria: 1) Has been histologically confirmed to be WHO grade 3 or 4, and recurrence or growth of tumor has been recognized in spite of standard treatment.<br>2) MRI brain image measured  within 14 days prior to the administration of Ad-SGE-REIC-NS is more than 1.0cm both in major and minor axis.<br>3) Karnofsky Performance Scale (KPS) measured  within 14 days prior to the administration of Ad-SGE-REIC-NS is 60% or more.<br>4) The patient's age upon enrollment is over 18 and under 80 years.<br>5) The administration of steroid (60mg equivalent of prednisolone) is allowed, but the dose should be stable within 7 days prior to the administration of Ad-SGE-REIC-NS.<br>6) Life expectancy should be more than 3 months.<br>7) The function of major organs should be normal and, in principle, the results of checkup examination conducted within 14 days prior to the administration of Ad-SGE-REIC-NS should fulfill the following criteria. <br>   (1)Neutrophil >= 1.0 x 10^3/microL.<br>   (2)Hemoglobin >= 9.0g/dL.<br>   (3)Platelet >= 100 x 10^3/microL.<br>   (4)Leucocyte>= 2.0 x 10^3/microL.<br>   (5)AST/ALT < 4 times of upper limit of standard value<br>   (6)PT-INR or APTT < 1.3 times of upper limit of standard value<br>   (7)Creatinine <= 1.7mg/dL..<br>8) Must agree to use an acceptable method of birth control during the period of clinical study.<br>9) Willing and able to provide written informed consent prior to undergoing any study-specific procedures.","Exclusion criteria: 1) Has received chemotherapy (other than gliadel wafer therapy), immunotherapy or any other therapy including investigational drug treatment and resection of glioma within 28 days prior to the administration of Ad-SGE-REIC-NS. When Temozolomide is prescribed, however, it can be administered until the day before the Ad-SGE-REIC-NS therapy starts.<br>2) Has received radiotherapy within 90 days prior to the administration of Ad-SGE-REIC-NS. <br>3) Has extracerebral metastasis or more than 2 extracerebral malignant glioma.<br>4) Has to be injected in brain ventricle or brain stem, or through brain ventricles.<br>5) Has subependymoma or subarachnoidal disseminated cancer.<br>6) Has considered  other malignancies to be cured within 3 years.<br>7) Has contraindication to MRI examination, such as allergic reaction to MRI contrast media.<br>8) Has HBsAg antibody positivity, or HCV antibody or RNA positivity <br>9) Has HIV antibody positivityor with previous history of HIV.<br>10) Has active bacterial, fungal and virus infection (except for hepatitis B and C) or active double cancer.<br>11) Has a history of interstitial pneumonia.<br>12) Has a history of angina, heart failure or heart attack within 1 year. <br>13) Has a history of hypersensitivity to the test drug or any other drug used for the trial including pretreatment.<br>14) Has uncontrolled diabetes.<br>15) Requires immunosuppressive treatment except for systemic corticosteroid treatment.<br>16) Has a history of cerebritis, multiple sclerosis, central neurological infectious disease and addiction to alcohol or drugs, or has addiction to alcohol or drugs.<br>17) Women during pregnancy, women of childbearing potential or breast-feeding women. <br>18) Any patient judged inadequate to enroll in the trial by a doctor in charge.","1. Safety :<br>  1) Adverse Effect<br>  2) Physical Examination<br>  3) Vital Signs (including blood pressure, pulse, and temprature)<br>  4) A 12-lead Electrocardiogram<br>  5) Chest X-ray<br>  6) Laboratory Assessment (Hematology, Serum Chemistry and Urinalysis)<br>2. Dose Limiting Toxicity (DLT)<br>3. Maximum Tolerated Dose (MTD)",1. Efficacy :<br>   1) Antitumor Efficacy [Objective Responce Rate (ORR)]<br>   2) Immunological Assessment,NA,NULL,anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Apr  2 2019 12:00AM,ouh-crrb@adm.okayama-u.ac.jp,Okayama University Certified Review Board,+81-86-235-7361,ouh-crrb@adm.okayama-u.ac.jp
JPRN-jRCT2031190020,https://jrct.niph.go.jp/latest-detail/jRCT2031190020,Phase I study of pevonedistat in combination with capecitabine and oxaliplatin (CapeOX) in patients with advanced gastric cancer refractory to platinum - CaPevOX-1,stomach cancer,"In a 21-day-administration cycle, pevonedistat at 15 mg/m^2 (level 0: initiation dose) will be administered on days 1, 3, and 5. Oxaliplatin at 130 g/m^2 will be administered on day 1, and capecitabine will be orally administered at 2000 mg/m^2 split in 2 approximately every 12 hour for 14 days and then it was withdrawn for 7 days.",Phase I study of pevonedistat in combination with capecitabine and oxaliplatin (CapeOX) in patients with advanced gastric cancer refractory to platinum,JPRN,2019-05-10,2019-08-28,FALSE,Interventional,"single arm study, open(masking not used), no treatment control, single assignment, treatment purpose",1,23,Boku Narikazu,Japan,NA,NULL,10/05/2019,28/08/2019,JPRN-j,7 September 2020,NULL,Hirokazu,Shoji,"5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan",hshouji@ncc.go.jp,+81-3-3542-2511,National Cancer Center Hospital,Narikazu,Boku,"5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan",nboku@ncc.go.jp,+81-3-3542-2511,National Cancer Center Hospital,Recruiting,NULL,Takeda Pharmaceutical Company Limited,>= 20age old,Not applicable,Both,"Inclusion criteria: 1) Patients who are diagnosed as having any of adenocarcinoma (pupillary adenocarcinoma, tubular adenocarcinoma, or poorly differentiated adenocarcinoma), signet-ring cell carcinoma and mucinous carcinoma.<br>2) Patients with unresectable advanced gastric cancer or those with recurrent gastric cancer (including those with carcinoma of gastroesophageal junction).<br>3) Patients whose CT images show no massive ascites toward the upper abdomen over the pelvic cavity, and patients without massive ascites requiring drainage.<br>4) Patients who can take food orally.<br>5) Patients who are 20 years old or older at the registration.<br>6) Patients with ECOG performance status (PS) of 0 or 1.<br>7) Patients in whom at least 1 measurable lesion* was proven with thoracic-abdominal-pelvic CT scan.<br>8) Patients who are refractory or intolerant to fluoropyrimidines (at least one of 5-FU, capecitabine or S-1), first-line chemotherapy containing cisplatin or oxaliplatin, or second-line chemotherapy containing taxanes for gastric cancer and have been treated with two or more regimens of anticancer therapy previously.<br>9) Peripheral sensory neuropathy and peripheral motor neuropathy<br>less than Grade 1 defined by CTCAE v5.0<br>10) Patients who were not treated with systemic antineoplastic therapy (including investigational drugs) within 14 days before the registration.<br>11) Patients who were not radiated to their spinal cord or pelvis within 28 days before the registration, and those who did not receive radiation to the organs other than the spinal cord and pelvis within 14 days before the registration.<br>12) Patient whose clinical laboratory test values obtained within 3 days before the registration meet the following criteria.<br>13) Female patients who agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug.<br>14) Male patients, even if surgically sterilized (ie, status postvasectomy), who agree to practice effective barrier contraception during the entire study treatment  period and through 4 months after the last dose of study drug.<br>15) Patients who have provided a written informed consent to participate in the trial.","Exclusion criteria: 1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy.<br>2) Patients with an infectious disease requiring systemic treatment.<br>3) Intorelant to capecitabine and/or oxaliplatin.<br>4) Prothrombin time (PT) or activated partial thromboplastin time (APTT) exceeds 1.5 times the institution standard value or has poorly controlled active coagulopathy or hemorrhagic disease<br>5) Known cardiopulmonary disease.<br>6) Left ventricular ejection fraction (LVEF) measured using echocardiography (ECHO), less than 50%<br>7) Major surgery or laparotomized biopsy under general anesthesia within 14 days prior to registration<br>8) Metastasis to the central nervous system (brain, spinal cord, meningeal) is evident<br>9) Patients with Liver cirrhosis or severe hepatic disorder<br>10) Have a life-threatening disease not related to gastric cancer<br>11) A positive test result for any of the followings: Human immunodeficiency virus antibody, hepatitis B surfaces (HBs) antigen, or hepatitis C virus antibody.  <br>12) Positive test result for either HBs antibody or hepatitis B core antibody, with a detectable level of hepatitis B virus-deoxyribonucleic acid (HBV-DNA) even in case of negative HBs antigen test<br>13) Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.<br>14) Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).<br>15) Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).<br>16) Judged to be incapable of providing consent for certain reasons, such as concurrent dementia<br>17) Require or have received systemic corticosteroids or immunosuppressants<br>18) Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg).<br>19) Prolonged rate corrected QT (QTc) interval more than 500 msec, calculated according to institutional guidelines.<br>20) Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis.<br>21) Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.",The safety and tolerability of the combination of pevonedistat and CapeOX in Japanese patients with unresectable advanced/recurrent gastric cancer who are refractory or intolerant to platinum (cisplatin or oxaliplatin) in order to determine the recommended dose (RD).<br>The pharmacokinetics (PK) of pevonedistat under its combined administration with CapeOX in Japanese patients with unresectable advanced/recurrent gastric cancer who are refractory or intolerant to platinum (cisplatin or oxaliplatin).,The therapeutic effect of the combination of pevonedistat and CapeOX on gastric cancer.,NA,NULL,actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Apr 10 2019 12:00AM,chiken_CT@ml.res.ncc.go.jp,National Cancer Center IRB,+81-3-3547-5201,chiken_CT@ml.res.ncc.go.jp
JPRN-jRCTs031180183,https://jrct.niph.go.jp/latest-detail/jRCTs031180183,Phase 1 study of Disulfiram and Nivolumab for gastric cancer - Phase 1 study of Disulfiram and Nivolumab for gastric cancer,Gastric cancer <br>gastric cancer,Disulfiram (po): 160mg three times daily (480mg/day) or 80mg three times daily (240mg/day) for maximum 6 cycles.<br>Nivolumab (iv): 240mg every 2 weeks for maximum 6 cycles.<br>1 cycle is for 28 days.,Phase 1 study of Disulfiram and Nivolumab for gastric cancer,JPRN,2019-03-05,2019-04-03,FALSE,Interventional,"single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose",1,16,Shitara Kohei,Japan,NA,NULL,05/03/2019,03/04/2019,JPRN-j,23 March 2020,NULL,Kohei,Shitara,"6-5-1 Kashiwanoha Kashiwa-shi Chiba, Japan",kshitara@east.ncc.go.jp,+81-4-7133-1111,National Cancer Center Hospital East,Kohei,Shitara,"6-5-1 Kashiwanoha Kashiwa-shi Chiba, Japan",kshitara@east.ncc.go.jp,+81-4-7133-1111,National Cancer Center Hospital East,Recruiting,Matsuhisma Kouji,AMED,>= 20age old,Not applicable,Both,"Inclusion criteria: 1) Patients with histologically or cytologically confirmed advanced/recurrent gastric cancer after previous chemotherapy<br>2) Patients without previous treatment with anti-PD1/PDL1 inhibitor.<br>3) Patients with at least one measurable lesion based on the Response Evaluation Criteria in Solid Tumors (RECIST) guideline ver.1.1.<br>4) Patients who are aged more than 20 years at the time of informed consent.<br>5) Patient with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.<br>6) Patients with adequate oral intake<br>7) Patients with adequate organ functions as determined by laboratory test values measured within 7 days before enrollment in the study (laboratory testing on the same day of the week at 7 days before enrollment was permitted). <br>a) Neutrophils: more than 1200/mm3<br>b) Platelets: more than 75,000/mm3<br>c) Hemoglobin: more than 8.5 g/dL<br>d) Total bilirubin: less than or equal to 1.5 mg/dL<br>e) AST: less than or equal to 100 U/L (with liver metastasis, less than or equal to 150 U/L)<br>f) ALT: less than or equal to 100 U/L (with liver metastasis, less than or equal to 150 U/L)<br>g) Creatinine: less than or equal to 1.5 mg/dL or creatinine clearance using the Cockcroft-Gault equation of more than 40 mL/min<br>8) Patients who have recovered from a previous treatment regimen with a toxicity level lower than CTCAE Grade 1. The following symptoms were excluded: hair loss, peripheral sensory neuropathy, excessive skin pigmentation, and dysgeusia.<br>9) Patients who have not received a transfusion or hematopoietic factors, such as granulocyte colony-stimulating factor (G-CSF), within 7 days prior to enrollment.<br>10) Patients who have agreed to use appropriate contraceptive methods during the study period and 6 months after cessation of the test drug. Premenopausal female patients who have a possibility of becoming pregnant should have had a negative urine pregnancy test within 7 days prior to enrollment.<br>Contraception methods approved or certified in Japan should be used, including condoms, a pessary, an intrauterine contraceptive device (IUD), implant contraceptive devices (currently there are no approved such devices in Japan), vasectomy, and tubal ligation.<br>Menopause: Defined as the time during which there are no menstrual periods for more than 1 year after the last menstrual period and no other medical reasons for menorrhea have been identified.<br>11) Patients who are expected to survive more than 3 months from the date of the initial administration of the clinical drug.<br>12) Written informed consent has been obtained from the patient for participation in this study","Exclusion criteria: 1) Patients with a primary tumor of the central nervous system or symptomatic or progressive central nervous system metastasis. If no growth and symptoms were observed during more than past 2 months, the patient is eligible<br>2) Patients with acquired immunodeficiency syndrome or with active autoimmune diseases <br>3) Patients who have received treatments, such as chemotherapy, radiotherapy, or other any other drug under trial, within 2 weeks prior to enrollment in the study. <br>4) Patients who have received treatments with cancer therapeutic vaccines; genetically modified viruses, such as oncolytic virus therapy; or genetically modified cell therapy within 4 weeks prior to enrollment in the study.<br>5) Patients who had received live vaccination within 30 days before protocol treatment<br>6) Patients with active infectious diseases requiring systemic treatment.<br>7) Patients with clinical symptoms or image findings consistent with those of interstitial pneumonia or pulmonary fibrosis.<br>8) Patients who were HIV-1 antibody-positive, HBs antigen-positive, or HCV antibody-positive.<br>9) Patients with severe cardiovascular disease that met criteria III or higher of the New York Heart Association [NYHA] classification for congestive heart failure within 6 months prior to enrollment in the study, unstable angina, or a history of myocardial infarction or complication of serious arrhythmia. <br>10) Patients who require steroid (glucocorticoid) treatment or other immunosuppressants.<br>11) Patients with poorly controlled diabetes mellitus.<br>12) Patients who can not withdraw from alcohol drinking, medications, foods and cosmetics containing alcohol<br>13) Pregnant or lactating patients. If breastfeeding, even if breastfeeding is interrupted, patients cannot be enrolled.<br>14) Patients who have difficulty adhering to scheduled visits, treatment plans, clinical laboratory testing, or other study procedures.<br>15) Patients whom the investigator considers would influence the assessment or safety of the test drug or the interpretation of the results.",Rate of DLT (dose limiting toxicities) expression,"Progression-free survival (PFS), Response rate (RR), Duration of response (DOR), Percentage of subjects treated with surgical resection after chemotherapy(complete resection), Percentage of subjects with adverse events",NA,NULL,actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Feb 12 2019 12:00AM,ncche-irb@east.ncc.go.jp,National Cancer Center Hospital East Certified Review Board,+81-4-7133-1111,ncche-irb@east.ncc.go.jp
JPRN-JapicCTI-194635,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194635,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Dose or Multiple Dose Study of KHK4323 in Healthy Volunteers, and Subjects with Atopic Dermatitis",Atopic dermatitis,"Intervention name : KHK4323<br>INN of the intervention : -<br>Dosage And administration of the intervention : Part 1: Single administration IV/SC, Part 2: Repeated administration IV<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Part 1: Single administration, IV/SC, Part 2: Repeated administration, IV","A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Dose or Multiple Dose Study of KHK4323 in Healthy Volunteers, and Subjects with Atopic Dermatitis",JPRN,2019-02-18,2019-02-22,FALSE,INTERVENTIONAL,"Double-Blind, Placebo-Controlled",1,120,"Kyowa Kirin Co., Ltd.",Japan,NA,NULL,18/02/2019,22/2/2019,JPRN-J,25 February 2020,NCT03846466,"Kyowa Kirin Co., Ltd. R&D Planning Department, R&D Division",NA,"1-9-2 Otemachi, Chiyoda-ku, Tokyo",clinical.info.jp@kyowakirin.com,NA,NA,"Kyowa Kirin Co., Ltd. R&D Planning Department, R&D Division",NA,"1-9-2 Otemachi, Chiyoda-ku, Tokyo",clinical.info.jp@kyowakirin.com,NA,NA,other,NULL,-,18,NA,BOTH,Inclusion criteria: Part 1: <br>-Japanese or Caucasian male aged 20 to under 45 years old at the time consent was obtained<br>-BMI >= 18.5 to < 30.0 at time of screening tests<br>Part 2:<br>-Men and women aged 18 years or older at the time of consent<br>-Patients with EASI >= 16 in pre-administration testing<br>-Patients with IGA of 3: Moderate or higher in pre-administration testing<br>-Patients with BSA >= 10% at screening in pre-administration testing,"Exclusion criteria: Part 1:<br>-Persons with existing respiratory disease, heart disease, gastrointestinal disease, kidney disease, or liver disease<br>-Persons confirmed to have a bacterial, viral, fungal, or parasitic infection within 28 days prior to obtainment of consent<br>-Persons who have contracted an infectious disease requiring hospitalization or IV administration of an antibiotic within 6 months prior to obtainment of consent<br>-Persons who have been treated with a biological preparation (antibody, etc.) or have been administered an investigational drug within 6 months prior to the obtainment of consent<br>-Persons who have used a medication (including over-the-counter drugs, topical agents, vitamins, and herbal medicines) within 2 weeks prior to obtainment of consent (for an immunosuppressant drug, within 60 days)<br>-Persons who routinely smoke an average of more than 10 cigarettes a day (to be confirmed in interview at time of screening tests) or cannot follow the rules regarding smoking during the clinical trial period<br>Part 2:<br>-Patients with severe complications judged to affect the implementation and evaluation of the study in the opinion of the investigator or sub-investigator. Includes but is not limited to the following. Severe cardiovascular disease (e.g., class III or IV according to New York Heart Association functional classification), poorly controlled diabetes mellitus (HbA1c > 8.5%), poorly controlled hypertension, liver disease with severity of moderate or higher (e.g., class B or C according to Child-Pugh classification), kidney disease, respiratory disease, gastrointestinal disease, blood dyscrasia, central nervous system disease, psychiatric disease, autoimmune disease, etc.<br>-Patients observed to have one of the following laboratory test abnormalities in screening tests<br>   Neutrophil count: < 1500/uL<br>   Serum creatinine: > 1.5 mg/dL<br>   AST or ALT: > 2.5-fold the upper limit of the reference range<br>   Other laboratory test abnormalities that the investigator or sub-investigator thinks could affect the completion or evaluation of the clinical trial",safety<br>Adverse events<br>Laboratory data<br>Vital signs<br>Standard 12-lead ECG,"pharmacokinetics<br>Serum KHK4323 concentration<br>Pharmacokinetic parameters (tmax, Cmax, AUC, etc.)<br>Anti-KHK4323 antibodies",NA,NULL,actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,2019-12-11,NULL,Approved,Feb  1 2019 12:00AM,NA,Osaka Pharmacology Clinical Research Hospital,06-6395-9000,NA
JPRN-jRCTs031180139,https://jrct.niph.go.jp/latest-detail/jRCTs031180139,JCOG0601: Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma - NHL-R-CHOP-P2/3,CD20 positive diffuse large B cell lmyphoma,"A: R-CHOP (tri-weekly rituximab plus CHOP), 8 cycles<br>Cyclophosphamide 750 mg/m2, day 1<br>Doxorubicin 50 mg/m2, day 1<br>Vincristine 1.4 mg/m2 (max 2.0 mg/body), day 1<br>Prednisolone 100 mg/body, day 1-5<br>Rituximab 375 mg/m2, day 1<br>B: RW+CHOP (weekly rituximab plus CHOP) , 8 cycles<br>Cyclophosphamide 750 mg/m2, day 1<br>Doxorubicin 50 mg/m2, day 1<br>Vincristine 1.4 mg/m2 (max 2.0 mg/body), day 1<br>Prednisolone 100 mg/body, day 1-5<br>Rituximab 375 mg/m2, day 1,8,15,22,29,36,43,50",JCOG0601: Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma,JPRN,2019-02-20,2008-01-10,FALSE,Interventional,"randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose",2-3,422,ANDO Kiyoshi,Japan,NA,1,20/02/2019,10/01/2008,JPRN-j,20 April 2020,UMIN000000929,Ken,OHMACHI,"142, Shimokasuya, Isehara, Kanagawa, 259-1193",8jmmd004@is.icc.u-tokai.ac.jp,+81-463-93-1121,Tokai University Hospital,Kiyoshi,ANDO,"143, Shimokasuya, Isehara, Kanagawa, 259-1193",andok@keyaki.cc.u-tokai.ac.jp,+81-463-93-1121,Tokai University Hospital,Not Recruiting,Kinoshita Tomohiro,"National Cancer Center Japan;Ministry of Health, Labour and Welfare",>= 20age old,<= 79age old,Both,"Inclusion criteria: 1)Histologically proven CD20 positive diffuse large B-cell lymphoma (WHO classification), excluding histological transformation form marginal zone B cell lymphoma or follicular lymphoma and immunodeficiency associated lymphoproliferative disorders.<br>2)lymphoma with CD20 positive by immunohistochemistry or flow cytometry of biopsy epecimen or surgical specimen<br>3)clinical staging is evaluated by diagnostic imaging procedures within 28 days before entry.<br>4)stage I disease without bulky mass inappropriate for chemo-radiotherapy<br>5)lymphoma cells in peripheral blood: no more than 10,000 /mm3<br>6)ECOG Performance Status: 0-2<br>7)no clinical 0CNS invasion<br>8)having measurable lesion<br>9)no prior chemotherapy, radiotherapy and anti-body therapy<br>10)sufficient organ function<br>i)WBC: more than 3000 /mm3<br>ii)Neutrophil: more than 1000 /mm3<br>iii)Platlets: more than 10x104 /mm3<br>iv)AST: no more than 150 U/L<br>v)male ALT: no more than 210 U/L, female: ALT: no more than 115 U/L<br>vi)T-bil: no more than 2.0mg/dl<br>vii)Creatinine: no more than 2.0mg/dl<br>viii)normal ECG without ischemic change, atrial fibrillation, and ventricular arrhythmia<br>ix)ejection fraction: more than 50% by echocardiogram<br>x)PaO2: more than 65mmHg (room air)<br>11)written informed consent","Exclusion criteria: 1)Anamnesis of glaucoma<br>2)Diabetes mellitus under treatment with insulin or uncontrolled<br>3)Uncontrollable hypertension<br>4)Coronary artery disorder, cardiomyopathy and heart failure requiring treatment, antiarrhyshmic treated  arrhythmia<br>5)HBs antigen positive<br>6)HCV antibody positive<br>7)HIV antibody positive<br>8)Interstitial pneumonia, or plumonary fiblosis<br>9)Severe infection<br>10)Synchronous or metachronous active malignancy. With a history of malignant lymphoma, myelodysplastic syndrome, or leukemia during complete remission<br>11)Interstitial pneumonia, fibroid lung, or severe emphysema<br>12)psychosis or psychiatric symptoms are judged not to be able to participate in this clinical study<br>13)given systemic steroid",phase II: complete response rate<br>phase III: progression free survival,"phase II: progression free survival, overall survival, adverse events, seriouse adverse events<br>phaseIII: overall survival, adverse events, seriouse adverse events",NA,NULL,actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Nov 29 2018 12:00AM,ncch-irb@ml.res.ncc.go.jp,National Cancer Center Hospital Certified Review Board,+81-3-3542-2511,ncch-irb@ml.res.ncc.go.jp
JPRN-jRCTs031180097,https://jrct.niph.go.jp/latest-detail/jRCTs031180097,"JCOG1105: Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma - IMPROVE-MPB study",Elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma,"Arm A: modified PETHEMA-MPB therapy consists of nine cycles: one cycle of subcutaneous or intravenous bortezomib given twice per week for 6 weeks (1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32), plus oral melphalan 9 mg/m2 and oral prednisolone 60 mg/m2 on days 1-4, followed by eight cycles of subcutaneous or intravenous bortezomib once per week for 5 weeks (1.3 mg/m2 on days 1, 8, 15, and 22) plus the same doses of oral melphalan and prednisolone.<br>Arm B: JCOG-MPB therapy consists of nine cycles of subcutaneous or intravenous bortezomib give once per week for 4 weeks (1.3 mg/m2 on days 1, 8 and 15), plus oral melphalan 7 mg/m2 and oral prednisolone 60 mg/m2 on days 1-4.","JCOG1105: Randomized phase II study of two induction treatments, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma",JPRN,2019-01-28,2013-07-22,FALSE,Interventional,"randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose",2,90,IIDA Shinsuke,Japan,NA,1,28/01/2019,22/07/2013,JPRN-j,4 November 2020,UMIN000011180,Shinsuke,IIDA,"1, Aza Kawasumi, Mizuho-cho, Mizuho-ku,Nagoya City, Aichi, 467-8602 Japan",iida@med.nagoya-cu.ac.jp,+81-52-853-8738,Nagoya City University Hospital,Shinsuke,IIDA,"1, Aza Kawasumi, Mizuho-cho, Mizuho-ku,Nagoya City, Aichi, 467-8602 Japan",iida@med.nagoya-cu.ac.jp,+81-52-851-5511,Nagoya City University Hospital,Complete,NULL,National Cancer Center Japan;Japan Agency for Medical Research and Development,>= 20age old,<= 79age old,Both,"Inclusion criteria: 1) Diagnosed as having symptomatic multiple myeloma <br>2) Aged 65 to 79 years old, or 20 to 64 years old who refused high-dose therapy followed by autologous stem-cell transplantation <br>3) Untreated for multiple myeloma <br>4) Having measurable paraprotein defined as serum monoclonal immunoglobulin concentration of at least 1.0 g/dL of IgG, or at least 0.5 g/dL of absolute serum concentration of IgA/IgD, or urinary excretion of at least 0.2 g of paraprotein per 24 hours regardless of the type of myeloma <br>5) Not having plasma cell leukemia <br>6) Having neither of cardiac amyloidosis nor gastrointestinal amyloidosis <br>7) Performance status: 0-2, or 3 due to osteolytic lesions alone <br>8) Absolute neutrophil count: no less than 1,000/mm3, platelet count: no less than 75,000/mm3, hemoglobin concentration: at least 8.0 g/dL, AST/ALT: no more than 100 IU/L, total bilirubin: 1.8 mg/dL or below, serum creatinene: 2.5 mg/dL or below, PaO2 (room air) at least 70 torr, ECG: neither ischemic change nor arrhythmia requiring medical intervention, cardiac ejection fraction: at least 50% <br>9) Peripheral neuropathy of grade 1 or less and no neuralgia <br>10) Written informed consent by the patient including contraception","Exclusion criteria: 1) Synchronous or metachronous malignancy <br>2) Active infection <br>3) Pregnant or nursing women <br>4) Psychiatric disease <br>5) Continuous systemic treatment with steroids for non-malignant disorders <br>6) Insulin-dependent or uncontrollable diabetes mellitus <br>7) Uncontrollable hypertension <br>8) HBs-Ag positive or HCV-Ab positive <br>9) HIV-Ab positive <br>10) Interstitial pneoumonia, pulmonary fibrosis, severe pulmonary emphysema, or severe pleural effusion on chest CT <br>11) Uncontrollable Glaucoma <br>12) Allergic history to borate or mannitol",Complete response rate,"proportion of treatment completion, overall response rate, stringent complete response rate, overall survival, progression-free survival, time to next treatment, adverse events, serious adverse events, efficacy according to chromosomal translocation-associated protooncogene expression",NA,NULL,actual,91,https://pubmed.ncbi.nlm.nih.gov/32583431/,"The results of JCOG1105 demonstrated that the twice-weekly dosing of bortezomib in the first cycle along with higher dose of melphalan and high cumulative dose of both bortezomib and melphalan confers sustained PFS benefit and no new concern of adverse events were observed. The continued risk of relapse warrants further development of more effective treatments for pts with transplant-ineligible NDMM. Based on the results of this study, we are preparing for next phase III trial (JCOG1911).",2020-10-06,2020-06-24,Please find the JCOG1105 clinical study report file in the Attached files: statistical analysis plan section below. You will also find the statistical analysis plan file in the same section.,Please find the JCOG1105 clinical study report file in the Attached files: statistical analysis plan section below. You will also find the statistical analysis plan file in the same section.,Please find the JCOG1105 clinical study report file in the Attached files: statistical analysis plan section below. You will also find the statistical analysis plan file in the same section.,Please find the JCOG1105 clinical study report file in the Attached files: statistical analysis plan section below. You will also find the statistical analysis plan file in the same section.,https://jrct.niph.go.jp/latest-detail/jRCTs031180097,No,None,2020-02-17,Yes,Approval,Oct 25 2018 12:00AM,ncch-irb@ml.res.ncc.go.jp,National Cancer Center Hospital Certified Review Board,+81-3-3542-2511,ncch-irb@ml.res.ncc.go.jp
KCT0004211,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14441,Optimal dose for topical use of tranexamic acid after cardiovascular surgery,;Diseases of the circulatory system,"Drug : If a cardiac and cardiovascular surgery is carried out in the same way as a conventional surgery and it is determined that there are no more bleeding areas, the assigned test drug is applied around the heart and the surgery is terminated. The test drug is assigned and applied to clinical subjects, divided into one to one placebo group and one to one for the Tranexamatic acid low dose group (1g) and two to one for the high dose group (2.5g) according to a random assignment table.",Optimal dose for topical use of tranexamic acid after cardiovascular surgery,KCT,2019-08-19,2019-09-02,FALSE,Interventional Study,"Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Allocation : RCT",Phase4,123,Korea University Anam Hospital,"Korea, Republic of",NA,NULL,2019-08-19,2019-09-02,KCT000,26 August 2019,NULL,Huh,Young,Korea University Anam Hospital,ayoung128@naver.com,+82-2-920-6453,Korea University,Son,Sung,Korea University Anam Hospital,hssonmd@gmail.com,+82-2-920-6453,Korea University Anam Hospital,Not yet recruiting,NULL,Korea University Anam Hospital,19(Year),80(Year),Both,Inclusion criteria: -An adult who has been operated on for heart and aortic disease<br>-Men and women aged 19 and over<br>-Those who voluntarily agree to this study,Exclusion criteria: -In case of preoperative antifibrinolytics used<br>-In case who was diagnosed with preoperative blood clot disease<br>-In case of liver cirrhosis<br>-Patients with thrombotic thrombosis and such a history<br>-Patients who overreact to this drug and its constituent parts,Bleeding flow (verified by blood test),Blood transfusion flow;arterial blood gas analysis;Chest tube drainage;Cardiac ultrasonography;surgical complication;Survival status,NA,NULL,Anticipated,NA,NA,NA,2019-08-19,1900-01-01,NA,NA,NA,NA,NA,Undecided,NA,2020-03-31,NULL,Submitted approval,Jan  1 1900 12:00AM,NA,Korea University Anam Hospital All Right reserved,+82-2-920-6566,NA
KCT0003909,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=13801,Whole genomic landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib,;Neoplasms,Drug : Osimertinib 80mg once daily po every 6 weeks (=1 cycle),Whole genomic landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib,KCT,2019-05-14,2019-05-30,FALSE,Interventional Study,"Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable",Not applicable,148,Seoul National University Hospital,"Korea, Republic of",NA,NULL,2019-05-14,2019-05-30,KCT000,20 May 2019,NULL,TaeMin,Kim,"101 Daehack-ro, Jongno-gu, Seoul, KOREA",tmgabriel7@gmail.com,+82-2-3668-7062,Seoul National University Hospital,TaeMin,Kim,"101 Daehack-ro, Jongno-gu, Seoul, KOREA",tmgabriel7@gmail.com,+82-2-3668-7062,Seoul National University Hospital,Not yet recruiting,NULL,AstraZeneca Korea,19(Year),No Limit,Both,"Inclusion criteria: 1.Provision of informed consent prior to any study specific procedures <br>2.Male or female must be &gt; 19 years of age<br>3.Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:<br>1)Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments <br>2)Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution <br>3)Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation <br><br>4.Male subjects should be willing to use barrier contraception (i.e., by use of condoms) <br>5.Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy with local confirmation of the presence of EGFR TKI-sensitizing mutation (EGFR exon 19 deletion or L858R mutation), either alone or in combination with other EGFR mutations excluding EGFR exon 20 insertion mutation<br>6.Mandatory provision of fresh tumor sample before osimertinib via a biopsy or surgical resection<br>7.Eastern Cooperative Oncology Group (ECOG) performance status 0-1<br>8.Patients must have a life expectancy = 12 weeks.<br>9.At least one lesion, not previously irradiated, that can be accurately measured at baseline as = 10 mm in the longest diameter (except lymph nodes which must have short axis = 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements<br>10.Provision of informed consent for whole-genome and whole-exome sequencings","Exclusion criteria: 1.Involvement in the planning and/or conduct of the study<br>2.Previous treatment with an EGFR TKI<br>3.Treatment with an investigational drug within five half-lives or 3 months, whichever is greater of the compound<br>4.Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4<br>5.Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2, prior platinum-therapy–related neuropathy<br>6.Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required<br>7.Patients with spinal cord compression, symptomatic or unstable brain metastases except for those patients who have completed definitive therapy and have had a stable neurological status for at least 2 weeks after completion of definitive therapy. Patients who may be on corticosteroids to control brain metastases if they have been on a stable dose for 2 weeks (14 days) prior to the start of study treatment and are clinically asymptomatic are eligible<br>8.Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib<br>9.Any of the following cardiac criteria:<br>- Mean resting corrected QT interval (QTc) &gt; 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value<br>- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.<br>-  Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes.<br>10.Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease<br>11.Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values: absolute neutrophil count &lt;1.5 x 109/L; platelet count &lt;100 x 109/L; haemoglobin &lt;90 g/L; alanine aminotransferase &gt;2.5 times ULN if no demonstrable liver metastases or &gt;5 times ULN in the presence of liver metastases; aspartate aminotransferase &gt;2.5 times ULN if no demonstrable liver metastases or &gt;5 times ULN in the presence of liver metastases; total bilirubin &gt;1.5 times ULN if no liver metastases or &gt;3 times ULN in the presence of documented Gilbert’s Syndrome [unconjugated hyperbilirubinaemia] or liver metastases; serum crea",identify acquired resistance mechanisms to osimertinib at disease progression,evaluate the safety and tolerability of first-line osimertinib;Progression-Free Survival (PFS).;Overall Survival (OS),NA,NULL,Anticipated,NA,NA,NA,2019-05-14,1900-01-01,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Submitted approval,Jan  1 1900 12:00AM,NA,Seoul National University College of Medicine/ Seoul National University Hospital Institutional Review Board,+82-2-2072-0694,NA
PACTR201908793583382,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8297,Tranexamic Acid versus Carbetocin for Reduction of Blood loss during Abdominal Myomectomy,<br>myomectomy surgery;myomectomy surgery,;tranexamic acid group;carbetocin group,Carbetocin for the reduction of blood loss during myomectomy,PACTR,2019-08-03,2016-05-01,FALSE,Interventional,"Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes",Not Applicable,132,faculty pf medicine suez canal university,Egypt,NA,1,03/08/2019,01/05/2016,PACTR2,4 November 2020,NULL,omima,taha,ring road kilo 4.5,omimatharwat@yahoo.com,002001223423685,suez canal university,omima,taha,ring road kilo 4.5,omimatharwat@yahoo.com,002001223423685,suez canal university,Complete,NULL,sherehan magdi elkeplawy,19 Year(s),44 Year(s),Female,"Inclusion criteria: - age ranging from 18 to 50 years with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within last 12 months, <br>- patients complaining of abnormal vaginal bleeding, chronic pelvic pain, pressure symptoms or reproductive disorders<br>- pre-operative hemoglobin > 8g/dl.","Exclusion criteria: - post-menopausal women <br>- patients previously treated with Depo-Lupron, Depo-Provera or oral contraceptive pills, <br>- patients with known bleeding/clotting disorders, active liver, kidney or cardiovascular disease or receiving anticoagulant, NSAIDs or antiplatelet, <br>- previous history of gynecological malignancy, <br>- previous abdominal myomectomy or venous thromboembolism.",Studying the effect of tranexamic acid versus carbetocin on operative blood loss ( intra-and post operative ) and  the needs of blood transfusion in women undergoing myomectomy.,"the need for blood transfusion, patients hemoglobin level after the operation",NA,NULL,Anticipated,03/08/2019,https://www.dropbox.com/s/kigmb1zem91n2d3/sherehan%20protocol-1.docx?dl=0,Total blood loss was significantly lower in the Carbetocin group (399.27 ± 28.94 ml) than the tranexamic acid group (535.15 ± 80.30 ml) (p <0.001). Intra-operative blood loss was significantly lower in the Carbetocin group (371.39 ± 27.54 ml) than the tranexamic acid group (478.48 ± 60.4 ml) (p <0.001). Post-operative blood loss was significantly lower in the Carbetocin group (27.88 ± 32.32 ml) than the tranexamic acid group (56.67 ± 53.13 ml) (p 0.001).,2019-08-03,2019-08-03,demographics,"150 were recruited, 132 completed the study with 66 patients in each group",none,primary outcome measure: blood loss among both groups secondry outcome measures: need for blood transfusion,https://www.dropbox.com/s/kigmb1zem91n2d3/sherehan%20protocol-1.docx?dl=0,Yes,through the research and after approval of our ethical committee,NULL,Yes,Approved,Apr 17 2016 12:00AM,rec@med.suez.edu.eg,research ethics committee faculty of medicine suez canl univerity,0643200789,rec@med.suez.edu.eg
TCTR20190109001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4325,"A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levocetirizine 5 mg relative to XyzalÂ® 5 mg tablets in healthy Thai volunteers under fasting condition",Bioequivalence study <br>Bioequivalence Bioequivalence study;Bioequivalence Bioequivalence study,"A randomized, open-labeled, single-dose, two-way crossover design with two-period, two-treatment, two-sequence under fasting conditions and at least 7 days washout period between the doses., A randomized, open-labeled, single-dose, two-way crossover design with two-period, two-treatment, two-sequence under fasting conditions and at least 7 days washout period between the doses.","A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levocetirizine 5 mg relative to XyzalÂ® 5 mg tablets in healthy Thai volunteers under fasting condition",TCTR,2019-01-08,2019-03-01,FALSE,Interventional,Randomized controlled trial,Phase 1,24,"Bio-innova and Synchron.Co.,Ltd",Thailand,NA,NULL,08/01/2019,01/03/2019,TCTR20,4 November 2020,NULL,Sasitorn,Kittivoravitkul,Bangkok Bangkok 10110,sasitorn_k@bio-innova.com,0-2254-9008-9,"Bio-innova and Synchron.Co.,Ltd",Sasitorn,Kittivoravitkul,Bangkok Bangkok 10110,sasitorn_k@bio-innova.com,0-2254-9008-9,"Bio-innova and Synchron.Co.,Ltd",Pending (Not yet recruiting),NULL,"Bio-innova and Synchron.Co.,Ltd",18 Years,55 Years,Both,"Inclusion criteria: 1.Willingness to provide written informed consent prior to participate in the study.  <br>2.Healthy Thai subjects are between 18 to 55 years of age.<br>3.The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.<br>4.Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjectsâ?? safety after the completion of the study.<br>5.Negative urine pregnancy test for women and no breast-feeding.<br>6.Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician<br>","Exclusion criteria: 1.History or evidence of allergy or hypersensitivity to Levocetirizine or any related drugs or any of the excipients of this product.<br>2.Subject with B.P. is Systolic B.P < 90, â?¥140 mm/Hg, Diastolic B.P < 60, â?¥90 mm/Hg or pulse rate > 100 beats per minute.<br>3.Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*<br>4.Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*<br>5.Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*<br>6.Positive of hepatitis B or C virus.<br>7.Have more than one abnormal EKG, which is considered as clinically significant. *<br>8.History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension, glaucoma.<br>9.History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.<br>10.Any major illness in the past 3 months or any significant ongoing chronic medical illness.<br>11.History of psychiatric disorder.<br>12.History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study. <br>13.History of usually smoking (more than 10 cigarettes per day), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study. <br>14.High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study. <br>15.Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Amphetamine, Cocaine and Opioids).<br>16.Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-ProveraÂ® must be discontinued at least 6 months) prior to receiving the first dose of study medication. <br>17.History of difficulty in accessibility of veins in left and right arm.<br>18.Blood donation (one unit or 450 mL) within the past 3 months before the study.<br>19.Participation in any clinical study within the past 3 months before the study. <br>20.Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.<br>","Cmax, AUC0-t and AUC0-inf [Timeframe 0,.17,0.33,0.5,0.67,0.83,1,1.25,1.5,1.75,2,3,4,6,8,12, 24,36 Hrs Pharmacokinetic parameters]","Safety; Adverse events [Timeframe 1.0, 2.0, 4.0, 8.0, 12.0, 24.0 and 36.0 hrs Safety monitoring, vital sign]",NA,NULL,Anticipated,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,2019-05-01,NULL,NA,Jan  1 1900 12:00AM,NA,NA,NA,NA
TCTR20190614007,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4900,"Comparative sebum control efficacy of BGM complex (Bakuchiol, Ginkgo, and Mannitol) combined with adapalene 0.1%/benzoyl peroxide 2.5% gel and adapalene 0.1%/benzoyl peroxide 2.5% gel monotherapy in mild to moderate acne vulgaris patients",dysseborrheaacne vulgaris,"Sebium sensitive cream contains Bakuchiol, Ginkgo, and Mannitol (BGM complex), adapalene 0.1%/benzoyl peroxide 2.5% gel mono therapy","Comparative sebum control efficacy of BGM complex (Bakuchiol, Ginkgo, and Mannitol) combined with adapalene 0.1%/benzoyl peroxide 2.5% gel and adapalene 0.1%/benzoyl peroxide 2.5% gel monotherapy in mild to moderate acne vulgaris patients",TCTR,2019-06-14,2019-07-01,FALSE,Interventional,Randomized controlled trial,Phase 2/Phase 3,18,"Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital",Thailand,NA,NULL,14/06/2019,01/07/2019,TCTR20,4 November 2020,NULL,Ratchathorn,Panchaprateep,"1873 Rama IV Rd., Pathumwun Bangkok 10330",rpanchaprateep@gmail.com,0898923819,"Faculty of Medicine, Chulalongkorn University",Ratchathorn,Panchaprateep,"1873 Rama IV Rd., Pathumwun Bangkok 10330",rpanchaprateep@gmail.com,0898923819,"Faculty of Medicine, Chulalongkorn University",Recruiting,"Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital","Naos (Thailand) Co., Ltd",18 Years,29 Years,Both,Inclusion criteria: mild to moderate degree acne vulgaris patients,Exclusion criteria: -patients who receive topical treatments within 2 weeks or oral treatments within 4 weeks.<br>-pregnant or lactating women<br>-subjects who have known allergy or sensitivity to skincare products<br>,"Sebum content [Timeframe week 0,1,2,3,4 multi-probe adapter system Cutometer dual MPA580]","clinical grading of acne severity [Timeframe week 0,1,2,3,4 The LEEDs revised acne grading system, physician's global assessment]",NA,NULL,Actual,NA,NA,NA,NULL,1900-01-01,NA,NA,NA,NA,NA,NA,NA,2019-07-30,NULL,NA,Jan  1 1900 12:00AM,NA,NA,NA,NA
